var images_info;if (!images_info) images_info =[]; images_info["112"]={"112000":{"type":"graphic_picture","displayName":"Saddleback caterpillar (Acharia stimulea) 2","title":"Saddleback caterpillar (<EM>Acharia stimulea</EM>)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saddleback caterpillar (<EM>Acharia stimulea</EM>)</div><div class=\"cntnt\"><img style=\"width:427px; height:640px;\" src=\"images/DERM/112000_Saddleback_caterpillar2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The saddleback caterpillar is a type of slug caterpillar bearing numerous clusters of urticating spines.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 112000 Version 1.0</div></div></div>"},"112001":{"type":"graphic_picture","displayName":"Spiny oak slug (Euclea delphinii)","title":"Spiny oak slug (<EM>Euclea delphinii</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Spiny oak slug (<EM>Euclea delphinii</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:506px;\" src=\"images/DERM/112001_Spiny_oak_slug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This slug caterpillar is variably patterned and is found in the United States.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 112001 Version 1.0</div></div></div>"},"112002":{"type":"graphic_picture","displayName":"Stinging rose caterpillar (Parasa indetermina)","title":"Stinging rose caterpillar (<EM>Parasa indetermina</EM>)","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Stinging rose caterpillar (<EM>Parasa indetermina</EM>)</div><div class=\"cntnt\"><img style=\"width:550px; height:407px;\" src=\"images/DERM/112002_Stinging_rose_caterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This slug caterpillar is found in the United States.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 112002 Version 1.0</div></div></div>"},"112003":{"type":"graphic_picture","displayName":"Puss caterpillar (Megalopyge opercularis)","title":"Puss caterpillar (<EM>Megalopyge opercularis</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Puss caterpillar (<EM>Megalopyge opercularis</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/112003_Puss_caterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This woolly caterpillar is found in the southeastern United States.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 112003 Version 1.0</div></div></div>"},"112004":{"type":"graphic_picture","displayName":"Gypsy moth caterpillar (Lymantria dispar)","title":"Gypsy moth caterpillar (<EM>Lymantria dispar</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Gypsy moth caterpillar (<EM>Lymantria dispar</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:506px;\" src=\"images/DERM/112004_Gypsy_moth_caterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Originally from Europe, this invasive species is now found throughout the northeastern United States.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 112004 Version 1.0</div></div></div>"},"112005":{"type":"graphic_picture","displayName":"Hickory tussock moth (Lophocampa caryae)","title":"Hickory tussock moth (<EM>Lophocampa caryae</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hickory tussock moth (<EM>Lophocampa caryae</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/112005_Hickory_tussock_moth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These caterpillars are commonly found in the late summer and fall in the northeastern United States.</div><div id=\"graphicVersion\">Graphic 112005 Version 1.0</div></div></div>"},"112006":{"type":"graphic_picture","displayName":"Female yellowtail moth (Hylesia nigricans)","title":"Yellowtail moth (<EM>Hylesia nigricans</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Yellowtail moth (<EM>Hylesia nigricans</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:496px;\" src=\"images/DERM/112006_Yellowtail_moth_Hylesia_nig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Female yellowtail moths bear urticating scales on the ventral abdomen.</div><div class=\"graphic_reference\">From: Specht A, Formentini AC, Corseuil E. Biologia de Hylesia nigricans (Berg) (Lepidoptera, Saturniidae, Hemileucinae). Revista Brasileira de Zoologia 2006; 23:248. Copyright © 2006 Sociedade Brasileira de Zoologia. Available at: <A href=\"http://www.scielo.br/scielo.php?pid=S0101-81752006000100018&amp;script=sci_abstract\" target=_blank>http://www.scielo.br/scielo.php?pid=S0101-81752006000100018&amp;script=sci_abstract</A> (Accessed March 7, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/4.0/deed.en\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 112006 Version 1.0</div></div></div>"},"112007":{"type":"graphic_table","displayName":"Alopecia with selected chemotherapy agents and combinations","title":"Frequency and severity of alopecia for selected chemotherapy agents and combinations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency and severity of alopecia for selected chemotherapy agents and combinations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Severe</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Mild</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Frequent</strong></td> <td> <ul> <li>Doxorubicin (&#62;40 mg/m<sup>2</sup>) </li> <li>Epirubicin (&#62;30 mg/m<sup>2</sup>) </li> <li>Daunorubicin </li> <li>Paclitaxel (every 2 to 3 weeks) </li> <li>Docetaxel </li> <li>Cyclophosphamide (IV at doses &#62;300 mg/m<sup>2</sup>) </li> <li>Ifosfamide </li> <li>Etoposide (IV) </li> <li>Ixabepilone </li> <li>Eribulin </li> <li>Combination chemotherapy with doxorubicin, docetaxel, paclitaxel, etoposide </li> </ul> </td> <td> <ul> <li>Mechlorethamine </li> <li>Methotrexate </li> <li>Carboplatin (AUC 5 to 6) </li> <li>Paclitaxel (weekly) </li> </ul> </td> <td> <ul> <li>Bleomycin </li> </ul> </td> </tr> <tr> <td><strong>Infrequent</strong></td> <td> <ul> <li>Vincristine </li> <li>Vinblastine </li> <li>Etoposide (oral) </li> </ul> </td> <td> <ul> <li>Oxaliplatin </li> <li>Cyclophosphamide (oral) </li> </ul> </td> <td> <ul> <li>Fluorouracil </li> <li>Capecitabine </li> <li>Hydroxyurea </li> <li>Thiotepa </li> <li>Carboplatin (weekly) </li> <li>Cisplatin </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; AUC: area under the curve.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Rugo HS, Klein P, Melin SA, et al. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA 2017; 317:606.</LI>&#xD;&#xA;<LI>Nangia J, Wang T, Osborne C, et al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA 2017; 317:596.</LI>&#xD;&#xA;<LI>Batchelor D. Hair and cancer chemotherapy: consequences and nursing care--a literature study. Eur J Cancer Care (Engl) 2001; 10:147.</LI>&#xD;&#xA;<LI>Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.</LI>&#xD;&#xA;<LI>Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol 2012; 67:e37.</LI></OL></div><div id=\"graphicVersion\">Graphic 112007 Version 1.0</div></div></div>"},"112008":{"type":"graphic_picture","displayName":"Lonomia obliqua caterpillar","title":"<EM>Lonomia obliqua</EM> caterpillar","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\"><EM>Lonomia obliqua</EM> caterpillar</div><div class=\"cntnt\"><img style=\"width:783px; height:296px;\" src=\"images/DERM/112008_Lonomia_obliqua_caterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contact with this caterpillar causes a painful sting and a potentially fatal hemorrhagic diathesis.</div><div class=\"graphic_reference\">From: Pinto AF, Berger M, Reck J Jr, et al. Lonomia obliqua venom: In vivo effects and molecular aspects associated with the hemorrhagic syndrome. Toxicon 2010; 56:1103. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112008 Version 1.0</div></div></div>"},"112011":{"type":"graphic_table","displayName":"Modified Dean scale for quantification of chemo-induced alopecia","title":"Modified Dean scale for quantification of chemotherapy-induced alopecia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Dean scale for quantification of chemotherapy-induced alopecia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Dean score</td> <td class=\"subtitle1\">Percentage of hair loss</td> </tr> <tr> <td class=\"centered\">Grade 0</td> <td>No hair loss</td> </tr> <tr> <td class=\"centered\">Grade 1</td> <td>&#62;0 to &#8804;25% hair loss</td> </tr> <tr> <td class=\"centered\">Grade 2</td> <td>&#62;25 to &#8804;50% hair loss</td> </tr> <tr> <td class=\"centered\">Grade 3</td> <td>&#62;50 to &#8804;75% hair loss</td> </tr> <tr> <td class=\"centered\">Grade 4</td> <td>&#62;75% hair loss</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dean JC, Salmon SE, Griffith KS. Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med 1979; 301:1427.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 112011 Version 1.0</div></div></div>"},"112013":{"type":"graphic_table","displayName":"Empiric parenteral Rx for acute bacterial arthritis in children","title":"Suggested empiric parenteral regimens for acute bacterial arthritis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested empiric parenteral regimens for acute bacterial arthritis in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Children &#60;3 months of age</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Antibiotic agent*</td> <td class=\"subtitle2\">Comment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Coverage for <em>Staphylococcus aureus</em> and GBS</strong></td> <td>One of the following: <ul class=\"decimal_heading\"> <li>Nafcillin </li> <li>Oxacillin </li> <li>Vancomycin </li> </ul> </td> <td> <ul> <li>Vancomycin is preferred for infants &#60;1 month of age who have been in the ICU for &#62;1 week (to cover MRSA) and in communities where &#8805;10 to 15&nbsp;percent of community <em>S. aureus</em> isolates are MRSA </li> <li>For severely ill infants (eg, those with hemodynamic instability), initial empiric therapy with combination vancomycin and nafcillin/oxacillin is suggested </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"3\">PLUS</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Coverage for gram-negative bacilli</strong></td> <td>One of the following: <ul class=\"decimal_heading\"> <li>Cefotaxime (preferred) </li> <li>Ceftazidime </li> <li>Cefepime </li> </ul> </td> <td> <ul> <li>Cefotaxime is preferred for infants &#60;1 month of age (to cover <em>Neisseria gonorrhoeae</em>) </li> <li>Cefotaxime also provides coverage for GBS, including meningitis </li> <li>Cefepime is preferred if <em>Pseudomonas aeruginosa</em> is a consideration </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Children &#8805;3 months of age</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Antibiotic agent*</td> <td class=\"subtitle2\">Comment</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Coverage for <em>S. aureus</em></strong></td> <td class=\"subtitle2_left\" colspan=\"2\">Severe illness (ie, hemodynamic instability)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vancomycin <strong>PLUS</strong> either nafcillin or oxacillin</td> <td> <ul> <li>Nafcillin or oxacillin is superior to vancomycin for MSSA </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nonsevere illness and &#60;10 to 15 percent of community <em>S. aureus</em> isolates are MRSA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">One of the following: <ul class=\"decimal_heading\"> <li>Cefazolin </li> <li>Nafcillin </li> <li>Oxacillin </li> </ul> </td> <td> <ul> <li>Cefazolin also provides coverage for <em>Kingella kingae</em> (eg, for children 6 to 36 months of age who attend day care or had oral ulcers before onset of musculoskeletal symptoms) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nonsevere illness and &#8805;10 to 15 percent of community <em>S. aureus</em> isolates are MRSA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Clindamycin or vancomycin</td> <td> <ul> <li>Vancomycin is preferred: <ul> <li>For life-threatening infections (in combination with nafcillin/oxacillin pending susceptibility results) </li> <li>If &#8805;10 percent of community MRSA isolates are clindamycin-resistant </li> <li>For children with prosthetic joints (CoNS) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"3\">PLUS</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Indication</td> <td class=\"subtitle2\">Antibiotic agent(s)* </td> </tr> <tr> <td rowspan=\"9\"><strong>Additional coverage as clinically indicated</strong></td> <td>Gram-negative organisms on Gram stain</td> <td> <ul> <li>Cefotaxime, ceftriaxone, or cefuroxime </li> </ul> </td> </tr> <tr> <td>Penetrating trauma or history of penetrating trauma (polymicrobial, including <em>P. aeruginosa</em>)</td> <td> <ul> <li>Cefepime monotherapy,<sup>&#182;</sup> or </li> <li>Combination therapy<sup>&#916;</sup> with: <ul> <li>Either cefepime or ceftazidime <strong>PLUS</strong> </li> <li>Either clindamycin or vancomycin </li> </ul> </li> </ul> </td> </tr> <tr> <td>Age 6 to 36 months and day care attendance or history of oral ulcers before onset of musculoskeletal symptoms (<em>K. kingae</em>)</td> <td> <ul> <li>Use cefazolin for antistaphylococcal coverage, if possible<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr> <td>Incomplete Hib immunization in child &#60;2 years of age in area with low rates of Hib immunization (Hib)</td> <td rowspan=\"3\"> <ul> <li>Cefotaxime or ceftriaxone </li> </ul> </td> </tr> <tr> <td>Incomplete pneumococcal immunization in a child &#60;2 years of age, or high-risk condition for invasive pneumococcal disease<sup>&#167;</sup>, or antibiotic therapy within four weeks of diagnosis of bacterial arthritis (penicillin-nonsusceptible <em>S. pneumoniae</em>)</td> </tr> <tr> <td>Sickle cell disease or related hemoglobinopathies (<em>Salmonella</em>)</td> </tr> <tr> <td>Recent GI surgery or complex urinary tract anatomy (enteric gram-negative organism)</td> <td> <ul> <li>One of the following: <ul> <li>Cefotaxime </li> <li>Ceftriaxone </li> <li>Cefepime (if <em>P. aeruginosa</em> is a concern) </li> </ul> </li> </ul> </td> </tr> <tr> <td>Sexually active adolescent (<em>N. gonorrhoeae</em>)<sup>&#165;</sup></td> <td> <ul> <li>Either cefotaxime or ceftriaxone <strong>PLUS</strong> azithromycin (single dose) </li> </ul> </td> </tr> <tr> <td>Injection drug user (<em>P. aeruginosa</em>)</td> <td> <ul> <li>Ceftazidime </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GBS: group B <EM>Streptococcus</EM>; ICU: intensive care unit; MRSA: methicillin-resistant <EM>S. aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>; CoNS: coagulase-negative <EM>S. aureus</EM>; Hib: <EM>Haemophilus influenzae</EM> type b; GI: gastrointestinal.<br />* Refer to UpToDate topic on treatment of bacterial arthritis in children for dosing.<br />¶&nbsp;Provides coverage for <EM>P. aeruginosa</EM> and MSSA.<br />Δ&nbsp;Provides coverage for <EM>P. aeruginosa</EM> and MRSA.<br />◊&nbsp;We do not generally provide initial empiric coverage for <EM>K. kingae</EM> in young children if <EM>K. kingae</EM> coverage requires two drugs; we add coverage for <EM>K. kingae</EM> if the child does not improve.*<br />§&nbsp;Refer to UpToDate topic on pneumococcal vaccination in children for details.<br />¥&nbsp;Refer to UpToDate topic on disseminated gonococcal infection for details.</div><div id=\"graphicVersion\">Graphic 112013 Version 2.0</div></div></div>"},"112017":{"type":"graphic_algorithm","displayName":"Initial management of non-muscle invasive bladder cancer","title":"Initial management of non-muscle invasive bladder cancer","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Initial management of non-muscle invasive bladder cancer</div><div class=\"cntnt\"><img style=\"width:724px; height:426px;\" src=\"images/ONC/112017_Mgmt_nonmusc_invsv_blddr_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TURBT: transurethral resection of bladder tumor; CIS: carcinoma in situ; Ta: papillary tumor; BCG: Bacillus Calmette-Guerin.<br />* European Association of Urology (EAU) risk stratification scheme.<br />¶ Restaging TURBT is indicated for all high-grade T1 lesions and select patients with high-grade Ta disease. Restaging needs to demonstrate absence of distant involvement at time of local recurrence if salvage cystectomy is to be done.<br />Δ Indications for cystectomy include T1 tumors with lymphovascular invasion or micropapillary features, large or diffuse T1 grade 3 tumors, pure squamous cell or adenocarcinoma histology, prostatic duct/acinar CIS in men, T1 grade 3 disease associated with CIS, deep or extensive involvement of lamina propria, persistent T1 grade 3 tumors on resection, recurrent or persistent high grade disease within 6 to 12 months after initial BCG therapy, or large-volume high grade disease.<br /><FONT class=lozenge>◊</FONT>​ Careful follow-up is required for all patients with non-muscle invasive bladder cancer including the bladder, renal pelvis, ureters, and urethra for patients with intermediate or high risk disease. For those with a low risk disease, surveillance of the upper urinary tract is not indicated. The frequency and intensity of follow-up should consider the risk of recurrence. In addition to cystoscopy, follow-up may include urine cytology and evaluation of the upper urinary tract.</div><div id=\"graphicVersion\">Graphic 112017 Version 2.0</div></div></div>"},"112031":{"type":"graphic_table","displayName":"Scalp cooling devices for prevention of chemo alopecia","title":"Available scalp cooling devices for the prevention of chemotherapy-induced alopecia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available scalp cooling devices for the prevention of chemotherapy-induced alopecia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device</td> <td class=\"subtitle1\">Details</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Free-standing with circulating coolant (automated)</td> </tr> <tr> <td class=\"indent1\">DigniCap</td> <td>FDA cleared</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Paxman</td> <td>FDA clearance pending</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Frozen cold caps (manual)</td> </tr> <tr> <td class=\"indent1\">Penguin caps</td> <td rowspan=\"5\">Cap must be frozen and changed every 30 minutes as it begins to thaw. The Penguin cap can be molded to the shape of the head.</td> </tr> <tr> <td class=\"indent1\">Elastogel caps</td> </tr> <tr> <td class=\"indent2\">Polar cold caps</td> </tr> <tr> <td class=\"indent2\">Artic cold caps</td> </tr> <tr> <td class=\"indent2\">Chemo cold caps</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: US Food and Drug Administration; Chemo: chemotherapy.</div><div id=\"graphicVersion\">Graphic 112031 Version 1.0</div></div></div>"},"112044":{"type":"graphic_table","displayName":"Headache characteristics warranting prompt evaluation","title":"Headache characteristics warranting prompt evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Headache characteristics warranting prompt evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Headache with altered mental status, seizures, papilledema, changes in vision, stiff neck, or focal neurological signs/symptoms </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sudden onset of severe headache (\"worst headache of my life\") </li> </ul> </td> </tr> <tr> <td> <ul> <li>New-onset of migraine-type headache </li> </ul> </td> </tr> <tr> <td> <ul> <li>Headache in an immunosuppressed woman </li> </ul> </td> </tr> <tr> <td> <ul> <li>Change in headache characteristics (eg, pain, pattern, severity) from usual headaches </li> </ul> </td> </tr> <tr> <td> <ul> <li>Headache associated with/precipitated by fever, head trauma, nonprescription drug use, toxic exposure, cough, exertion, sexual activity, or Valsalva maneuver </li> </ul> </td> </tr> <tr> <td> <ul> <li>Headache that awakens the woman from sleep </li> </ul> </td> </tr> <tr> <td> <ul> <li>Headache unrelieved by pain medication </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112044 Version 1.0</div></div></div>"},"112057":{"type":"graphic_table","displayName":"Topical analgesics for treatment of knee and hand osteoarthritis","title":"Topical analgesics for treatment of knee and hand osteoarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical analgesics for treatment of knee and hand osteoarthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Topical analgesic</td> <td class=\"subtitle1\">Usual dose (adult)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Topical nonsteroidal antiinflammatory drugs (NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical gel (1%)</td> <td>Apply dose (depends on joint size and location) three to four times daily (maximum total 32 g of gel per day)</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical patch (1.3%)</td> <td>One patch twice daily</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical solution (1.5, 1.6, or 2%)</td> <td>Apply (depends on joint size and location) two to four times daily (twice for the 2%)</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical spray (4%); not available in the United States</td> <td>Four sprays (total of 32 mg of diclofenac) applied up to three times daily (maximum 120 mg per day); refer to product-specific information</td> </tr> <tr> <td class=\"indent1\">Ibuprofen topical gel (5%); not available in the United States</td> <td>1 to 2.5 g of gel up to three times daily (maximum 7.5 g of gel per day); refer to product-specific information</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketoprofen topical gel (2.5%); not available in the United States</td> <td>Apply two to four times daily (usual recommended dose is 15 g of gel per day); refer to product-specific information</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Topical capsaicin</td> </tr> <tr> <td class=\"indent1\">Capsaicin creams, gels, liquids or lotions (0.025 to 0.1%)</td> <td>Apply a thin film one to four times daily until benefit achieved or for one-month trial; the dosage most often studied in osteoarthritis was 0.025%</td> </tr> <tr> <td class=\"indent1\">Capsaicin topical patches (standard concentration 0.025, 0.0375%)</td> <td>Apply up to three to four times daily</td> </tr> <tr> <td class=\"indent1\">Capsaicin topical patch (high concentration 8%)</td> <td>Used to treat postherpetic neuralgia (single treatment); not studied in osteoarthritis patients</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Anon. Drugs for pain. Treatment guidelines from the Medical Letter 2013; 11:31.</LI>&#xD;&#xA;<LI>Barkin R, Beckerman M, Blum S. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010; 27:775.</LI>&#xD;&#xA;<LI>Sawynok J. Topical analgesics for neuropathic pain in the elderly: Current and future prospects. Drugs Aging 2014; 31:853.</LI></OL></div><div id=\"graphicVersion\">Graphic 112057 Version 2.0</div></div></div>"},"112058":{"type":"graphic_diagnosticimage","displayName":"Resolution of collateral veins following iliac vein stenting","title":"Resolution of collateral veins following iliac vein stenting","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Resolution of collateral veins following iliac vein stenting</div><div class=\"cntnt\"><img style=\"width:765px; height:450px;\" src=\"images/SURG/112058_Vein_stenosis_collateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The venogram (A) shows compression of the proximal left iliac vein (arrow). There are large venous collaterals in the area of severe stenosis (asterisk). The completion venogram after left iliac vein stenting demonstrates a widely patent vein and disappearance of all adjacent collateral veins.</div><div id=\"graphicVersion\">Graphic 112058 Version 2.0</div></div></div>"},"112059":{"type":"graphic_picture","displayName":"Trichomegaly","title":"Trichomegaly","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Trichomegaly</div><div class=\"cntnt\"><img style=\"width:556px; height:500px;\" src=\"images/ONC/112059_Trichomegaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichomegaly appeared 3 months after erlotinib was administered. Notice the uneven, curly, and aberrant elongation of the eyelashes.</div><div class=\"graphic_reference\">From: Chanprapaph K, Pongcharoen P, Vachiramon V. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases. Indian J Dermatol Venereol Leprol 2015; 81(5):547. DOI: <A href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2015;volume=81;issue=5;spage=547;epage=547;aulast=Chanprapaph\" target=_blank>10.4103/0378-6323.157448</A>. Copyright © 2015 Indian Association of Dermatologists, Venereologists &amp; Leprologists (IADVL). Reproduced with permission from Wolters Kluwer Medknow. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112059 Version 2.0</div></div></div>"},"112060":{"type":"graphic_movie","displayName":"IVUS image and video before vein stent","title":"IVUS image and video before vein stent","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">IVUS image and video before vein stent</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/112060_IVUSbeforeveinstentvid.mp4\" style=\"width:496px;height:544px\"></div><img style=\"width:648px; height:600px;\" src=\"images/SURG/112060_IVUSbeforeveinstentimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The IVUS image and video show severe stenosis of the left iliac vein.</div><div class=\"graphic_footnotes\">IVUS: intravascular ultrasound.</div><div id=\"graphicVersion\">Graphic 112060 Version 1.0</div></div></div>"},"112061":{"type":"graphic_movie","displayName":"IVUS image and video after vein stent","title":"IVUS image and video after vein stent","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IVUS image and video after vein stent</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/112061_IVUSafterveinstentvid.mp4\" style=\"width:432px;height:496px\"></div><img style=\"width:648px; height:579px;\" src=\"images/SURG/112061_IVUSafterveinstentimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The IVUS image and video show a widely patent left iliac vein with proper coaptation between stent and venous wall (arrow in image).</div><div class=\"graphic_footnotes\">IVUS: intravascular ultrasound.</div><div id=\"graphicVersion\">Graphic 112061 Version 1.0</div></div></div>"},"112062":{"type":"graphic_algorithm","displayName":"Approach to peritonsillar abscess in the emergency department","title":"Approach to the diagnosis and treatment of peritonsillar abscess in the emergency department","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis and treatment of peritonsillar abscess in the emergency department</div><div class=\"cntnt\"><img style=\"width:626px; height:884px;\" src=\"images/EM/112062_Approach_PTA_ED.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; US: ultrasound; OR: operating room.<br />* Maintenance of the airway is the mainstay of treatment. In patients with signs of total or near-total airway obstruction; airway control necessarily precedes diagnostic evaluation. If available, activate a critical airway team consisting of an anesthesiologist, emergency and/or critical care specialist, and an otolaryngologist to assist with securing the airway.<br />¶ Intraoral or submandibular ultrasound has significantly better sensitivity for distinguishing peritonsillar abscess from peritonsillar cellulitis than physical examination alone and improves the success of needle aspiration. Needle aspiration should be performed by a properly trained and experienced physician, typically an otolaryngologist. However, if US is equivocal or not available, then patients without airway compromise may undergo a trial of IV antibiotics and hospital observation instead of needle aspiration.<br />Δ For suggested antibiotic regimens, refer to UpToDate topics on peritonsillar abscess. Patients with peritonsillar cellulitis and patients with improvement after drainage of a peritonsillar abscess may be discharged home if they are well hydrated, have no airway compromise, and can tolerate oral intake including oral antibiotics. Otherwise, hospitalization is warranted.</div><div id=\"graphicVersion\">Graphic 112062 Version 1.0</div></div></div>"},"112075":{"type":"graphic_diagnosticimage","displayName":"Rib plating on plain chest radiography","title":"Rib plating on plain chest radiography","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Rib plating on plain chest radiography</div><div class=\"cntnt\"><img style=\"width:640px; height:433px;\" src=\"images/SURG/112075_Rib_plating_chest_rdgrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph shows multiple rib plates placed for fixation of severe traumatic rib fractures.</div><div id=\"graphicVersion\">Graphic 112075 Version 1.0</div></div></div>"},"112076":{"type":"graphic_picture","displayName":"Intraoperative appearance of rib plating","title":"Intraoperative appearance of rib plating","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Intraoperative appearance of rib plating</div><div class=\"cntnt\"><img style=\"width:608px; height:534px;\" src=\"images/SURG/112076_Rib_plating.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows the intraoperative appearance of&nbsp;rib plates used for fixation of severe rib fractures.</div><div id=\"graphicVersion\">Graphic 112076 Version 1.0</div></div></div>"},"112077":{"type":"graphic_picture","displayName":"U-plating of a flail segment","title":"U-plating of a flail segment","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">U-plating of a flail segment</div><div class=\"cntnt\"><img style=\"width:756px; height:464px;\" src=\"images/SURG/112077_U-plating_flail_segment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intraoperative photograph shows a U-plate with the fractured rib evident beneath the midportion of the plate. This plate was used to span a flail segment (ie, two adjacent fracture lines on the same rib). The screw in the midportion of the plate is stabilizing the floating segment of rib, while two adjacent screws at each end of the plate are anchoring the plate to the intact segments of the rib.</div><div id=\"graphicVersion\">Graphic 112077 Version 1.0</div></div></div>"},"112078":{"type":"graphic_diagnosticimage","displayName":"Postoperative chest radiograph motorcycle collision","title":"Postoperative chest radiograph motorcycle collision","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Postoperative chest radiograph motorcycle collision</div><div class=\"cntnt\"><img style=\"width:756px; height:661px;\" src=\"images/SURG/112078_Postop_chest_xray_mtrcycl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This postoperative&nbsp;chest radiograph is from a patient in her late thirties who was ejected off a motorcycle, sustaining multiple right-sided rib fractures. The implanted plates can be seen laterally and are&nbsp;stabilizing ribs 5 through 9. Even though nearly all the ribs laterally on the right were fractured, operative fixation of the ribs of the mid-chest was sufficient to stabilize the entire chest wall.<br /></div><div id=\"graphicVersion\">Graphic 112078 Version 1.0</div></div></div>"},"112079":{"type":"graphic_figure","displayName":"Mechanisms in Cushing's syndrome","title":"Summary of genetic and molecular mechanisms implicated in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Summary of genetic and molecular mechanisms implicated in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:788px; height:512px;\" src=\"images/ENDO/112079_Mechanisms_Cushing_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For each cause, the various genetic mutations or abnormal protein expression believed to play a part in the pathophysiology are shown. The most frequent mechanisms are highlighted in blue characters; the well-characterized mechanisms are highlighted in bold characters, and other potential mechanisms are in normal characters; a question marks shows an unconfirmed association or genetic predisposition.</div><div class=\"graphic_footnotes\">ACTH: corticotropin; AC: adenylate cyclase; GPCR: G-protein-coupled receptor; Gs-alpha: alpha subunit of Gs; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; PDEs: phosphodiesterases; GEP-NETs: gastroenteropancreatic neuroendocrine tumors; PKA: protein kinase; R1-alpha: type 1-alpha regulatory subunit of PKA; C-alpha: catalytic subunit of PKA; BMAH: bilateral macronodular adrenal hyperplasia; PPNAD: primary pigmented nodular adrenocortical disease.</div><div class=\"graphic_reference\">From: Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015; 386:913. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112079 Version 1.0</div></div></div>"},"112081":{"type":"graphic_algorithm","displayName":"Therapy for bladder preservation in muscle invasive bladder CA","title":"Combined modality therapy for bladder preservation in patients with muscle invasive bladder cancer*","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Combined modality therapy for bladder preservation in patients with muscle invasive bladder cancer*</div><div class=\"cntnt\"><img style=\"width:566px; height:614px;\" src=\"images/ONC/112081_Blddr_prsrvtn_mscl_blddr_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TURBT: transurethral resection of bladder tumor.<br />* A bladder preservation approach may be indicated for patients who are medically unfit for radical cystectomy or who have a strong desire to preserve the native bladder.<br />¶ Radiation therapy may be given as either a split-course or continuous-course approach; there are no trials comparing these two approaches, and the choice of approach is based upon institutional expertise and preferences.</div><div id=\"graphicVersion\">Graphic 112081 Version 1.0</div></div></div>"},"112084":{"type":"graphic_table","displayName":"Antihistamines for sleep in children","title":"Considerations regarding antihistamines for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding antihistamines for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Rapid onset of action and relatively short half-life </li> <li>Caregiver acceptance high </li> <li>Generally well-tolerated </li> <li>Widely available </li> <li>Low cost </li> <li>Liquid formulations available </li> <li>Combination formulations advantageous in some situations </li> </ul> </td> <td> <ul> <li>Mixed empirical evidence of efficacy </li> <li>Adverse reactions include anticholinergic (eg, dry mouth, constipation, urinary retention, blurred vision), paradoxical excitation, residual morning sleepiness (\"hangover\") </li> <li>Development of tolerance to sedation common </li> <li>Possible interaction with other anticholinergics </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> Consider for short-term situational and/or occasional use in younger children, especially with comorbid atopic disease.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112084 Version 1.0</div></div></div>"},"112085":{"type":"graphic_table","displayName":"Melatonin for sleep in children","title":"Considerations regarding melatonin for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding melatonin for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Empiric evidence for efficacy in improving sleep onset, in typically-developing children and those with neurodevelopmental disorders </li> <li>Minimal effects on sleep architecture </li> <li>Acceptability to caregivers </li> <li>Low side effect profile </li> <li>Widely available </li> <li>Low cost </li> <li>Low dose and liquid preparations available </li> </ul> </td> <td> <ul> <li>Long-term side effects uncertain </li> <li>Few or no studies in other psychiatric populations (eg, anxiety, mood disorders) </li> <li>Dosing timing&nbsp;is important,&nbsp;and depends on clinical use (several hours before bedtime for circadian rhythm effects, or shortly before bedtime for sleep onset insomnia) </li> <li>Little evidence to support the use of extended-release formulation for sleep maintenance insomnia </li> <li>Reliability of OTC preparations uncertain </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> Most appropriately used in patients with circadian phase delay. <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">It is also a reasonable choice for children with sleep onset insomnia who may need long-term pharmacotherapy, including those with autism spectrum disorder (ASD) or attention deficit hyperactivity disorder&nbsp;(ADHD).</span>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OTC: over-the-counter.</div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112085 Version 3.0</div></div></div>"},"112086":{"type":"graphic_table","displayName":"Melatonin receptor agonist for sleep in children","title":"Considerations regarding melatonin receptor agonist* for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding melatonin receptor agonist* for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Decreases circadian-mediated arousal at bedtime, not sedating </li> <li>Minimal changes&nbsp;in sleep architecture </li> <li>Little interaction with other neurotransmitters </li> <li>More consistent preparation </li> <li>No evidence of residual daytime effects </li> <li>Classified by the FDA as a hypnotic (non-schedule IV). No limitations on duration of use; no abuse potential </li> </ul> </td> <td> <ul> <li>Treatment of sleep onset insomnia only </li> <li>Moderate efficacy. Objective (PSG-documented)&nbsp;improvements are more prominent than&nbsp;subjective&nbsp;(patient-perceived) improvements&nbsp; </li> <li>Side effects: <ul> <li>Dizziness, fatigue </li> <li>Increased prolactin or decreased testosterone reported </li> </ul> </li> <li>Avoid co-administration with fluvoxamine </li> <li>Cost; lack of insurance coverage </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> May be reasonable choice for mild sleep onset insomnia, especially with circadian component, but cost and lack of insurance coverage limits use.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: United States Food and Drug Administration; PSG: polysomnography. <br />* Ramelteon (Rozerem).</div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112086 Version 1.0</div></div></div>"},"112087":{"type":"graphic_table","displayName":"Benzodiazepines for sleep in children","title":"Considerations regarding benzodiazepines (GABA receptor agonists) for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding benzodiazepines (GABA receptor agonists) for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Half-lives vary; some appropriate for sleep maintenance insomnia </li> <li>Anticonvulsant, anxiolytic, myorelaxant properties </li> <li>Decrease SOL, decrease&nbsp;WASO; increase TST, decrease arousals (depending on drug's duration of action) </li> </ul> </td> <td> <ul> <li>Effects on sleep architecture: Most suppress SWS </li> <li>Side effects: <ul> <li>Potential daytime sedation/cognitive impairment, rebound insomnia; anterograde amnesia, disinhibition </li> <li>Respiratory depression; OSA is a relative contraindication </li> <li>Ethanol use or CNS depressants may potentiate effects </li> </ul> </li> <li>Dependence/abuse potential </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> Limited utility in pediatric populations; other properties (eg, anxiolytic, long duration of action) may be useful in some patients.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GABA: gamma-aminobutyric acid; SOL; sleep onset latency; WASO: wake after sleep onset; TST: total sleep time; SWS: slow-wave sleep; OSA: obstructive sleep apnea; CNS: central nervous system.</div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112087 Version 3.0</div></div></div>"},"112088":{"type":"graphic_table","displayName":"Nonbenzodiazepines for sleep in children","title":"Considerations regarding nonbenzodiazepine receptor agonists for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding nonbenzodiazepine receptor agonists for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Preparations available for&nbsp;either&nbsp;sleep onset insomnia or&nbsp;sleep maintenance insomnia </li> <li>Little effect on sleep architecture: Some SWS suppression </li> <li>Generally well-tolerated (unpleasant taste, headache, anterograde amnesia, daytime drowsiness) </li> <li>Some preparations have limitations on duration of use&nbsp;</li> <li>Alternative formulations available (sublingual, oral spray) </li> </ul> </td> <td> <ul> <li>Little empirical evidence of efficacy in children </li> <li>Uncommon but significant side effects <ul> <li>Hallucinations </li> <li>Complex sleep-related behaviors </li> </ul> </li> <li>Abrupt withdrawal with prolonged use (&#62;2 weeks) may be associated with rebound </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> Lack of documented efficacy and sleep-related behavior side effects limit utility except in older adolescents.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SWS: slow-wave sleep.</div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112088 Version 2.0</div></div></div>"},"112089":{"type":"graphic_table","displayName":"Alpha agonists for sleep in children","title":"Considerations regarding alpha agonists for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding alpha agonists for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Pharmacokinetics: Rapid absorption, onset action within 1 hour, peak effects 2 to 4 hours </li> <li>Generally well-tolerated </li> <li>Widespread usage/acceptability </li> <li>Short half-life (clonidine) creates potential for middle-of-the-night dosing </li> </ul> </td> <td> <ul> <li>Little empirical evidence for efficacy, tolerability </li> <li>Effects on sleep architecture: Increased SWS, reduced REM </li> <li>May cause mid-sleep wakening </li> <li>Side effects: <ul> <li>Hypotension </li> <li>Anticholinergic </li> <li>Irritability, dysphoria </li> <li>Rebound hypertension on discontinuation </li> <li>Exacerbation </li> <li>Parasomnias </li> </ul> </li> <li>Tolerance often develops </li> <li>Narrow therapeutic index; risk&nbsp;of overdose&nbsp; </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> Little data to support current level of clinician preference, but clinical experience suggests generally effective and well-tolerated in ADHD.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SWS: slow-wave sleep;&nbsp;REM: rapid eye movement;&nbsp;ADHD: attention deficit hyperactivity disorder.</div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112089 Version 1.0</div></div></div>"},"112090":{"type":"graphic_table","displayName":"Antidepressants for sleep in children","title":"Considerations regarding antidepressants for sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations regarding antidepressants for sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pros</td> <td class=\"subtitle1\">Cons</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Wide range of choices (half-life, side effects) </li> <li>All affect non-GABA neurotransmitters (muscarinic, histaminergic, serotoninergic blockade) </li> <li>Dosing for insomnia typically&nbsp;is lower than dosing as an&nbsp;antidepressant</li> </ul> </td> <td> <ul> <li>Many have significant safety concerns; risk-benefit ratio </li> <li>Very few data on efficacy for insomnia </li> <li>Some have sleep-disrupting effects </li> <li>Most suppress REM; rebound may lead to nightmares </li> <li>May exacerbate RLS/PLMD </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Bottom line:</strong> Likely most useful in the setting of comorbid mood disorders and/or anxiety; little rationale for trazadone as drug of choice.*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GABA: gamma aminobutyric acid; REM: rapid eye movement;&nbsp;RLS: restless legs syndrome;&nbsp;PLMD: periodic limb movement disorder.<br />* The American Academy of Sleep Medicine (AASM) practice guideline suggests against the use of trazodone for sleep maintenance insomnia in adults with primary insomnia, based on paucity of data and the small effect sizes observed in the single randomized trial.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.<br /><OL>&#xD;&#xA;<LI>​Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13:307.</LI></OL></div><div id=\"graphicVersion\">Graphic 112090 Version 2.0</div></div></div>"},"112093":{"type":"graphic_picture","displayName":"Pitted keratolysis on ball of foot","title":"Pitted keratolysis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pitted keratolysis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/112093_Pittd_keratolysis_ball_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shallow pits and erosions on the ball of the foot.</div><div id=\"graphicVersion\">Graphic 112093 Version 1.0</div></div></div>"},"112094":{"type":"graphic_picture","displayName":"Pitted keratolysis on heel","title":"Pitted keratolysis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pitted keratolysis</div><div class=\"cntnt\"><img style=\"width:756px; height:581px;\" src=\"images/DERM/112094_Pitted_keratolysis_heel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shallow pits and erosions on the heel.</div><div id=\"graphicVersion\">Graphic 112094 Version 1.0</div></div></div>"},"112095":{"type":"graphic_picture","displayName":"Pitted keratolysis on foot","title":"Pitted keratolysis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Pitted keratolysis</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/DERM/112095_Pitted_keratolysis_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Punched-out pits and erosions on the left plantar foot.</div><div id=\"graphicVersion\">Graphic 112095 Version 1.0</div></div></div>"},"112096":{"type":"graphic_picture","displayName":"Pitted keratolysis extensive","title":"Pitted keratolysis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pitted keratolysis</div><div class=\"cntnt\"><img style=\"width:756px; height:546px;\" src=\"images/DERM/112096_Pittd_keratolysis_extensive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pits, erosions, sulci, and macerated areas on both feet.</div><div id=\"graphicVersion\">Graphic 112096 Version 1.0</div></div></div>"},"112097":{"type":"graphic_picture","displayName":"Pitted keratolysis plaque-like variant","title":"Pitted keratolysis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Pitted keratolysis</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/DERM/112097_Pttd_keratolysis_plq-lk_var.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A tender violaceous plaque with erosions on the ball of the right foot.</div><div id=\"graphicVersion\">Graphic 112097 Version 1.0</div></div></div>"},"112098":{"type":"graphic_picture","displayName":"Tinea pedis moccasin-type","title":"Tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Tinea pedis</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/DERM/112098_Tinea_pedis_moccasin-type.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moccasin-type of tinea pedis characterized by silvery scaling and erythema affecting the entire plantar surface of an adult.</div><div id=\"graphicVersion\">Graphic 112098 Version 1.0</div></div></div>"},"112099":{"type":"graphic_picture","displayName":"Juvenile plantar dermatosis in child","title":"Juvenile plantar dermatosis","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Juvenile plantar dermatosis</div><div class=\"cntnt\"><img style=\"width:626px; height:756px;\" src=\"images/DERM/112099_Juvplantrdermatosischild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forefoot and heel desquamation and mild erythema in a child.</div><div id=\"graphicVersion\">Graphic 112099 Version 3.0</div></div></div>"},"112100":{"type":"graphic_picture","displayName":"Plantar warts","title":"Plantar warts","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Plantar warts</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/DERM/112100_Plantar_warts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous-grouped papules with black dots with disruption of normal dermatoglyphics in a localized area of the sole.</div><div id=\"graphicVersion\">Graphic 112100 Version 1.0</div></div></div>"},"112101":{"type":"graphic_picture","displayName":"Aquagenic palmoplantar keratoderma","title":"Aquagenic palmoplantar keratoderma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Aquagenic palmoplantar keratoderma</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/112101_Aqgnc_palmoplntr_keratoderm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous white, nonscaling, smooth-surfaced, flat-topped papules on the hyperwrinkled palm following immersion of the hand in water for 10 minutes.</div><div id=\"graphicVersion\">Graphic 112101 Version 1.0</div></div></div>"},"112102":{"type":"graphic_picture","displayName":"Dyshidrotic eczema on lateral foot","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/112102_Dyshidrotic_eczema_lat_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral aspect of foot showing erythema and vesiculation, along with some mild desquamation.</div><div id=\"graphicVersion\">Graphic 112102 Version 1.0</div></div></div>"},"112103":{"type":"graphic_picture","displayName":"Darier disease papules on palm","title":"Darier disease","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Darier disease</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/112103_Darier_disease_papules_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Greasy, discrete, flat-topped, yellow-brown papules on the palm.</div><div id=\"graphicVersion\">Graphic 112103 Version 1.0</div></div></div>"},"112104":{"type":"graphic_picture","displayName":"Punctate palmoplantar keratoderma","title":"Punctate palmoplantar keratoderma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Punctate palmoplantar keratoderma</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/112104_Pnct_palmoplantr_keratoderm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous punctate hyperkeratotic papules on the sole.</div><div id=\"graphicVersion\">Graphic 112104 Version 1.0</div></div></div>"},"112105":{"type":"graphic_picture","displayName":"Nevoid basal cell carcinoma syndrome","title":"Nevoid basal cell carcinoma syndrome","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Nevoid basal cell carcinoma syndrome</div><div class=\"cntnt\"><img style=\"width:756px; height:591px;\" src=\"images/DERM/112105_Nevoid_basal_cell_CA_syndrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pit is evident in the center of the palm.</div><div id=\"graphicVersion\">Graphic 112105 Version 1.0</div></div></div>"},"112110":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis with scale","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/DERM/112110_Erythrodrm_psoriasis_scale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized erythema with overlying white scale on the trunk and upper extremities.</div><div class=\"graphic_reference\">Courtesy of Kristina Callis Duffin, MD.</div><div id=\"graphicVersion\">Graphic 112110 Version 1.0</div></div></div>"},"112111":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis with scale on extremities","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:720px; height:593px;\" src=\"images/DERM/112111_Erythr_psoriasis_scale_extr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent erythema with thick scale on the bilateral lower extremities.</div><div class=\"graphic_reference\">Courtesy of Kristina Callis Duffin, MD.</div><div id=\"graphicVersion\">Graphic 112111 Version 1.0</div></div></div>"},"112112":{"type":"graphic_picture","displayName":"Cutaneous myxoma areola","title":"Carney complex: Cutaneous myxoma","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Cutaneous myxoma</div><div class=\"cntnt\"><img style=\"width:720px; height:571px;\" src=\"images/DERM/112112_Cutaneous_myxoma_areola.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous myxoma in a patient with Carney complex presenting as a skin-colored nodule on the areola.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112112 Version 1.0</div></div></div>"},"112113":{"type":"graphic_picture","displayName":"Cutaneous myxoma eyelid","title":"Carney complex: Cutaneous myxoma","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Cutaneous myxoma</div><div class=\"cntnt\"><img style=\"width:720px; height:469px;\" src=\"images/DERM/112113_Cutaneous_myxoma_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Translucent papule on the upper eyelid margin in a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112113 Version 1.0</div></div></div>"},"112116":{"type":"graphic_table","displayName":"Medical issues of particular concern for pediatric anesthesia","title":"Medical issues of particular concern for pediatric anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical issues of particular concern for pediatric anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cardiac</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Heart murmur </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Cyanosis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Hypertension </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Exercise intolerance </li> </ul> </td> </tr> <tr> <td>Pulmonary</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Asthma/reactive airway disease (RAD) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Recent upper respiratory infection (URI) (&#60;4 weeks prior to surgery) </li> </ul> </td> </tr> <tr> <td>Hematologic</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Anemia </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Bruising, abnormal bleeding, coagulopathy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Sickle cell anemia </li> </ul> </td> </tr> <tr> <td>Neuromuscular disease including hypotonia</td> </tr> <tr> <td>Congenital abnormalities including genetic syndromes, especially those associated with anatomic craniofacial abnormalities that may predispose to difficult airway management</td> </tr> <tr> <td>Medications</td> </tr> <tr> <td>Family history including adverse reactions to anesthesia</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Malignant hyperthermia </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Prolonged paralysis or need for ventilation after anesthesia </li> </ul> </td> </tr> <tr> <td>Allergies</td> </tr> <tr> <td>Prior anesthetic experience including preoperative anxiety and compliance with anesthetic induction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112116 Version 1.0</div></div></div>"},"112117":{"type":"graphic_table","displayName":"Preoperative physical examination for pediatric anesthesia","title":"Preoperative physical examination for pediatric anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative physical examination for pediatric anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General exam</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Obesity </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Airway exam</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Mouth opening </li> <li>Thyromental distance <ul> <li>Mandibular or maxillary hypoplasia </li> </ul> </li> <li>Cervical range of motion </li> <li>Presence of loose teeth </li> <li>Large tongue (macroglossia) </li> <li>Mallampati classification <ul> <li>Young children may not cooperate to assess Mallampati </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac exam</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Murmurs </li> <li>Arrhythmias </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary exam</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Respiratory rate and depth </li> <li>Auscultation <ul> <li>Wheezes </li> <li>Rales </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Neuromuscular exam</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Strength </li> <li>Tone <ul> <li>Hypotonia </li> <li>Hypertonia </li> </ul> </li> <li>Range of motion </li> <li>Appropriate developmental milestones </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Skin</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Skin fragility or sensitivity </li> <li>Predicted ease of venous access </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112117 Version 1.0</div></div></div>"},"112119":{"type":"graphic_table","displayName":"Differences between adult and infant respiratory physiology","title":"Differences between adult and infant respiratory physiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between adult and infant respiratory physiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Adult</td> <td class=\"subtitle1\">Infant</td> </tr> <tr> <td><strong>FRC (mL/kg)</strong></td> <td class=\"centered\">27 to 30</td> <td class=\"centered\">30</td> </tr> <tr> <td><strong>TV (mL/kg)</strong></td> <td class=\"centered\">7</td> <td class=\"centered\">7</td> </tr> <tr> <td><strong>MV (mL/kg/min)</strong></td> <td class=\"centered\">60</td> <td class=\"centered\">100 to 150</td> </tr> <tr> <td><strong>RR (min<sup>&ndash;1</sup>)</strong></td> <td class=\"centered\">12 to 16</td> <td class=\"centered\">30 to 50</td> </tr> <tr> <td><strong>O<sub>2</sub> consumption (mL/kg/min)</strong></td> <td class=\"centered\">3</td> <td class=\"centered\">7 to 9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FRC: functional residual capacity; TV: tidal volume; MV: minute ventilation; RR: respiratory rate; O<sub>2</sub>: oxygen.</div><div id=\"graphicVersion\">Graphic 112119 Version 1.0</div></div></div>"},"112121":{"type":"graphic_table","displayName":"Microcuff tube size chart","title":"Microcuff tube size chart","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microcuff tube size chart</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tube size ID</td> <td class=\"subtitle1\">Age/weight/years/kg</td> </tr> <tr> <td class=\"centered\">3.0 mm</td> <td>Term &#8805;3 kg to &#60;8 months</td> </tr> <tr> <td class=\"centered\">3.5 mm</td> <td>8 months to &#60;2 years</td> </tr> <tr> <td class=\"centered\">4.0 mm</td> <td>2 to &#60;4 years</td> </tr> <tr> <td class=\"centered\">4.5 mm</td> <td>4 to &#60;6 years</td> </tr> <tr> <td class=\"centered\">5.0 mm</td> <td>6 to &#60;8 years</td> </tr> <tr> <td class=\"centered\">5.5 mm</td> <td>8 to &#60;10 years</td> </tr> <tr> <td class=\"centered\">6.0 mm</td> <td>10 to &#60;12 years</td> </tr> <tr> <td class=\"centered\">6.5 mm</td> <td>12 to &#60;14 years</td> </tr> <tr> <td class=\"centered\">7.0 mm</td> <td>14 to &#60;16 years</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This chart shows the sizes of Microcuff endotracheal tubes that are recommended by the manufacturer.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Weiss M, Gerber AC, Dullenkopf A. Appropriate placement of intubation depth marks in a new cuffed paediatric tracheal tube. Br J Anaesth 2004; 94:80.</LI>&#xD;&#xA;<LI>Kimberly-Clark Microcuff Pediatric Endotracheal Tube. Available at: http://www.na.kccustomerportal.com/documents/digitalassets/BROCHURES/RESP/Microcuff_Pediatric_pedia_h8346_final.pdf (accessed on February 28, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 112121 Version 1.0</div></div></div>"},"112122":{"type":"graphic_figure","displayName":"Illustration of robotic surgery setup","title":"Illustration of robotic surgery setup","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Illustration of robotic surgery setup</div><div class=\"cntnt\"><img style=\"width:650px; height:566px;\" src=\"images/SURG/112122_Illus_robotic_surgery_setup.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">© 2017 Intuitive Surgical, Inc. Used with permission.</div><div id=\"graphicVersion\">Graphic 112122 Version 1.0</div></div></div>"},"112123":{"type":"graphic_picture","displayName":"Cutaneous myxoma","title":"Carney complex: Cutaneous myxoma","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Cutaneous myxoma</div><div class=\"cntnt\"><img style=\"width:720px; height:480px;\" src=\"images/DERM/112123_Carney_cutaneous_myxoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous myxoma presenting as a&nbsp;domed, soft papule on the abdomen of a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112123 Version 1.0</div></div></div>"},"112124":{"type":"graphic_picture","displayName":"Cutaneous myxoma thigh","title":"Carney complex: Cutaneous myxoma","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Cutaneous myxoma</div><div class=\"cntnt\"><img style=\"width:720px; height:469px;\" src=\"images/DERM/112124_Cutaneous_myxoma_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous myxoma presenting as a translucent lobulated papule on the thigh of a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112124 Version 1.0</div></div></div>"},"112125":{"type":"graphic_picture","displayName":"Cutaneous myxoma 2","title":"Carney complex: Cutaneous myxoma","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Cutaneous myxoma</div><div class=\"cntnt\"><img style=\"width:720px; height:480px;\" src=\"images/DERM/112125_Cutaneous_myxoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous myxoma in a patient with Carney complex presenting as a skin-colored papule on the abdomen with round, translucent surface.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112125 Version 1.0</div></div></div>"},"112126":{"type":"graphic_picture","displayName":"Carney complex blue nevus","title":"Carney complex: Blue nevus","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Blue nevus</div><div class=\"cntnt\"><img style=\"width:720px; height:503px;\" src=\"images/DERM/112126_CNC_blue_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue nevus presenting as a firm, dark gray/blue papule on the back of a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112126 Version 1.0</div></div></div>"},"112127":{"type":"graphic_picture","displayName":"Carney complex blue nevus face","title":"Carney complex: Blue nevus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Carney complex: Blue nevus</div><div class=\"cntnt\"><img style=\"width:756px; height:390px;\" src=\"images/DERM/112127_CNC_blue_nevus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue nevus presenting as a dark blue papule on the face in a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112127 Version 1.0</div></div></div>"},"112129":{"type":"graphic_picture","displayName":"Carney complex genital lentigo","title":"Carney complex: Genital lentigines","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Carney complex: Genital lentigines</div><div class=\"cntnt\"><img style=\"width:493px; height:756px;\" src=\"images/DERM/112129_Carneycmplxgenitallentig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black lentiginous macule on the genital mucosa of a woman with Carney complex.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Familial Cancer. Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011; 10:481. Copyright © 2011. <A spellcheck=true href=\"https://link.springer.com/journal/10689\" target=_blank>https://link.springer.com/journal/10689</A>.</div><div id=\"graphicVersion\">Graphic 112129 Version 2.0</div></div></div>"},"112130":{"type":"graphic_picture","displayName":"Carney complex genital lentigines","title":"Carney complex: Genital lentigines","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Carney complex: Genital lentigines</div><div class=\"cntnt\"><img style=\"width:493px; height:756px;\" src=\"images/DERM/112130_Carney_cmplx_gntl_lentigine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive, gray/black lentiginous macules on the genital mucosa of a woman with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112130 Version 1.0</div></div></div>"},"112132":{"type":"graphic_picture","displayName":"Carney complex lentigo ink spot","title":"Carney complex: Lentigo","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Carney complex: Lentigo</div><div class=\"cntnt\"><img style=\"width:720px; height:478px;\" src=\"images/DERM/112132_CNC_lentigo_ink_spot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, reticulated lentiginous macule on the torso of an adolescent with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112132 Version 1.0</div></div></div>"},"112133":{"type":"graphic_table","displayName":"Medications associated with pancytopenia","title":"Some medications and other substances associated with pancytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medications and other substances associated with pancytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Examples</td> </tr> <tr class=\"divider_bottom\"> <td>Nonsteroidal anti-inflammatory drugs </td> <td> <ul> <li>Aspirin</li> <li>Diclofenac </li> <li>Ibuprofen </li> <li>Indomethacin</li> <li>Phenylbutazone*</li> <li>Salicylates</li> <li>Sulindac </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Anti-gout</td> <td> <ul> <li>Allopurinol </li> <li>Colchicine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antimicrobials (including antiviral, antihelmintic, and antimalarial)</td> <td> <ul> <li>Albendazole </li> <li>Chloramphenicol<sup>&#182;</sup> </li> <li>Cidofovir </li> <li>Dapsone </li> <li>Foscarnet </li> <li>Ganciclovir </li> <li>Linezolid<sup>&#916;</sup> </li> <li>Quinidine </li> <li>Quinine </li> <li>Sulfonamides (eg, sulfamethoxazole, sulfisoxazole) </li> <li>Zidovudine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Anti-epileptics</td> <td> <ul> <li>Carbamazepine </li> <li>Fosphenytoin </li> <li>Felbamate </li> <li>Levetiracetam </li> <li>Phenytoin </li> <li>Phenobarbital </li> <li>Valproate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Anti-thyroid</td> <td> <ul> <li>Methimazole </li> <li>Propylthiouracil </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cardiovascular (also refer to diuretics)</td> <td> <ul> <li>Aspirin </li> <li>Amiodarone </li> <li>Captopril </li> <li>Lisinopril </li> <li>Nifedipine </li> <li>Quinidine </li> <li>Ticlopidine* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Chelating</td> <td> <ul> <li>Penicillamine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Diuretics</td> <td> <ul> <li>Acetazolamide </li> <li>Furosemide </li> <li>Thiazides </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Endocrine</td> <td> <ul> <li>Refer to anti-thyroid above </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Immunosuppressant (anti-rejection therapy in solid organ transplantation)</td> <td> <ul> <li>Azathioprine<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Gastrointestinal (acid suppression)</td> <td> <ul> <li>Cimetidine </li> <li>Nizatidine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Gastrointestinal (inflammatory bowel disease)</td> <td> <ul> <li>Azathioprine<sup>&#9674;</sup> </li> <li>Mercaptopurine<sup>&#9674;</sup> </li> <li>Mesalamine </li> <li>Sulfasalazine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Psychiatric</td> <td> <ul> <li>Bupropion </li> <li>Carbamazepine </li> <li>Lithium </li> <li>Valproate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Rheumatologic (also refer to anti-gout)</td> <td> <ul> <li>Azathioprine<sup>&#9674;</sup> </li> <li>Gold sodium thiomalate and other gold salts* </li> <li>Leflunomide </li> <li>Methotrexate </li> <li>Penicillamine </li> <li>Sulfasalazine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Travel medicine (altitude sickness)</td> <td> <ul> <li>Acetazolamide </li> </ul> </td> </tr> <tr> <td>Other exposures</td> <td> <ul> <li>Benzene </li> <li>MDMA (ecstasy) </li> <li>Glue vapors </li> <li>Pesticides </li> <li>Radiation </li> <li>Solvents, organic </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table does not report all medications that have been associated with pancytopenia. In some cases, the report of an association between a medication and cytopenias does not prove causality. Refer to accompanying text for details.<br />Directly cytotoxic chemotherapeutic agents are omitted from this list, as myelosuppression is an anticipated effect. However, immune-mediated pancytopenia has been rarely associated with some directly cytotoxic agents (eg, platinum-based chemotherapy).</div><div class=\"graphic_footnotes\">* Not available in the United States; may have limited availability in other countries.<br />¶ Dose-related reversible bone-marrow suppression is frequently seen with use of chloramphenicol. A rare, non-dose-related form of severe and often fatal aplastic anemia can also occur in about 1 in 20,000 treated patients; as a result, use of chloramphenicol is restricted in many countries. Systemic absorption from ophthalmic use can reportedly occur, but the incidence of serious hematologic toxicity appears to be very low.<br />Δ Risk factors for linezolid-induced myelosuppression include renal impairment, low baseline blood cell counts, and duration of therapy &gt;14 days.<br /><FONT class=lozenge>◊</FONT> Azathioprine is a prodrug of mercaptopurine, and both have been associated with aplastic anemia in patients with very low or absent thiopurine methyltransferase (TPMT) enzyme activity. Refer to the UpToDate clinical review of 6-mercaptopurine metabolite monitoring and TPMT testing for additional details.</div><div id=\"graphicVersion\">Graphic 112133 Version 4.0</div></div></div>"},"112134":{"type":"graphic_table","displayName":"Causes of pancytopenia","title":"Causes of pancytopenia (organized by mechanism*)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pancytopenia (organized by mechanism*)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Bone marrow infiltration/replacement <ul> <li>Malignant <ul> <li>Acute leukemias </li> <li>Chronic leukemias/myeloproliferative neoplasms (MPN) </li> <li>Myelodysplastic syndromes (MDS) </li> <li>Multiple myeloma </li> <li>Metastatic cancer </li> </ul> </li> <li>Non-malignant <ul> <li>Myelofibrosis </li> <li>Infectious (eg, fungal, tuberculous) </li> <li>Storage diseases </li> </ul> </li> </ul> </li> <li>Bone marrow failure <ul> <li>Immune destruction/suppression <ul> <li>Aplastic anemia/paroxysmal nocturnal hemoglobinuria </li> <li>Medications<sup>&#182;</sup> <ul> <li>Cytotoxic drugs </li> <li>Idiosyncratic reactions to medications </li> </ul> </li> <li>Large granular lymphocyte leukemia </li> <li>Autoimmune disorders (eg, systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], sarcoidosis) </li> <li>Hemophagocytic lymphohistiocytosis (HLH) </li> </ul> </li> <li>Nutritional <ul> <li>Megaloblastic (vitamin B12, folate) </li> <li>Excessive alcohol </li> <li>Other (eg, copper deficiency, zinc toxicity) </li> <li>Malnutrition/anorexia nervosa with gelatinous degeneration </li> </ul> </li> <li>Marrow suppression <ul> <li>Viral infection (eg, HIV, hepatitis, Epstein-Barr virus [EBV]) </li> </ul> </li> <li>Ineffective hematopoiesis (eg, MDS, nutritional) </li> </ul> </li> <li>Destruction/sequestration/redistribution <ul> <li>Consumption <ul> <li>Disseminated intravascular coagulation (eg, associated with sepsis, acute promyelocytic leukemia)&nbsp; </li> </ul> </li> <li>Splenomegaly <ul> <li>Portal hypertension/cirrhosis </li> <li>Infections (eg, EBV) </li> <li>Autoimmune disorders (eg, SLE, RA/Felty syndrome) </li> <li>Malignancies (eg, lymphomas, MPN) </li> <li>Myelofibrosis with myeloid metaplasia </li> <li>Storage diseases (eg, Gaucher) </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Wiskott Aldrich syndrome </li> <li>Fanconi anemia </li> <li>Dyskeratosis congenital/telomere biology disorders </li> <li>Shwachman-Diamond syndrome </li> <li>GATA2 deficiency </li> <li>Hemophagocytic lymphohistiocytosis (HLH) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Note that some disorders are included in more than one category, as they may cause cytopenias by multiple mechanisms (eg, lymphomas may be associated with bone marrow failure due to marrow replacement, increased sequestration due to splenomegaly, and immune destruction).<br />¶ Refer to accompanying table of drugs associated with cytopenias.</div><div id=\"graphicVersion\">Graphic 112134 Version 4.0</div></div></div>"},"112135":{"type":"graphic_table","displayName":"Emergencies associated with pancytopenia","title":"Emergencies associated with pancytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergencies associated with pancytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Neutropenia (new diagnosis or associated with fever/infection) </li> <li>Symptomatic anemia (eg, cardiac ischemia, hemodynamic instability, worsening congestive heart failure) </li> <li>Thrombocytopenia (platelets &#60;10,000/microL, or &#60;50,000/microL associated with bleeding)</li> <li>Disseminated intravascular coagulation</li> <li>Abnormal peripheral blood smear (eg, microangiopathy, blasts) </li> <li>Severe aplastic anemia </li> <li>Hemophagocytic lymphohistiocytosis </li> <li>Metabolic emergencies (eg, symptomatic hypercalcemia, hyperkalemia, tumor lysis syndrome) </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112135 Version 2.0</div></div></div>"},"112136":{"type":"graphic_picture","displayName":"Subcutaneous fat necrosis newborn 2","title":"Subcutaneous fat necrosis of the newborn","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Subcutaneous fat necrosis of the newborn</div><div class=\"cntnt\"><img style=\"width:602px; height:563px;\" src=\"images/DERM/112136_Subctns_fat_ncrss_newborn2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodules and plaques on the back of a term newborn.</div><div class=\"graphic_reference\">Courtesy of Moise Levy, MD.</div><div id=\"graphicVersion\">Graphic 112136 Version 1.0</div></div></div>"},"112139":{"type":"graphic_picture","displayName":"Restrictive dermopathy 2","title":"Restrictive dermopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Restrictive dermopathy</div><div class=\"cntnt\"><img style=\"width:387px; height:756px;\" src=\"images/DERM/112139_Restrictive_dermopathy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hard, adherent, and shiny skin in a premature neonate with restrictive dermopathy.</div><div class=\"graphic_reference\">Courtesy of Moise Levy, MD.</div><div id=\"graphicVersion\">Graphic 112139 Version 1.0</div></div></div>"},"112158":{"type":"graphic_table","displayName":"ABCDE communication tool","title":"ABCDE communication tool for handoffs of trauma patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ABCDE communication tool for handoffs of trauma patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Airway</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Airway plan (intubated [yes/no, any difficulty], intubate in trauma bay, intubate in OR) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Breathing</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Oxygenation (nasal cannula, face mask, FiO<sub>2</sub>) </li> <li>Ventilator settings (if not 'standard') </li> <li>Pulmonary injuries </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Circulation</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Hemodynamic status </li> <li>Access (number of&nbsp;peripheral IVs, trauma line) </li> <li>Blood given/availability </li> <li>Uncrossmatched blood (to come with patient?) </li> <li>Crossmatch (underway?) </li> <li>Exsanguination protocol or cell saver activated? </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Disability/drugs</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>C-spine status/neurologic injuries </li> <li>All known (or suspected) injuries </li> <li>Medications (drugs) received in ED </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Extremity/exposure/everything else</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Patient name and medical record&nbsp;number </li> <li>Procedure(s) </li> <li>Operating room number </li> <li>Exchange contact information (name and number)&nbsp;of surgery and anesthesiology providers for ongoing communication&nbsp; </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OR: operating room; FiO<sub>2</sub>: fraction of inspired oxygen; ED: emergency department.</div><div class=\"graphic_reference\">Source: The ABCDE Communication Tool was developed by Maureen McCunn, MD, MIPP, University of Maryland, Department of Anesthesiology and Critical Care.</div><div id=\"graphicVersion\">Graphic 112158 Version 2.0</div></div></div>"},"112159":{"type":"graphic_table","displayName":"A checklist for trauma and emergency anesthesia","title":"A checklist for trauma and emergency anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A checklist for trauma and emergency anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Before patient arrival</td> </tr> <tr class=\"divider_bottom\"> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Room temperature 25&#176;C or higher </li> <li><span class=\"primarybox_left\">&nbsp;</span>Warm IV line available </li> <li><span class=\"primarybox_left\">&nbsp;</span>Machine checked </li> <li><span class=\"primarybox_left\">&nbsp;</span>Airway equipment ready </li> <li><span class=\"primarybox_left\">&nbsp;</span>Emergency medications drawn </li> <li><span class=\"primarybox_left\">&nbsp;</span>Blood bank called to order: <ul class=\"decimal_heading\"> <li>6 units of type O negative PRBC </li> <li>6 units of type AB FFP </li> <li>6 units (ie, one \"6-pack\") of platelets (any blood type) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Patient arrival</td> </tr> <tr class=\"divider_bottom\"> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Patient correctly identified (ie, site/side) for emergency surgery </li> <li><span class=\"primarybox_left\">&nbsp;</span>Blood bank called <ul class=\"decimal_heading\"> <li>Send blood for&nbsp;immediate type and cross </li> <li>Initiate institutional massive transfusion protocol </li> </ul> </li> <li><span class=\"primarybox_left\">&nbsp;</span>Establish IV access </li> <li><span class=\"primarybox_left\">&nbsp;</span>Monitors (ECG, SpO<sub>2</sub>, blood pressure) </li> <li><span class=\"primarybox_left\">&nbsp;</span>Pre-oxygenation </li> <li><span class=\"primarybox_left\">&nbsp;</span>Instruct surgeon to \"prep and drape\" </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Induction</td> </tr> <tr class=\"divider_bottom\"> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Sedative hypnotic (ie, propofol versus ketamine versus etomidate) + neuromuscular blocking agent </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Intubation</td> </tr> <tr class=\"divider_bottom\"> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Once ETCO<sub>2</sub> confirmed, surgeon to make incision </li> <li><span class=\"primarybox_left\">&nbsp;</span>Place orogastric tube </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Anesthetic</td> </tr> <tr class=\"divider_bottom\"> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Volatile and/or benzodiazepine (ie, midazolam) + opioid (ie, fentanyl) </li> <li><span class=\"primarybox_left\">&nbsp;</span>Consider TIVA </li> <li><span class=\"primarybox_left\">&nbsp;</span>Insert additional IV line and/or arterial catheter </li> <li><span class=\"primarybox_left\">&nbsp;</span>Administer appropriate antibiotics </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Resuscitation</td> </tr> <tr class=\"divider_bottom\"> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Send baseline labs (ie, lactate, CBC, chem-7, coagulation panel, thromboelastogram/ROTEM) </li> <li><span class=\"primarybox_left\">&nbsp;</span>Follow MAP trend </li> <li><span class=\"primarybox_left\">&nbsp;</span>Consider hypotensive resuscitation (ie, MAP goal &#62;50/SBP goal &#62;90 mmHg) </li> <li><span class=\"primarybox_left\">&nbsp;</span>Consider early FFP; use 1:1:1 (PRBC:FFP:platelets) ratio for blood product administration </li> <li><span class=\"primarybox_left\">&nbsp;</span>Goal urine output: 0.5 to 1.0 mL/kg/hr </li> <li><span class=\"primarybox_left\">&nbsp;</span>Consider tranexemic acid <ul class=\"decimal_heading\"> <li>Maximal benefit if given &#60;3 hours from injury </li> <li>Initial dose: 1 g over 10 minutes </li> <li>Second dose: 1 g over 8 hours </li> </ul> </li> <li><span class=\"primarybox_left\">&nbsp;</span>Consider calcium chloride 1 g IV </li> <li><span class=\"primarybox_left\">&nbsp;</span>Consider hydrocortisone 100 mg </li> <li><span class=\"primarybox_left\">&nbsp;</span>Goals for concurrent traumatic brain injury: <ul class=\"decimal_heading\"> <li>SBP &#62;100 mmHg </li> <li>SPO<sub>2</sub> &#62;90% </li> <li>pCO<sub>2</sub> 35 to 45 mmHg </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Closing/post-op</td> </tr> <tr> <td> <ul style=\"list-style-type: none;\"> <li><span class=\"primarybox_left\">&nbsp;</span>Contact ICU for a bed/sign-out to ICU team </li> <li><span class=\"primarybox_left\">&nbsp;</span>Initiate lung-protective ventilation (tidal volume = 6 to 8 mL/kg predicted body weight) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; PRBC: packed red blood cells; FFP: fresh frozen plasma; STAT: immediately; ECG: electrocardiogram; SpO<SUB>2</SUB>: peripheral oxygen saturation; ETCO<SUB>2</SUB>: end-tidal carbon dioxide; TIVA: total intravenous anesthetic; CBC: complete blood count; ROTEM: rotational thromboelastometry; MAP: mean arterial pressure; SBP: systolic blood pressure; pCO<SUB>2</SUB>: partial pressure of carbon dioxide; ICU: intensive care unit.</div><div class=\"graphic_reference\">Adapted from: Tobin JM, Grabinsky A, McCunn M, et al. A checklist for trauma and emergency anesthesia. Anesth Analg 2013; 117:1178.</div><div id=\"graphicVersion\">Graphic 112159 Version 1.0</div></div></div>"},"112164":{"type":"graphic_picture","displayName":"MGRS lesions with organized deposits","title":"MGRS lesions with organized deposits","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">MGRS lesions with organized deposits</div><div class=\"cntnt\"><img style=\"width:766px; height:537px;\" src=\"images/NEPH/112164_MGRS_lesions_org_deposits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Randomly arranged solid fibrillar deposits (diameter of 8 to 12 nm) in AL amyloidosis.<br />(B) Microtubular deposits (diameter of 17 to 52 nm), characterized by their hollow center, in immunotactoid glomerulopathy. They are commonly arranged in parallel arrays.<br />(C) Intracellular needle and rhomboid-shaped crystalline inclusions in light chain proximal tubulopathy.</div><div class=\"graphic_footnotes\">MGRS: monoclonal gammopathy of renal significance; AL: immunoglobulin light chain.</div><div class=\"graphic_reference\">Courtesy of Samih H Nasr, MD, College of Medicine, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 112164 Version 2.0</div></div></div>"},"112171":{"type":"graphic_table","displayName":"Recommended first-line therapies for H pylori infection","title":"Recommended first-line therapies for <em>H pylori</em> infection (American College of Gastroenterology)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended first-line therapies for <em>H pylori</em> infection (American College of Gastroenterology)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Drugs (doses)</td> <td class=\"subtitle1\">Dosing frequency</td> <td class=\"subtitle1\">Duration (days)</td> <td class=\"subtitle1\">FDA approval</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Clarithromycin triple</td> <td>PPI (standard* or double dose)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"3\">14</td> <td class=\"divider_bottom centered\" rowspan=\"3\">Yes<sup>&#182;</sup></td> </tr> <tr> <td>Clarithromycin (500 mg)</td> <td>Twice daily</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin (1 gram)<br /> <strong>or</strong><br /> Metronidazole (500 mg)</td> <td> <p>Twice daily (amoxicillin)<br /> Three times daily (metronidazole)</p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Bismuth quadruple</td> <td>PPI (standard dose*)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"5\">10 to 14<sup>&#916;</sup></td> <td class=\"divider_bottom centered\" rowspan=\"5\">No<sup><sup>&#9674; </sup></sup></td> </tr> <tr> <td>Bismuth subcitrate (120 to 300 mg [not available in US] or 420 mg [available in North America and elsewhere as part of Pylera combination pill])<sup>[1]</sup><br /> <strong>or</strong><br /> Bismuth subsalicylate (300 or 524 mg)<sup>[1]</sup></td> <td>Four times daily</td> </tr> <tr> <td>Tetracycline (500 mg)</td> <td>Four times daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Metronidazole (250 to 500 mg)</td> <td>Four times daily (250 mg)</td> </tr> <tr class=\"divider_bottom\"> <td>Three to four times daily (500 mg)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Clarithromycin-based concomitant</td> <td>PPI (standard dose*)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"4\">10 to 14</td> <td class=\"divider_bottom centered\" rowspan=\"4\">No</td> </tr> <tr> <td>Clarithromycin (500 mg)</td> <td>Twice daily</td> </tr> <tr> <td>Amoxicillin (1 gram)</td> <td>Twice daily</td> </tr> <tr class=\"divider_bottom\"> <td>Metronidazole or tinidazole (500 mg)</td> <td>Twice daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Clarithromycin-based sequential</td> <td>PPI (standard dose*) plus amoxicillin (1 gram) for 5 days followed by:</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"2\">10 (total)</td> <td class=\"divider_bottom centered\" rowspan=\"2\">No</td> </tr> <tr class=\"divider_bottom\"> <td>PPI, clarithromycin (500 mg) plus either metronidazole or tinidazole (500 mg) for an additional 5 days</td> <td>Twice daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Clarithromycin-based hybrid</td> <td>PPI (standard dose*) plus amoxicillin (1 gram) for 7 days followed by:</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"2\">14 (total)</td> <td class=\"divider_bottom centered\" rowspan=\"2\">No</td> </tr> <tr class=\"divider_bottom\"> <td>PPI, amoxicillin, clarithromycin (500 mg), plus either metronidazole or tinidazole (500 mg) for an additional 7 days</td> <td>Twice daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: United States Food and Drug Administration; PPI: proton pump inhibitor.<br />* Standard dosing of orally administered proton pump inhibitors include: Lansoprazole 30 mg twice daily, omeprazole 20 mg twice daily, pantoprazole 40 mg twice daily, rabeprazole 20 mg twice daily, or esomeprazole 20 mg twice daily or 40 mg once daily.<br />¶ Several PPI, clarithromycin, and amoxicillin combinations have achieved FDA approval. PPI, clarithromycin, and metronidazole is not an FDA-approved treatment regimen.<br />Δ 14 days is&nbsp;recommended. Refer to UpToDate&nbsp;topic on treatment for H pylori infection. <br />◊ PPI, bismuth, tetracycline, and metronidazole prescribed separately is not an FDA-approved treatment regimen. However, Pylera, a combination product containing bismuth subcitrate, tetracycline, and metronidazole combined with a PPI for 10 days is an FDA-approved treatment regimen.</div><div class=\"graphic_reference\">Reference: <br />1. Fallone CA, Chiba N, Van Zanteri et al. The Toronto Consensus for Treatment of Helicobacter pylori infection in Adults. Gastro 2016; 15:51.<br /><br />Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212. Copyright © 2017. <A href=\"http://www.nature.com/ajg\" target=_blank>www.nature.com/ajg</A>.</div><div id=\"graphicVersion\">Graphic 112171 Version 2.0</div></div></div>"},"112172":{"type":"graphic_table","displayName":"Salvage therapies for H pylori infection","title":"Salvage therapies for <EM>H. pylori</EM> infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Salvage therapies for <EM>H. pylori</EM> infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Drugs (doses)*</td> <td class=\"subtitle1\">Dosing frequency</td> <td class=\"subtitle1\">Duration (days)</td> <td class=\"subtitle1\">FDA approval</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Bismuth quadruple</td> <td>PPI (standard dose<sup>&#182;</sup>)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"4\">14</td> <td class=\"divider_bottom centered\" rowspan=\"4\">No<sup>&#916;</sup></td> </tr> <tr> <td>Bismuth subcitrate (120 to 300 mg [not available in US] or 420 mg [available in North America and elsewhere as part of Pylera combination pill])<sup>[1]</sup><br /> <strong>or</strong><br /> Bismuth subsalicylate (300 or 524 mg)<sup>[1]</sup></td> <td>Four times daily</td> </tr> <tr> <td>Tetracycline (500 mg)</td> <td>Four times daily</td> </tr> <tr class=\"divider_bottom\"> <td>Metronidazole (250 to 500 mg)</td> <td>Three to four times daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Levofloxacin triple</td> <td>PPI (standard dose<sup>&#182;</sup>)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"3\">14</td> <td class=\"divider_bottom centered\" rowspan=\"3\">No</td> </tr> <tr> <td>Levofloxacin (500 mg)</td> <td>Once daily</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin (1 gram)</td> <td>Twice daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Concomitant</td> <td>PPI (standard dose<sup>&#182;</sup>)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"4\">10 to 14</td> <td class=\"divider_bottom centered\" rowspan=\"4\">No</td> </tr> <tr> <td>Clarithromycin (500 mg)</td> <td>Twice daily</td> </tr> <tr> <td>Amoxicillin (1 gram)</td> <td>Twice daily</td> </tr> <tr class=\"divider_bottom\"> <td>Metronidazole or tinidazole (500 mg)</td> <td>Two or three times daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Rifabutin triple<sup>&#9674;</sup></td> <td>PPI (standard dose<sup>&#182;</sup>)</td> <td>Twice daily</td> <td class=\"divider_bottom centered\" rowspan=\"3\">10</td> <td class=\"divider_bottom centered\" rowspan=\"3\">No</td> </tr> <tr> <td>Rifabutin (300 mg)</td> <td>Once daily</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin (1 gram)</td> <td>Twice daily</td> </tr> <tr> <td rowspan=\"2\">High-dose dual</td> <td>PPI (standard to double dose<sup>&#182;</sup>)</td> <td>Three to four times daily</td> <td class=\"centered\" rowspan=\"2\">14</td> <td class=\"centered\" rowspan=\"2\">No</td> </tr> <tr> <td>Amoxicillin (1 gram three times daily or 750 mg four times daily)</td> <td>Three to four times daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: United States Food and Drug Administration; PPI: proton pump inhibitor.<br />* Doses are for adults with normal renal function. Dose adjustment is warranted in patients with renal impairment for certain antibiotics (eg, levofloxacin, rifabutin, clarithromycin if end-stage disease).<br />&para; Standard dosing of orally administered proton pump inhibitors include: Lansoprazole 30 mg twice daily, omeprazole 20 mg twice daily, pantoprazole 40 mg twice daily, rabeprazole 20 mg twice daily, or esomeprazole 20 mg twice daily or 40 mg once daily.<br />&Delta; PPI, bismuth, tetracycline, and metronidazole prescribed separately is not an FDA-approved treatment regimen. However, Pylera, a combination product containing bismuth subcitrate, tetracycline, and metronidazole combined with a PPI for 10 days is an FDA-approved treatment regimen.<br /><span class=\"lozenge\">&loz;</span> Rifabutin-containing regimens should be reserved for patients with &ge;3 previous eradication failures.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastro 2016; 151:51.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212. Copyright &copy; 2017. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 112172 Version 2.0</div></div></div>"},"112175":{"type":"graphic_table","displayName":"Approaches to conversations about lowering sodium intake","title":"Approaches to provider-patient conversations about lowering sodium intake","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approaches to provider-patient conversations about lowering sodium intake</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Strategies for sodium reduction that can be communicated quickly to patients</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Make reading food labels a habit </li> <li>Stick to fresh foods (eg, meats, fruits, and vegetables) rather than their packaged counterparts </li> <li>Avoid spices and seasonings that contain added sodium </li> <li>Check restaurant websites before dining out; request that your food be prepared without any added salt </li> <li>In 6 to 8 weeks, one can adjust to eating less salt </li> <li>Cook rice, pasta, and hot cereals without salt </li> <li>Choose ready-to-eat breakfast cereals that are lower in sodium </li> <li>Choose \"convenience\" foods that are lower in sodium </li> <li>Rinse canned foods to remove some sodium </li> <li>When available, buy low-sodium, reduced-sodium, or no-sodium versions of foods </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Features of an effective counseling session</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Assess readiness for change </li> <li>Discuss importance of reduced sodium intake </li> <li>Discuss overall concept of DASH diet and give tips for successful adoption </li> <li>Assess patient barriers to adherence, and give tips for better adherence </li> <li>Set goal(s) </li> <li>Distribute written material </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Tools needed for an effective counseling session</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assessment of readiness for change </li> <li>Attitude that sodium reduction is possible </li> <li>Assessment for barriers to eating well </li> <li>Assessment for literacy and numeracy </li> <li>Sample food label </li> <li>Written material </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DASH: Dietary Approaches to Stop Hypertension.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Current Treatment Options in Cardiovascular Medicine. Cobb LK, Appel LJ, Anderson CA. Strategies to reduce dietary sodium intake. Curr Treat Options Cardiovasc Med 2012; 14:425. Copyright © 2012. <A spellcheck=true href=\"https://link.springer.com/journal/11936\" target=_blank>https://link.springer.com/journal/11936</A>.</div><div id=\"graphicVersion\">Graphic 112175 Version 2.0</div></div></div>"},"112177":{"type":"graphic_table","displayName":"Mean BP reductions from sodium reduction in various groups","title":"Mean BP reductions from sodium reduction in African Americans and non-African Americans with prehypertension and hypertension and in patients with medication-resistant hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mean BP reductions from sodium reduction in African Americans and non-African Americans with prehypertension and hypertension and in patients with medication-resistant hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">African American:<br /> Prehypertension</td> <td class=\"subtitle1\">Non-African American:<br /> Prehypertension</td> <td class=\"subtitle1\">African American:<br /> Hypertension</td> <td class=\"subtitle1\">Non-African American:<br /> Hypertension</td> <td class=\"subtitle1\">Resistant hypertension</td> </tr> <tr> <td><strong>SBP reduction (mmHg)</strong></td> <td class=\"centered\">&ndash;6.9</td> <td class=\"centered\">&ndash;4.0</td> <td class=\"centered\">&ndash;9.4</td> <td class=\"centered\">&ndash;6.8</td> <td class=\"centered\">&ndash;22.7</td> </tr> <tr> <td><strong>DBP reduction (mmHg)</strong></td> <td class=\"centered\">&ndash;4.0</td> <td class=\"centered\">&ndash;1.4</td> <td class=\"centered\">&ndash;5.2</td> <td class=\"centered\">&ndash;3.3</td> <td class=\"centered\">&ndash;9.1</td> </tr> <tr> <td><strong>Mg of sodium reduction</strong></td> <td class=\"centered\">&ndash;1800</td> <td class=\"centered\">&ndash;1800</td> <td class=\"centered\">&ndash;1800</td> <td class=\"centered\">&ndash;1800</td> <td class=\"centered\">&ndash;2300</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Results are from two controlled feeding trials.</div><div class=\"graphic_footnotes\">BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bray GA, Vollmer WM, Sacks FM, et al. A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: Results of the DASH-Sodium Trial. Am J Cardiol 2004; 94:222.</LI>&#xD;&#xA;<LI>Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial. Hypertension 2009; 54:475.</LI></OL></div><div id=\"graphicVersion\">Graphic 112177 Version 1.0</div></div></div>"},"112185":{"type":"graphic_picture","displayName":"Airway setup for endoscopy","title":"Airway setup for endoscopy","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Airway setup for endoscopy</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/ANEST/112185_Airway_setup_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows one option for airway management for gastrointestinal endoscopy, in this case for endoscopic retrograde cholangiopancreatography (ERCP). A nasal trumpet is connected to a Mapleson C breathing circuit using an endotracheal tube connector. For further details, refer to UpToDate topics on anesthesia for gastrointestinal endoscopy.</div><div id=\"graphicVersion\">Graphic 112185 Version 1.0</div></div></div>"},"112186":{"type":"graphic_picture","displayName":"Mapleson C circuit","title":"Mapleson C circuit for endoscopy","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Mapleson C circuit for endoscopy</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/ANEST/112186_Mapleson_C_circuit_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows one option for airway management and ventilation for gastrointestinal endoscopy, in this case endoscopic retrograde cholangiopancreatography (ERCP). A nasal trumpet is connected to a Mapleson C breathing circuit using an endotracheal tube connector. The Mapleson C circuit is widely available and allows ventilation with a breathing bag without the need for an anesthesia machine. For further details, refer to UpToDate topics on anesthesia for gastrointestinal endoscopy.</div><div id=\"graphicVersion\">Graphic 112186 Version 1.0</div></div></div>"},"112187":{"type":"graphic_figure","displayName":"Mean sodium intake in US by age and sex: NHANES data 2011-2012","title":"Mean sodium intake (mg per day) in the United States, by age group and sex: NHANES data 2011-2012","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Mean sodium intake (mg per day) in the United States, by age group and sex: NHANES data 2011-2012</div><div class=\"cntnt\"><img style=\"width:694px; height:370px;\" src=\"images/NEPH/112187_SodiumintkUSagesex1112.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NHANES: National Health and Nutrition Examination Survey.<br />* Recommended upper limit of intake for adults.<br />¶ Recommended intake for blacks, hypertensives, and middle- and older-aged adults.<br />Δ Minimum physiologic need.</div><div class=\"graphic_reference\">Data from: U.S. Department of Agriculture, Agricultural Research Service. 2014. Nutrient Intakes from Food and Beverages: Mean Amounts Consumed per Individual, by Gender and Age, What We Eat in America, NHANES 2011-2012. Available at: <A spellcheck=true href=\"https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/1112/Table_1_NIN_GEN_11.pdf\" target=_blank>https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/1112/Table_1_NIN_GEN_11.pdf </A>(Accessed on March 14, 2018).</div><div id=\"graphicVersion\">Graphic 112187 Version 2.0</div></div></div>"},"112190":{"type":"graphic_figure","displayName":"Overall survival metastatic choroidal and ciliary body CA","title":"Observed melanoma-related overall Kaplan-Meier survival rates metastatic primary choroidal and ciliary body melanomas","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Observed melanoma-related overall Kaplan-Meier survival rates metastatic primary choroidal and ciliary body melanomas</div><div class=\"cntnt\"><img style=\"width:690px; height:588px;\" src=\"images/ONC/112190_MetastchoroidalciliaryCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Observed melanoma-related overall Kaplan-Meier survival rates for metastatic primary choroidal and ciliary body melanomas.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 112190 Version 2.0</div></div></div>"},"112194":{"type":"graphic_table","displayName":"Assessment of response in HCL","title":"Assessment of response in hairy cell leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of response in hairy cell leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Criteria for response</td> </tr> <tr> <td>Timing of response assessment</td> <td>The bone marrow examination for evaluating response in patients treated with cladribine should not be done before four to six months after therapy. In those patients being treated with pentostatin, the bone marrow can be evaluated after the blood counts have nearly normalized and the physical examination shows no splenomegaly.</td> </tr> <tr> <td>Complete response (CR)</td> <td>Near normalization of peripheral blood counts: hemoglobin &#62;11 g/dL (without transfusion); platelets &#62;100,000/microL; absolute neutrophil count &#62;1500/microL. Regression of splenomegaly on physical examination. Absence of morphologic evidence of HCL on both the peripheral blood smear and the bone marrow examination.</td> </tr> <tr> <td>CR with or without MRD</td> <td>In patients who achieved a CR, an immunohistochemical assessment of the percentage of MRD will enable patients to be separated into those with CR with or without evidence of MRD.</td> </tr> <tr> <td>Partial response (PR)</td> <td>A PR requires near normalization of the peripheral blood count (as in CR) with a minimum of 50% improvement in organomegaly and bone marrow biopsy infiltration with HCL.</td> </tr> <tr> <td>Stable disease (SD)</td> <td>Patients who have not met the criteria for an objective remission after therapy are considered to have SD. Because patients with HCL are treated for specific reasons, including disease-related symptoms or decline in their hematologic parameters, SD is not an acceptable response.</td> </tr> <tr> <td>Progressive disease (PD)</td> <td>Patients who have an increase in symptoms related to disease, a 25% increase in organomegaly, or a 25% decline in their hematologic parameters qualify for PD. An effort must be made to differentiate a decline in blood counts related to myelosuppression effects of therapy versus PD.</td> </tr> <tr> <td>HCL in relapse</td> <td>Morphologic relapse is defined as the reappearance of HCL in the peripheral blood, the bone marrow biopsy, or both by morphologic stains in the absence of hematologic relapse. Hematologic relapse is defined as reappearance of cytopenia(s) below the thresholds defined above for CR and PR. Whereas no treatment is necessarily needed in case of morphologic relapse, treatment decisions for a hematologic relapse are based upon several parameters (eg, hematologic parameters warranting intervention, reoccurrence of disease-related symptoms).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCL: hairy cell leukemia;&nbsp;MRD: minimal residual disease.</div><div class=\"graphic_reference\">This research was originally published in Blood. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017; 129:553. Copyright &copy; 2017 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 112194 Version 3.0</div></div></div>"},"112196":{"type":"graphic_table","displayName":"Pediatric firearm injury prevention anticipatory guidance","title":"Pediatric firearm injury prevention anticipatory guidance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric firearm injury prevention anticipatory guidance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Visit</td> <td class=\"subtitle1\">Anticipatory guidance for parents</td> <td class=\"subtitle1\">Background, rationale</td> </tr> <tr class=\"divider_bottom\"> <td>All ages</td> <td>The best way to keep your child safe from injury or death from guns is never to have a gun in the home.<br /> <br /> If it is necessary to keep a gun in your home, or if the people you visit have guns: <ul class=\"decimal_heading\"> <li>The guns should be stored unloaded and locked. </li> <li>The ammunition should be locked away separately from the gun. </li> <li>The keys should be kept where children cannot have access. </li> </ul> </td> <td>A gun kept in the home: <ul class=\"decimal_heading\"> <li>Increases the risk of homicide or completed suicide. </li> <li>Is more likely to kill or injure someone known to the family than to kill or injure an intruder. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>9 months through 2 years</td> <td>As above for all ages.</td> <td>Many young children are unintentionally killed or injured by guns each year; most are injured by a sibling, a friend, or themselves.</td> </tr> <tr class=\"divider_bottom\"> <td>3 through 4 years</td> <td>As above for all ages, plus: <ul class=\"decimal_heading\"> <li>Encourage parents to ask if there are guns in the homes where their child plays. </li> </ul> </td> <td>Children this age are naturally curious and will get into everything. They do not understand the consequences of firing a weapon.<br /> <br /> Loaded guns, like other safety hazards (eg, medications, cleaning solutions, etc) should be kept out of the reach of children.</td> </tr> <tr class=\"divider_bottom\"> <td>5 through 6 years</td> <td>As above for all ages, plus: <ul class=\"decimal_heading\"> <li>Encourage parents to ask if there are guns in the homes where their child plays. </li> </ul> </td> <td>Children this age lack the maturity or cognitive capacity to reliably follow advice concerning guns.<br /> <br /> They do not understand how dangerous guns can be even if they have been warned by adults and demonstrate that they understand that they should not touch guns, should get away from guns, and should tell an adult.</td> </tr> <tr class=\"divider_bottom\"> <td>7 through 8 years</td> <td>As above for all ages, plus: <ul class=\"decimal_heading\"> <li>Encourage parents to ask if there are guns in the homes where their child plays. </li> </ul> <br /> Ask the child: <ul class=\"decimal_heading\"> <li>\"What would you do if you saw a gun?\" </li> </ul> </td> <td>Children this age lack the maturity or cognitive capacity to reliably follow advice concerning guns.<br /> <br /> Given the potential serious consequences of gun injury, children this age cannot be relied upon to avoid handling a weapon.<br /> <br /> There is evidence that programs designed to teach children to avoid contact with guns are not effective in overcoming the child's innate curiosity and social pressure to handle guns.</td> </tr> <tr class=\"divider_bottom\"> <td>9 through 10 years</td> <td>As above for all ages, plus: <ul class=\"decimal_heading\"> <li>Encourage parents to ask if there are guns in the homes where their child plays. </li> </ul> <br /> Ask the child: <ul class=\"decimal_heading\"> <li>\"What have your parents taught you about guns and what not to do with them?\" </li> </ul> <br /> Children who are beginning to hunt should be taught how to use guns and hunting knives safely &ndash; and only under adult supervision.*</td> <td>Children this age lack the maturity or cognitive capacity to reliably follow advice concerning guns.<br /> <br /> There is evidence that programs designed to teach children to avoid contact with guns are not effective in overcoming the child's innate curiosity and social pressure to handle guns.<br /> <br /> Approximately 10% of unintentional firearm injury deaths in children &#60;15 years of age occur while hunting; approximately 40% of unintentional hunting deaths in children &#60;15 years are self-inflicted.</td> </tr> <tr class=\"divider_bottom\"> <td>11 through 14 years</td> <td>As above for all ages, plus: <ul class=\"decimal_heading\"> <li>Encourage parents to ask if there are guns in the homes where their child plays or visits. </li> <li>Guns should be removed from the homes of adolescents who have a history of suicide attempts or other risk factors for suicide, depression, or aggressive or violent behaviors. </li> </ul> <br /> Ask the child/adolescent: <ul class=\"decimal_heading\"> <li>\"Is there a gun at home?\" </li> <li>\"Do you ever carry a gun?\"<sup>&#182;</sup> </li> </ul> <br /> Children who are beginning to hunt should be taught how to use guns and hunting knives safely &ndash; and only under adult supervision.*</td> <td>Most unintentional firearm injury deaths in children &#60;15 years of age occur in this age group. Approximately 40% of such incidents occur at the home of a friend. The shooter is most often a brother, another family member, or friend.<br /> <br /> Approximately 10% of unintentional firearm injury deaths in children &#60;15 years of age occur while hunting; approximately 40% of unintentional hunting deaths in children &#60;15 years are self-inflicted.</td> </tr> <tr> <td>15 through 21 years</td> <td>As above for all ages, plus: <ul class=\"decimal_heading\"> <li>Guns should be removed from the homes of adolescents who have a history of suicide attempts or other risk factors for suicide, depression, or aggressive or violent behaviors. </li> <li>When considering colleges, be aware of policies that allow individuals to legally carry guns on campus. </li> </ul> <br /> Ask the adolescent: <ul class=\"decimal_heading\"> <li>\"Is there a gun at home?\" </li> <li>\"Do you know anyone with a weapon?\" </li> <li>\"Do you ever carry a gun?\"<sup>&#182;</sup> </li> <li>\"Can you get a gun if you want to?\" </li> </ul> </td> <td>A gun kept in the home: <ul class=\"decimal_heading\"> <li>Increases the risk of homicide or completed suicide. </li> <li>Is more likely to kill or injure someone known to the family than to kill or injure an intruder. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Information regarding safe handling and storage of firearms is provided by <a href=\"http://www.projectchildsafe.org/\" target=\"_blank\">Project ChildSafe</a>.<br />&para; Information regarding youth violence prevention and additional resources are available from the <a href=\"https://www.cdc.gov/violenceprevention/youthviolence/prevention.html\" target=\"_blank\">Centers for Disease Control and Prevention</a>.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Anglemyer A, Horvath T, Rutherford G. The accessibility of firearms and risk for suicide and homicide victimization among household members: A systematic review and meta-analysis. Ann Intern Med 2014; 160:101.</LI>&#xD;&#xA;<LI>Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4<SUP>th</SUP> ed, Hagen JF, Shaw JS, Duncan PM (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2017.</LI>&#xD;&#xA;<LI>Dowd MD, Sege RD, Council on Injury, Violence, and Poison Prevention Executive Committee, American Academy of Pediatrics. Firearm-related injuries affecting the pediatric population. Pediatrics 2012; 130:e1416.</LI>&#xD;&#xA;<LI>Hemenway D, Solnick SJ. Children and unintentional firearm death. Inj Epidemiol 2015; 2:26.</LI>&#xD;&#xA;<LI>Webster D, et al. Firearms on college campuses: Research evidence and policy implications. Johns Hopkins Bloomberg School of Public Health. October 15, 2016. Available at: <A href=\"http://www.jhsph.edu/research/centers-and-institutes/johns-hopkins-center-for-gun-policy-and-research/_pdfs/GunsOnCampus.pdf\" target=_blank>http://www.jhsph.edu/research/centers-and-institutes/johns-hopkins-center-for-gun-policy-and-research/_pdfs/GunsOnCampus.pdf</A>. Accessed on February 22, 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 112196 Version 4.0</div></div></div>"},"112198":{"type":"graphic_table","displayName":"Tests/procedures for a patient with AML","title":"Tests/procedures for a patient with AML","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tests/procedures for a patient with AML</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tests to establish the diagnosis</td> <td class=\"subtitle1\">Additional tests/procedures at diagnosis</td> </tr> <tr> <td>Complete blood count and differential count</td> <td>Demographics and medical history*</td> </tr> <tr> <td>Bone marrow aspirate</td> <td>Detailed family history<sup>&#182;</sup></td> </tr> <tr> <td>Bone marrow trephine biopsy<sup>&#916;</sup></td> <td>Patient bleeding history<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\">Immunophenotyping</td> <td>Performance status (ECOG/WHO score)</td> </tr> <tr> <td class=\"subtitle1\">Genetic analyses</td> <td>Analysis of comorbidities</td> </tr> <tr> <td>Cytogenetics<sup>&#167;</sup></td> <td>Biochemistry, coagulation tests, urine analysis<sup>&#165;</sup></td> </tr> <tr> <td>Screening for gene mutations including:<sup>&#135;</sup></td> <td>Serum pregnancy test<sup>&#134;</sup></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li><em>NPM1</em>, <em>CEBPA</em>, <em>RUNX1</em>, <em>FLT3</em>, <em>TP53</em>, <em>ASXL1</em> </li> </ul> </td> <td>Information on oocyte and sperm cryopreservation**</td> </tr> <tr> <td>Screening for gene rearrangements:<sup>&#182;&#182;</sup></td> <td>Eligibility assessment for allogeneic HCT (including HLA typing)<sup>&#916;&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\"> <ul class=\"decimal_heading\"> <li><em>PML-RARA</em>, <em>CBFB-MYH11</em>, <em>RUNX1-RUNX1T1</em>, <em>BCR-ABL1</em>, other fusion genes (if available) </li> </ul> </td> <td>Hepatitis A, B, C; HIV-1 testing</td> </tr> <tr> <td class=\"subtitle1\">Sensitive assessment of response by RT-qPCR or MFC<sup>&#9674;&#9674;</sup></td> <td>Chest radiograph, 12-lead electrocardiogram, and echocardiography or MUGA (on indication)</td> </tr> <tr> <td>RT-qPCR<sup>&#167;&#167;</sup><sup>,</sup><sup>&#165;&#165;</sup> for <em>NPM1</em> mutation, <em>CBFB-MYH11</em>, <em>RUNX1-RUNX1T1</em>, <em>BCR-ABL1</em>, other fusion genes (if available)<sup>&#9674;&#9674;</sup></td> <td>Lumbar puncture<sup>&#135;&#135;</sup></td> </tr> <tr> <td>Multiparameter flow cytometry (MFC)<sup>&#165;&#165;</sup><sup>,</sup><sup>&#134;&#134;</sup></td> <td>Biobanking***</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; ECOG: Eastern Cooperative Oncology Group; WHO: World Health Organization; HIV-1: human immunodeficiency type 1; MUGA: multigated acquisition; CMV: cytomegalovirus;&nbsp;RT-qPCR: real-time quantitative polymerase chain reaction; MFC: multiparameter flow cytometry; HCT: hematopoietic cell transplantation; HLA: human leukocyte antigen;&nbsp;MRD: minimal residual disease; CNS: central nervous system.<br />* Including race or ethnicity, prior exposure to toxic agents, prior malignancy, therapy for prior malignancy, information on smoking.<br />¶ Thorough family history needed to identify potential myeloid neoplasms with germ line predisposition.<br />Δ In patients with a dry tap (punctio sicca).<br /><FONT class=lozenge>◊</FONT> History of bleeding episodes may inform cases of myeloid neoplasms with germ line predisposition and preexisting platelet disorders.<br />§ Results from cytogenetics should be obtained preferably within 5 to 7 days. At least 20 bone marrow metaphases are needed to define a normal karyotype, and recommended to describe an abnormal karyotype. Abnormal karyotypes may be diagnosed from blood specimens.<br />¥ Biochemistry: Glucose, sodium, potassium, calcium, creatinine, aspartate amino transferase, alanine amino transferase, alkaline phosphatase, lactate dehydrogenase, bilirubin, urea, total protein, uric acid, total cholesterol, total triglycerides, creatinine phosphokinase. Coagulation tests: Prothrombin time, international normalized ratio where indicated, activated partial thromboplastin time. Urine analysis: pH, glucose, erythrocytes, leukocytes, protein, nitrite.<br />‡ Results from <EM>NPM1</EM> and <EM>FLT3</EM> mutational screening should be available within 48 to 72 hours (at least in patients eligible for intensive chemotherapy), and results from additional molecular genetics within the first treatment cycle. Screening for gene mutations is an evolving field of research; screening for single genes may be replaced by gene panel diagnostics.<br />† In women with childbearing potential.<br />** Cryopreservation to be done in accordance with the wish of the patient.<br />¶¶ Screening for gene rearrangements should be performed if rapid information is needed for recommendation of suitable therapy, if chromosome morphology is of poor quality, or if there is typical morphology but the suspected cytogenetic abnormality is not present.<br />ΔΔ HLA typing and CMV testing should be performed in those patients eligible for allogeneic HCT.<br /><FONT class=lozenge>◊◊</FONT> Sensitive assessment of response can be performed at early time points, for example, following induction and consolidation courses to assess remission status and determine kinetics of disease response, and sequentially beyond consolidation to detect impending morphologic relapse. No generally applicable time points can be defined because kinetics of MRD response differs by treatment given, marker analyzed, and method used.<br />§§ Monitoring of response by RT-qPCR recommended in clinical trials and clinical practice.<br />¥¥ Sensitivity of response assessment varies by method used, and by marker tested; test used and sensitivity of the assay should always be reported; analyses should be done in experienced laboratories (centralized diagnostics).<br />‡‡ Required in patients with clinical symptoms suspicious of CNS involvement; patient should be evaluated by imaging study for intracranial bleeding, leptomeningeal disease, and mass lesion; lumbar puncture considered optional in other settings (eg, high white blood cell count).<br />†† Increasing evidence that response assessment by multiparameter flow cytometry&nbsp;qualitatively provides a better remission status than morphologic assessment and is of high prognostic impact.<br />*** Pretreatment leukemic bone marrow and blood sample.</div><div class=\"graphic_reference\">This research was originally published in Blood. D&ouml;hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424. Copyright &copy; 2017 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 112198 Version 1.0</div></div></div>"},"112202":{"type":"graphic_table","displayName":"Existential domains and clinical manifestations","title":"Descriptions and manifestations of existential domains","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Descriptions and manifestations of existential domains</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Existential domain</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Clinical manifestation</td> </tr> <tr> <td>Mortality</td> <td>Awareness of the inevitability of death and a wish for life to continue</td> <td>Anxiety about dying or the afterlife; concern about separating from loved ones</td> </tr> <tr> <td>Freedom</td> <td>Reality that humans must always choose and all choices have consequences</td> <td>Regret about past choices; unresolved conflict with one's self or others</td> </tr> <tr> <td>Meaningless</td> <td>Struggle to find meaning in life despite the universal reality of death</td> <td>Loss of purpose; questioning the meaning of their illness, suffering, or faith</td> </tr> <tr> <td>Isolation</td> <td>Sense of isolation from part of a larger community (church, family, etc)</td> <td>Feeling of abandonment by community or God; a sense of disconnectedness</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Grech A, Marks A. Existential Suffering Part 1: Definition and Diagnosis #319. J Palliat Med 2017; 20:93. Copyright © 2017 Mary Ann Liebert, Inc. publishers.</div><div id=\"graphicVersion\">Graphic 112202 Version 1.0</div></div></div>"},"112205":{"type":"graphic_algorithm","displayName":"Approach to well-appearing febrile infant 61 to 90 days of age","title":"Approach to well-appearing, otherwise healthy febrile infants 61 to 90 days of age with no bacterial focus of infection on examination","html":"<div class=\"graphic\"><div style=\"width: 674px\" class=\"figure\"><div class=\"ttl\">Approach to well-appearing, otherwise healthy febrile infants 61 to 90 days of age with no bacterial focus of infection on examination</div><div class=\"cntnt\"><img style=\"width:654px; height:861px;\" src=\"images/EM/112205_Aprwlaprfbrlnft6190d.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RSV: respiratory syncytial virus; PCR: polymerase chain reaction; WBC: white blood cell; UTI: urinary tract infection.<br />​* Urine tests should be obtained by bladder catheterization or suprapubic aspiration. Some experts would also recommend a complete blood count with differential and a blood culture, especially for patients who have not received conjugate vaccines, and, for patients with an elevated WBC or absolute neutrophil count, intravenous antibiotics, and hospital admission.<br />&para; No testing is most appropriate for patients seen &lt;24 hours after immunization and who have a rectal temperature &lt;38.6&deg;C (101.5&deg;F). Some clinicians may choose to obtain a urinalysis and urine blood culture by bladder catheterization or suprapubic aspiration, especially for infants who received immunizations within the previous 24 to 48 hours. Refer to UpToDate topics on outpatient evaluation of recently immunized febrile young infants.<br />&Delta; Empiric antibiotics should be adjusted based upon susceptibility of organisms in the region. Although risk of bacteremia is low in febrile infants who are 61 to 90 days of age with a UTI, some clinicians may choose to perform a complete blood count with differential and a blood culture. Refer to UpToDate topics on treatment of UTI in infants and children.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate topics on treatment of seasonal influenza in children.</div><div id=\"graphicVersion\">Graphic 112205 Version 2.0</div></div></div>"},"112212":{"type":"graphic_table","displayName":"Chronic inflammatory conditions associated with AA amyloidosis","title":"Chronic inflammatory conditions associated with AA amyloidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic inflammatory conditions associated with AA amyloidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chronic inflammatory arthritides</td> <td class=\"subtitle1\">Periodic fevers</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Rheumatoid arthritis </li> <li>Juvenile idiopathic arthritis </li> <li>Ankylosing spondylitis </li> <li>Psoriatic arthropathy </li> <li>Reactive arthritis </li> <li>Adult Still's disease </li> <li>Systemic lupus erythematosus </li> </ul> </td> <td> <ul> <li>Familial Mediterranean fever </li> <li>Cryopyrin-associated periodic syndrome (CAPS) </li> <li>TNF receptor-associated periodic syndrome (TRAPS) </li> <li>Mevalonate kinase deficiency </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Vasculitides</td> <td class=\"subtitle1\">Neoplasia</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Polyarteritis nodosa </li> <li>Takayasu arteritis </li> <li>Beh&#231;et's&nbsp;syndrome </li> <li>Giant cell arteritis/polymyalgia rheumatica </li> </ul> </td> <td> <ul> <li>Hodgkin disease </li> <li>Renal cell carcinoma </li> <li>Adenocarcinoma of the lung, gut, urogenital tract </li> <li>Basal cell carcinoma </li> <li>Hairy cell leukemia </li> <li>Castleman disease </li> <li>Hepatic adenoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Chronic infections</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td class=\"divider_bottom\"> <ul> <li>Bronchiectasis </li> <li>Chronic cutaneous ulcers </li> <li>Chronic pyelonephritis </li> <li>Chronic osteomyelitis </li> <li>Subacute bacterial endocarditis </li> <li>Leprosy </li> <li>Tuberculosis </li> <li>Whipple's disease </li> </ul> </td> <td rowspan=\"3\"> <ul> <li>IV and subcutaneous drug misuse </li> <li>Cystic fibrosis </li> <li>Hidradenitis suppurativa </li> <li>Kartagener's syndrome </li> <li>Epidermolysis bullosa </li> <li>Hypogammaglobulinemia </li> <li>Cyclic neutropenia </li> <li>Common variable immunodeficiency </li> <li>Hyperimmunoglobulin M syndrome </li> <li>SAPHO syndrome </li> <li>Obesity </li> <li>IgG4-related disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Inflammatory bowel disease</td> </tr> <tr> <td> <ul> <li>Crohn disease </li> <li>Ulcerative colitis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNF: tumor necrosis factor; IV: intravenous; SAPHO: synovitis, acne, pustulosis, hyperostosis, and osteitis; IgG4: immunoglobulin G4.</div><div id=\"graphicVersion\">Graphic 112212 Version 1.0</div></div></div>"},"112214":{"type":"graphic_table","displayName":"Differential diagnosis of pitted keratolysis","title":"Differential diagnosis of pitted keratolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pitted keratolysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical findings</td> </tr> <tr> <td>Aquagenic palmoplantar keratoderma</td> <td>Asymptomatic, translucent white papules or plaques on the palms and/or soles that appear after brief exposure to water; clinical findings disappear after drying within minutes to hours.</td> </tr> <tr> <td>Arsenical keratosis</td> <td>Multiple, asymptomatic, hard, corn-like papules on the palms and soles; papules may coalesce to form verrucous plaques.</td> </tr> <tr> <td>Basal cell nevus syndrome</td> <td>Palmar or plantar pits; other features of the syndrome (eg, basal cell carcinomas, odontogenic keratocysts, rib abnormalities, calcification of the falx cerebri).</td> </tr> <tr> <td>Darier disease</td> <td>Hyperkeratotic papules and centrally depressed pits on palms and soles; associated yellow-brown or brown hyperkeratotic papules and plaques in seborrheic areas, nail changes (red longitudinal stripes with a peripheral notch or split).</td> </tr> <tr> <td>Dyshidrotic eczema</td> <td>Pruritic, tense, deep-seated vesicles on palms and/or soles, especially on lateral aspect of digits.</td> </tr> <tr> <td>Exfoliative keratolysis</td> <td>Air-filled blisters/bullae on an erythematous base and superficial desquamation leaving collarettes of scale.</td> </tr> <tr> <td>Focal acral hyperkeratosis</td> <td>Small, yellow to white keratotic papules on the palms and soles preferentially located on plantar and palmar margins; may coalesce to form plaques.</td> </tr> <tr> <td>Juvenile plantar dermatosis</td> <td>Erythema, hyperkeratosis, and fissures on plantar surfaces of toes and anterior soles of the feet in children; bilateral distribution.</td> </tr> <tr> <td>Plantar warts</td> <td>Firm, rough papules that may coalesce into a mosaic plaque; thrombosed capillaries visible, particularly after paring of stratum corneum.</td> </tr> <tr> <td>Porokeratosis</td> <td> <p>Punctate porokeratosis: Multiple seed-like keratotic lesions with thin, raised margins and/or pits on palms and soles.</p> Porokeratosis palmaris et plantaris disseminata: Small, uniform macules on palms and soles with slightly raised peripheral ridge and atrophic center.</td> </tr> <tr> <td>Punctate palmoplantar keratoderma</td> <td>Multiple punctate hyperkeratotic papules on palms and soles; may form hyperkeratotic plaques in sites of friction or pressure.</td> </tr> <tr> <td>Tinea pedis</td> <td>Interdigital macerated and erythematous plaques, fine scaling on the plantar and lateral surfaces of the feet, or a vesicobullous eruption on the instep of the foot; potassium hydroxide preparation reveals fungal hyphae.</td> </tr> <tr> <td>Tungiasis</td> <td>Ectoparasitic infection caused by gravid female sand flea; nonmigratory papule or nodule with central black dot; often located on feet.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112214 Version 1.0</div></div></div>"},"112215":{"type":"graphic_table","displayName":"Ischemic heart disease-based prediction algorithms","title":"Ischemic heart disease-based prediction algorithms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ischemic heart disease-based prediction algorithms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Study group<br /> (diagnostic criteria for entry)</td> </tr> <tr> <td class=\"subtitle2\">TIMI<br /> (unstable angina)</td> <td class=\"subtitle2\">GRACE<br /> (post-STEMI or NSTEMI ACS)</td> <td class=\"subtitle2\">HEART<br /> (ED observation unit evaluation)</td> <td class=\"subtitle2\">DAPT<br /> (PCI patients)</td> <td class=\"subtitle2\">ACTION<br /> (hospitalized MI)</td> </tr> <tr> <td><strong>Year of publication</strong></td> <td class=\"centered\">2000</td> <td class=\"centered\">2004</td> <td class=\"centered\">2015</td> <td class=\"centered\">2016</td> <td class=\"centered\">2016</td> </tr> <tr> <td><strong>Age</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>Traditional CV factors (various)</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>ECG ST-segment elevation</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>2+ ischemic episodes past 24 hours</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Strong history of ischemic symptoms</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Troponin levels</strong></td> <td class=\"centered\">X<br /> (older assay)</td> <td class=\"centered\">X<br /> (older assay)</td> <td class=\"centered\">X<br /> (newer assay)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X<br /> (newer assay)</td> </tr> <tr> <td><strong>Nontroponin CV biomarkers</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">Serum creatinine</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Renal function</td> <td class=\"centered\">eGFR</td> </tr> <tr> <td><strong>Heart rate</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>Heart failure</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">At presentation</td> </tr> <tr> <td><strong>History of stroke or PAD</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Cardiac arrest</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">At presentation</td> </tr> <tr> <td><strong>Cardiogenic shock</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">At presentation</td> </tr> <tr> <td><strong>Stent information</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Validation</strong></td> <td class=\"centered\">Multiple</td> <td class=\"centered\">Multiple</td> <td class=\"centered\">External</td> <td class=\"centered\">Internal</td> <td class=\"centered\">Internal</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">X denotes that the information was used for that scoring system.</div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; ACTION: Acute Coronary Treatment and Intervention Outcomes Network; CV: cardiovascular; DAPT: Dual Antiplatelet Therapy; ED: emergency department; eGFR: estimated glomerular filtration rate; GRACE: Global Registry of Acute Coronary Events; HEART: History, ECG, Age, Risk factor, Troponin; MI: myocardial infarction; NSTEMI: non-ST elevation myocardial infarction; PAD: peripheral arterial disease; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; TIMI: Thrombolysis In Myocardial Infarction.</div><div class=\"graphic_reference\">From: Wilson PWF, D'Agostino RB. No one size fits all: Scoring risk of in-hospital death after myocardial infarction. J Am Coll Cardiol 2016; 68:636. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112215 Version 1.0</div></div></div>"},"112217":{"type":"graphic_table","displayName":"Malignancies associated with glomerular diseases","title":"Malignancies associated with glomerular diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignancies associated with glomerular diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Malignancy</td> <td class=\"subtitle1\">Glomerular diseases reported</td> </tr> <tr> <td>Lung cancer*</td> <td>MN, MCD, MPGN, IgAN, FSGS, CGN, TMA</td> </tr> <tr> <td>Colon cancer</td> <td>MN, MCD, CGN</td> </tr> <tr> <td>Stomach cancer</td> <td>MN</td> </tr> <tr> <td>Pancreas cancer</td> <td>MN, MCD, IgAN</td> </tr> <tr> <td>Bladder cancer</td> <td>MCD</td> </tr> <tr> <td>Renal cell cancer</td> <td>AAA, CGN, IgAN, MCD, FSGS, MPGN</td> </tr> <tr> <td>Prostate cancer</td> <td>MN, CGN</td> </tr> <tr> <td>Breast cancer</td> <td>MN, FSGS, MPGN, TMA</td> </tr> <tr> <td>Esophageal cancer</td> <td>MPGN, FSGS</td> </tr> <tr> <td>Gastrointestinal stromal tumor</td> <td>AAA</td> </tr> <tr> <td>Gastric cancer</td> <td>MPGN, CGN, TMA</td> </tr> <tr> <td>Spleen sarcoma</td> <td>AAA</td> </tr> <tr> <td>Head and neck cancer</td> <td>MN, IgAN</td> </tr> <tr> <td>Wilm's tumor</td> <td>MN, MPGN</td> </tr> <tr> <td>Teratoma</td> <td>MN</td> </tr> <tr> <td>Ovarian cancer</td> <td>MN, MCD</td> </tr> <tr> <td>Cervical cancer</td> <td>MN</td> </tr> <tr> <td>Endometrial cancer</td> <td>MN</td> </tr> <tr> <td>Tongue cancer</td> <td>IgAN</td> </tr> <tr> <td>Mesothelioma</td> <td>MCD</td> </tr> <tr> <td>Melanoma</td> <td>MN, MPGN</td> </tr> <tr> <td>Skin cancers (basal or squamous cell)</td> <td>MN</td> </tr> <tr> <td>Pheochromocytoma</td> <td>MN</td> </tr> <tr> <td>Thymoma</td> <td>MCD, FSGS, CGN, MPGN</td> </tr> <tr> <td>Hodgkin lymphoma</td> <td>MCD, MN, MPGN, IgAN, FSGS, CGN, AAA, Anti-GBM</td> </tr> <tr> <td>Non-Hodgkin lymphoma</td> <td>MN, MCD, MPGN, IgAN, FSGS</td> </tr> <tr> <td>CLL</td> <td>MN, MCD, MPGN, FSGS, CGN</td> </tr> <tr> <td>AML</td> <td>MN, FSGS</td> </tr> <tr> <td>CML</td> <td>MN, MCD, MPGN</td> </tr> <tr> <td>MGUS</td> <td>MPGN</td> </tr> <tr> <td>T-cell leukemia</td> <td>FSGS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MN: membranous nephropathy; MCD: minimal change disease; MPGN: membranoproliferative glomerulonephritis; IgAN: IgA nephropathy; FSGS: focal segmental glomerulosclerosis; CGN: crescentic glomerulonephritis; TMA: thrombotic microangiopathy; AAA: AA amyloidosis; GBM: glomerular basement membrane; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MGUS: monoclonal gammopathy of undetermined significance.<br />* Includes small cell, non-small cell, squamous cell, and bronchogenic cancers.</div><div class=\"graphic_reference\">From: Jhaveri KD, Rosner MH. Cancer and chronic kidney disease. In: Chronic Renal Disease, 1st ed, Kimmel PL, Rosenberg ME (Eds), Academic Press 2014. p.574. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112217 Version 1.0</div></div></div>"},"112218":{"type":"graphic_table","displayName":"Etiologies of acute kidney injury in the cancer patient","title":"Etiologies of acute kidney injury in the cancer patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of acute kidney injury in the cancer patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Prerenal causes</td> <td class=\"subtitle1\">Intrinsic renal causes</td> <td class=\"subtitle1\">Postrenal causes</td> </tr> <tr> <td> <ul> <li>Volume depletion <ul> <li>Decreased oral intake </li> <li>Gastrointestinal losses </li> </ul> </li> <li>Sepsis </li> <li>Hypercalcemia </li> <li>Medications <ul> <li>ACE inhibitors or angiotensin receptor blockers </li> <li>Diuretics </li> <li>Iodinated contrast </li> <li>NSAIDs </li> </ul> </li> <li>Sinusoidal obstruction syndrome (venoocclusive disease) </li> </ul> </td> <td> <ul> <li>Glomerular <ul> <li>Monoclonal gammopathy-associated proliferative glomerulonephritis </li> <li>Rapidly progressive glomerulonephritis </li> </ul> </li> <li>Tubulointerstitial <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular necrosis </li> <li>Light chain cast nephropathy </li> <li>Lysozymuria </li> <li>Nephrotoxic anticancer agents </li> <li>Tumor infiltration of the kidney </li> <li>Tumor lysis syndrome </li> </ul> </li> <li>Vascular <ul> <li>Thrombotic microangiopathy </li> </ul> </li> </ul> </td> <td> <ul> <li>Obstructive uropathy </li> <li>Retroperitoneal fibrosis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 112218 Version 1.0</div></div></div>"},"112219":{"type":"graphic_table","displayName":"Anticancer drug-related nephrotoxicity","title":"Anticancer drug-related nephrotoxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticancer drug-related nephrotoxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Clinical renal syndrome</td> <td class=\"subtitle1\">Renal histopathology</td> <td class=\"subtitle1\">Prevention*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cytotoxic drugs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cyclophosphamide</td> <td> <ul> <li>Hyponatremia (SIADH) </li> <li>Hemorrhagic cystitis </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> <li>Mesna </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gemcitabine</td> <td> <ul> <li>AKI </li> <li>Hematuria </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ifosfamide</td> <td> <ul> <li>AKI </li> <li>NDI </li> <li>Proximal tubulopathy (Fanconi syndrome) </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methotrexate</td> <td> <ul> <li>AKI </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Crystalline nephropathy </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> <li>Urinary alkalinization </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mitomycin C</td> <td> <ul> <li>AKI </li> <li>Hematuria </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nitrosoureas</td> <td> <ul> <li>Chronic kidney disease </li> </ul> </td> <td> <ul> <li>Chronic interstitial nephritis </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pemetrexed</td> <td> <ul> <li>AKI </li> <li>NDI </li> <li>Proximal tubulopathy (Fanconi syndrome) </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Interstitial fibrosis </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Platinum agents (cisplatin, carboplatin, oxaliplatin)</td> <td> <ul> <li>AKI </li> <li>Hypomagnesemia </li> <li>NDI </li> <li>Proximal tubulopathy (Fanconi syndrome) </li> <li>Salt wasting </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> <li>Intravenous fluids </li> <li>Intravenous magnesium </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vinca alkaloids</td> <td> <ul> <li>Hyponatremia (SIADH) </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Targeted agents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ALK inhibitors (crizotinib)</td> <td> <ul> <li>AKI </li> <li>Electrolyte disorders </li> <li>Renal microcysts </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anti-VEGF agents (aflibercept, bevacizumab)</td> <td> <ul> <li>AKI </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">BRAF inhibitors (dabrafenib, vemurafenib)</td> <td> <ul> <li>AKI </li> <li>Electrolyte disorders </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">EGFR inhibitors (cetuximab, erlotinib, gefitinib, panitumumab)</td> <td> <ul> <li>Hypomagnesemia </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Imatinib</td> <td> <ul> <li>AKI </li> <li>Chronic kidney disease </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rituximab</td> <td> <ul> <li>AKI (tumor lysis syndrome) </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Crystalline (uric acid) nephropathy </li> </ul> </td> <td> <ul> <li>Hypouricemic agents (allopurinol, rasburicase) </li> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tyrosine kinase inhibitors (axitinib, pazopanib, sorafenib, regorafenib, sunitinib)</td> <td> <ul> <li>AKI </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> <li>Focal segmental glomerulosclerosis </li> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Immunotherapy agents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chimeric antigen receptor (CAR) T cells</td> <td> <ul> <li>Capillary leak syndrome with AKI </li> <li>Electrolyte disorders </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Glucocorticoid prophylaxis </li> <li>Chemotherapy to reduce tumor burden </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">CTLA-4 inhibitors (ipilimumab)</td> <td> <ul> <li>AKI </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Lupus-like glomerulonephritis </li> <li>Minimal change disease </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Interferons (alpha, beta, gamma)</td> <td> <ul> <li>AKI </li> <li>Nephrotic-range proteinuria </li> </ul> </td> <td> <ul> <li>Focal segmental glomerulosclerosis </li> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Interleukin-2</td> <td> <ul> <li>AKI </li> <li>Capillary leak syndrome </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Intravenous fluids</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PD-1 inhibitors (nivolumab, pembrolizumab)</td> <td> <ul> <li>AKI </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other drugs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Deferasirox</td> <td> <ul> <li>AKI </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> <li>Fanconi syndrome </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pamidronate</td> <td> <ul> <li>AKI </li> <li>Nephrotic syndrome </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Focal segmental glomerulosclerosis </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> <li>Increase infusion time </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sirolimus</td> <td> <ul> <li>AKI </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Focal segmental glomerulosclerosis </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Not available </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Zoledronate</td> <td> <ul> <li>AKI </li> <li>Nephrotic syndrome </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Focal segmental glomerulosclerosis (rare) </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIADH: syndrome of inappropriate antidiuretic hormone; AKI: acute kidney injury; NDI: nephrogenic diabetes insipidus; ALK: anaplastic lymphoma kinase; VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; PD-1: programmed death 1.<br />* In addition to minimizing exposure to other nephrotoxins.</div><div id=\"graphicVersion\">Graphic 112219 Version 1.0</div></div></div>"},"112220":{"type":"graphic_algorithm","displayName":"Surgery for chronic pancreatitis","title":"Surgical treatment of intractable abdominal pain due to chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 864px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of intractable abdominal pain due to chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:844px; height:288px;\" src=\"images/SURG/112220_Surgery_chronic_pancreatiti.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Although only surgical treatments are described here, symptomatic chronic pancreatitis can be treated medically, endoscopically, or surgically. Refer to UpToDate topics for information on how to choose among various treatments.</div><div id=\"graphicVersion\">Graphic 112220 Version 1.0</div></div></div>"},"112221":{"type":"graphic_figure","displayName":"Beger procedure","title":"Beger procedure","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Beger procedure</div><div class=\"cntnt\"><img style=\"width:534px; height:528px;\" src=\"images/SURG/112221_Beger_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A duodenal-preserving pancreatic head resection (DPPHR) technique was described by Beger in 1980 for&nbsp;chronic pancreatitis&nbsp;in an effort to decrease the morbidity of pancreatic head resection. In DPPHR, the pancreas neck is transected (A), followed by a subtotal resection of the head. A rim of pancreatic parenchyma along the duodenal wall, which contains the arcade of duodenal arterial blood supply, is preserved (B). A Roux-en-Y limb of jejunum is then used to create a pancreaticojejunostomy (C). DPPHR is an alternative to pancreaticoduodenectomy in patients with a small-diameter main pancreatic duct (&lt;6 to 7 mm) and head-dominant chronic pancreatitis.&nbsp; </div><div class=\"graphic_reference\">Modified from: Beger HG, Kunz R, Poch B. The Beger Procedure—Duodenum-Preserving Pancreatic Head Resection. J Gastrointest Surg 2004; 8:1090.</div><div id=\"graphicVersion\">Graphic 112221 Version 1.0</div></div></div>"},"112222":{"type":"graphic_picture","displayName":"Neonate with hydrocephalus","title":"Neonate with marked macrocephaly due to hydrocephalus","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Neonate with marked macrocephaly due to hydrocephalus</div><div class=\"cntnt\"><img style=\"width:765px; height:589px;\" src=\"images/PEDS/112222_Hydrocephalus_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A full-term neonate with congenital obstructive hydrocephalus. Findings include marked macrocephaly, frontal bossing, and prominent scalp veins.</div><div id=\"graphicVersion\">Graphic 112222 Version 1.0</div></div></div>"},"112224":{"type":"graphic_table","displayName":"Clinical classification SMA","title":"Clinical classification of spinal muscular atrophy (SMA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of spinal muscular atrophy (SMA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Age of onset</td> <td class=\"subtitle1\">Requires respiratory support at birth</td> <td class=\"subtitle1\">Able to sit</td> <td class=\"subtitle1\">Able to stand</td> <td class=\"subtitle1\">Able to walk</td> <td class=\"subtitle1\">Life expectancy</td> <td class=\"subtitle1\">Predicted <em>SMN2</em> copy number</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">Prenatal</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">&#60;6 months</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">&#60;6 months</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">&#60;2 years</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">6 to 18 months</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">10 to 40 years</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">&#62;18 months</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Assisted</td> <td class=\"centered\">Adult</td> <td class=\"centered\">3 to 4</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">&#62;5 years</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Adult</td> <td class=\"centered\">&#62;4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci 2016; 3:7. Copyright © 2016 Butchbach. Available at: <A href=\"http://journal.frontiersin.org/article/10.3389/fmolb.2016.00007/full\" target=_blank>http://journal.frontiersin.org/article/10.3389/fmolb.2016.00007/full</A> (Accessed on March 27, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/4.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 112224 Version 2.0</div></div></div>"},"112225":{"type":"graphic_figure","displayName":"C-to-T transition in exon 7","title":"The effect of the C-to-T transition in exon 7 between <em>SMN1</em> and <em>SMN2</em> on splicing","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">The effect of the C-to-T transition in exon 7 between <em>SMN1</em> and <em>SMN2</em> on splicing</div><div class=\"cntnt\"><img style=\"width:732px; height:517px;\" src=\"images/NEURO/112225_C_T_transition_exon_7.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><EM>SMN1</EM>: survival motor neuron 1 gene; <EM>SMN2</EM>: survival motor neuron 2 gene.</div><div class=\"graphic_reference\">Original figure modified for this publication. Butchbach ME, Burghes AH. Perspectives on models of spinal muscular atrophy for drug discovery. Drug Discov Today Dis Models 2004; 1:151. Illustration used with the permission of Elsevier Inc. All rights reserved. From: Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci 2016; 3:7. Copyright &copy; 2016 Butchbach. Available at: <a href=\"http://journal.frontiersin.org/article/10.3389/fmolb.2016.00007/full\" target=\"_blank\">http://journal.frontiersin.org/article/10.3389/fmolb.2016.00007/full</a> (Accessed March 27, 2017). Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 112225 Version 1.0</div></div></div>"},"112228":{"type":"graphic_algorithm","displayName":"Management of postgastrectomy duodenal leak","title":"Management of postgastrectomy duodenal leak","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Management of postgastrectomy duodenal leak</div><div class=\"cntnt\"><img style=\"width:586px; height:602px;\" src=\"images/SURG/112228_Mgmt_postgastrctmy_ddnl_lk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Patients who present with diffuse peritonitis, intra-abdominal hemorrhage, major wound dehiscence, uncontrolled sepsis, clinical deterioration, or multiorgan failure/shock should undergo immediate surgical exploration.<br />¶ For empirical choices of antibiotics, refer to UpToDate topic on antimicrobial approach to intra-abdominal infections in adults.<br />Δ The following procedures augment the primary duodenal leak closure or control. With the exception of paraduodenal drain, they are performed selectively at the discretion of the surgeon; one or more paraduodenal drains is always placed. Refer to UpToDate topic for details of each procedure.</div><div id=\"graphicVersion\">Graphic 112228 Version 1.0</div></div></div>"},"112229":{"type":"graphic_diagnosticimage","displayName":"Bilateral parotid gland enlargement in Sjögren's syndrome","title":"Bilateral parotid gland enlargement in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Bilateral parotid gland enlargement in Sjögren's syndrome</div><div class=\"cntnt\"><img style=\"width:766px; height:643px;\" src=\"images/RHEUM/112229_BilatglndenlrgmntSjogren.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnostic evaluation of a patient with Sjögren's syndrome and bilateral parotid gland enlargement.<br />(A) Multiple hyperintense foci are seen in the enlarged parotid glands (arrows) on T2-weighted MRI.<br />(B) Multiple ovoid hypoechoic lesions (arrow) are evident in the left parotid gland parenchyma.<br />(C) A core needle biopsy of the parotid gland shows a dense lymphocytic infiltrate (arrow) adjacent to normal parotid acinar tissue. Fatty replacement of parotid parenchymal tissue is a normal finding.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Alan Baer, MD.</div><div id=\"graphicVersion\">Graphic 112229 Version 1.0</div></div></div>"},"112230":{"type":"graphic_diagnosticimage","displayName":"Salivary gland histopathology in Sjögren's syndrome","title":"Salivary gland histopathology in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 757px\" class=\"figure\"><div class=\"ttl\">Salivary gland histopathology in Sjögren's syndrome</div><div class=\"cntnt\"><img style=\"width:737px; height:765px;\" src=\"images/RHEUM/112230_Slvry_glnd_histo_Sjogrens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Salivary gland histopathology.<br />(A) Normal minor labial salivary gland tissue. Note the striated duct in the center (arrow) and the surrounding mucus-secreting acini.<br />(B) A cross-section of a salivary gland lobule from a patient with Sjögren's syndrome. Note the multiple dense lymphocytic aggregates adjacent to normal-appearing mucus-secreting acini. This histopathologic pattern is designated \"focal lymphocytic sialadenitis.\"<br />(C) Parotid gland parenchymal tissue from a patient with Sjögren's syndrome. There are dense lymphocytic aggregates surrounding excretory ducts. Lymphoid follicles are present in the infiltrates (arrow). This histologic pattern is designated \"benign lymphoepithelial sialadenitis.\"</div><div class=\"graphic_reference\">Courtesy of Alan Baer, MD.</div><div id=\"graphicVersion\">Graphic 112230 Version 1.0</div></div></div>"},"112236":{"type":"graphic_picture","displayName":"Peutz-Jeghers lentigines lip","title":"Peutz-Jeghers syndrome","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Peutz-Jeghers syndrome</div><div class=\"cntnt\"><img style=\"width:756px; height:503px;\" src=\"images/DERM/112236_PeutzJeghers_lentigines_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominent dark brown macular pigmentation confined to the lips in an adolescent with Peutz-Jeghers syndrome.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112236 Version 1.0</div></div></div>"},"112243":{"type":"graphic_algorithm","displayName":"Risk stratification and initial chemo for metastatic GCTs","title":"Risk stratification and initial chemotherapy for men with metastatic germ cell tumors","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Risk stratification and initial chemotherapy for men with metastatic germ cell tumors</div><div class=\"cntnt\"><img style=\"width:828px; height:450px;\" src=\"images/ONC/112243_Risk_init_chemo_metastc_GCT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; beta-hCG: beta-human chorionic gonadotropin; LDH: lactate dehydrogenase; ULN: upper limit of normal; BEP: bleomycin, etoposide, cisplatin; EP: etoposide, cisplatin; VIP: ifosfamide, etoposide, cisplatin.<br />* Patients with elevated tumor markers are considered to have non-seminomatous germ cell tumors, even if histology is consistent with seminoma.<br />&para; For intermediate and poor risk disease, 4 cycles of BEP is generally preferred. 4 cycles of VIP is preferred if the patient has a primary, mediastinal non-seminomatous germ cell tumor or any contraindication to bleomycin.</div><div id=\"graphicVersion\">Graphic 112243 Version 1.0</div></div></div>"},"112247":{"type":"graphic_table","displayName":"Major veins and associated pathologies","title":"Major veins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major veins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anatomic classification or compartment</td> <td class=\"subtitle1\">Consequence of thrombosis and associated pathologies</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">BRAIN</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dural veins:</strong> Superior sagittal sinus; inferior sagittal sinus; straight sinus; basilar sinus; intercavernous sinus; transverse sinuses (right, left); sigmoid sinuses (right, left); occipital sinuses (right, left); cavernous sinuses (right, left); petrosal sinuses (right, left; superior, inferior); sphenoparietal sinuses (right, left); great cerebral vein (of Galen)</td> <td> <p>Cerebral sinus thrombosis is a serious condition that can affect the veins on the surface of the brain or deep within the cerebral cortex.</p> Isolated thrombosis of the different sinuses and veins produces diverse clinical pictures. First-line treatment generally consists of antithrombotic therapy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other veins of the brain:</strong> Ophthalmic veins (right, left); cerebral veins (superficial, deep)</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">HEAD/NECK</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Superficial neck veins</strong></td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Anterior jugular veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">External jugular veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Deep neck</strong></td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Internal jugular veins (right, left)</td> <td>Thrombosis is typically related to instrumentation. Lemierre's syndrome is a rare complication of acute tonsillitis that can be associated with internal jugular vein thrombosis.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Scalp veins</strong></td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Facial veins (right, left)</td> <td>Thrombosis can occur as a consequence of sinusitis or extension of vein thrombosis related to oropharyngeal infection.</td> </tr> <tr> <td class=\"indent2\">Frontal veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Temporal veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">UPPER EXTREMITY</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Deep compartment veins</strong></td> <td>Thrombosis of the deep veins of the upper extremities is usually treated with anticoagulation to reduce the potential for pulmonary embolism. </td> </tr> <tr> <td class=\"indent2\">Axillary veins (right, left)</td> <td>Thrombosis is often related to compression (eg, thoracic outlet syndrome, crutch use).</td> </tr> <tr> <td class=\"indent2\">Brachial veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Ulnar veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Radial veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Interosseous veins</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Superficial compartment veins</strong></td> <td>Thrombosis of the superficial veins of the upper extremities is typically related to instrumentation, often phlebotomy, or peripherally inserted lines. Thrombosis of upper arm veins in the absence of instrumentation is unusual and can happen as a part of migratory phlebitis pattern signaling malignancy (ie, Trousseau's syndrome) or Buerger's disease (thromboangiitis obliterans).</td> </tr> <tr> <td class=\"indent2\">Basilic veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Cephalic veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Median antecubital veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Accessory cephalic veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Median veins of the forearm (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">CHEST</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Central veins</strong></td> <td>Thrombosis of the central veins is usually treated with anticoagulation in the absence of contraindications.</td> </tr> <tr> <td class=\"indent2\">Brachiocephalic vein</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Subclavian veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Superior vena cava</td> <td>Thrombosis is often due to compression from a nearby mass/tumor but may be from extension of thrombus from other central veins.</td> </tr> <tr> <td class=\"indent2\">Inferior vena cava</td> <td>Thrombosis is often related to prior inferior vena cava filter placement. May also be related to tumor compression or extension of thrombus from the renal vein(s) in patients with renal cell carcinoma.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Azygous and hemiazygos veins</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Chest wall veins</strong></td> <td>Dilation of the veins of the chest wall may be a sign of chronic central venous obstruction. Thrombosis of chest wall veins is unusual and can happen as a part of migratory phlebitis pattern signaling malignancy (ie, Trousseau's syndrome). It may also occur with cirrhosis due to portal hypertension.</td> </tr> <tr> <td class=\"indent2\">Lateral thoracic veins (right, left)</td> <td>Mondor's disease (superficial phlebitis of the chest wall).</td> </tr> <tr> <td class=\"indent2\">Internal thoracic veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Intercostal veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Musculophrenic veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">ABDOMEN</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Abdominal wall veins</strong></td> <td>Dilation of the veins of the abdominal wall may be a sign of chronic iliocaval venous obstruction. Thrombosis of abdominal wall veins is unusual and can happen as a part of migratory phlebitis pattern signaling malignancy (ie, Trousseau's syndrome) and Mondor's disease.</td> </tr> <tr> <td class=\"indent2\">Superficial epigastric veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Inferior epigastric veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Subcostal veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatoportal system</strong></td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Hepatic veins</td> <td>Hepatic venous outflow tract obstruction is Budd-Chiari syndrome.</td> </tr> <tr> <td class=\"indent2\">Portal vein</td> <td>Thrombosis may lead to portal hypertension, variceal hemorrhage (gastroesophageal varices), intestinal ischemia, and portal cholangiopathy.</td> </tr> <tr> <td class=\"indent2\">Splenic vein</td> <td>Thrombosis may lead to isolated gastric varices.</td> </tr> <tr> <td class=\"indent2\">Pancreaticoduodenal veins (anterior, posterior, superior, inferior)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Gastric veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Superior mesenteric vein</td> <td>Thrombosis causes abdominal pain due to venous congestion, which may lead to full-thickness bowel infarction. In the absence of severe bowel ischemia, anticoagulation is the mainstay of therapy.</td> </tr> <tr> <td class=\"indent2\">Inferior mesenteric vein</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Colic veins (right, middle, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Retroperitoneal veins</strong></td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Renal veins (right, left)</td> <td>Renal vein thrombosis can cause nephrotic syndrome, renal infarction, and acute kidney injury. Renal carcinoma can be intraluminal and often mimics renal vein thrombosis. Compression of the left renal vein between the superior mesenteric artery and aorta (ie, Nutcracker syndrome) can lead to left renal vein thrombosis.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Adrenal veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">PELVIS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Retroperitoneal veins</strong></td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Iliac veins (common, internal, external; right, left)</td> <td>Iliac vein thrombosis can be related to extension of lower extremity vein thrombosis or as a consequence of iliac vein stenosis and subsequent thrombosis (May-Thurner syndrome). Thrombus associated with large, proximal veins is more likely to embolize.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Internal pudendal veins</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pelvic organ veins</strong></td> <td>When septic thrombophlebitis of the veins associated with the female pelvic organs occurs, it is usually in association with pregnancy and delivery.</td> </tr> <tr> <td class=\"indent2\">Gonadal veins (ovarian, testicular; right, left)</td> <td>Dilation of veins can lead to pelvic congestion syndrome and&nbsp;can cause aspermia in men. May be related to Nutcracker syndrome of left renal vein.</td> </tr> <tr> <td class=\"indent2\">Uterine veins</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Vaginal veins</td> <td>Dilation of veins can cause dyspareunia. Vaginal varicosities do not typically thrombose, but it can happen.</td> </tr> <tr> <td class=\"indent2\">Vesicular veins (superior, inferior; right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Rectal veins (superior, middle, inferior; right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Gluteal veins (superior, inferior; right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Internal hemorrhoidal plexus</td> <td>Thrombosis of the veins of the internal hemorrhoidal plexus can cause constipation and are not painful. </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Groin/perineum veins</strong></td> <td>Dilation of the veins of the lower abdominal wall may be a sign of chronic iliofemoral venous obstruction.</td> </tr> <tr> <td class=\"indent2\">Superficial circumflex iliac veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Superficial epigastric veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Deep circumflex iliac veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">External pudendal veins (right, left)</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">External hemorrhoidal plexus</td> <td>Thrombosis of the veins of the external hemorrhoidal plexus are extremely painful.</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"2\">LOWER EXTREMITY</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Deep compartment veins</strong></td> <td>Thrombosis of the deep veins of the lower extremities is usually treated with anticoagulation to reduce the potential for pulmonary embolism. Thrombus associated with large, proximal veins is more likely to embolize. The femoral vein may be duplicated.</td> </tr> <tr> <td class=\"indent2\">Common femoral veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Deep femoral veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Femoral veins (right, left)</td> <td>Vein may be duplicated.</td> </tr> <tr> <td class=\"indent2\">Popliteal veins (right, left)</td> <td>Vein may be duplicated.</td> </tr> <tr> <td class=\"indent2\">Gastrocnemius veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Soleal sinuses</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Tibial veins (anterior, posterior; right, left)</td> <td>Typically paired veins.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Fibular (peroneal) veins (right, left)</td> <td>Typically paired veins.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Superficial compartment veins</strong></td> <td>Phlebitis and thrombosis of the superficial veins of the lower extremities are usually treated conservatively; however, if thrombus is identified in a location that is near a confluence with the deep venous system, antithrombotic therapy is advocated.</td> </tr> <tr> <td class=\"indent2\">Great saphenous veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Small saphenous veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Anterior accessory saphenous veins (right, left)</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent2\">Intersaphenous veins (formerly vein of Giacomini)</td> <td>&ndash;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112247 Version 1.0</div></div></div>"},"112251":{"type":"graphic_algorithm","displayName":"Interpretation AFB/NAA for diagnosis of pulmonary TB in adults","title":"Approach to interpretation of sputum AFB smear and NAA test for diagnosis of pulmonary tuberculosis disease in adults","html":"<div class=\"graphic\"><div style=\"width: 810px\" class=\"figure\"><div class=\"ttl\">Approach to interpretation of sputum AFB smear and NAA test for diagnosis of pulmonary tuberculosis disease in adults</div><div class=\"cntnt\"><img style=\"width:790px; height:452px;\" src=\"images/ID/112251_Intp_AFBNAA_Dx_pulm_TB_adlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli; NAA: nucleic acid amplification; TB: tuberculosis; NTM: nontuberculous mycobacteria.<br />* A negative NAA result should be accompanied by a negative test for inhibitors that may limit amplification (if the Enhanced Amplified Mycobacterium Tuberculosis Direct Test [E-MTD] assay was used). The Xpert MTB/RIF assay contains a positive control that signals an invalid result if an inhibitor is detected.<br />¶ An invalid NAA result indicates failure of the assay. An invalid result is usually reported after the test has been repeated using the same specimen. Receipt of an invalid NAA result should prompt a repeat test using a new specimen.<br />Δ TB remains possible; the organism burden may be too low to meet the sensitivity threshold for detection via NAA or smear.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.</LI>&#xD;&#xA;<LI>World Health Organization. Global Tuberculosis Report, 2016. WHO, Geneva 2016. Available at: <A href=\"http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1\" target=_blank>http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1</A> (Accessed on March 9, 2017).</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7.</LI></OL></div><div id=\"graphicVersion\">Graphic 112251 Version 1.0</div></div></div>"},"112252":{"type":"graphic_algorithm","displayName":"Management of urethral stricture in men","title":"Management of urethral stricture in men","html":"<div class=\"graphic\"><div style=\"width: 1026px\" class=\"figure\"><div class=\"ttl\">Management of urethral stricture in men</div><div class=\"cntnt\"><img style=\"width:1006px; height:694px;\" src=\"images/SURG/112252_Mgmt_urethral_stricture_men.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* More than one treatment option exists for this type of stricture. The choice is determined by surgeon/patient preference.<br />¶ Author's preference.<br />Δ Candidates for surgical reconstruction must be medically fit for extensive surgery, must consent to the surgery, and must not have failed multiple attempts of repair previously.</div><div id=\"graphicVersion\">Graphic 112252 Version 2.0</div></div></div>"},"112256":{"type":"graphic_picture","displayName":"JMML smear 1","title":"JMML smear 1","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">JMML smear 1</div><div class=\"cntnt\"><img style=\"width:756px; height:633px;\" src=\"images/HEME/112256_JMML_smear1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear: Leukocytosis may be striking (Wright stain, 40X).</div><div class=\"graphic_reference\">Courtesy of Madeline Kraus, MD, Director of Hematopathology at Nemours Children's Hospital.</div><div id=\"graphicVersion\">Graphic 112256 Version 1.0</div></div></div>"},"112257":{"type":"graphic_picture","displayName":"JMML smear 2","title":"JMML smear 2","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">JMML smear 2</div><div class=\"cntnt\"><img style=\"width:756px; height:632px;\" src=\"images/HEME/112257_JMML_smear2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear: Myeloid immaturity, with a monocyte and two myelocytes (Wright stain, 100X).</div><div class=\"graphic_reference\">Courtesy of Madeline Kraus, MD, Director of Hematopathology at Nemours Children's Hospital.</div><div id=\"graphicVersion\">Graphic 112257 Version 1.0</div></div></div>"},"112258":{"type":"graphic_picture","displayName":"Lonomia obliqua caterpillars","title":"<EM>Lonomia obliqua</EM> caterpillars","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Lonomia obliqua</EM> caterpillars</div><div class=\"cntnt\"><img style=\"width:427px; height:640px;\" src=\"images/DERM/112258_Lonomiaobliquacaterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Centro de Informações Toxicológicas de Santa Catarina.</div><div id=\"graphicVersion\">Graphic 112258 Version 3.0</div></div></div>"},"112265":{"type":"graphic_algorithm","displayName":"Algorithm for management of infertility in women age 35 and over","title":"Algorithm for management of infertility in women age 35 and over*","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of infertility in women age 35 and over*</div><div class=\"cntnt\"><img style=\"width:610px; height:642px;\" src=\"images/OBGYN/112265_Alg_mgmt_infrtlty_wmn_35ovr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone.<br />* For more information on the evaluation of women with infertility, refer to UpToDate content on the evaluation of female infertility.<br />¶ Factors to discuss include cost, religious beliefs, treatment availability, and legality.</div><div id=\"graphicVersion\">Graphic 112265 Version 1.0</div></div></div>"},"112276":{"type":"graphic_algorithm","displayName":"Approach to diff dx ob-gyn causes acute abd pain in pregnancy","title":"Initial basic approach to the differential diagnosis of obstetrical and gynecological causes of acute abdominal pain in pregnant women","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Initial basic approach to the differential diagnosis of obstetrical and gynecological causes of acute abdominal pain in pregnant women</div><div class=\"cntnt\"><img style=\"width:748px; height:336px;\" src=\"images/OBGYN/112276_Dx_acute_ab_pain_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The goal in the evaluation of pregnant patients with abdominal/pelvic pain is to quickly identify those who have a serious or even life-threatening etiology for their symptoms and require urgent intervention. Two key signs of a potentially serious obstetric etiology of abdominal pain are vaginal bleeding and hypertension.<br />This algorithm presents a basic approach to the differential diagnosis of obstetrical and gynecological causes of acute abdominal pain in pregnant women. Nonobstetrical-gynecological causes of abdominal pain are not included, but remain in the differential diagnosis. These disorders are reviewed in the UpToDate topic on approach to acute abdominal pain in pregnant and postpartum women.<br />Disorders in bold font can be life-threatening. It should be noted that some of these disorders, such as uterine rupture and uterine incarceration, are rare. Also note that some life-threatening disorders, such as uterine rupture and ectopic pregnancy, may or may not be associated with vaginal bleeding.</div><div class=\"graphic_footnotes\">* Pregnancy-related liver diseases can cause epigastric or right upper quadrant abdominal pain. These disorders (preeclampsia with severe features, HELLP syndrome, and acute fatty liver of pregnancy) have overlapping features and can be difficult to distinguish. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Preeclampsia is characterized by the new onset of hypertension and usually proteinuria after 20 weeks of gestation in a previously normotensive woman; right upper quadrant or epigastric pain is a sign of liver involvement and signifies the severe spectrum of the disease. The pain may be caused by stretching of Glisson's capsule due periportal or subcapsular bleeding or, rarely, hepatic rupture.</LI>&#xD;&#xA;<LI>Hemolysis with a microangiopathic blood smear, elevated liver chemistries, and a low platelet count are the findings in HELLP syndrome. The most common clinical presentation is abdominal pain and tenderness in the midepigastrium, in the right upper quadrant, or below the sternum. As with preeclampsia, the pain may be caused by stretching of Glisson's capsule due to periportal or subcapsular bleeding or, rarely, hepatic rupture. It may not be possible to distinguish HELLP from preeclampsia with severe features, and they may be different manifestations of the same disease.</LI>&#xD;&#xA;<LI>Acute fatty liver occurs in the second half of pregnancy, usually in the third trimester. The most frequent initial symptoms are nausea or vomiting, abdominal pain (particularly epigastric), anorexia, and jaundice. About one-half of patients have signs of preeclampsia at presentation or at some time during the course of illness. The diagnosis is usually made clinically based upon the setting, presentation, and compatible laboratory and imaging results. Laboratory tests may show elevated aminotransferases, elevated bilirubin, thrombocytopenia, prolonged prothrombin time, low glucose levels, increased uric acid levels, increased creatinine levels, and elevated white cell count. Imaging tests of the liver are primarily used to exclude other diagnoses, such as a hepatic infarct or hematoma.</LI></UL>¶ Uterine rupture can be a catastrophic event. Signs and symptoms include nonreassuring fetal heart rate tracing or fetal death, uterine tenderness, peritoneal irritation, loss of fetal station, shock (due to intra-abdominal bleeding), and sometimes vaginal bleeding (which is generally modest). The possibility of rupture should always be excluded in women with a previous cesarean delivery and abdominal pain. Most uterine ruptures occur in laboring women with a prior cesarean delivery or prior transmyometrial uterine surgery (eg, myomectomy). Spontaneous rupture in the absence of labor may occur in women with a scarred uterus, but usually results from sharp or blunt abdominal trauma. Spontaneous rupture may also be related to a cornual pregnancy, pregnancy in a rudimentary uterine horn, or an interstitial pregnancy.<br />Δ Ectopic pregnancies usually occur in the fallopian tube, but sometimes occur within the cervical canal or a cesarean delivery scar. Rarely, an ectopic pregnancy occurs concurrently with an intrauterine pregnancy. A pregnancy conceived via assisted reproductive technology (eg, in vitro fertilization) is a strong risk factor. Abdominal pain is a common symptom of all types of extrauterine pregnancy; vaginal bleeding, nausea, and vomiting&nbsp;sometimes occur&nbsp;but may be absent. Patients may present with tachycardia and hypotension due to intraabdominal bleeding. They may also have a&nbsp;low-grade temperature and a mild elevation in the white cell count. The diagnosis of ectopic pregnancy is usually based upon results from ultrasound examination and human chorionic gonadotropin hormone testing.<br /><FONT class=lozenge>◊</FONT> Acute abruption classically presents with vaginal bleeding, abdominal and/or back pain, uterine tenderness, uterine rigidity, and uterine contractions; the fetal heart rate pattern may be abnormal. If significant placental separation develops, maternal disseminated intravascular coagulation and/or fetal death commonly occur. A retroplacental or subchorionic clot is the classic ultrasound finding of placental abruption, but is not always present. Diagnosis is based on clinical findings, and delivery is usually indicated.</div><div id=\"graphicVersion\">Graphic 112276 Version 1.0</div></div></div>"},"112296":{"type":"graphic_picture","displayName":"Atrophie blanche","title":"Atrophie blanche","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Atrophie blanche</div><div class=\"cntnt\"><img style=\"width:599px; height:756px;\" src=\"images/SURG/112296_Atrophie_blanche.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture demonstrates skin findings of venous insufficiency, including atrophie blanche (thin arrow), a stasis ulcer (thick arrow) as well as other small ulcers, and areas of hyperpigmentation (asterisk) due to hemosiderin deposition.</div><div id=\"graphicVersion\">Graphic 112296 Version 1.0</div></div></div>"},"112297":{"type":"graphic_algorithm","displayName":"Epiglottitis initial airway management","title":"Initial airway management for patients with epiglottitis","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Initial airway management for patients with epiglottitis</div><div class=\"cntnt\"><img style=\"width:670px; height:610px;\" src=\"images/EM/112297_Epiglottitis_airway_mgmt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RSI: rapid sequence intubation.<br />* Until the airway is secured in young children (6 years of age or younger), avoid intravenous access, unnecessary physical examination (oropharyngeal or laryngeal examination with a tongue blade or other instruments), and diagnostic tests (eg, phlebotomy or epiglottic cultures) which may provoke anxiety or crying with abrupt airway obstruction.<br />¶ Supraglottic airway use is contraindicated in patients with severe hypopharyngeal pathology, such as epiglottitis. Refer to UpToDate topics on rapid sequence intubation in children.<br />Δ Refer to UpToDate topics on needle and surgical cricothyrotomy.<br /><FONT class=lozenge>◊</FONT> Children with epiglottitis should receive ongoing care in a pediatric intensive care unit.</div><div id=\"graphicVersion\">Graphic 112297 Version 2.0</div></div></div>"},"112299":{"type":"graphic_table","displayName":"DOAC reversal agents for life-threatening bleeding","title":"Direct oral anticoagulant reversal agents for life-threatening bleeding (imminent risk of death from bleeding)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Direct oral anticoagulant reversal agents for life-threatening bleeding (imminent risk of death from bleeding)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Reversal agent</td> <td class=\"subtitle1\">Initial dose</td> </tr> <tr> <td>Dabigatran (Pradaxa)</td> <td>Idarucizumab (Praxbind)</td> <td>5 grams</td> </tr> <tr> <td>Apixaban (Eliquis)</td> <td>4 factor PCC (Kcentra, Octaplex)</td> <td>50 units per kg</td> </tr> <tr> <td>Betrixaban (Bevyxxa)</td> <td>4 factor PCC (Kcentra, Octaplex)</td> <td>50 units per kg</td> </tr> <tr> <td>Edoxaban (Lixiana, Savaysa)</td> <td>4 factor PCC (Kcentra, Octaplex)</td> <td>50 units per kg</td> </tr> <tr> <td>Rivaroxaban (Xarelto)</td> <td>4 factor PCC (Kcentra, Octaplex)</td> <td>50 units per kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These agents have the potential to cause life-threatening thrombosis and should only be used under the direction of a specialist with expertise in their use and/or in a patient at imminent risk of death from bleeding. Although there are preclinical data that suggest PCCs may partially overcome the effects of a DOAC, there is no high-quality evidence that establishes the benefit of PCCs in DOAC-treated patients who are bleeding. Refer to UpToDate topics on treatment of bleeding in patients receiving a DOAC or perioperative management of patients receiving a DOAC for information on additional risks and alternatives for treating bleeding.</div><div class=\"graphic_footnotes\">PCC: prothrombin complex concentrate; DOAC: direct oral anticoagulant.</div><div id=\"graphicVersion\">Graphic 112299 Version 2.0</div></div></div>"},"112300":{"type":"graphic_picture","displayName":"Blood smear ES, splenectomized recovering from babesiosis","title":"Peripheral blood smear of a splenectomized patient who developed Evans syndrome during recovery from babesiosis","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear of a splenectomized&nbsp;patient who developed Evans syndrome during recovery from babesiosis</div><div class=\"cntnt\"><img style=\"width:728px; height:289px;\" src=\"images/HEME/112300_Babesia_AIHA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral blood smear has findings consistent with splenectomy&nbsp;including spherocytes and&nbsp;Howell-Jolly bodies (arrow in panel A), as well as low-level parasitemia (arrow in panel B). Refer to discussion&nbsp;of the causes of&nbsp;AIHA and ES in&nbsp;UpToDate for more information about this phenomenon.</div><div class=\"graphic_footnotes\">ES: Evans syndrome; AIHA: autoimmune hemolytic anemia.</div><div class=\"graphic_reference\">From: Shatzel JJ, Donohoe K, Chu NQ, et al. Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis. Transfusion 2015; 55:661. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.12901/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.12901/abstract</a>. Copyright &copy; 2015 AABB. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 112300 Version 1.0</div></div></div>"},"112304":{"type":"graphic_figure","displayName":"Telomerase mutations in DC","title":"Telomerase mutations in dyskeratosis congenita","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Telomerase mutations in dyskeratosis congenita</div><div class=\"cntnt\"><img style=\"width:740px; height:504px;\" src=\"images/HEME/112304_Telomerase_function.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cartoon shows proteins involved in telomerase function. Pathogenic variants in the genes that encode&nbsp;many of these proteins have been implicated in DC and other telomere biology disorders. Proteins shown but not yet reported to have a disease association are TRF1, TRF2, RAP1, TEN1, and GAR1. Refer to discussions of DC in UpToDate for additional information.</div><div class=\"graphic_footnotes\">DC: dyskeratosis congenita; TCAB1: telomere Cajal body associated protein 1 (gene: <EM>WRAP53</EM>); TIN2: TRF1-interacting nuclear factor 2 (gene: <EM>TINF2</EM>); NOP10: NOP10 ribonucleoprotein (gene: <EM>NOP10</EM>); NHP2: non-histone protein 2, also called nucleolar protein family A, member 2 (NOLA2; gene: <EM>NHP2/NOLA2</EM>); DKC1: dyskerin (gene: <EM>DKC1</EM>); TERC: telomerase RNA component (gene: <EM>TERC</EM>); TERT: telomerase reverse transcriptase&nbsp;(gene:<EM> TERT</EM>); RTEL1: regulator of telomere elongation helicase 1 (gene: <EM>RTEL1</EM>); POT1: protection of telomeres 1 (gene: <EM>POT1</EM>); TPP1: telomere protection protein 1 (gene: <EM>ACD</EM>); CTC1: CTS telomere maintenance complex component 1 (gene: <EM>CTC1</EM>); STN1: oligonucleotide/oligosaccharide binding fold containing 1 (gene: <EM>OBFC1</EM>); NAF1: nuclear assembly factor 1 ribonucleoprotein (gene: <EM>NAF1</EM>); PARN: poly(A)-specific ribonuclease (gene: <EM>PARN</EM>); TRF1: telomeric repeat-binding&nbsp;factor 1&nbsp;(gene: <EM>TERF1</EM>);&nbsp;TRF2: telomeric repeat-binding factor 2&nbsp;(gene:<EM> TERF2</EM>); RAP1: repressor/activator site binding protein, also called TERF2-interacting protein&nbsp;(TERF2IP; gene: <EM>TERF2IP</EM>); TEN1: telomeric pathways with STN1 (gene: <EM>TEN1</EM>); GAR1: glycine-arginine-rich, also called nucleolar protein family A, member 1 (NOLA1;&nbsp;gene: <EM>GAR1/NOLA1</EM>). </div><div class=\"graphic_reference\">Reproduced from: Wegman-Ostrosky T, Savage SA. The genomics of inherited bone marrow failure: from mechanism to the clinic. Br J Haematol 2017. DOI: 10.1111/bjh.14535. Figure originally published in a U.S. Government work in the public domain in the United States.</div><div id=\"graphicVersion\">Graphic 112304 Version 1.0</div></div></div>"},"112306":{"type":"graphic_figure","displayName":"Digestive system child PI","title":"Digestive system in a child","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Digestive system in a child</div><div class=\"cntnt\"><img style=\"width:509px; height:685px;\" src=\"images/PI/112306_Digestive_system_in_a_child_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the organs in the body that process food. Together, these organs are called \"the digestive system\" or \"digestive tract.\" As food travels through the child's digestive system, the body absorbs nutrients and water.</div><div id=\"graphicVersion\">Graphic 112306 Version 2.0</div></div></div>"},"112309":{"type":"graphic_table","displayName":"Intermittent Explosive Disorder Screening Questionnaire (IED-SQ)","title":"Intermittent Explosive Disorder Screening Questionnaire (IED-SQ)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intermittent Explosive Disorder Screening Questionnaire (IED-SQ)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"6\" width=\"12%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"7\"><strong>Instructions:</strong> Most everyone experiences aggressive thoughts or behaviors at different points in life. Please answer the following questions about your experiences regarding this as accurately as possible. Your responses will remain completely confidential.</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"7\">Part 1:</td> </tr> <tr> <td colspan=\"7\"><strong>How many times would you say you have done the following things over the course of your life, since you turned age 13?</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>0 =</strong> Never happened (eg, zero)<br /> <strong>1 =</strong> Only happened \"once\" (eg, one)<br /> <strong>2 =</strong> Happened \"a couple\" or \"a few\" times (eg, two to three)<br /> <strong>3 =</strong> Happened \"several\" times (eg, four to nine)<br /> <strong>4 =</strong> Happened \"many\" times (eg, 10 or more)<br /> <strong>5 =</strong> Happened \"so many\" times that I couldn't give a number</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> <td class=\"subtitle2\">5</td> </tr> <tr> <td class=\"indent1\"><strong>1.</strong> \"Throw\" a temper tantrum (eg, screaming, slamming doors, throwing things when frustrated to the \"breaking point\")</td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\"><strong>2.</strong> Get into verbal fights or arguments with other people</td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\"><strong>3.</strong> Deliberately struck or deliberately broke objects (eg, windows, dishes, etc) in anger</td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\"><strong>4.</strong> Get into physical fights with other people</td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>5.</strong> Deliberately struck or hit another person in anger</td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"7\">Part 2:</td> </tr> <tr> <td colspan=\"7\">Here, we are asking for a bit more detail on your response in Part 1.<br /> <strong>Please answer the following questions for the time since you turned age 13.</strong></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\" colspan=\"5\"><strong>1.</strong> Have you ever had periods when you had weekly arguments/temper outbursts or times when you broke something/hit someone in anger?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr> <td colspan=\"2\">(If \"yes\", go to question 1a.)</td> </tr> <tr> <td class=\"indent2\" colspan=\"5\"><strong>1a.</strong> What was the longest number of consecutive months in which you had at least two \"arguments\" or \"temper outbursts\" each week?</td> <td colspan=\"2\"><strong>Number of months:</strong><br /> ________________<br /> (If this period is less than three months, go to question 2.)</td> </tr> <tr> <td class=\"indent2\" colspan=\"5\"><strong>1b.</strong> How old were you when you last had two or more arguments/temper outbursts each week for at least three months in a row?</td> <td colspan=\"2\"><strong>Age in years:</strong><br /> ________________</td> </tr> <tr> <td class=\"indent2\" colspan=\"5\"><strong>1c.</strong> Are these anger outbursts, at this level, happening now?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>2.</strong> What is the greatest number of times you broke something in anger, and/or you physically injured&nbsp;someone in anger (eg, a scratch, red mark, or bruise at the least) over the course of a year? (Your answer should be a total of the number of times you broke objects plus the number of times you physically injured someone in anger.)</td> <td colspan=\"2\"><strong>Number of times breaking +&nbsp;hitting over the year:</strong><br /> ________________<br /> (If number of times is less than three per year, go to question 3.)</td> </tr> <tr> <td class=\"indent2\" colspan=\"5\"><strong>2a.</strong> How old were you when you most recently broke things and/or hit someone three or more times over the course of a year?</td> <td colspan=\"2\"><strong>Age in years:</strong><br /> ________________</td> </tr> <tr> <td class=\"indent2\" colspan=\"5\"><strong>2b.</strong> Are these aggressive outbursts, at this level, happening now?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>3.</strong> Has most of the \"arguing\", \"breaking things\", and/or \"hitting\" done as a part of a plan to gain some advantage (eg, intimidation) or was it usually an unplanned, response to becoming angry?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Planned</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Unplanned</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>4a.</strong> Has the frequency and intensity of your \"arguing\", \"breaking things\", and/or \"hitting others\" ever bothered you?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>4b.</strong> Has the frequency and intensity of your \"arguing\", \"breaking things\", and/or \"hitting others\" ever caused you any problems (eg, at work or school, or with family, friends, partners, or acquaintances)?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>5a.</strong> Has there been a time in your life when you were getting into two or more \"arguments\" or \"temper outbursts\" per week for three or more months when you were <strong>not</strong> taking any medication, drinking alcohol, or experiencing the effects (high or withdrawal) of any drug?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"><strong>5b.</strong> Has there been a time in your life when you hit individuals and/or \"broke things\" in anger a total of three or more times in a year when you were <strong>not</strong> taking any medication, drinking alcohol, or experiencing the effects (high or withdrawal) of any drug?</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span> No</td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"centered\" colspan=\"7\"><strong>Thank you for completing the Intermittent Explosive Disorder Screening Questionnaire.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"7\">IED-SQ scoring key:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"7\"><strong>Part 1</strong> <ul class=\"decimal_heading\"> <li>Lifetime aggression positive: &#8805;12 on Part 1 items </li> </ul> <strong>Part 2</strong> <ul class=\"decimal_heading\"> <li>A<sub>1</sub> positive: &#8805;3 months on question 1a. </li> <li>A<sub>2</sub> positive: &#8805;3 times on question 2. </li> <li>C positive: \"Unplanned\" on question 3. </li> <li>D positive: \"Yes\" on question 4a or 4b. </li> <li>E positive: &#8805;6 years of age on question 1b or 2a. </li> <li>F positive: \"Yes\" on question 5a or 5b. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">IED-5 positive if:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"7\"> <ul> <li>Lifetime aggression positive and </li> <li>A<sub>1</sub> or A<sub>2</sub> positive and </li> <li>C positive and </li> <li>D positive and </li> <li>E positive and </li> <li>F positive </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">IED-5 current if:</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"> <ul> <li>\"Yes\" on question 1C and/or 2b </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Cocccaro EF, Bernman ME, McCloskey MS. Development of a screening questionnaire for DSM-5 intermittent explosive disorder (IED-SQ). Compr Psychiatry 2016; 74:21. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112309 Version 1.0</div></div></div>"},"112311":{"type":"graphic_picture","displayName":"Carney complex caruncle","title":"Carney complex","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Carney complex</div><div class=\"cntnt\"><img style=\"width:756px; height:493px;\" src=\"images/DERM/112311_Carney_complex_caruncle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic pigmentation of the left lacrimal caruncle in a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112311 Version 1.0</div></div></div>"},"112312":{"type":"graphic_picture","displayName":"Carney complex lateral canthus","title":"Carney complex","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Carney complex</div><div class=\"cntnt\"><img style=\"width:756px; height:540px;\" src=\"images/DERM/112312_Carney_cmplx_ltrl_canthus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dark brown pigmentation near the lateral canthus in an African-American patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112312 Version 1.0</div></div></div>"},"112315":{"type":"graphic_picture","displayName":"Hypersensitivity reaction to caterpillar on neck","title":"Hypersensitivity reaction to caterpillar","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hypersensitivity reaction to caterpillar</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/112315_Hypersnstvty_rctn_ctrpllr1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aeromediated papulo-urticarial eruption due to setae of pine caterpillar.</div><div class=\"graphic_reference\">From: Bonamonte D, Foti C, Vestita M, Angelini G. Skin Reactions to pine processionary caterpillar Thaumetopoea pityocampa Schiff. ScientificWorldJournal 2013; 2013:867431. Copyright © 2013 Domenico Bonamonte et al. Available at: <A href=\"https://www.hindawi.com/journals/tswj/2013/867431/\" target=_blank>https://www.hindawi.com/journals/tswj/2013/867431/</A> (Accessed March 23, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/3.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 112315 Version 1.0</div></div></div>"},"112316":{"type":"graphic_picture","displayName":"Hypersensitivity reaction to caterpillar papular eruption","title":"Hypersensitivity reaction to caterpillar","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hypersensitivity reaction to caterpillar</div><div class=\"cntnt\"><img style=\"width:756px; height:683px;\" src=\"images/DERM/112316_Hypersnstvty_rctn_ctrpllr2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papules on the neck due to setae of pine caterpillar.</div><div class=\"graphic_reference\">From: Bonamonte D, Foti C, Vestita M, Angelini G. Skin Reactions to pine processionary caterpillar Thaumetopoea pityocampa Schiff. ScientificWorldJournal 2013; 2013:867431. Copyright © 2013 Domenico Bonamonte et al. Available at: <A href=\"https://www.hindawi.com/journals/tswj/2013/867431/\" target=_blank>https://www.hindawi.com/journals/tswj/2013/867431/</A> (Accessed March 23, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/3.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 112316 Version 1.0</div></div></div>"},"112317":{"type":"graphic_picture","displayName":"Hypersensitivity reaction to caterpillar","title":"Hypersensitivity reaction to caterpillar","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hypersensitivity reaction to caterpillar</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/112317_Hypersensitvty_rctn_ctrpllr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112317 Version 1.0</div></div></div>"},"112319":{"type":"graphic_picture","displayName":"Io caterpillar on branch","title":"Io caterpillar (<EM>Automeris io</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Io caterpillar (<EM>Automeris io</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/112319_Io_caterpillar_on_branch.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Robert L. Anderson, USDA Forest Service, Bugwood.org. Available at: <A href=\"https://www.forestryimages.org/browse/detail.cfm?imgnum=1748026\" target=_blank>https://www.forestryimages.org/browse/detail.cfm?imgnum=1748026</A> (Accessed March 23, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/3.0/us/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 112319 Version 1.0</div></div></div>"},"112321":{"type":"graphic_picture","displayName":"Restraint for infant circumcision","title":"Restraint for infant circumcision","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Restraint for infant circumcision</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/OBGYN/112321_Restraint_infant_circumcisn.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112321 Version 1.0</div></div></div>"},"112322":{"type":"graphic_picture","displayName":"Aquagenic wrinkling of the palms in CF","title":"Aquagenic wrinkling of the palms in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Aquagenic wrinkling of the palms in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:764px; height:435px;\" src=\"images/PEDS/112322_AquagenicwrinklingpalmCF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) White, slightly translucent papules on the left palm of a 23-year-old woman with cystic fibrosis.<br />(B) The papules became enlarged and edematous after a brief immersion in water, with excess wrinkling of the skin.</div><div class=\"graphic_reference\">From: Katz M, Ramot Y. Aquagenic wrinkling of the palms. CMAJ 2015; 187:E515. Copyright © 2015 Canadian Medical Association. This work is protected by copyright and the making of this copy was with permission of Access Copyright. Any alternation of its content or further copying in any form whatsoever is strictly prohibited unless otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 112322 Version 2.0</div></div></div>"},"112323":{"type":"graphic_picture","displayName":"Infant prep for circumcision","title":"Infant prep for circumcision","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Infant prep for circumcision</div><div class=\"cntnt\"><img style=\"width:756px; height:668px;\" src=\"images/OBGYN/112323_Infant_prep_circumcision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112323 Version 1.0</div></div></div>"},"112324":{"type":"graphic_picture","displayName":"Infant draped and penis exposed for circumcision","title":"Infant draped and penis exposed for circumcision","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Infant draped and penis exposed for circumcision</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/OBGYN/112324_Infant_draped_circumcision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112324 Version 1.0</div></div></div>"},"112326":{"type":"graphic_picture","displayName":"Spreading preputial opening during circumcision","title":"Spreading clamp to open preputial opening and break up adhesions between foreskin and glans","html":"<div class=\"graphic\"><div style=\"width: 757px\" class=\"figure\"><div class=\"ttl\">Spreading clamp to open preputial opening and break up adhesions between foreskin and glans</div><div class=\"cntnt\"><img style=\"width:737px; height:756px;\" src=\"images/OBGYN/112326_Sprdng_preputial_opnng_crcm.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112326 Version 1.0</div></div></div>"},"112327":{"type":"graphic_picture","displayName":"Placement of midline clamp on foreskin","title":"Placement of midline clamp on foreskin during circumcision","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">Placement of midline clamp on foreskin during circumcision</div><div class=\"cntnt\"><img style=\"width:732px; height:756px;\" src=\"images/OBGYN/112327_Plcmnt_mdln_clamp_foreskin.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112327 Version 1.0</div></div></div>"},"112328":{"type":"graphic_picture","displayName":"Midline incision of foreskin during infant circumcision","title":"Midline incision of foreskin during infant circumcision","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Midline incision of foreskin during infant circumcision</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/OBGYN/112328_Mdln_incsn_frskn_infnt_crcm.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112328 Version 1.0</div></div></div>"},"112329":{"type":"graphic_picture","displayName":"Carney complex periocular lentignes","title":"Carney complex​","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Carney complex​</div><div class=\"cntnt\"><img style=\"width:756px; height:505px;\" src=\"images/DERM/112329_Carney_cmplx_perioculr_lent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered lentiginous macules around the eyes with brown pigmentation of the left lacrimal caruncle in a patient with Carney complex.</div><div class=\"graphic_reference\">Courtesy of Edward W. Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 112329 Version 1.0</div></div></div>"},"112330":{"type":"graphic_picture","displayName":"Dorsal penile block through single midline injection","title":"Dorsal penile block through single midline injection","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Dorsal penile block through single midline injection</div><div class=\"cntnt\"><img style=\"width:536px; height:756px;\" src=\"images/OBGYN/112330_Drsl_penile_blck_sngl_mdln.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112330 Version 1.0</div></div></div>"},"112331":{"type":"graphic_picture","displayName":"Gomco clamp unassembled","title":"Gomco clamp unassembled","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Gomco clamp unassembled</div><div class=\"cntnt\"><img style=\"width:756px; height:489px;\" src=\"images/OBGYN/112331_Gomco_clamp_unassembled.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112331 Version 1.0</div></div></div>"},"112332":{"type":"graphic_picture","displayName":"Gomco clamp assembled","title":"Gomco clamp assembled","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Gomco clamp assembled</div><div class=\"cntnt\"><img style=\"width:756px; height:579px;\" src=\"images/OBGYN/112332_Gomco_clamp_assembled.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112332 Version 1.0</div></div></div>"},"112333":{"type":"graphic_picture","displayName":"Plastibell device and string","title":"Plastibell device and string","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Plastibell device and string</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/OBGYN/112333_Plastibell_device_string.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112333 Version 1.0</div></div></div>"},"112334":{"type":"graphic_picture","displayName":"Partial retraction of foreskin to expose urethral meatus","title":"Partial retraction of foreskin to expose urethral meatus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Partial retraction of foreskin to expose urethral meatus</div><div class=\"cntnt\"><img style=\"width:756px; height:630px;\" src=\"images/OBGYN/112334_Prtl_rtrctn_foreskin_urthrl.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112334 Version 1.0</div></div></div>"},"112335":{"type":"graphic_picture","displayName":"Retraction of foreskin to base of glans","title":"Retraction of foreskin to base of glans","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Retraction of foreskin to base of glans</div><div class=\"cntnt\"><img style=\"width:756px; height:684px;\" src=\"images/OBGYN/112335_Rtrctn_foreskin_base_glans .jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112335 Version 1.0</div></div></div>"},"112336":{"type":"graphic_picture","displayName":"Gomco bell under foreskin and covering glans","title":"Gomco bell under foreskin and covering glans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gomco bell under foreskin and covering glans</div><div class=\"cntnt\"><img style=\"width:432px; height:426px;\" src=\"images/OBGYN/112336_Gomco_bell_under_foreskin.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112336 Version 1.0</div></div></div>"},"112337":{"type":"graphic_picture","displayName":"Gomco clamp with foreskin delivered through base plate","title":"Gomco clamp with foreskin delivered through base plate","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Gomco clamp with foreskin delivered through base plate</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/OBGYN/112337_Gomco_clmp_w_frskn_thrgh_bs.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112337 Version 1.0</div></div></div>"},"112338":{"type":"graphic_picture","displayName":"Plastibell device under foreskin and covering glans","title":"Plastibell device under foreskin and covering glans","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Plastibell device under foreskin and covering glans</div><div class=\"cntnt\"><img style=\"width:756px; height:653px;\" src=\"images/OBGYN/112338_Plastibell_dvc_undr_foreskn.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112338 Version 1.0</div></div></div>"},"112339":{"type":"graphic_picture","displayName":"Plastibell device with string being applied","title":"Plastibell device with string being applied","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Plastibell device with string being applied</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/OBGYN/112339_Plastibell_dvc_w_strng_appl.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112339 Version 1.0</div></div></div>"},"112340":{"type":"graphic_picture","displayName":"Plastibell device with string fully tied","title":"Plastibell device with string fully tied and foreskin still in place","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Plastibell device with string fully tied and foreskin still in place</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/OBGYN/112340_Plastibll_dvc_w_string_tied.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112340 Version 1.0</div></div></div>"},"112341":{"type":"graphic_picture","displayName":"Plastibell circumcision after foreskin and tab removed","title":"Plastibell circumcision after foreskin and tab removed","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Plastibell circumcision after foreskin and tab removed</div><div class=\"cntnt\"><img style=\"width:756px; height:402px;\" src=\"images/OBGYN/112341_Plastibell_crcmcsn_aftr_frs.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112341 Version 1.0</div></div></div>"},"112342":{"type":"graphic_picture","displayName":"Partial removal of Gomco bell after circumcision","title":"Partial removal of Gomco bell after circumcision","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Partial removal of Gomco bell after circumcision</div><div class=\"cntnt\"><img style=\"width:586px; height:756px;\" src=\"images/OBGYN/112342_Prtl_rmvl_Gomco_bll_aftr_cr.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112342 Version 1.0</div></div></div>"},"112343":{"type":"graphic_picture","displayName":"Completed Gomco clamp circumcision","title":"Completed Gomco clamp circumcision","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Completed Gomco clamp circumcision</div><div class=\"cntnt\"><img style=\"width:486px; height:756px;\" src=\"images/OBGYN/112343_Cmpltd_Gomco_clamp_crcmcsn.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112343 Version 1.0</div></div></div>"},"112344":{"type":"graphic_table","displayName":"Risk factors for postoperative pulmonary complications","title":"Risk factors for postoperative pulmonary complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for postoperative pulmonary complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient characteristics</td> <td class=\"subtitle1\">Preoperative testing</td> <td class=\"subtitle1\">Surgery</td> <td class=\"subtitle1\">Anesthetic management</td> </tr> <tr> <td>Age</td> <td>Low albumin</td> <td>Open thoracic surgery</td> <td>General anesthesia</td> </tr> <tr> <td>Male sex</td> <td>Low SpO<sub>2</sub> (&#8804;95%)</td> <td>Cardiac surgery</td> <td>High respiratory driving pressure (&#8805;13 cm H<sub>2</sub>O)</td> </tr> <tr> <td>ASA class &#8805;3</td> <td>Anemia (Hb &#60;10 g/dL)</td> <td>Open upper abdominal surgery</td> <td>High inspiratory oxygen fraction</td> </tr> <tr> <td>Previous respiratory infection</td> <td>&nbsp;</td> <td>Major vascular surgery</td> <td>High volume of crystalloid administration</td> </tr> <tr> <td>Functional dependency</td> <td>&nbsp;</td> <td>Neurosurgery</td> <td>Erythrocyte transfusion</td> </tr> <tr> <td>Congestive heart failure</td> <td>&nbsp;</td> <td>Urology</td> <td>Residual neuromuscular blockade</td> </tr> <tr> <td>COPD</td> <td>&nbsp;</td> <td>Duration of surgery &#62;2 hours</td> <td>Nasogastric tube use</td> </tr> <tr> <td>Smoking</td> <td>&nbsp;</td> <td>Emergent surgery</td> <td>&nbsp;</td> </tr> <tr> <td>Renal failure</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Gastroesophageal reflux disease</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Weight loss</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Respiratory driving pressure is defined as inspiratory plateau airway pressure minus positive end-expiratory pressure.</div><div class=\"graphic_footnotes\">ASA: American Society of Anesthesiologists; COPD: chronic obstructive pulmonary disease; Hb: hemoglobin concentration; SpO<SUB>2</SUB>: oxygen saturation as measured by pulse oximetry.</div><div class=\"graphic_reference\">From: Güldner A, Kiss T, Serpa Neto A, et al. Intraoperative protective mechanical ventilation for prevention of postoperative pulmonary complications: a comprehensive review of the role of tidal volume, positive end-expiratory pressure, and lung recruitment maneuvers. Anesthesiology 2015; 123(3):692-713. DOI: <A href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2383205\" target=_blank>10.1097/ALN.0000000000000754</A>. Copyright © 2015 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112344 Version 2.0</div></div></div>"},"112345":{"type":"graphic_table","displayName":"Comparison of male circumcision devices","title":"Comparison of factors for consideration in selecting a device for male circumcision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of factors for consideration in selecting a device for male circumcision</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Consideration</td> <td class=\"subtitle1\">Mogen</td> <td class=\"subtitle1\">Gomco</td> <td class=\"subtitle1\">Plastibell</td> </tr> <tr> <td>Single or multiple sizes</td> <td>Single infant size can be used for all infant males.</td> <td class=\"highlight_blue_text\">Various sizes must be available.</td> <td class=\"highlight_blue_text\">Various sizes must be available.</td> </tr> <tr> <td>Number of parts</td> <td>Single part simplifies inventory.</td> <td>Various sizes and multiple parts complicate inventory.</td> <td>Multiple sizes but a single part simplifies inventory.</td> </tr> <tr> <td>Sizing errors</td> <td> <p>Reduced risk.</p> One size for all infants (slot size must be checked).</td> <td class=\"highlight_blue_text\">Increased risk (related to mismatching device parts).</td> <td class=\"highlight_blue_text\">Increased risk (complications associated with bell of wrong size).</td> </tr> <tr> <td>Duration of procedure</td> <td>Requires the least amount of time to perform.</td> <td class=\"highlight_blue_text\">Requires more time.</td> <td>Requires more time.</td> </tr> <tr> <td>Use in older infant males and young boys without suturing*</td> <td class=\"highlight_blue_text\">Routinely requires closure of the wound in infants &#62;60 days of age.</td> <td class=\"highlight_blue_text\">Routinely requires closure of the wound in infants &#62;60 days of age.</td> <td>Routinely does not require closure of the wound, regardless of age.</td> </tr> <tr> <td>Disposable/reusable</td> <td> <p>Reusable.</p> Requires reprocessing.<sup>&#182;</sup></td> <td> <p>Reusable.</p> Requires reprocessing.<sup>&#182;</sup></td> <td>Device itself is disposable (instruments may require reprocessing).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The shaded areas represent undesirable features that should be taken into account when each technique is being considered for program introduction.</div><div class=\"graphic_footnotes\">* This manual addresses early infant male circumcision. For more information on male circumcision later in life, refer to the World Health Organization Manual for male circumcision under local anaesthesia.<br />¶ The Mogen and Gomco clamps are reusable. This could be a benefit if the infrastructure is available to reprocess the instruments and the cost of sterilization is less than that of purchasing a disposable device.</div><div class=\"graphic_reference\">Reprinted from: Manual for early infant male circumcision under local anaesthesia, Overview of surgical devices, World Health Organization, p. 49, Copyright © 2010. Available from: <A href=\"http://www.who.int/hiv/pub/malecircumcision/manual_infant/en/\" target=_blank>http://www.who.int/hiv/pub/malecircumcision/manual_infant/en/</A> (accessed on May 12, 2017).</div><div id=\"graphicVersion\">Graphic 112345 Version 1.0</div></div></div>"},"112346":{"type":"graphic_table","displayName":"Comparison of complications of infant circumcision devices","title":"Comparison of complications of infant circumcision devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of complications of infant circumcision devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Consideration</td> <td class=\"subtitle1\">Mogen</td> <td class=\"subtitle1\">Gomco</td> <td class=\"subtitle1\">Plastibell</td> </tr> <tr> <td>Bleeding</td> <td class=\"highlight_blue_text\">Similar risk (1.0%).</td> <td class=\"highlight_blue_text\">Similar risk (1.0%).</td> <td class=\"highlight_blue_text\"> <p>Similar risk (1.0%).</p> Associated with injury to the frenulum during application of the bell and/or loose ligature.</td> </tr> <tr> <td>Urethral injury</td> <td>Reduced risk (dorsal slit is not routinely required).</td> <td class=\"highlight_blue_text\">Increased risk (dorsal slit routinely required).</td> <td class=\"highlight_blue_text\">Increased risk (dorsal slit routinely required).</td> </tr> <tr> <td>Penile laceration/amputation</td> <td class=\"highlight_blue_text\">Increased risk (glans may not be protected).</td> <td class=\"highlight_blue_text\">Increased risk (related to mismatching device parts).</td> <td>Reduced risk.</td> </tr> <tr> <td>Urinary retention, bladder rupture, injury from retained parts</td> <td>No risk (no retained parts).</td> <td>No risk (no retained parts).</td> <td class=\"highlight_blue_text\">Increased risk if bell of wrong size is used, as it can slip back on to shaft of penis, causing gangrene, urinary retention and bladder rupture.</td> </tr> <tr> <td>Buried glans</td> <td class=\"highlight_blue_text\">Increased risk if surgeon does not free glans.</td> <td>Similar risk.</td> <td>Similar risk.</td> </tr> <tr> <td>Other comment</td> <td class=\"highlight_blue_text\">Penile amputations can occur even under ideal circumstances.</td> <td>When matching non-defective parts are used there is essentially no risk of injury to the glans.</td> <td class=\"highlight_blue_text\">Complications from retained parts can occur even under ideal circumstances.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted from: Manual for early infant male circumcision under local anaesthesia, Overview of surgical devices, World Health Organization, p. 49, Copyright © 2010. Available from: <A href=\"http://www.who.int/hiv/pub/malecircumcision/manual_infant/en/\" target=_blank>http://www.who.int/hiv/pub/malecircumcision/manual_infant/en/</A> (accessed on May 12, 2017).</div><div id=\"graphicVersion\">Graphic 112346 Version 1.0</div></div></div>"},"112347":{"type":"graphic_table","displayName":"Capecitabine plus oxaliplatin advanced esophagogastric cancer","title":"Capecitabine plus oxaliplatin for advanced esophagogastric cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine plus oxaliplatin for advanced esophagogastric cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Duration of therapy:</strong> Treatment is continued until disease progression, unacceptable toxicity, or patient withdrawal. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>130 mg/m<sup>2</sup> IV*</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#916;</sup></td> <td>1000 mg/m<sup>2</sup> per dose, by mouth</td> <td>Twice daily (total dose 2000 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#9674;</sup></td> <td>Days 1 to 14</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin: MODERATE. </li> <li>Oral capecitabine: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for oxaliplatin. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated (estimated risk of febrile neutropenia is &#60;5%). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT (QTc) interval and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QTc interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function every three weeks prior to each new cycle of treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment. </li> <li>Refer to UpToDate topics on \"Enterotoxicity of chemotherapeutic agents\" and \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle of treatment should not start until neutrophils recover to &#62;1500/microL and platelets recover to &#62;100,000/microL.<sup>[2]</sup> Interrupt capecitabine until the next cycle begins for any grade 2 or worse hematologic toxicity and delay treatment until complete recovery or improvement to &#8804;grade 1. After recovery, reduce doses of both drugs by 20% for febrile neutropenia in the preceding cycle.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine until the initiation of the next cycle and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1. Reduce the capecitabine dose by 20% in subsequent cycles at the first occurrence of grade 2 gastrointestinal toxicity, and by 30% for grade 3 or 4 toxicity including mucositis.<sup>[1]</sup> After recovery, reduce the dose of oxaliplatin by 25% for grade 4 diarrhea.<sup>[1]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong><sup>&#167;</sup></td> <td colspan=\"3\"> <ul> <li>Reduce the dose of oxaliplatin by 25% for persistent (14 days or longer) paresthesia or temporary (7 to 14 days) painful paresthesia or functional impairment.<sup>[2]</sup> For persistent painful paresthesia or functional impairment omit oxaliplatin until recovery and restart at 50% of dose.<sup>[2]</sup> Discontinue if toxicities recur despite dose reduction. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[2]</sup> Reduce the dose of oxaliplatin by 25% for any drug-related grade 3 toxicity other than that described above. Reduce the capecitabine dose by 20 to 30% in subsequent cycles for grade 2 or grade 3 toxicity (including hand-foot syndrome) during a preceding cycle.<sup>[1]</sup> Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the fourth time at grade 2, third time at grade 3, or a second time at grade 4.<sup>[3]</sup> For transient renal insufficiency in the preceding cycle, reduce doses of both drugs. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine omitted for toxicity are not replaced or restored; instead the patient should resume with the next planned treatment cycle.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio.<br />* Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline and a D5W flush is recommended prior to starting the drug infusion.<br />Δ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br /><FONT class=lozenge>◊</FONT> Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.<br />§ Neurotoxicity was graded in the original study based on the Levis scale: Grade 1, paresthesias of moderate intensity lasting less than seven days; grade 2, painful paresthesias lasting 8 to 14 days (without functional impairment); grade 3, persistent (&gt;14 days) paresthesias (without functional impairment); grade 4, beginning functional impairment.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jatoi A, et al. Ann Oncol 2006; 17:29.</LI>&#xD;&#xA;<LI>van Meerten E, et al. Br J cancer 2007; 96:1348.</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on March 17, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 112347 Version 6.0</div></div></div>"},"112348":{"type":"graphic_table","displayName":"Oral lentiginosis differential diagnosis","title":"Differential diagnosis of disorders associated with oral lentiginosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of disorders associated with oral lentiginosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Inheritance/gene</td> <td class=\"subtitle1\">Cutaneous pigmentation</td> <td class=\"subtitle1\">Testicular tumors</td> <td class=\"subtitle1\">Gastrointestinal involvement</td> <td class=\"subtitle1\">Malignancy</td> <td class=\"subtitle1\">Thyroid abnormalities</td> <td class=\"subtitle1\">Other endocrinopathies</td> </tr> <tr> <td>McCune-Albright syndrome</td> <td>Somatic/<em>GNAS</em></td> <td>\"Coast of Maine\" caf&#233;-au-lait patches; oral mucosal lentigines</td> <td>Leydig cell hyperplasia; Sertoli cell hyperplasia</td> <td>Possible hamartomatous polyps; IPMN</td> <td>Small increase in risk of malignancies in affected tissues (thyroid, bone, pancreas)</td> <td>Patchy heterogeneity and cystic changes; hyperthyroid</td> <td>Precocious puberty; GH excess; neonatal Cushing syndrome</td> </tr> <tr> <td>Peutz-Jeghers syndrome</td> <td>AD/<em>STK11</em> (<em>LKB1</em>)*</td> <td>Mucosal and cutaneous lentigines</td> <td>Large cell calcifying Sertoli cell tumor</td> <td>Hamartomatous polyps</td> <td>Ovarian; breast; pancreatic; thyroid; cervix; cholangiocarcinoma</td> <td>Malignancy</td> <td>None</td> </tr> <tr> <td>Carney complex</td> <td>AD/<em>PRKAR1a</em><sup>&#182;</sup></td> <td>Cutaneous and mucosal lentigines; blue nevi; melanocytic nevi; CALM; hypopigmented lesions</td> <td>Large cell calcifying Sertoli cell tumor; Leydig cell tumor</td> <td>Psammomatous melanocytic schwannoma; pancreatic lesions including IPMN</td> <td>Adrenal; hepatocellular; pancreatic; osteochondromyxomas</td> <td>Hyperplasia; cystic changes; malignancy</td> <td>PPNAD; GH excess; prolactin excess; pituitary adenomas; Cushing syndrome</td> </tr> <tr> <td>Laugier-Hunziker syndrome</td> <td>Acquired</td> <td>Melanonychia striata; genital pigmentation; palmoplantar pigmentation</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>GNAS</EM>: complex locus, guanine nucleotide alpha-stimulating; IPMN: intraductal papillary mucinous neoplasms of the pancreas; GH: growth hormone; AD: autosomal dominant; <EM>STK11</EM>: serine/threonine kinase 11; <EM>PRKAR1a</EM>: protein kinase cyclic adenosine monophosphate-dependent regulatory, type 1-alpha; CALM: café-au-lait macule; PNAD: primary pigmented nodular adrenocortical disease.<br />* In 50 to 70 percent&nbsp;of reported Carney complex cases.<br />¶ Majority due to mutation of <EM>PRKAR1a</EM>; second locus on chromosome 2p16 identified but gene unknown.</div><div class=\"graphic_reference\">Reproduced with permission from: Pichard DC, Boyce AM, Collins MT, Cowen EW. Oral pigmentation in McCune-Albright syndrome. JAMA Dermatol 2014; 150:760. Copyright © 2014 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112348 Version 2.0</div></div></div>"},"112354":{"type":"graphic_table","displayName":"Approach to sleep disorders in children with cancer","title":"Approach to sleep disorders in children with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to sleep disorders in children with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Predominant symptom(s)</td> <td class=\"subtitle1\">Potential diagnoses, causes,&nbsp;and risk factors</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Evaluation and management</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Excessive daytime sleepiness (EDS)</strong></td> <td> <ul> <li>Physiologic effects of cancer (especially brain cancer) </li> <li>Effects of cancer-directed therapies (especially dexamethasone) </li> <li>Obstructive sleep apnea (described below) </li> <li>Circadian rhythm disturbance (described below) </li> <li>Chronic insomnia (described below) </li> </ul> </td> <td> <ul> <li>Difficulty remaining alert during daytime activities </li> <li>Increased duration of sleep time </li> <li>Increased daytime napping </li> </ul> </td> <td> <ul> <li>Distinguish EDS from fatigue </li> <li>Diagnose and treat specific underlying sleep disorders </li> <li>Address&nbsp;behavioral or environmental contributors </li> <li>Pharmacotherapy for refractory cases </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Insomnia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Bedtime resistance; frequent or prolonged awakenings</td> <td> <p>Chronic insomnia, behavioral insomnia of childhood subtype</p> <ul> <li>Due to inadequate parental limit-setting or sleep onset associations </li> <li>Can be related to parents' caretaking at night, which may condition the child to require parental presence at bedtime </li> <li>Common in preschool or school-aged children </li> </ul> </td> <td> <ul> <li>Resistance to going to bed at night </li> <li>Awakenings with refusal to go back to sleep without presence of the parent </li> </ul> </td> <td> <ul> <li>Sleep hygiene* </li> <li>Parental education about limit-setting and sleep-onset associations </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Difficulty with sleep onset or maintenance</td> <td> <p>Chronic insomnia, psychophysiologic insomnia subtype (also known as conditioned insomnia)</p> <ul> <li>Common in school-aged children or adolescents </li> </ul> </td> <td> <ul> <li>Concern or anxiety specifically about difficulty sleeping causes or exacerbates the insomnia </li> <li>Difficulty sleeping at specific times of the night becomes&nbsp;habitual </li> </ul> </td> <td> <ul> <li>Sleep hygiene* </li> <li>Refer for cognitive-behavioral therapy for insomnia </li> <li>Evaluate and treat any underlying anxiety or mood disorder that may be contributing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\">Difficulty with sleep onset or maintenance, in the setting of chronic or recurrent sleep-wake rhythm disruption&nbsp;&nbsp;</span></td> <td> <p>Circadian rhythm sleep-wake disorder</p> <ul> <li>Brain tumors (direct effects) </li> <li>Dexamethasone, radiotherapy </li> <li>Environmental contributors: <ul> <li>Frequent or prolonged hospitalizations </li> <li>Low daytime activity or light exposure </li> <li>Nighttime stimulation (eg, electronics) </li> </ul> </li> <li>Adolescence </li> </ul> </td> <td> <ul> <li>Presence of risk factors </li> <li>Complaints of disrupted circadian patterns, if not explained by sleep hygiene </li> </ul> </td> <td> <ul> <li>Optimize sleep hygiene and emphasize regularity of sleep schedule </li> <li>Consider melatonin supplementation&nbsp; </li> <li>Consider bright light therapy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\">Urge to move legs, or related dysesthesias</span></td> <td> <p>Restless legs syndrome (RLS)</p> <ul> <li>Iron deficiency, with or without anemia </li> <li>Family history of RLS </li> </ul> </td> <td> <ul> <li>Unpleasant sensation with urge to move legs, exacerbated when sedentary, worse in the evening, and ameliorated by walking or movement </li> <li>Children may describe a wide range of sensations, and may report pain that is difficult to distinguish from \"growing pains\" </li> <li>May interfere with sleep onset or maintenance </li> <li>Leg discomfort is essential to the diagnosis, but may not be the presenting complaint </li> </ul> </td> <td> <ul> <li>Measure serum ferritin </li> <li>Consider iron replacement therapy </li> <li>Refer to UpToDate topic review on RLS in children for details and options for management </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Snoring or breathing problems</strong></td> <td> <ul> <li>Obstructive sleep apnea, eg, from: <ul> <li>Brain tumors </li> <li>Obesity </li> </ul> </li> </ul> </td> <td> <ul> <li>Frequent or loud snoring, witnessed apnea or labored breathing, obesity, behavioral changes (eg, daytime inattention, hyperactivity) </li> <li>May or may not cause EDS </li> </ul> </td> <td> <ul> <li>Polysomnography </li> <li>Assess behavioral symptoms (eg, ADHD) </li> <li>Refer to UpToDate topic reviews on sleep apnea in children </li> </ul> </td> </tr> <tr> <td><strong>Fatigue</strong></td> <td> <ul> <li>Many contributors </li> </ul> </td> <td> <ul> <li>Subjective feeling of physical, emotional, or cognitive tiredness </li> </ul> </td> <td> <ul> <li>Determine if there is a component of EDS, anxiety, or depression, and treat as indicated </li> <li>Diagnose and treat any underlying sleep disorders, which can contribute to fatigue even in the absence of reported sleepiness </li> <li>Optimize sleep hygiene* </li> <li>Encourage physical activity </li> <li>Consider&nbsp;bright light therapy </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RLS: restless legs syndrome; ADHD: attention-deficit/hyperactivity disorder.<br />* To optimize sleep hygiene, evaluate and educate family about healthy sleep practices, including stable bedtime and wake time, soothing pre-bedtime routine, avoiding electronics prior to bedtime, and a quiet and comfortable sleeping environment. Refer to UpToDate topic on behavioral sleep problems in children.</div><div id=\"graphicVersion\">Graphic 112354 Version 3.0</div></div></div>"},"112355":{"type":"graphic_figure","displayName":"Lawrence classification of venous ablation level","title":"Lawrence classification of venous ablation level","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Lawrence classification of venous ablation level</div><div class=\"cntnt\"><img style=\"width:531px; height:484px;\" src=\"images/SURG/112355_Classification_of_closure_level_and_treatment_algorithm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates a proposed classification system describing six levels of proximal great saphenous vein thrombus due to EHIT for the purpose of guiding clinical therapy and further research.<br /><ul>&#xD;&#xA;    <li><strong>Superficial vein thrombosis (EHIT):</strong>&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Level I: Thrombus below the superficial epigastric vein</li>&#xD;&#xA;        <li>Level II: Thrombus up to the origin of the superficial epigastric vein</li>&#xD;&#xA;        <li>Level III: Thrombus up to but not into the common femoral vein</li>&#xD;&#xA;        <li>Level IV: Thrombus bulging into the common femoral vein but not adherent to the wall of the common femoral vein</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;    <li><strong>Deep vein thrombosis:</strong>&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Level V: Thrombus extending into the common femoral vein and adherent to the adjacent wall</li>&#xD;&#xA;        <li>Level VI: Occlusive thrombus of the common femoral vein</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">EHIT: endovenous heat-induced thrombus.</div><div class=\"graphic_reference\">Modified from: Lawrence PF, Chandra A, Wu M, et al. Classification of proximal endovenous closure levels and treatment algorithm. J Vasc Surg 2010; 52:388.</div><div id=\"graphicVersion\">Graphic 112355 Version 3.0</div></div></div>"},"112358":{"type":"graphic_figure","displayName":"Manual detorsion of the testicle","title":"Manual detorsion of the testicle","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Manual detorsion of the testicle</div><div class=\"cntnt\"><img style=\"width:472px; height:657px;\" src=\"images/EM/112358_Manual_detorsion_of_the_testicle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The right testicle shows the characteristic medial torsion with elevation and horizontal lie of the testis.<br />(B) After appropriate sedation and analgesia has been administered, manual detorsion is performed by grasping the testicle and rotating it within the scrotum outward (medial to lateral) one to two full 360 degree turns. Prompt relief of pain, lower position of the testis in the scrotum, and return of arterial flow on Doppler ultrasound suggests detorsion. If there is no improvement, try rotating the testicle in the opposite direction (lateral to medial) because approximately one-third of torsed testicles may have lateral rotation.</div><div class=\"graphic_reference\">Modified from: Cronan KM, Zderic SA. Manual detorsion of the testes. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008.</div><div id=\"graphicVersion\">Graphic 112358 Version 2.0</div></div></div>"},"112360":{"type":"graphic_picture","displayName":"Testicular torsion","title":"Testicular torsion","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Testicular torsion</div><div class=\"cntnt\"><img style=\"width:800px; height:368px;\" src=\"images/EM/112360_Testicular_torsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Note that the left testicle is high riding. This patient had a 12 hour history of pain with vomiting and had no cremasteric reflex on examination.<br />(B) At surgery, the patient had torsion with ischemia of the left testicle. Contralateral exploration demonstrated a bell clapper deformity on the right side.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 112360 Version 1.0</div></div></div>"},"112361":{"type":"graphic_table","displayName":"Healthy sleep habits","title":"Healthy sleep habits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Healthy sleep habits</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Principle</td> <td class=\"subtitle1\">Advice to patients</td> </tr> <tr class=\"divider_bottom\"> <td>Have a consistent sleep schedule</td> <td>Wake up and go to bed at about the same time on weeknights and weekend nights. Bedtime and wake time should not differ from day to day by more than an hour.</td> </tr> <tr class=\"divider_bottom\"> <td>Establish a regular, relaxing bedtime routine</td> <td>Make the 30 minutes before bed wind-down time. Do not watch TV, use electronic devices (smartphones, tablets, etc), the Internet, or exercise during this time; rather, do something relaxing, such as playing with quiet toys, reading a book, or listening to soothing music.</td> </tr> <tr class=\"divider_bottom\"> <td>Create an environment that is only for sleeping</td> <td>This means the bedroom should be comfortable, quiet, and dark. Also, make sure the room is not too warm (75 degrees or higher), as warm temperatures interfere with sleep. It is also very important to get all technology (TV, cell phones, computers, tablets, etc) out of the bedroom.</td> </tr> <tr class=\"divider_bottom\"> <td>Have a light snack before bed</td> <td>Eat regular meals throughout the day and have a light snack before bed. There is truth to cookies and milk helping facilitate sleep! Healthier snack choices include yogurt, milk, or cheese. Do not eat large amounts of sugar or chocolate.</td> </tr> <tr class=\"divider_bottom\"> <td>Exercise regularly (but not too close to bedtime)</td> <td>The best time to exercise is first thing in the morning or in the late afternoon. Avoid strenuous physical exertion right before bed.</td> </tr> <tr class=\"divider_bottom\"> <td>Enjoy the sunshine in the morning</td> <td>Spend time outside every day, especially in the morning, as exposure to sunlight or bright light helps to keep the body's internal clock on track. However, it is important to limit light exposure in the evening, especially after dinner. This means turning down overhead lights and reducing the brightness of screens (eg, computers, tablets).</td> </tr> <tr class=\"divider_bottom\"> <td>Avoid naps if you are having trouble falling asleep at bedtime</td> <td>Naps are developmentally appropriate in young children, and some adolescents benefit from a short afternoon nap (45 minutes right after school). However, for those who have difficulties falling asleep at bedtime, naps can make this even worse.</td> </tr> <tr> <td>Do not consume caffeine after 4&nbsp;PM or within 6 hours of bedtime</td> <td>Caffeine has a half-life of four to six hours, which means it should still be helping you stay awake four to six hours after you take it but then can also make it hard to fall asleep! Be aware of all the things that have caffeine. You may know that many sodas, coffee, iced tea, and dark chocolate have caffeine. But you can also find caffeine in less obvious products like certain waters, juice drinks, gum, and candy bars. Some medications also contain caffeine. In general, children should not be consuming caffeine.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Healthy sleep habits will help you fall asleep faster, stay asleep, and wake more refreshed in the morning. Consistency in following these rules is essential to achieve quality sleep.</div><div class=\"graphic_reference\">Reproduced from: Meltzer LJ, McLaughlin Crabtree V. Pediatric sleep problems: A clinician's guide to behavioral interventions. American Psychological Association, 2015. Copyright &copy; 2015 American Psychological Association.</div><div id=\"graphicVersion\">Graphic 112361 Version 1.0</div></div></div>"},"112380":{"type":"graphic_figure","displayName":"Latch on breastfeeding","title":"Latch on breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Latch on breastfeeding</div><div class=\"cntnt\"><img style=\"width:514px; height:554px;\" src=\"images/PEDS/112380_Latch_on_breastfeeding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During latch-on, the infant's mouth forms a tight seal around the nipple and most of the areola. Signs that the infant has a good latch-on include:<br /><UL>&#xD;&#xA;<LI>The top and bottom lips are wide open. </LI>&#xD;&#xA;<LI>The lower lip is turned outward against the breast. </LI>&#xD;&#xA;<LI>The chin is touching the breast, and the nose is close to the breast. </LI>&#xD;&#xA;<LI>The cheeks are full. </LI>&#xD;&#xA;<LI>The tongue is extended over the lower dental ridge and is in contact with the breast; this can be seen if the lower lip is pulled away.</LI></UL></div><div id=\"graphicVersion\">Graphic 112380 Version 2.0</div></div></div>"},"112382":{"type":"graphic_picture","displayName":"Chromhidrosis on cheek","title":"Chromhidrosis","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Chromhidrosis</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/DERM/112382_Chromhidrosis_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black-colored secretions from the cheek visible upon mild exertion.</div><div class=\"graphic_reference\">From: Wang A, Wysong A, Nord KM, et al. Chromhidrosis: A Rare Diagnosis Requiring Clinicopathologic Correlation. Am J Dermatopathol 2014; 36:853. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00015&amp;type=abstract\" target=_blank>10.1097/DAD.0b013e3182871a17</A>. Copyright © 2014 International Society of Dermatopathology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112382 Version 1.0</div></div></div>"},"112388":{"type":"graphic_table","displayName":"Women at increased risk of having an STI","title":"Women at increased risk of having a sexually transmitted infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Women at increased risk of having a sexually transmitted infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Personal history of a prior sexually transmitted infection </li> <li>Age &#60;25 years </li> <li>New sex partner in past 60 days </li> <li>More than one sex partner or sex partner with multiple concurrent sex partners </li> <li>Sex partner diagnosed with a sexually transmitted infection </li> <li>No or inconsistent condom use outside a mutually monogamous sexual partnership </li> <li>Trading sex for money or drugs </li> <li>Sexual contact with sex workers </li> <li>Meeting anonymous partners on the internet </li> <li>Unmarried status </li> <li>Lower socioeconomic status or high school education or less </li> <li>Admission to correctional facility or juvenile detention center </li> <li>Use of illicit drugs </li> <li>Living in a community with a high prevalence of sexually transmitted infections </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112388 Version 1.0</div></div></div>"},"112390":{"type":"graphic_table","displayName":"Lifestyle interventions to lower blood pressure","title":"Lifestyle interventions to lower blood pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifestyle interventions to lower blood pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Approximate reduction in blood pressure</td> </tr> <tr> <td>Weight reduction</td> <td>5 to 20 mmHg/10 kg weight loss</td> </tr> <tr> <td>Adopt DASH eating plan</td> <td>8 to 14 mmHg</td> </tr> <tr> <td>Dietary sodium (salt) reduction</td> <td>2 to 8 mmHg</td> </tr> <tr> <td>Increase physical activity</td> <td>4 to 9 mmHg</td> </tr> <tr> <td>Moderate alcohol consumption</td> <td>2 to 4 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DASH: Dietary Approaches to Stop Hypertension.</div><div class=\"graphic_reference\">Adapted from: Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206.</div><div id=\"graphicVersion\">Graphic 112390 Version 1.0</div></div></div>"},"112412":{"type":"graphic_table","displayName":"Common species implicated in lepidopterism","title":"Some common species implicated in lepidopterism (skin disorders secondary to caterpillars and moths)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some common species implicated in lepidopterism (skin disorders secondary to caterpillars and moths)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reaction</td> <td class=\"subtitle1\">Species (common name)</td> <td class=\"subtitle1\">Distribution</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Sting reactions</td> <td><em>Automeris io</em> (Io moth caterpillar)</td> <td>Southern Canada to Central America</td> </tr> <tr> <td><em>Hemileuca maia</em> (Buck moth caterpillar)</td> <td>Eastern United States</td> </tr> <tr> <td><em>Megalopyge opercularis</em> and <em>Megalopyge crispata</em> (Puss moth caterpillar)</td> <td>Eastern United States to Central America</td> </tr> <tr> <td><em>Parasa lepida</em> (Blue-striped grub moth caterpillar)</td> <td>Southeast Asia, Japan</td> </tr> <tr> <td><em>Acharia stimulea</em> (Saddleback caterpillar)</td> <td>Eastern United States</td> </tr> <tr> <td><em>Doratifera </em>spp (Cup moth caterpillar)</td> <td>Australia</td> </tr> <tr> <td><em>Thosea penthima</em> (Billygoat plum stinging caterpillar)</td> <td>Australia</td> </tr> <tr class=\"divider_bottom\"> <td><em>Chelepteryx collesi</em> (White-stemmed gum moth caterpillar)</td> <td>Australia</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Hypersensitivity</td> <td><em>Hylesia metabus</em> and <em>Hylesia nigricans</em> (Yellowtail moth*)</td> <td>Central and South America</td> </tr> <tr> <td><em>Thaumetopoea </em>spp (Processionary caterpillar)</td> <td>Europe, North Africa, Mediterranean basin</td> </tr> <tr> <td><em>Lophocampa caryae</em> (Hickory tussock moth caterpillar)</td> <td>Eastern United States, Canada</td> </tr> <tr> <td><em>Lymantria dispar</em> (Gypsy moth caterpillar)</td> <td>Eastern United States, Europe, Asia</td> </tr> <tr> <td><em>Euproctis chrysorrhoea</em> (Browntail moth caterpillar)</td> <td>Europe, United States (coastal Maine, Cape Cod)</td> </tr> <tr> <td><em>Euproctis edwardsi</em> (Mistletoe browntail moth caterpillar)</td> <td>Australia</td> </tr> <tr class=\"divider_bottom\"> <td><em>Orgyia pseudotsugata</em> (Douglas-fir tussock moth caterpillar)</td> <td>Western United States and Canada</td> </tr> <tr> <td rowspan=\"2\">Lonomism</td> <td><em>Lonomia obliqua</em></td> <td>Southern Brazil</td> </tr> <tr> <td><em>Lonomia achelous</em></td> <td>Venezuela, Guyana, northern Brazil</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In the case of <EM>Hylesia</EM>, the moth is the main cause of lepidopterism.</div><div id=\"graphicVersion\">Graphic 112412 Version 1.0</div></div></div>"},"112424":{"type":"graphic_algorithm","displayName":"Approach to gram-positive bacilli","title":"Classification of gram-positive bacilli by laboratory features","html":"<div class=\"graphic\"><div style=\"width: 912px\" class=\"figure\"><div class=\"ttl\">Classification of gram-positive bacilli by laboratory features</div><div class=\"cntnt\"><img style=\"width:892px; height:352px;\" src=\"images/ID/112424_Apprh_gram-positive_bacilli.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112424 Version 1.0</div></div></div>"},"112425":{"type":"graphic_figure","displayName":"ILAE seizure and epilepsy classification framework","title":"International League Against Epilepsy (ILAE) framework for seizure and epilepsy classification","html":"<div class=\"graphic\"><div style=\"width: 799px\" class=\"figure\"><div class=\"ttl\">International League Against Epilepsy (ILAE) framework for seizure and epilepsy classification</div><div class=\"cntnt\"><img style=\"width:779px; height:480px;\" src=\"images/NEURO/112425_ILAE_schema_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Scheffer IE, Berkovic S, Capovila G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017. DOI: 10.1111/epi.13709. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.13709/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.13709/abstract</A>. Copyright © 2017 The International League Against Epilepsy. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 112425 Version 1.0</div></div></div>"},"112426":{"type":"graphic_figure","displayName":"Effects of chemo on hair cycle","title":"Effects of chemotherapy on hair cycle","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Effects of chemotherapy on hair cycle</div><div class=\"cntnt\"><img style=\"width:537px; height:536px;\" src=\"images/ONC/112426_Effects_of_chemo_on_hair_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair follicles are continuously cycling with periods of active growth characterized by cell differentiation and division (anagen), regression (catagen), and rest (telogen). After the rest period, hair is shed as part of the normal hair cycle (exogen).&nbsp;The majority of follicles are in the active growth phase. The main damage from chemotherapy is during the anagen (growing) phase, while chemotherapy also increases shedding during the resting phase.</div><div class=\"graphic_reference\">Adapted from: Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 2013; 14:e50.</div><div id=\"graphicVersion\">Graphic 112426 Version 1.0</div></div></div>"},"112427":{"type":"graphic_algorithm","displayName":"Genetic eval fetus w soft markers after a neg serum screening","title":"Genetic evaluation of the fetus found to have soft markers for fetal aneuploidy on ultrasound after a negative serum aneuploidy marker screen","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Genetic evaluation of the fetus found to have soft markers for fetal aneuploidy on ultrasound after a negative serum aneuploidy marker screen</div><div class=\"cntnt\"><img style=\"width:725px; height:409px;\" src=\"images/OBGYN/112427_Gnvlftsstmknegsrmscn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft markers may include mild pyelectasis, single umbilical artery, cerebral ventriculomegaly, echogenic bowel, thick nuchal fold, hypoplastic nasal bone, or shortened humerus or femur.</div><div class=\"graphic_footnotes\">cfDNA: cell-free DNA; FISH: fluorescence in situ hybridization.<br />* Some soft markers in euploid fetuses are associated with disorders other than aneuploidy (eg, echogenic bowel and cystic fibrosis, nuchal translucency and congenital heart disease or Noonan syndrome), which may require additional evaluation, including invasive diagnostic testing. Refer to the UpToDate topic on prenatal genetic evaluation of the anomalous fetus.<br />¶ Some isolated soft markers, particularly nuchal translucency, absent nasal bone, and echogenic bowel, are more strongly associated with fetal aneuploidy than other soft markers (eg, pyelectasis). Genetic counseling should address this issue.<br />Δ Although FISH provides a rapid result, it also adds to the cost of the fetal evaluation, so it is also reasonable to proceed directly to chromosomal microarray analysis.</div><div id=\"graphicVersion\">Graphic 112427 Version 2.0</div></div></div>"},"112429":{"type":"graphic_table","displayName":"DC mutations","title":"Mutations in dyskeratosis congenita and other telomere biology disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mutations in dyskeratosis congenita and other telomere biology disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mutated gene</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Inheritance</td> </tr> <tr> <td class=\"centered\"><em>ACD</em></td> <td>Classic DC; Hoyeraal-Hreidarsson syndrome</td> <td>AD or AR</td> </tr> <tr> <td class=\"centered\"><em>CTC1</em></td> <td>Classic DC; Coats plus syndrome</td> <td>AR</td> </tr> <tr> <td class=\"centered\"><em>DKC1</em></td> <td>Classic DC; Hoyeraal-Hreidarsson syndrome</td> <td>X-linked</td> </tr> <tr> <td class=\"centered\"><em>NAF1</em></td> <td>Classic DC</td> <td>AD</td> </tr> <tr> <td class=\"centered\"><em>NHP2</em></td> <td>Classic DC</td> <td>AR</td> </tr> <tr> <td class=\"centered\"><em>NOP10</em></td> <td>Classic DC</td> <td>AR</td> </tr> <tr> <td class=\"centered\"><em>PARN</em></td> <td>Classic DC, pulmonary fibrosis, Hoyeraal-Hreidarsson syndrome</td> <td>AR</td> </tr> <tr> <td class=\"centered\"><em>RTEL1</em></td> <td>Classic DC, pulmonary fibrosis, Hoyeraal-Hreidarsson syndrome</td> <td>AD or AR</td> </tr> <tr> <td class=\"centered\"><em>STN1</em></td> <td>Coats plus syndrome</td> <td>AR</td> </tr> <tr> <td class=\"centered\"><em>TERC</em></td> <td>Classic DC, pulmonary fibrosis</td> <td>AD or AR</td> </tr> <tr> <td class=\"centered\"><em>TERT</em></td> <td>Classic DC, familial melanoma, pulmonary fibrosis</td> <td>AD or AR</td> </tr> <tr> <td class=\"centered\"><em>TINF2</em></td> <td>Classic DC, Hoyeraal-Hreidarsson syndrome, Revesz syndrome</td> <td>AD</td> </tr> <tr> <td class=\"centered\"><em>WRAP53</em></td> <td>Classic DC</td> <td>AR</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on DC, pulmonary fibrosis, and regulation of cell division for further information.</div><div class=\"graphic_footnotes\">DC: dyskeratosis congenita; AR: autosomal recessive; AD: autosomal dominant.</div><div id=\"graphicVersion\">Graphic 112429 Version 1.0</div></div></div>"},"112432":{"type":"graphic_table","displayName":"Conversion of T4 monotherapy to T4-T3 therapy","title":"Approach to conversion of T4 monotherapy to combined T4 and T3 therapy<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to conversion of T4 monotherapy to combined T4 and T3 therapy<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Current T4 therapy (mcg/day)</td> <td class=\"subtitle1\" colspan=\"2\">Combined T4 and T3 oral therapy reflecting a physiologic T4-to-T3 ratio of 13:1 to 16:1*</td> </tr> <tr> <td class=\"subtitle2\">T4 oral dose (mcg/day)</td> <td class=\"subtitle2\">T3 dose</td> </tr> <tr> <td>75-100</td> <td>50-75</td> <td>2.5 mcg twice daily</td> </tr> <tr> <td>112-137</td> <td>88-112</td> <td> <p>2.5 mcg three times daily <strong>or</strong></p> 5 mcg AM and 2.5 mcg PM</td> </tr> <tr> <td>150-175</td> <td>112-137</td> <td>5 mcg twice daily</td> </tr> <tr> <td>200-250</td> <td>150-200</td> <td>7.5 mcg AM <strong>and</strong> 5 mcg PM</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For patients in whom combined T4 and T3 therapy is pursued, the T4 and T3 components should be prescribed as separate levothyroxine and liothyronine pills according to the above conversions, which provide T4:T3 in a dose ratio that approximates normal physiology. Refer to UpToDate topic on treatment of primary hypothyroidism in adults for details, including patient selection considerations.</div><div class=\"graphic_footnotes\">T4: levothyroxine; T3: liothyronine.<br />* Commercially available T4-T3 combination pills (liotrix) are a 4:1 ratio mixture that deliver a supraphysiologic T3 dose relative to T4 and are not suitable for providing a T4:T3 dose ratio that approximates the physiologic ratio shown in this table.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA guidelines: The use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1:55.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Douglas S Ross, MD.</div><div id=\"graphicVersion\">Graphic 112432 Version 1.0</div></div></div>"},"112446":{"type":"graphic_figure","displayName":"Jackson table (Spinal Table System)","title":"Jackson table (Spinal Table System)","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Jackson table (Spinal Table System)</div><div class=\"cntnt\"><img style=\"width:593px; height:448px;\" src=\"images/ANEST/112446_Jackson_frame_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows a patient positioned on the Spinal Table System, which was formerly known as the Jackson table.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2017 Mizuho OSI. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112446 Version 1.0</div></div></div>"},"112448":{"type":"graphic_picture","displayName":"Andrews frame","title":"Andrews frame","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Andrews frame</div><div class=\"cntnt\"><img style=\"width:756px; height:465px;\" src=\"images/ANEST/112448_Andrews_frame_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2017 Mizuho OSI. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112448 Version 1.0</div></div></div>"},"112450":{"type":"graphic_figure","displayName":"Prone foam head support","title":"Prone foam head support","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Prone foam head support</div><div class=\"cntnt\"><img style=\"width:500px; height:447px;\" src=\"images/ANEST/112450_Prone_foam_head_support_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a foam support for the patient's head in the prone position. The T shaped opening is designed to allow the eyes and nose to be free. The headrest is placed over the patient's face while supine, making sure that the eyes and nose are free in the respective openings in the device, and turned in place. The endotracheal tube is positioned so that it sits within the opening on&nbsp;the side (left side in this photo).</div><div class=\"graphic_reference\">© 2017 Medtronic. All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 112450 Version 1.0</div></div></div>"},"112451":{"type":"graphic_figure","displayName":"Foam arm cradle","title":"Foam arm cradle","html":"<div class=\"graphic\"><div style=\"width: 754px\" class=\"figure\"><div class=\"ttl\">Foam arm cradle</div><div class=\"cntnt\"><img style=\"width:734px; height:466px;\" src=\"images/ANEST/112451_Foam_arm_cradle_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This foam cradle can be used to support the arm during anesthesia, and can be used with the arm straight or elbow flexed.&nbsp;</div><div class=\"graphic_reference\">© 2017 Medtronic. All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 112451 Version 1.0</div></div></div>"},"112452":{"type":"graphic_figure","displayName":"Foam headrest donut","title":"Foam headrest donut","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Foam headrest donut</div><div class=\"cntnt\"><img style=\"width:504px; height:400px;\" src=\"images/ANEST/112452_Foam_headrest_donut_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This donut shaped foam headrest is an example of the devices that may be used to support and stabilize the head, and prevent pressure injury of the occiput.</div><div class=\"graphic_reference\">© 2017 Medtronic. All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 112452 Version 1.0</div></div></div>"},"112453":{"type":"graphic_picture","displayName":"Gel chest rolls","title":"Gel chest rolls","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Gel chest rolls</div><div class=\"cntnt\"><img style=\"width:756px; height:539px;\" src=\"images/ANEST/112453_Gel_chest_rolls.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2017 Action Products, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112453 Version 1.0</div></div></div>"},"112454":{"type":"graphic_figure","displayName":"Pediatric end tidal CO2 curve","title":"Pediatric end tidal CO<SUB>2</SUB> curve","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pediatric end tidal CO<SUB>2</SUB> curve</div><div class=\"cntnt\"><img style=\"width:504px; height:268px;\" src=\"images/ANEST/112454_ETCO2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figures shows a capnogram during ventilation of a small child. With the rapid respiratory rate that is necessary in children, inspiration may occur before full expiration, and may give a falsely low end tidal carbon dioxide (ETCO<SUB innerHtml>2</SUB>) value (solid line). A brief ventilator pause allows full expiration and display of the true ETCO<SUB innerHtml>2 </SUB>(dashed line).</div><div class=\"graphic_footnotes\">CO<SUB innerHtml>2</SUB>: carbon dioxide</div><div id=\"graphicVersion\">Graphic 112454 Version 1.0</div></div></div>"},"112455":{"type":"graphic_picture","displayName":"Intraoperative cortical mapping","title":"Intraoperative electrocorticography and cortical mapping","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Intraoperative electrocorticography and cortical mapping</div><div class=\"cntnt\"><img style=\"width:756px; height:582px;\" src=\"images/ANEST/112455_Awake_craniotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows the open cranium, with the Medusa frame and intracranial electrodes for electrocorticography. Cortical areas that produce informative responses during cortical mapping are labeled with paper tickets.</div><div id=\"graphicVersion\">Graphic 112455 Version 1.0</div></div></div>"},"112457":{"type":"graphic_movie","displayName":"Apical stress cardiomyopathy","title":"Apical stress cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Apical stress cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/112457_Apicalstresscrdmypthyvid.mp4\" style=\"width:512px;height:528px\"></div><img style=\"width:510px; height:468px;\" src=\"images/CARD/112457_Apicalstresscrdmypthyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stress cardiomyopathy, apical variant. Left ventriculography shows akinesis of the anterolateral, apical, and inferior apical segments with hyperdynamic function of the basal segments.</div><div id=\"graphicVersion\">Graphic 112457 Version 1.0</div></div></div>"},"112458":{"type":"graphic_picture","displayName":"Body weight squat","title":"Body weight squat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Body weight squat</div><div class=\"cntnt\"><img style=\"width:275px; height:456px;\" src=\"images/SM/112458_BodyweightsquatPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photograph of the body weight&nbsp;squat exercise, note how the model sits back (hips are well posterior of the feet) and maintains a neutral spine position (without rounding of the back or extension of the neck). Depth may be increased gradually, beginning with only slight knee flexion and progressing to&nbsp;deep knee and hip flexion&nbsp;until the hips are just below the knees.&nbsp;</div><div class=\"graphic_reference\">From: Kritz M, Cronin J, Hume P. The bodyweight squat: A movement screen for the squat pattern. Strength Condition J 2009; 31(1):76-85. DOI: <A href=\"http://journals.lww.com/nsca-scj/Abstract/2009/02000/The_Bodyweight_Squat__A_Movement_Screen_for_the.14.aspx\" target=_blank>10.1519/SSC.0b013e318195eb2f</A>. Copyright © 2009 National Strength and Conditioning Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112458 Version 3.0</div></div></div>"},"112459":{"type":"graphic_movie","displayName":"Mid-left ventricular stress cardiomyopathy","title":"Mid-left ventricular stress cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Mid-left ventricular stress cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/112459_MidLVstresscrdmypthyvid.mp4\" style=\"width:512px;height:528px\"></div><img style=\"width:512px; height:468px;\" src=\"images/CARD/112459_MidLVstresscrdmypthyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stress cardiomyopathy, midventricular variant. Left ventriculography shows akinesis of the mid anterolateral and mid inferior segments with preserved function of the apex and basal segments.</div><div id=\"graphicVersion\">Graphic 112459 Version 1.0</div></div></div>"},"112463":{"type":"graphic_algorithm","displayName":"Screening for diabetes in pregnancy","title":"Screening for diabetes mellitus in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Screening for diabetes mellitus in pregnancy</div><div class=\"cntnt\"><img style=\"width:612px; height:554px;\" src=\"images/OBGYN/112463_Screening_diabetes_pregnanc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index; GDM: gestational diabetes mellitus; A1C: glycated hemoglobin; HDL: high-density lipoprotein.<br />* The American Diabetes Association (ADA) suggests considering testing for diabetes or prediabetes in asymptomatic adults with these characteristics.<SUP>[1]</SUP> We have added age ≥40 years.<br />​¶ There is no consensus regarding whether or how to test for diabetes at the first prenatal visit. If clinicians choose to test, any of the standard diagnostic tests for type 2 diabetes may be performed. In women at increased risk for diabetes, we obtain an A1C with the initial prenatal laboratory tests because this is the most convenient approach.<br />Δ Two-step test: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Step one: 50-gram glucose load without regard to time of day. Glucose thresholds of 130 mg/dL (7.2 mmol/L), ≥135 mg/dL (7.5 mmol/L), or ≥140 mg/dL (7.8 mmol/L) for a positive test have been proposed.</LI>&#xD;&#xA;<LI>Step two: 100-gram three-hour glucose tolerance test. The diagnosis of GDM is based on abnormal values at ≥2 time points using either Carpenter/Coustan or National Diabetes Data Group (NDDG) criteria. Carpenter/Coustan glucose thresholds are fasting 95 mg/dL (5.3 mmol/L), one hour 180 mg/dL (10.0 mmol/L), two hours 155 mg/dL (8.6 mmol/L), and three hours 140 mg/dL (7.8 mmol/L). NDDG thresholds are fasting 105 mg/dL (5.8 mmol/L), one hour 190 mg/dL (10.6 mmol/L), two hours 165 mg/dL (9.2 mmol/L), and three hours 145 mg/dL (8.0 mmol/L).</LI></UL>One-step test: 75-gram two-hour glucose tolerance test. The diagnosis of GDM is based on abnormal glucose values at ≥1 time point: Fasting ≥92 mg/dL (5.1 mmol/L), one hour ≥180 mg/dL (10.0 mmol/L), or two hours ≥153 mg/dL (8.5 mmol/L).</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2017; 40:S11.</LI></OL></div><div id=\"graphicVersion\">Graphic 112463 Version 1.0</div></div></div>"},"112464":{"type":"graphic_table","displayName":"Gene defects in hyperpigmentation syndromes","title":"Overview of affected genes in genetic hyperpigmentation syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of affected genes in genetic hyperpigmentation syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Gene(s)</td> <td class=\"subtitle1\">Gene locus</td> <td class=\"subtitle1\">Gene function</td> <td class=\"subtitle1\">Caused defect</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genes involved in early melanocyte development and function</td> </tr> <tr> <td class=\"indent1\">Dyschromatosis symmetrica hereditaria (DSH, OMIM #127400)</td> <td class=\"centered\"><em>ADAR</em></td> <td class=\"centered\">1q21.3</td> <td>Catalyzing the deamination of adenosine to inosine in dsRNA substrates</td> <td>Failure of correct RNA editing during melanoblast migration: Irregular distribution of hyper- or hypoactive melanocytes in the skin</td> </tr> <tr> <td class=\"indent1\">Incontinentia pigmenti (IP, OMIM #308300)</td> <td class=\"centered\"><em>NEMO</em></td> <td class=\"centered\">Xq28</td> <td>Essential for NF-&#922;B activation</td> <td>Mutations or deletions: Abnormal self-destruction (apoptosis) of MCs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neurofibromatosis type I (NF1, OMIM #162200)</td> <td class=\"centered\"><em>NF1</em></td> <td class=\"centered\">17q11.2</td> <td>Gene involved in melanosome localization</td> <td>Disruption of NF1-dynein heavy chain 1 interaction: Increased trafficking of melanosomes in melanocytes of caf&#233;-au-lait macules</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genes involved in pigmentation and related pathways</td> </tr> <tr> <td class=\"indent1\">Familial progressive hyperpigmentation (FPH, OMIM #145250)</td> <td class=\"centered\"><em>KITLG</em></td> <td class=\"centered\">12q22</td> <td>Melanogenesis</td> <td>Gain-of-function mutations: Increased TYR activity</td> </tr> <tr> <td class=\"indent1\">Carney complex (CNC1, OMIM #160980)</td> <td class=\"centered\"><em>PRKAR1A</em></td> <td class=\"centered\">17q24.2</td> <td>Crucial signaling factor in cAMP pathway</td> <td>Mutated <em>PRKAR1A</em>: Increased cAMP activity</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">McCune-Albright syndrome (MAS, OMIM #174800)</td> <td class=\"centered\"><em>GNAS1</em></td> <td class=\"centered\">20q13.32</td> <td>alpha-subunit of Gs protein (GTPase)</td> <td>Gain-of-function mutations: Increased cAMP activity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Deregulation of the tyrosinase gene</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">Fanconi's anemia</td> </tr> <tr> <td class=\"indent2\">(FANCA, OMIM #227650)</td> <td class=\"centered\"><em>FANCA</em></td> <td class=\"centered\">16q24.3</td> <td class=\"divider_bottom\" rowspan=\"6\">DNA repair maintenance of chromosomal integrity</td> <td class=\"divider_bottom\" rowspan=\"6\">Overactivation of TYR activity due to reduced thioredoxin levels</td> </tr> <tr> <td class=\"indent2\">(FANCB, OMIM #300514)</td> <td class=\"centered\"><em>FANCB</em></td> <td class=\"centered\">Xp22.2</td> </tr> <tr> <td class=\"indent2\">(FANCC, OMIM #227645)</td> <td class=\"centered\"><em>FANCC</em></td> <td class=\"centered\">9q22.32</td> </tr> <tr> <td class=\"indent2\">(FANCD1, OMIM #605724)</td> <td class=\"centered\"><em>BRCA2</em></td> <td class=\"centered\">13q13.1</td> </tr> <tr> <td class=\"indent2\">(FANCD2, OMIM #227646)</td> <td class=\"centered\"><em>FANCD2</em></td> <td class=\"centered\">3p25.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">(FANCE, OMIM #600901)</td> <td class=\"centered\"><em>FANCE</em></td> <td class=\"centered\">6p21.31</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genes involved in cell structure and metabolism</td> </tr> <tr> <td class=\"indent1\">Naegeli-Franceschetti-Jadassohn syndrome (NFJ, OMIM #161000)</td> <td class=\"centered\"><em>KRT14</em></td> <td class=\"centered\">17q21.2</td> <td>Melanosome uptake in keratinocytes</td> <td>Abnormal melanin distribution in keratinocytes</td> </tr> <tr> <td class=\"indent1\">Dowling-Degos syndrome (DGS, OMIM #179850)</td> <td class=\"centered\"><em>KRT5</em></td> <td class=\"centered\">12q13.13</td> <td>Melanosome uptake in keratinocytes; organelle transport</td> <td>Deficient melanin aggregation in keratinocytes</td> </tr> <tr> <td class=\"indent1\">Peutz-Jeghers syndrome (PJS, OMIN #175200)</td> <td class=\"centered\"><em>STK11</em></td> <td class=\"centered\">19p13.3</td> <td>Serine/threonine kinase regulates cell polarity and tumor suppressor function</td> <td>Dysregulation of mTOR pathway; dysregulation of Wnt pathway</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">LEOPARD syndrome (LS, OMIM #151100)</td> <td class=\"centered\"><em>PTPN11</em></td> <td class=\"centered\">12q24.13</td> <td>Tyrosine phosphatase</td> <td>Dysregulation of mTOR pathway; increased RAS activity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genes involved in DNA repair or senescence</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">Xeroderma pigmentosum</td> </tr> <tr> <td class=\"indent2\">(XPA, OMIM #278700)</td> <td class=\"centered\"><em>XPA</em></td> <td class=\"centered\">9q22.33</td> <td rowspan=\"7\">DNA repair gene</td> <td rowspan=\"7\">Failure of nucleotide excision repair machinery</td> </tr> <tr> <td class=\"indent2\">(XPB, OMIM #610651)</td> <td class=\"centered\"><em>ERCC3</em></td> <td class=\"centered\">2q14.3</td> </tr> <tr> <td class=\"indent2\">(XPC, OMIM #278720)</td> <td class=\"centered\"><em>XPC</em></td> <td class=\"centered\">3p25.1</td> </tr> <tr> <td class=\"indent2\">(XPD, OMIM #278730)</td> <td class=\"centered\"><em>ERCC2</em></td> <td class=\"centered\">19q13.32</td> </tr> <tr> <td class=\"indent2\">(XPE, OMIM #278740)</td> <td class=\"centered\"><em>DDB2</em></td> <td class=\"centered\">11p11.2</td> </tr> <tr> <td class=\"indent2\">(XPF, OMIM #278760)</td> <td class=\"centered\"><em>ERCC4</em></td> <td class=\"centered\">16p13.12</td> </tr> <tr> <td class=\"indent2\">(XPG, OMIM #278780)</td> <td class=\"centered\"><em>ERCC5</em></td> <td class=\"centered\">13q33.1</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">Dyskeratosis congenita</td> </tr> <tr> <td class=\"indent2\">(DKCX, OMIM #305000)</td> <td class=\"centered\"><em>DKC1</em></td> <td class=\"centered\">Xq28</td> <td rowspan=\"3\">Components of the telomerase complex</td> <td rowspan=\"3\">Accumulation of DNA damage increased melanin synthesis in senescent melanocytes</td> </tr> <tr> <td class=\"indent2\">(DKCA1, OMIM #127550)</td> <td class=\"centered\"><em>TERC</em></td> <td class=\"centered\">3q26.2</td> </tr> <tr> <td class=\"indent2\">(DKCA2, OMIM #613989)</td> <td class=\"centered\"><em>TERT</em></td> <td class=\"centered\">5p15.3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LEOPARD: lentigines, electrocardiogram&nbsp;abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, deafness.</div><div class=\"graphic_reference\">From: Speeckaert R, Van Gele M, Speeckaert MM, et al. The biology of hyperpigmentation syndromes. Pigment Cell Melanoma Res 2014; 27:512. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12235/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12235/abstract</a>. Copyright &copy; 2014 John Wiley &amp; Sons A/S. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 112464 Version 1.0</div></div></div>"},"112469":{"type":"graphic_algorithm","displayName":"Management of PFAPA syndrome","title":"Management of PFAPA syndrome in patients who fulfill the diagnostic criteria including response to a test dose of glucocorticoids","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of PFAPA syndrome in patients who fulfill the diagnostic criteria including response to a test dose of glucocorticoids</div><div class=\"cntnt\"><img style=\"width:720px; height:682px;\" src=\"images/ALLRG/112469_Mgmt_PFAPA_syndrome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis.</div><div class=\"graphic_footnotes\">* Glucocorticoid therapy: Initial single dose of prednisone or prednisolone 2 mg/kg orally (maximum dose 60 mg) OR, if available, betamethasone 0.3 mg/kg (maximum dose 9 mg). The dose is tapered with each episode (eg, decrease prednisolone by 3 mg or betamethasone by 0.5 mg) down to the last effective dose. A dose is too small when fever recurs two to three days following administration.</div><div id=\"graphicVersion\">Graphic 112469 Version 1.0</div></div></div>"},"112475":{"type":"graphic_figure","displayName":"Risk of kernicterus based on neonatal bilirubin","title":"Risk of kernicterus based on neonatal bilirubin","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Risk of kernicterus based on neonatal bilirubin</div><div class=\"cntnt\"><img style=\"width:723px; height:508px;\" src=\"images/PEDS/112475_Rsk_kernicterus_nntl_blrbn.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Bhutani VK, Vilms RJ, Hamerman-Johnson L. Universal bilirubin screening for severe neonatal hyperbilirubinemia. J Perinatol 2010; 30:S6.</div><div id=\"graphicVersion\">Graphic 112475 Version 1.0</div></div></div>"},"112477":{"type":"graphic_table","displayName":"Consensus diagnostic criteria for iMCD","title":"Consensus diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consensus diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Major criteria (need both)</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>Histopathologic lymph node features consistent with the iMCD spectrum. Features along the iMCD spectrum include (need grade 2-3 for either regressive GCs or plasmacytosis at minimum): </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Regressed/atrophic/atretic germinal centers, often with expanded mantle zones composed of concentric rings of lymphocytes in an \"onion skinning\" appearance </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>FDC prominence </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Vascularity, often with prominent endothelium in the interfollicular space and vessels penetrating into the GCs with a \"lollipop\" appearance </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Sheetlike, polytypic plasmacytosis in the interfollicular space </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Hyperplastic GCs </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Enlarged lymph nodes (&#8805;1 cm in short-axis diameter) in &#8805;2 lymph node stations </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">II. Minor criteria (need at least 2 of 11 criteria with at least 1 laboratory criterion)</td> </tr> <tr> <td class=\"indent1\"><strong>Laboratory:</strong>*</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Elevated CRP (&#62;10 mg/L) or ESR (&#62;15 mm/hour)<sup>&#182;</sup> </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Anemia (hemoglobin &#60;12.5 g/dL for males, hemoglobin &#60;11.5 g/dL for females) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Thrombocytopenia (platelet count &#60;150 k/microL) or thrombocytosis (platelet count &#62;400 k/microL) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>Hypoalbuminemia (albumin &#60;3.5 g/dL) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"5\"> <li>Renal dysfunction (eGFR &#60;60 mL/min/1.73 m<sup>2</sup>) or proteinuria (total protein 150 mg/24 hours or 10 mg/100 mL) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"6\"> <li>Polyclonal hypergammaglobulinemia (total gamma-globulin or immunoglobulin G &#62;1700 mg/dL) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>Clinical:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Constitutional symptoms: Night sweats, fever (&#62;38&#176;C), weight loss, or fatigue (&#8805;2 CTCAE lymphoma score for B-symptoms) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Large spleen and/or liver </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Fluid accumulation: Edema, anasarca, ascites, or pleural effusion </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>Eruptive cherry hemangiomatosis or violaceous papules </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"5\"> <li>Lymphocytic interstitial pneumonitis </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">III. Exclusion criteria (must rule out each of these diseases that can mimic iMCD)</td> </tr> <tr> <td class=\"indent1\"><strong>Infection-related disorders:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol> <li>HHV-8 (infection can be documented by blood PCR, diagnosis of HHV-8&ndash;associated MCD requires positive LANA-1 staining by IHC, which excludes iMCD) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Clinical EBV-lymphoproliferative disorders such as infectious mononucleosis or chronic active EBV (detectable EBV viral load not necessarily exclusionary) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Inflammation and adenopathy caused by other uncontrolled infections (eg, acute or uncontrolled CMV, toxoplasmosis, HIV, active tuberculosis) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>Autoimmune/autoinflammatory diseases (requires full clinical criteria, detection of autoimmune antibodies alone is not exclusionary):</strong></td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Systemic lupus erythematosus </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Rheumatoid arthritis </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Adult-onset Still disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>Juvenile idiopathic arthritis </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"5\"> <li>Autoimmune lymphoproliferative syndrome </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>Malignant/lymphoproliferative disorders (these disorders must be diagnosed before or at the same time as iMCD to be exclusionary):</strong></td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Lymphoma (Hodgkin and non-Hodgkin) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Multiple myeloma </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Primary lymph node plasmacytoma </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>FDC sarcoma </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"5\"> <li>POEMS syndrome<sup>&#916;</sup> </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>Select additional features supportive of, but not required for diagnosis:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Elevated IL-6, sIL-2R, VEGF, IgA, IgE, LDH, and/or B2M </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Reticulin fibrosis of bone marrow (particularly in patients with TAFRO syndrome) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Diagnosis of disorders that have been associated with iMCD: Paraneoplastic pemphigus, bronchiolitis obliterans organizing pneumonia, autoimmune cytopenias, polyneuropathy (without diagnosing POEMS<sup>&#916;</sup>), glomerular nephropathy, inflammatory myofibroblastic tumor </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GC: germinal center; FDC: follicular dendritic cell; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; eGFR: estimated glomerular filtration rate;&nbsp;CTCAE: common terminology for adverse events; PCR: polymerase chain reaction; LANA-1: latency-associated nuclear antigen; IHC: immunohistochemistry; EBV: Epstein-Barr virus;&nbsp;CMV: cytomegalovirus; IL: interleukin; VEGF: vascular endothelial growth factor; Ig: immunoglobulin;&nbsp;LDH: lactate dehydrogenase; B2M: β-2-microglobulin. <br />* We have provided laboratory cutoff thresholds as guidance, but we recognize that some laboratories have slightly different ranges. We suggest that you use the upper and lower ranges from your particular laboratory to determine if a patient meets a particular laboratory Minor criterion.<br />¶ Evaluation of CRP is mandatory and tracking CRP levels is highly recommended, but ESR will be accepted if CRP is not available.<br />Δ POEMS is considered to be a disease \"associated\" with Castleman's disease. Because the monoclonal plasma cells are believed to drive the cytokine storm, we do not consider it iMCD, but rather \"POEMS-associated MCD.\"</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from: Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8&ndash;negative/idiopathic multicentric Castleman disease. Blood 2017; 129:1646; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2017.</div><div id=\"graphicVersion\">Graphic 112477 Version 3.0</div></div></div>"},"112488":{"type":"graphic_figure","displayName":"Immune DITMA mechanism","title":"Mechanism of immune-mediated drug-induced thrombotic microangiopathy","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Mechanism of immune-mediated drug-induced thrombotic microangiopathy</div><div class=\"cntnt\"><img style=\"width:519px; height:666px;\" src=\"images/HEME/112488_Immune_DITMA_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Naturally occurring antibodies can react very weakly with antigens on a number of cells. In immune-mediated DITMA, a drug such as quinine binds to the antibody’s complementarity-determining region (CDR), which enhances binding affinity by more than 10,000 times. Reaction of quinine-dependent antibodies with antigens on platelets and endothelial cells is illustrated here. GP IIb-IIIa is often the target of quinine-dependent antibodies on platelets; the relevant antigen(s) on endothelial and other cells have not been identified. Refer to UpToDate for more information about DITMA.</div><div class=\"graphic_footnotes\">DITMA: drug-induced thrombotic microangiopathy; GP: glycoprotein</div><div id=\"graphicVersion\">Graphic 112488 Version 1.0</div></div></div>"},"112489":{"type":"graphic_picture","displayName":"Scalp with permanent alopecia postchemo","title":"Scalp with permanent alopecia following chemotherapy treatment","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Scalp with permanent alopecia following chemotherapy treatment</div><div class=\"cntnt\"><img style=\"width:708px; height:752px;\" src=\"images/ONC/112489_Sclp_prmnnt_alopecia_pstchm.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112489 Version 1.0</div></div></div>"},"112496":{"type":"graphic_figure","displayName":"Relationship between Recurrence Score and 5-year recurrence risk","title":"Relationship between the continuous Recurrence Score (RS) from Oncotype DX and five-year recurrence risk by stage and treatment in NSABP C-07 trial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship between the continuous Recurrence Score (RS) from Oncotype DX and five-year recurrence risk by stage and treatment in NSABP C-07 trial</div><div class=\"cntnt\"><img style=\"width:413px; height:448px;\" src=\"images/ONC/112496_Rltnshp_Rcrrnc_Scr_5y_rcrrn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between the continuous RS and 5-year recurrence risk by stage and treatment in NSABP C-07. Thick lines represent fluorouracil (FU)-treated patients, thin lines represent FU plus oxaliplatin-treated patients. A rug plot depicting the distribution of RS is included at the bottom of the continuous RS and 5-year recurrence risk figure, and an estimated normal distribution of scores is provided below. The proportional hazards assumption held (p = 0.20 for the test of nonzero slope of Schoenfeld residuals versus time). The relationship between continuous RS and the log hazard of recurrence was linear (p = 0.84 for the test of nonlinearity).</div><div class=\"graphic_footnotes\">NSABP: National Surgical Adjuvant Breast and Bowel Project.</div><div class=\"graphic_reference\">From: Yothers G, O'Connell MJ, Lee M, et al. Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin. J Clin Oncol 2013; 31(36):4512-9. Reprinted with permission. Copyright © 2013 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112496 Version 1.0</div></div></div>"},"112500":{"type":"graphic_diagnosticimage","displayName":"PCP with ground glass opacities","title":"<EM>Pneumocystis</EM> pneumonia (PCP) in a patient with lymphoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\"><EM>Pneumocystis</EM> pneumonia (PCP) in a patient with lymphoma</div><div class=\"cntnt\"><img style=\"width:756px; height:481px;\" src=\"images/ID/112500_PCPgroundglassopacities.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computed tomography (CT) image (1-mm collimation) at the level of the aortic arch shows extensive bilateral ground-glass opacities. The findings are a common and characteristic feature of PCP.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Franquet T, Lee KS. Imaging of pulmonary infections. Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112500 Version 2.0</div></div></div>"},"112501":{"type":"graphic_diagnosticimage","displayName":"PCP with mosaic pattern","title":"<EM>Pneumocystis</EM> pneumonia showing asymmetric ground-glass opacities with a mosaic pattern","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\"><EM>Pneumocystis</EM> pneumonia showing asymmetric ground-glass opacities with a mosaic pattern</div><div class=\"cntnt\"><img style=\"width:612px; height:418px;\" src=\"images/ID/112501_PCPmosaicpattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Pneumocystis</EM> pneumonia following hematopoietic cell transplantation. High-resolution computed tomography (CT) image (1-mm collimation) at the level of the bronchus intermedius shows asymmetrical bilateral ground-glass opacities. Note sharp demarcation between the normal and abnormal lung resulting in a mosaic or geographic pattern.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Franquet T, Lee KS. Imaging of pulmonary infections. Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112501 Version 2.0</div></div></div>"},"112503":{"type":"graphic_diagnosticimage","displayName":"PCP with pneumatoceles","title":"<EM>Pneumocystis</EM> pneumonia (PCP) with pneumatocele formation","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\"><EM>Pneumocystis</EM> pneumonia (PCP) with pneumatocele formation</div><div class=\"cntnt\"><img style=\"width:766px; height:521px;\" src=\"images/ID/112503_PCPpneumatoceles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient was a 55-year-old woman who developed PCP while undergoing treatment for non-Hodgkin lymphoma. The pneumonia resolved but no follow-up images immediately following resolution of the pneumonia were available.<br />(A) High-resolution computed tomography (CT) image at the level of the main bronchi shows extensive bilateral ground-glass opacities.<br />(B) High-resolution CT image (1-mm collimation) at the same level one month later shows several pneumatoceles (arrows) in the right upper lobe. Also noted is a small left pneumothorax (arrowhead) and a left chest tube in the major fissure (thick arrow).<br />(C) High-resolution CT image three years later demonstrates resolution of the pneumatoceles.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Franquet T, Lee KS. Imaging of pulmonary infections. Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112503 Version 2.0</div></div></div>"},"112504":{"type":"graphic_diagnosticimage","displayName":"PCP atypical imaging findings","title":"<EM>Pneumocystis</EM> pneumonia (PCP) with ground-glass opacities, nodules, and consolidation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Pneumocystis</EM> pneumonia (PCP) with ground-glass opacities, nodules, and consolidation</div><div class=\"cntnt\"><img style=\"width:432px; height:504px;\" src=\"images/ID/112504_PCPatypicalimagngfindngs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical presentation of PCP. View of the right upper lobe on high-resolution computed tomography (CT) scan (1-mm collimation) shows ground-glass opacities, multiple nodular opacities, and foci of consolidation. Also noted is a small cavity (arrow). The patient was a 28-year-old man hematopoietic cell transplant recipient. Large nodules and nodular areas of consolidation are an uncommon presentation of PCP. Cavitation is rare.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Franquet T, Lee KS. Imaging of pulmonary infections. Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112504 Version 2.0</div></div></div>"},"112505":{"type":"graphic_diagnosticimage","displayName":"PCP histopathology and staining","title":"Histopathology and staining of lung tissue in a patient with <EM>Pneumocystis</EM> pneumonia","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Histopathology and staining of lung tissue in a patient with <EM>Pneumocystis</EM> pneumonia</div><div class=\"cntnt\"><img style=\"width:766px; height:323px;\" src=\"images/ID/112505_PCP_histopathology_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Photomicrograph shows mild alveolar interstitial thickening by a lymphocyte infiltrate and extensive filling of airspaces by finely vacuolated eosinophilic material.<br />(B) Magnified view of the material in one of the airspaces shows silver positive (black) round or helmet-shaped structures typical of <EM>Pneumocystis jirovecii</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Lee KS, Franquet T, Han J, Johkoh T. Müller's Diseases of the Lung: Radiologic and Pathologic Correlations, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 112505 Version 1.0</div></div></div>"},"112513":{"type":"graphic_algorithm","displayName":"Hydroxyurea in SCD","title":"Decision to start hydroxyurea in SCD","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Decision to start hydroxyurea in SCD</div><div class=\"cntnt\"><img style=\"width:658px; height:366px;\" src=\"images/HEME/112513_Hydroxyurea_in_SCD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Baseline testing is required before starting hydroxyurea, and monitoring (eg, complete blood count, reticulocyte count, percent HbF, creatinine) continues throughout administration, with more frequent monitoring during dose escalation. This algorithm does not substitute for the clinical judgment of the treating specialist. Patients with SCD should receive comprehensive care from a clinician with experience managing hemoglobinopathies. Refer to UpToDate topics on SCD management and the use of hydroxyurea in SCD for further information.</div><div class=\"graphic_footnotes\">SCD: sickle cell disease, which includes all homozygous (HbSS) or compound heterozygous genotypes; HU: hydroxyurea.<br />* Symptomatic disease as defined in clinical trials generally refers to more than three painful episodes in a one-year period or more than three episodes of acute chest syndrome in a two-year period. Different criteria may be needed for some individuals, such as a single clinically significant episode of dactylitis, hepatic sequestration, or splenic sequestration in an infant; chronic pain; severe, symptomatic anemia due to SCD in an adult; or repeated vaso-occlusive events at lower frequency than that used in trials for any age group.<br />¶ Genotype is usually inferred from hemoglobin analysis rather than DNA testing. Common genotypes are shown. Individuals with HbSS or sickle β<SUP>0</SUP> thalassemia are most likely to develop symptomatic disease if untreated. Those with HbSC or HbS/β<SUP>+</SUP> thalassemia are least likely to develop severe disease. Decisions for other genotypes are individualized.</div><div id=\"graphicVersion\">Graphic 112513 Version 2.0</div></div></div>"},"112514":{"type":"graphic_table","displayName":"Standard dosing of DOACs","title":"Standard dosing of direct oral anticoagulants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standard dosing of direct oral anticoagulants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Nonvalvular AF - stroke prophylaxis<sup>*</sup></td> <td class=\"subtitle1\">VTE treatment<sup>&#182;</sup></td> <td class=\"subtitle1\">VTE primary prophylaxis<sup>&#916;</sup></td> </tr> <tr> <td>Dabigatran (Pradaxa)</td> <td> <p>150 mg twice daily</p> </td> <td>Parenteral anticoagulation for 5 to 10 days; then dabigatran&nbsp;150 mg twice daily</td> <td>110 mg for the first day, then 220 mg once daily</td> </tr> <tr> <td>Apixaban (Eliquis)</td> <td>5 mg twice daily</td> <td>10 mg twice daily for one week, then 5 mg twice daily</td> <td>2.5 mg twice daily</td> </tr> <tr> <td>Betrixaban (Bevyxxa)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>160 mg on the first day, followed by 80 mg once daily, with food</td> </tr> <tr> <td>Edoxaban (Savaysa, Lixiana)</td> <td>60 mg once daily</td> <td>Parenteral anticoagulation for 5 to 10 days; then edoxaban 60 mg once daily</td> <td>&nbsp;</td> </tr> <tr> <td>Rivaroxaban (Xarelto)</td> <td>20 mg once daily with the evening meal</td> <td>15 mg twice daily with food&nbsp;for three weeks; then 20 mg once daily with food</td> <td>10 mg once daily, with or without food</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is a simplified table that lists the most common dosing in individuals with normal renal function, normal weight, and lack of concomitant interacting medications (eg, P-glycoprotein inhibitors or inducers). Refer to UpToDate topics on AF, VTE treatment, VTE prophylaxis, and DOAC dosing for possible changes based on impaired renal function or extremes of weight. Other factors may influence dosing in individual patients. </div><div class=\"graphic_footnotes\">AF: atrial fibrillation; VTE: venous thromboembolism, includes deep vein thrombosis and pulmonary embolism; DOAC: direct oral anticoagulant.<br />* Dosing may be reduced for certain drugs in certain settings (eg, use of dabigatran 110 mg twice daily for individuals who are at increased risk of bleeding; refer to UpToDate topic on anticoagulation for atrial fibrillation for other examples)<br />¶&nbsp;Treatment for acute VTE typically refers to the first three to six months of administration; continued treatment beyond six months may be done with a lower dose for&nbsp;some&nbsp;anticoagulants (eg, apixaban, rivaroxaban); the dose is not lowered whten therapy is continued using&nbsp;dabigatran&nbsp;or edoxaban. Refer to the latest prescribing information for each individual anticoagulant.<br />Δ Prophylaxis refers to primary prophylaxis in settings such as after knee or hip surgery.<br /></div><div id=\"graphicVersion\">Graphic 112514 Version 3.0</div></div></div>"},"112540":{"type":"graphic_algorithm","displayName":"Latent TB screening TNF-alpha with LTBI RFs","title":"Latent TB infection screening for patients preparing to receive a TNF-alpha inhibitor who have risk factors for latent TB","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Latent TB infection screening for patients preparing to receive a TNF-alpha inhibitor who have risk factors for latent TB</div><div class=\"cntnt\"><img style=\"width:542px; height:520px;\" src=\"images/ID/112540_Lat_TB_scrn_TNFa_w_LTBI_RF.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TB: tuberculosis; TNF: tumor necrosis factor; IGRA: interferon-gamma release assay; TST: tuberculin skin test; LTBI: latent tuberculosis infection; BCG: Bacille Calmette-Guérin.<br />* We prefer the IGRA over the TST as it is likely more sensitive under conditions of immunosuppression, it can be accomplished in one visit, and it eliminates the need to know a patient's BCG history (which is not always clear). In patients who have not received the BCG vaccine, the TST is a reasonable alternative to the IGRA.<br />¶ The two IGRAs are the QuantiFERON-TB Gold In-Tube and the T-SPOT.TB assay. When retesting, it is acceptable to use either the same IGRA or the other assay.<br />Δ In patients with a negative IGRA and no history of BCG vaccination, it is appropriate to check a TST. In patients with a negative IGRA and a history of BCG vaccination, we repeat the IGRA. When retesting, it is acceptable to use either the same IGRA or the other assay.<br /><FONT class=lozenge>◊</FONT> The treatment of patients with a negative LTBI screening test should be made on a case-by-case basis, depending on the risk of TB exposure and the likelihood that a negative test represents a false-negative result. The same concept applies to patients with indeterminate IGRA results. Treatment for LTBI should be considered if there is a strong likelihood of prior TB exposure (eg, evidence of remote TB disease on chest radiography [eg, regional fibrosis with or without hilar lymphadenopathy], history of close contact with a TB case, or having resided in a country with high TB prevalence), especially if the patient was immunocompromised at the time of testing for LTBI.</div><div id=\"graphicVersion\">Graphic 112540 Version 1.0</div></div></div>"},"112541":{"type":"graphic_algorithm","displayName":"Latent TB screening TNF-alpha no RFs","title":"Latent TB infection screening for patients preparing to receive a TNF-alpha inhibitor who do not have risk factors for latent TB","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Latent TB infection screening for patients preparing to receive a TNF-alpha inhibitor who do not have risk factors for latent TB</div><div class=\"cntnt\"><img style=\"width:570px; height:472px;\" src=\"images/ID/112541_Lat_TB_scrn_TNFalpha_no_RF.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TB: tuberculosis; TNF: tumor necrosis factor; IGRA: interferon-gamma release assay; TST: tuberculin skin test; LTBI: latent tuberculosis infection; BCG: Bacille Calmette-Guérin.<br />* We prefer the IGRA over the TST as it is likely more sensitive under conditions of immunosuppression, it can be accomplished in one visit, and it eliminates the need to know a patient's BCG history (which is not always clear). In patients who have not received the BCG vaccine, the TST is a reasonable alternative to the IGRA.<br />¶ The two IGRAs are the QuantiFERON-TB Gold In-Tube and the T-SPOT.TB assay. When retesting, it is acceptable to use either the same IGRA or the other assay. In patients who have not received the BCG vaccine, the TST is a reasonable alternative to the IGRA.</div><div id=\"graphicVersion\">Graphic 112541 Version 1.0</div></div></div>"},"112542":{"type":"graphic_movie","displayName":"Flail sternum","title":"Flail sternum","html":"<div class=\"graphic normal\"><div style=\"width: 852px\" class=\"figure\"><div class=\"ttl\">Flail sternum</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/112542_Flailsternumvid.mp4\" style=\"width:832px;height:480px\"></div><img style=\"width:648px; height:469px;\" src=\"images/SURG/112542_Flailsternumimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video illustrates paradoxical movement of the sternum during spontaneous ventilation in a patient who sustained a respiratory arrest followed by cardiac arrest due to choking. The patient was successfully resuscitated with cardiopulmonary resuscitation (CPR), which resulted in fractures of ribs 2 to 8 bilaterally, with most fractures located at the costochondral junction. There was no pain, but the patient was markedly short of breath and not able to ambulate. Following operative stabilization of ribs 3 and 4 bilaterally, the dyspnea resolved and the patient was discharged to a rehabilitation facility.</div><div id=\"graphicVersion\">Graphic 112542 Version 1.0</div></div></div>"},"112543":{"type":"graphic_algorithm","displayName":"Rx CAP ward","title":"Community-acquired pneumonia: Empiric antibiotic selection for adults admitted to the general medical ward*","html":"<div class=\"graphic\"><div style=\"width: 1342px\" class=\"figure\"><div class=\"ttl\">Community-acquired pneumonia: Empiric antibiotic selection for adults admitted to the general medical ward*</div><div class=\"cntnt\"><img style=\"width:1322px; height:908px;\" src=\"images/ID/112543_Rx_CAP_ward.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; COPD: chronic obstructive pulmonary disease.<br />* This algorithm is intended for patients in whom admission to a general medical ward is considered appropriate. Refer to related UpToDate content to determine the site of care. Antibiotics should be administered as soon as possible after diagnosing community-acquired pneumonia (CAP). If the etiology of CAP has been identified based upon reliable microbiologic methods and there is no laboratory or epidemiologic evidence of coinfection, treatment regimens should be simplified and directed to that pathogen.<br />¶ Individuals with a past reaction to penicillin that was mild (not Stevens Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms [DRESS]) and did not have features of an IgE-mediated reaction can receive a broad-spectrum (third- or fourth-generation) cephalosporin or carbapenem safely.<br />Δ Empiric therapy with aztreonam plus levofloxacin plus an aminoglycoside is generally appropriate for patients who warrant antipseudomonal coverage but have beta-lactam allergies that preclude the use of penicillins, cephalosporins, and carbapenems. However, patients with a prior life-threatening or anaphylactic reaction to ceftazidime should not be given aztreonam unless evaluated by an allergy specialist because of the possibility of cross-reactivity. Such patients can receive levofloxacin plus an aminoglycoside for antipseudomonal coverage in the interim.<br /><FONT class=lozenge>◊</FONT> Combination therapy with a beta-lactam plus a macrolide and monotherapy with a respiratory fluoroquinolone are of generally comparable efficacy for CAP overall. However, many observational studies have suggested that beta-lactam plus macrolide combination regimens are associated with better clinical outcomes in patients with severe CAP, possibly due to the immunomodulatory effects of macrolides. Furthermore, the severity of adverse effects (including the risk for <EM>Clostridium difficile</EM> infection) and the risk of selection for resistance in colonizing organisms are generally thought to be greater with fluoroquinolones than with the combination therapy regimens. For both of these reasons, we generally prefer combination therapy with a beta-lactam plus a macrolide rather than monotherapy with a fluoroquinolone. Nevertheless, cephalosporins and other antibiotic classes also increase the risk of <EM>C. difficile</EM> infection. Recent antibiotic use should also inform the decision about the most appropriate regimen; if the patient has used a beta-lactam in the prior three months, a fluoroquinolone should be chosen, if possible, and vice versa.<br />§ The combination of vancomycin and piperacillin-tazobactam has been associated with acute kidney injury. In patients who require an anti-MRSA agent and an antipseudomonal/antipneumococcal beta-lactam, options include using a beta-lactam other than piperacillin-tazobactam (eg, cefepime or ceftazidime) or, if piperacillin-tazobactam is favored, using linezolid instead of vancomycin.<br />¥ Examples of contraindications include increased risk for a prolonged QT interval and allergy.<br />‡ Doxycycline should not be used in pregnant women.</div><div id=\"graphicVersion\">Graphic 112543 Version 2.0</div></div></div>"},"112544":{"type":"graphic_algorithm","displayName":"Rx CAP ICU","title":"Community-acquired pneumonia: Empiric antibiotic selection for adults admitted to the intensive care unit*","html":"<div class=\"graphic\"><div style=\"width: 1334px\" class=\"figure\"><div class=\"ttl\">Community-acquired pneumonia: Empiric antibiotic selection for adults admitted to the intensive care unit*</div><div class=\"cntnt\"><img style=\"width:1314px; height:882px;\" src=\"images/ID/112544_Rx_CAP_ICU.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; COPD: chronic obstructive pulmonary disease.<br />* This algorithm is intended for patients in whom admission to an intensive care unit is considered appropriate. Refer to related UpToDate content to determine the site of care. Antibiotics should be administered as soon as possible after diagnosing community-acquired pneumonia (CAP). If the etiology of CAP has been identified based upon reliable microbiologic methods and there is no laboratory or epidemiologic evidence of coinfection, treatment regimens should be simplified and directed to that pathogen.<br />¶ Individuals with a past reaction to penicillin that was mild (not Stevens Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms [DRESS]) and did not have features of an IgE-mediated reaction can receive a broad-spectrum (third- or fourth-generation) cephalosporin or carbapenem safely.<br />Δ Empiric therapy with aztreonam plus levofloxacin plus an aminoglycoside is generally appropriate for patients who warrant antipseudomonal coverage but have beta-lactam allergies that preclude the use of penicillins, cephalosporins, and carbapenems. However, patients with a prior life-threatening or anaphylactic reaction to ceftazidime should not be given aztreonam unless evaluated by an allergy specialist because of the possibility of cross-reactivity. Such patients can receive levofloxacin plus an aminoglycoside for antipseudomonal coverage in the interim.<br /><FONT class=lozenge>◊</FONT> Regimens containing either a macrolide or fluoroquinolone have been generally comparable in clinical trials. However, many observational studies have suggested that macrolide-containing regimens are associated with better clinical outcomes for patients with severe CAP, possibly due to the immunomodulatory effects of macrolides. Furthermore, the severity of adverse effects (including the risk for <EM>Clostridium difficile</EM> infection) and the risk of selection for resistance in colonizing organisms are generally thought to be greater with fluoroquinolones than with other antibiotic classes. For this reason, we generally favor a macrolide-containing regimen in this setting, unless there is a specific reason to avoid macrolides, such as patient allergy or intolerance. Recent antibiotic use should also inform the decision about the most appropriate regimen; if the patient has used a beta-lactam in the prior three months, a fluoroquinolone should be chosen, if possible, and vice versa.<br />§ The combination of vancomycin and piperacillin-tazobactam has been associated with acute kidney injury. In patients who require an anti-MRSA agent and an antipseudomonal/antipneumococcal beta-lactam, options include using a beta-lactam other than piperacillin-tazobactam (eg, cefepime or ceftazidime) or, if piperacillin-tazobactam is favored, using linezolid instead of vancomycin.</div><div id=\"graphicVersion\">Graphic 112544 Version 2.0</div></div></div>"},"112545":{"type":"graphic_table","displayName":"Proposed indications for planned home birth in Canada","title":"Proposed indications for planned home birth in Canada","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed indications for planned home birth in Canada</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ol> <li>Client has chosen home birth on the basis of an informed decision. </li> <li>Singleton fetus. </li> <li>Cephalic presentation. </li> <li>Gestation between &#8805;37 completed weeks and &#60;42 completed weeks. </li> <li>Absence of pre-existing serous medical conditions (eg, cardiac or renal disease, insulin-dependent diabetes). </li> <li>Absence of proteinuric preeclampsia or eclampsia. </li> <li>Absence of symptomatic placental abruption. </li> <li>Absence of placenta previa at the onset of labor. </li> <li>Absence of thick meconium. </li> <li>Absence of active genital herpes. </li> <li>Absence of any other conditions arising during labor that meet requirements for transfer of care to a clinician. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Janssen PA, Lee SK, Ryan ER, Saxell L. An evaluation of process and protocols for planned home birth attended by regulated midwives in British Columbia. J Midwifery Womens Health 2003; 48:138. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1016/S1526-9523(02)00418-X/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1016/S1526-9523(02)00418-X/abstract</A>. Copyright © 2017 The American College of Nurse-Midwives. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\">permissions@wiley.com</A> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://www.onlinelibrary.wiley.com/\" target=_blank>www.onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 112545 Version 1.0</div></div></div>"},"112546":{"type":"graphic_figure","displayName":"NF-kappa-B-dependent signaling pathways","title":"NF-kappa-B-dependent signaling pathways","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">NF-kappa-B-dependent signaling pathways</div><div class=\"cntnt\"><img style=\"width:572px; height:400px;\" src=\"images/ALLRG/112546_NF-kappa-B-dpndnt_sgnlng_pt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD40 signals through NF-kappa-B2, the noncanonical NF-kappa-B pathway. All other receptors utilize the canonical NF-kappa-B1 pathway.</div><div class=\"graphic_footnotes\">TLR: toll-like receptor; MyD88: myeloid differentiation primary response protein 88; IRAK: interleukin-1 receptor-associated kinase; NLRs: nucleotide oligomerization domain (NOD)-like receptors; RLRs: retinoic acid-inducible gene-I (RIG-I)-like receptors; TCR: T cell receptor; BCR: B cell receptor; CD40: cluster of differentiation 40, a costimulatory protein found on antigen-presenting cells, which is required for their activation; EDAR: ectodysplasin A receptor; NF-kappa-B: nuclear factor (NF) for the kappa light chain enhancer in B cells.</div><div id=\"graphicVersion\">Graphic 112546 Version 1.0</div></div></div>"},"112547":{"type":"graphic_figure","displayName":"Role of DOCK8 in TLR9 signaling in B lymphocytes","title":"Role of DOCK8 in TLR9 signaling in B lymphocytes","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Role of DOCK8 in TLR9 signaling in B lymphocytes</div><div class=\"cntnt\"><img style=\"width:521px; height:386px;\" src=\"images/ALLRG/112547_DOCK8_TLR9_sgnlng_B_lymphcy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DOCK8: dedicator of cytokinesis 8; TLR9: toll-like receptor 9; MyD88: myeloid differentiation primary response protein 88; Pyk2: proline-rich tyrosine kinase 2; Lyn: a member of the Src family of protein tyrosine kinases, expressed in hematopoietic cells; Syk: spleen-associated tyrosine kinase; STAT3: signal transducer and activator of transcription 3.</div><div id=\"graphicVersion\">Graphic 112547 Version 1.0</div></div></div>"},"112550":{"type":"graphic_figure","displayName":"Effect of HOIL-1 and HOIP mutations in fibroblasts and monocytes","title":"Effect of HOIL-1 and HOIP mutations in fibroblasts and monocytes","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Effect of HOIL-1 and HOIP mutations in fibroblasts and monocytes</div><div class=\"cntnt\"><img style=\"width:716px; height:428px;\" src=\"images/ALLRG/112550_Effect_HOIL1_HOIP_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HOIL-1: heme-oxidized IRP2 ubiquitin ligase-1; HOIP: HOIL-1 interacting protein; IL-1R: interleukin-1 receptor; MyD88: myeloid differentiation primary response protein 88; IRAK: interleukin-1 receptor-associated kinase; NEMO: nuclear factor (NF)-kappa-B essential modulator; IKK: inhibitor of nuclear factor (NF)-kappa-B kinase; NF-kappa-B: nuclear factor (NF) for the kappa light chain enhancer in B cells.</div><div id=\"graphicVersion\">Graphic 112550 Version 1.0</div></div></div>"},"112557":{"type":"graphic_figure","displayName":"Toll-like receptor (TLR) pathway defects","title":"Toll-like receptor (TLR) pathway defects","html":"<div class=\"graphic\"><div style=\"width: 980px\" class=\"figure\"><div class=\"ttl\">Toll-like receptor (TLR) pathway defects</div><div class=\"cntnt\"><img style=\"width:960px; height:592px;\" src=\"images/ALLRG/112557_TLR_pathway_defects.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When mutated or deficient, the signaling molecules shown in red result in immunodeficiency.</div><div class=\"graphic_footnotes\">TLR: toll-like receptor; MyD88: myeloid differentiation primary response protein 88; IRAK: interleukin-1 receptor-associated kinase; TRAF: tumor necrosis factor (TNF) receptor-associated factor; TAK1: transforming growth factor (TGF)-beta-activated protein kinase 1; IRF: interferon regulatory factor; NEMO: nuclear factor (NF)-kappa-B essential modulator; IKK: inhibitor of nuclear factor (NF)-kappa-B kinase; NF-kappa-B: nuclear factor (NF) for the kappa light chain enhancer in B cells; MAPKs: mitogen-activated protein kinases; AP1: activating protein-1; MAL: MyD88 adapter-like; TRAM: TRIF-related adapter molecule; TRIF: toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter-inducing interferon-beta (IFN-beta); TBK1: tank-binding kinase 1; IKKi: I-kappa-B kinase i; UNC93B: UNC93 homolog B; RIP1: receptor-interacting protein kinase-1; BTK: Bruton tyrosine kinase; OPNi: osteopontin i.</div><div id=\"graphicVersion\">Graphic 112557 Version 1.0</div></div></div>"},"112567":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of rib fracture and overlying soft tissue","title":"Ultrasound of rib fracture and overlying soft tissue","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Ultrasound of rib fracture and overlying soft tissue</div><div class=\"cntnt\"><img style=\"width:765px; height:294px;\" src=\"images/EM/112567_Utrsd_rb_frct_vrlyg_sft_tss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diagnostic ultrasound image in the longitudinal plane of a rib during maximal inhalation demonstrating cortical offset (dashed arrow) consistent with a fracture, and surrounding hematoma (asterisk) displacing the overlying pectoralis minor muscle (pm) and a portion of the pectoralis major muscle (PM). The costochondral junction (arrow) is located medial to the fracture.<br />(B) Ultrasound image of the same rib demonstrates increased cortical offset during maximal exhalation.</div><div class=\"graphic_reference\">Reproduced from: Mattox R, Reckelhoff KE, Welk AB, Kettner NW. Sonography of occult rib and costal cartilage fractures: A case series. J Chiropractic Med 2014; 13:139. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112567 Version 1.0</div></div></div>"},"112568":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of rib fracture","title":"Ultrasound of rib fracture","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Ultrasound of rib fracture</div><div class=\"cntnt\"><img style=\"width:754px; height:463px;\" src=\"images/EM/112568_Ultrasound_of_rib_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a non-displaced rib fracture. A break in the cortex is indicated by the arrow.</div><div class=\"graphic_reference\">Reproduced with permission from: French AJ, English J, Stone MB, Frazee BW. Soft tissues and musculoskeletal procedures. In: Practical Guide to Emergency Ultrasound, 2nd ed, Cosby KS, Kendall JL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 112568 Version 1.0</div></div></div>"},"112571":{"type":"graphic_figure","displayName":"Extrinsic and intrinsic wrist ligaments","title":"Extrinsic and intrinsic wrist ligaments","html":"<div class=\"graphic\"><div style=\"width: 914px\" class=\"figure\"><div class=\"ttl\">Extrinsic and intrinsic wrist ligaments</div><div class=\"cntnt\"><img style=\"width:894px; height:407px;\" src=\"images/SM/112571_Extrinsc_intrnsc_wrst_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The palmar (A) and dorsal (B) ligaments of the wrist are shown in the images above as follows:<br /><br />(A) The palmar wrist ligaments of the right hand. Extrinsic ligaments: Radioscaphocapitate ligament, radial collateral ligament, radiolunate ligament, radioscapholunate ligament, ulnolunate ligament, meniscus homologue (radiotriquetral ligament), ulnar collateral ligament; the superficial palmar radiocarpal ligament and the triangular fibrocartilage are not shown. Intrinsic ligaments: scapholunate ligament, lunotriquetral ligament, and palmar intercarpal (deltoid, or V) ligaments. The short palmar intrinsics are not shown.<br /><br />(B) The dorsal wrist ligaments of the right hand. Extrinsic ligaments: Radiotriquetral, radiolunate, and radioscaphoid fascicles of the dorsal radiocarpal ligament. Intrinsic ligaments: Dorsal intercarpal, trapeziotrapezoid, trapeziocapitate, and capitohamate fascicles of the short intrinsic ligaments. The scaphotrapezium ligament is not shown.</div><div class=\"graphic_footnotes\">S: scaphoid; L: lunate; TQ: triquetrum; H: hamate; C: capitate; TZ: trapezoid; TP: trapezium; P: prestyloid recess.</div><div class=\"graphic_reference\">Reproduced with permission from: Barr AE, Bear-Lehman J. Biomechanics of the wrist and hand. In: Basic Biomechanics of the Musculoskeletal System, 4th ed, Nordin M, Frankel VH (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 112571 Version 1.0</div></div></div>"},"112575":{"type":"graphic_diagnosticimage","displayName":"Aortitis in GCA on PET and PET CT","title":"Aortitis in GCA on PET and PET CT","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Aortitis in GCA on PET and PET CT</div><div class=\"cntnt\"><img style=\"width:783px; height:458px;\" src=\"images/RHEUM/112575_Aortitis_GCA_PET_PET_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET (Panels A, B) and PET CT (Panel C) scans of a patient with proven GCA, showing large vessel involvement.<br />(Panel A) There is a focus of mildly increased FDG uptake at the bifurcation of the right innominate artery and diffuse FDG avidity of the bilateral subclavian arteries extending into the proximal axillary arteries.<br />(Panel B) Patchy increased FDG uptake is seen throughout the entire aorta.<br />(Panel C) Aortic involvement is also demonstrated on the 3D image from the fused PET CT scan.</div><div class=\"graphic_footnotes\">GCA: giant cell (temporal) arteritis; PET: positron emission tomography; CT: computed tomography;&nbsp;FDG: fluorodeoxyglucose; 3D: three-dimensional.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 112575 Version 1.0</div></div></div>"},"112577":{"type":"graphic_picture","displayName":"Deeply embedded hair tourniquet","title":"Deeply embedded hair tourniquet","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Deeply embedded hair tourniquet</div><div class=\"cntnt\"><img style=\"width:655px; height:296px;\" src=\"images/EM/112577_DeeplyembeddedtourniqtPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Swelling and sloughing of the skin on the fourth toe.<br />(B) Note marked indentation and demarcation by presumed \"constricting\" band.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics in Review, Vol. 32, Pages 253-5, Copyright © 2011 by the AAP.</div><div id=\"graphicVersion\">Graphic 112577 Version 2.0</div></div></div>"},"112579":{"type":"graphic_picture","displayName":"Cutaneous horn","title":"Cutaneous horn","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">Cutaneous horn</div><div class=\"cntnt\"><img style=\"width:673px; height:756px;\" src=\"images/ONC/112579_Cutaneous_horn.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112579 Version 1.0</div></div></div>"},"112582":{"type":"graphic_table","displayName":"Carrier frequency in specific ethnic groups","title":"Example of an expanded carrier screening panel*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of an expanded carrier screening panel*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Carrier frequency in general population</td> <td class=\"subtitle1\">Carrier frequency in specific ethnic groups</td> </tr> <tr> <td>alpha-thalassemia</td> <td class=\"centered\">Unknown</td> <td>African (particularly sub-Saharan): 1 in 3.<br /> Mediterranean: 1 in 30.<br /> Southeast Asian and Middle Eastern: 1 in 20.</td> </tr> <tr> <td>beta-thalassemia</td> <td class=\"centered\">Unknown</td> <td>African American: &#60;1 in 8.<br /> Ashkenazi Jewish: Varied.<br /> Asian: 1 in 20.<br /> Mediterranean: 1 in 7.</td> </tr> <tr> <td>Bloom syndrome</td> <td class=\"centered\">&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 100.</td> </tr> <tr> <td>Canavan disease</td> <td class=\"centered\">&#60;1 in 150</td> <td>Ashkenazi Jewish: 1 in 41.</td> </tr> <tr> <td>Cystic fibrosis</td> <td class=\"centered\">Unknown</td> <td>African American: 1 in 61.<br /> Asian: 1 in 94.<br /> Ashkenazi Jewish: 1 in 24.<br /> Caucasian: 1 in 25.<br /> Hispanic: 1 in 58.</td> </tr> <tr> <td>Familial dysautonomia</td> <td class=\"centered\">&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 31.</td> </tr> <tr> <td>Familial hyperinsulinism</td> <td class=\"centered\">&#60;1 in 150</td> <td>Ashkenazi Jewish: 1 in 52.</td> </tr> <tr> <td>Fanconi anemia C</td> <td class=\"centered\">&#60;1 in 790</td> <td>Ashkenazi Jewish: 1 in 89.</td> </tr> <tr> <td>Fragile X syndrome<sup>&#182;</sup></td> <td class=\"centered\">1 in 259</td> <td>&nbsp;</td> </tr> <tr> <td>Galactosemia</td> <td class=\"centered\">1 in 87</td> <td>Ashkenazi Jewish: 1 in 127.</td> </tr> <tr> <td>Gaucher disease</td> <td class=\"centered\">&#60;1 in 100</td> <td>Ashkenazi Jewish: 1 in 15.</td> </tr> <tr> <td>Glycogen storage disease type 1A</td> <td class=\"centered\">&#60;1 in 150</td> <td>Ashkenazi Jewish: 1 in 71.</td> </tr> <tr> <td>Joubert syndrome</td> <td class=\"centered\">&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 92.</td> </tr> <tr> <td>Medium-chain acyl-CoA dehydrogenase deficiency</td> <td class=\"centered\">Unknown</td> <td>Caucasian: 1 in 50.</td> </tr> <tr> <td>Maple syrup urine disease types 1A and 1B</td> <td class=\"centered\">&#60;1 in 240</td> <td>Ashkenazi Jewish: 1 in 81 (type 1B).<br /> Mennonite: 1 in 10 (type 1A-BCKDHA p.Y438N).</td> </tr> <tr> <td>Mucolipidosis IV</td> <td class=\"centered\">&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 96.</td> </tr> <tr> <td>Niemann-Pick disease type A</td> <td class=\"centered\">&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 90.</td> </tr> <tr> <td>Phenylketonuria</td> <td class=\"centered\">Unknown</td> <td>Caucasian: 1 in 50.<br /> Irish: 1 in 34.</td> </tr> <tr> <td>Sickle cell anemia</td> <td class=\"centered\">Unknown</td> <td>African American: 1 in 10.</td> </tr> <tr> <td>Smith-Lemli-Opitz syndrome</td> <td class=\"centered\">Unknown</td> <td>Caucasian: 1 in 70.</td> </tr> <tr> <td>Spinal muscular atrophy</td> <td class=\"centered\">Unknown</td> <td>African American: 1 in 66.<br /> Asian: 1 in 53.<br /> Ashkenazi Jewish: 1 in 41.<br /> Caucasian: 1 in 35.<br /> Hispanic: 1 in 117.</td> </tr> <tr> <td>Tay-Sachs disease<sup>&#916;</sup></td> <td class=\"centered\">&#60;1 in 300</td> <td>Ashkenazi Jewish: 1 in 30.<br /> French Canadian and Cajun: 1 in 30.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Conditions reasonable for inclusion in an expanded carrier screening panel as of 2016. After counseling regarding screening options, obstetrician-gynecologists or other health care providers and patients may elect to screen for fewer or more conditions than those listed here. The availability of expanded carrier screening does not preclude the appropriateness of ethnic-based screening or screening based on family history. Conditions were selected on the basis of the benefits of detection, the accuracy of current screening methods, and the following consensus-determined criteria: Have a carrier frequency of 1 in 100 or greater, have a well-defined phenotype, have a detrimental effect on quality of life, cause cognitive or physical impairment, require surgical or medical intervention, or have an onset early in life. Additionally, screened conditions should be able to be diagnosed prenatally and may afford opportunities for antenatal intervention to improve perinatal outcomes, changes to delivery management to optimize newborn and infant outcomes, and education of the parents about special care needs after birth.<br />¶ Included on this list despite a carrier frequency lower than 1 in 100 because, as an X-linked syndrome, fragile X syndrome is more prevalent than other conditions.<br />Δ DNA testing alone will miss up to 10% of carriers of Tay-Sachs disease, especially in lower-risk groups and, therefore, enzyme-based testing may be a more appropriate choice for some patients.</div><div class=\"graphic_reference\">Reprinted with permission from Carrier screening in the age of genomic medicine. ACOG Committee Opinion No. 690. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017; 129:e35-40.</div><div id=\"graphicVersion\">Graphic 112582 Version 1.0</div></div></div>"},"112594":{"type":"graphic_algorithm","displayName":"Treatment of monoclonal gammopathy-associated proliferative GN","title":"Treatment of monoclonal gammopathy-associated proliferative glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Treatment of monoclonal gammopathy-associated proliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:472px; height:542px;\" src=\"images/NEPH/112594_Trtmt_mnclnl_gmpthy-ascd_GN.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Ig: immunoglobulin; ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; VCD: bortezomib, cyclophosphamide, dexamethasone; RCD: rituximab, cyclophosphamide, dexamethasone; CP: cyclophosphamide plus prednisone.<br />* Among patients with C3 glomerulopathy with monoclonal gammopathy, the absence of monoclonal protein deposits within the kidney makes it difficult to establish a causal relationship between the circulating monoclonal protein and the renal injury. Although C3 glomerulopathy and monoclonal gammopathy may coexist in a patient, the circulating monoclonal protein may not be responsible for the C3 deposition. In some patients with biopsy findings consistent with C3 glomerulonephritis, monoclonal immunoglobulin deposits may not be detectable using standard immunofluorescence techniques. In such patients, paraffin immunofluorescence after pronase digestion should be performed to \"unmask\" hidden immunoglobulin deposits. <br />¶ In patients who have monoclonal immunoglobulin deposition in the kidney but no detectable monoclonal protein in the serum or urine, the decision to aggressively treat with chemotherapy is more difficult since there is no clear evidence that a pathologic clone is responsible for the kidney disease. In such patients, a more conservative approach to treatment is preferred.<br />Δ Treatment should be selected and administered in consultation with a hematologist or oncologist who is experienced in the use of antimyeloma and antilymphoma agents.</div><div class=\"graphic_reference\">Adapted from: Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013; 88:1284.</div><div id=\"graphicVersion\">Graphic 112594 Version 1.0</div></div></div>"},"112600":{"type":"graphic_figure","displayName":"Distribution of soft tissue sarcoma histologic subtype in adults","title":"Distribution of histologic subtypes in a modern database series of 10,000 adult soft tissue sarcomas, Memorial Sloan Kettering Cancer Center (MSKCC)","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Distribution of histologic subtypes in a modern database series of 10,000 adult soft tissue sarcomas, Memorial Sloan Kettering Cancer Center (MSKCC)</div><div class=\"cntnt\"><img style=\"width:526px; height:386px;\" src=\"images/ONC/112600_Sfttisssarcomasbtypadlt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution by histology for adult patients with soft tissue sarcoma, all sites. MSKCC 7/1/1982-5/31/2013 n = 10,000.</div><div class=\"graphic_footnotes\">MPNST: malignant peripheral nerve sheath tumor; GIST: gastrointestinal stromal tumor; UPS: undifferentiated pleomorphic sarcoma.</div><div class=\"graphic_reference\">Reprinted by permission from Springer: Management of Soft Tissue Sarcoma, 2nd ed, by Brennan M, Antonescu C, Alektiar K, Maki R (Eds). Copyright © 2013.</div><div id=\"graphicVersion\">Graphic 112600 Version 2.0</div></div></div>"},"112606":{"type":"graphic_table","displayName":"Patient Health Questionnaire - 15 Item (PHQ-15)","title":"Patient Health Questionnaire - 15 Item (PHQ-15)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient Health Questionnaire - 15 Item (PHQ-15)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">During the past four weeks, how much have you been bothered by any of the following problems?</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle2\">Not bothered at all (0)</td> <td class=\"subtitle2\">Bothered a little (1)</td> <td class=\"subtitle2\">Bothered a lot (2)</td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\"> <li>Stomach pain </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Back pain </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"3\"> <li>Pain in your arms, legs, or joints (knees, hips, etc) </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"4\"> <li>Menstrual cramps or other problems with your periods (women only) </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"5\"> <li>Headaches </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"6\"> <li>Chest pain </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"7\"> <li>Dizziness </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"8\"> <li>Fainting spells </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"9\"> <li>Feeling your heart pound or race </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"10\"> <li>Shortness of breath </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"11\"> <li>Pain or problems during sexual intercourse </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"12\"> <li>Constipation, loose bowels, or diarrhea </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"13\"> <li>Nausea, gas, or indigestion </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"14\"> <li>Feeling tired or having low energy </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol class=\"numbers_no_heading\" style=\"list-style-type: lower-alpha;\" start=\"15\"> <li>Trouble sleeping </li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr class=\"highlight_gray_text divider_top\"> <td style=\"font-size: 1.2em; text-align: right;\"><strong>Total score:</strong></td> <td style=\"font-size: 1.2em; text-align: right;\"><strong>=</strong></td> <td style=\"font-size: 1.2em; text-align: right;\"><strong>+</strong></td> <td style=\"font-size: 1.2em; text-align: right;\"><strong>+</strong></td> <td style=\"font-size:1.2em;\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PHQ-15 scores and severity of somatic symptoms:<br />0 to 4: Minimal.<br />5 to 9: Low.<br />10 to 14: Moderate.<br />15 to 30: High.</div><div class=\"graphic_reference\">Originally published in: Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64:258. Developed by Drs. Robert L Spitzer, Janet BW Williams, Kurt Kroenke, and colleagues, with an educational grant from Pfizer, Inc. No permission required to reproduce, translate, display or distribute.</div><div id=\"graphicVersion\">Graphic 112606 Version 1.0</div></div></div>"},"112609":{"type":"graphic_algorithm","displayName":"Hair tourniquet removal","title":"Removal of hair tourniquet, thread tourniquet, or other constricting band of the digits or genitalia","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Removal of hair tourniquet, thread tourniquet, or other constricting band of the digits or genitalia</div><div class=\"cntnt\"><img style=\"width:742px; height:584px;\" src=\"images/EM/112609_Hair_tourniquet_removal.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Apply chemical depilatory lotion, spray, or cream (eg, Nair, Magic Shave, or Veet) for three to six minutes according to specific product package instructions. Do not leave on longer than 10 minutes. Gently wipe off the depilatory with clean gauze and rinse with lukewarm water. The treatment can be reapplied in 10 to 15 minutes if the first treatment is unsuccessful. Do not use near mucosa (eg, tourniquets of the labia or clitoris) or on tourniquets associated with significant skin breakdown.<br />¶ Superficial tourniquets typically show prompt return to normal perfusion but decrease in swelling may be delayed for 1 to 2 days. Deeply embedded tourniquets show improvement in perfusion and decrease in pain soon after release but timing to normalization of appearance depends on the degree of necrosis or skin breakdown present.<br />Δ Depending on the site, regional anesthesia (eg, digital or dorsal penile block) with sedation or general anesthesia in the operating room may be warranted. Some physicians may prefer to consult a gynecologist for removal of tourniquets of the labia or clitoris.<br /><FONT class=lozenge>◊</FONT> Deeply embedded tourniquets with ischemia or necrosis of external genitalia (penis, labia, or clitoris) require excision and warrant consultation with a surgical specialist (ie, urologist for penile tourniquets or gynecologist for tourniquets of the vulva). Some experienced physicians may feel comfortable excising embedded digital tourniquets without surgical consultation. Otherwise, prompt consultation&nbsp;with a general surgeon, plastic surgeon, or orthopedic surgeon, depending upon local availability and practice is warranted.</div><div id=\"graphicVersion\">Graphic 112609 Version 1.0</div></div></div>"},"112613":{"type":"graphic_diagnosticimage","displayName":"Aortitis in GCA on CT","title":"Aortitis in GCA on CT","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Aortitis in GCA on CT</div><div class=\"cntnt\"><img style=\"width:454px; height:766px;\" src=\"images/RHEUM/112613_Aortitis_GCA_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Parasagittal CT angiography image of the aorta demonstrates diffuse thickening and enhancement of the aortic wall along the thoracic aorta and great vessels (thin arrows) in a patient with biopsy-proved GCA.<br />(B) Axial CT angiography image of the aorta demonstrates thickening and enhancement of the aortic wall at the level of the right renal artery.</div><div class=\"graphic_footnotes\">GCA: giant cell (temporal) arteritis; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 112613 Version 1.0</div></div></div>"},"112616":{"type":"graphic_table","displayName":"Summary anesthetic mgmt pts undergoing awake craniotomy","title":"Summary of anesthetic management of patients undergoing awake craniotomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of anesthetic management of patients undergoing awake craniotomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Preoperative</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Patient selection and preparation. <ul> <li>Reinforce rationale for awake craniotomy; establish rapport, psychological preparation, reassurance. </li> </ul> </li> <li>Optimize coexisting medical problems. </li> <li>Continue antiepileptic medications and steroids on day of surgery as indicated. </li> <li>Premedication as per institutional practice. <ul> <li>Avoid benzodiazepines if intraoperative electrocorticography is indicated. </li> </ul> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Discuss positioning and type of intraoperative mapping (ie, motor versus language) with surgeon. </li> <li>Ensure comfortable positioning and adequate access to the patient's airway. </li> <li>Standard monitors are used. Invasive monitoring is indicated in patients with significant comorbidity, at risk for major blood loss and/or when reliable blood pressure cannot be obtained, especially in lateral positions. </li> <li>Administer supplemental oxygen, with means of monitoring of end tidal CO<sub>2</sub> and respiratory rate. </li> <li>Avoid urinary catheter unless the duration of surgery is &#62;4 hours and/or mannitol will be administered. </li> <li>Ensure adequate local anesthesia for pin sites, scalp and incision, with scalp blocks or field infiltration. </li> <li>Surgical drapes should form a tent around the patient's face to allow access to the airway and communication with the patient. </li> <li>For conscious sedation, commonly used anesthetic agents include propofol, midazolam, fentanyl, remifentanil, and dexmedetomidine. </li> <li>For an asleep-awake-asleep technique, commonly used strategies include intravenous induction, airway management with a supraglottic airway, and maintenance of anesthesia with total intravenous anesthesia (eg, propofol and remifentanil) or inhalation anesthesia (eg, sevoflurane). </li> <li>Maintain vigilance for complications (eg, seizures, respiratory adverse events, nausea and vomiting, lack of patient cooperation) and institute rapid treatment. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative</td> </tr> <tr> <td> <ol> <li>Postoperative disposition is institution specific. </li> <li>Routine ICU admissions not needed, and indicated for patients with significant comorbidities or surgical complications. </li> <li>Extended PACU care followed by inpatient bed or same day discharge possible. </li> <li>Monitor for postoperative neurologic deficits, seizures. </li> <li>Treat pain, nausea and vomiting. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For further information, refer to UpToDate content on anesthesia for awake craniotomy.</div><div class=\"graphic_footnotes\">ICU: intensive care unit; PACU: post-anesthesia care unit.</div><div id=\"graphicVersion\">Graphic 112616 Version 1.0</div></div></div>"},"112617":{"type":"graphic_table","displayName":"Complications during awake neurosurgical procedures","title":"Complications during awake neurosurgical procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications during awake neurosurgical procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complications</td> <td class=\"subtitle1\">Causes</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Seizures, localized or generalized</td> <td>Preoperative history of seizures; frequently occurs during cortical stimulation. </td> <td> <p>No treatment if short. </p> <p>Initial treatment:</p> <ul> <li>Low dose propofol (10 to 20 mg) or midazolam (1 to 2 mg), protect from injury </li> <li>After dural opening, iced saline on cortex by surgeon</li> </ul> If prolonged, or generalized: <ul> <li>Airway, breathing/oxygenation, circulatory stability.</li> <li>Phenytoin</li> </ul> If repeated treatments required, patient may become drowsy and need airway support.</td> </tr> <tr class=\"divider_bottom\"> <td>Respiratory: Desaturation, decreased respiratory rate, hypercapnia</td> <td>Oversedation, loss of consciousness from an intracranial event or seizures, venous air embolism, aggravation of preoperative respiratory disease.</td> <td>Decrease or stop sedation.</td> </tr> <tr class=\"divider_bottom\"> <td>Airway obstruction</td> <td>Mechanical or oversedation.</td> <td> <p>Decrease or stop sedation.</p> <p>If necessary:</p> <ul> <li>Chin lift, jaw thrust </li> <li>Secure airway with oral or nasal airway, laryngeal mask airway, endotracheal tube </li> <li>Release head frame from table </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Pain</td> <td>Worse during pin fixation, dissection of the temporalis muscle, traction on the dura, manipulation of the intracerebral blood vessels.</td> <td>Additional local anesthesia, and/or analgesia, and/or sedation.</td> </tr> <tr class=\"divider_bottom\"> <td>Nausea/vomiting</td> <td> <p>Patient anxiety, medications, surgical stimulation.</p> Worse during stripping of the dura and manipulation of the temporal lobe and meningeal vessels.</td> <td>Antiemetics, propofol, sedation.</td> </tr> <tr> <td colspan=\"3\">Hemodynamic disturbances</td> </tr> <tr> <td class=\"indent1\">Hypertension, tachycardia</td> <td>Common causes: Anxiety, inadequate analgesia.</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Ensure adequate sedation and analgesia, antihypertensive agents if required.</p> Treat with appropriate sedation, analgesia, fluids, vasoactive agents.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypotension, bradycardia</td> <td>Common causes: Hypovolemia, excessive sedation, drug effect, trigemino-cardiac reflex.</td> </tr> <tr class=\"divider_bottom\"> <td>Tight brain</td> <td>Oversedation, airway obstruction.</td> <td>Decrease sedation, encourage deep breathing, head elevation, mannitol.</td> </tr> <tr> <td>Venous air embolism</td> <td> <p>Open veins: Burr hole, craniotomy, venous sinus.</p> </td> <td> <p>Presents with cough, shortness of breath, agitation, chest pain.</p> <p>Alert surgeon, cover area with saline, place head down if possible, supportive measures.</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112617 Version 1.0</div></div></div>"},"112618":{"type":"graphic_figure","displayName":"SIMV with pressure support","title":"Synchronized intermittent mandatory ventilation (SIMV) with pressure support","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Synchronized intermittent mandatory ventilation (SIMV) with pressure support</div><div class=\"cntnt\"><img style=\"width:488px; height:357px;\" src=\"images/ANEST/112618_SIMV_with_pressure_support.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112618 Version 1.0</div></div></div>"},"112619":{"type":"graphic_figure","displayName":"Capnogram with upsloping plateau","title":"Capnogram with upsloping plateau","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Capnogram with upsloping plateau</div><div class=\"cntnt\"><img style=\"width:510px; height:256px;\" src=\"images/ANEST/112619_Capnogram_with_upsloping_plateau.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with obstructive lung disease and an upsloping end tidal CO<SUB>2</SUB> plateau, inspiration may occur before the true end of expiration, and result in a falsely low ETCO<SUB innerHtml>2 </SUB>(solid line).&nbsp;Reducing the respiratory rate (or briefly stopping the ventilator) should allow full exhalation and an accurate ETCO<SUB>2</SUB> reading (dashed line).&nbsp;&nbsp; </div><div id=\"graphicVersion\">Graphic 112619 Version 1.0</div></div></div>"},"112620":{"type":"graphic_figure","displayName":"Normal pressure volume loop","title":"Normal pressure volume loop during positive pressure ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal pressure volume loop during positive pressure ventilation</div><div class=\"cntnt\"><img style=\"width:363px; height:294px;\" src=\"images/ANEST/112620_Normal_pressure_volume_loop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During positive pressure ventilation, breaths progress on a pressure volume loop in a counterclockwise direction, with inspiration curving upward, and expiration curving downward, as shown by the arrows in this figure. Thus the upper right point on the graph represents peak inspiratory pressure and tidal volume. The lower left point of the loop appears at zero volume, and the set level of positive end expiratory pressure (PEEP). In this example, PEEP is set at zero.</div><div class=\"graphic_footnotes\">TV: tidal volume; PIP: peak inspiratory pressure</div><div id=\"graphicVersion\">Graphic 112620 Version 1.0</div></div></div>"},"112621":{"type":"graphic_figure","displayName":"Pressure volume loops with decreased compliance","title":"Pressure volume loops with decreased compliance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure volume loops with decreased compliance</div><div class=\"cntnt\"><img style=\"width:441px; height:527px;\" src=\"images/ANEST/112621_Pressure_volume_loops_with_decreased_compliance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure volume loops are most useful as an indication of compliance. This figure shows the change in the pressure volume loop that might occur with decreased compliance during pressure controlled ventilation (panel a) and volume controlled ventilation (panel b). If compliance decreases, a line drawn from the zero point through the point of end inspiration becomes more horizontal, and the curve rotated to the right. The normal pressure volume loop is shown by the solid lines, and the dashed lines show the curve with decreased compliance.<br /><br />During pressure controlled ventilation, with a decrease in compliance the tidal volume is reduced. During volume controlled ventilation, with a decrease in compliance peak inspiratory pressure increases.</div><div class=\"graphic_footnotes\">TV: tidal volume; PIP: peak inspiratory pressure</div><div id=\"graphicVersion\">Graphic 112621 Version 1.0</div></div></div>"},"112622":{"type":"graphic_figure","displayName":"Pressure volume loop with excessive ventilation","title":"Pressure volume loop with excessive ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure volume loop with excessive ventilation</div><div class=\"cntnt\"><img style=\"width:363px; height:296px;\" src=\"images/ANEST/112622_Pressure_volume_loop_with_excessive_ventilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pressure volume loop shows a \"bird beak\" pattern in the portion of the curve in the red oval, in which the breath is increasing pressure without an appreciable increase in volume. The set ventilator pressure (during pressure controlled ventilation) or volume (during volume controlled ventilation) should be decreased to prevent barotrauma, and the effect of these maneuvers&nbsp;can be monitored by&nbsp;the change in the shape of the curve.</div><div id=\"graphicVersion\">Graphic 112622 Version 1.0</div></div></div>"},"112623":{"type":"graphic_figure","displayName":"Normal flow volume loop","title":"Normal flow volume loop","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal flow volume loop</div><div class=\"cntnt\"><img style=\"width:320px; height:289px;\" src=\"images/ANEST/112623_Normal_flow_volume_loop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow volume loops may be displayed on an anesthesia machine with inspiration above the horizontal axis, and volume increasing from left to right. When displayed this way, breaths progress in a clockwise direction, as shown by the arrows in this figure. Tidal volume (TV)&nbsp;is represented by the point on the volume axis where the flow curve crosses zero, and peak expiratory flow (PEF) occurs at the lowest point on the expiratory portion of the curve. </div><div id=\"graphicVersion\">Graphic 112623 Version 1.0</div></div></div>"},"112624":{"type":"graphic_figure","displayName":"Flow volume loop with increased resistance","title":"Flow volume loop with increased resistance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow volume loop with increased resistance</div><div class=\"cntnt\"><img style=\"width:320px; height:292px;\" src=\"images/ANEST/112624_Flow_volume_loop_with_increased_resistance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow volume loops may be displayed on an anesthesia machine with inspiration above the horizontal axis, and volume increasing from left to right. When displayed this way, breaths progress in a clockwise direction, as shown by the arrows in this figure. The normal curve is shown by the solid line. The dashed line shows the curve with increased lung resistance. Normalization of the flow volume loop can be used to monitor treatment. For further information, refer to UpToDate content on monitoring pulmonary mechanics during mechanical ventilation in anesthesia.</div><div id=\"graphicVersion\">Graphic 112624 Version 1.0</div></div></div>"},"112625":{"type":"graphic_algorithm","displayName":"Evaluation for suspected growth hormone insensitivity","title":"Evaluation for suspected growth hormone insensitivity in a child","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">Evaluation for suspected growth hormone insensitivity in a child</div><div class=\"cntnt\"><img style=\"width:780px; height:798px;\" src=\"images/PEDS/112625_Eval_suspected_GHI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GH: growth hormone; IGF-I: insulin-like growth factor I; IGFBP-3: insulin-like growth factor binding protein 3; GHBP: growth hormone binding protein.<br />* Refer to UpToDate topic reviews on the diagnostic approach to short stature, and diagnosis of growth hormone deficiency in children.<br />¶ Trials of growth hormone or IGF-I should be performed only if the epiphyses are open. An adequate growth response is an increase in height velocity by at least 2.5 cm/year. Children whose epiphyses are nearly closed may not achieve this degree of growth response even if they have GHD or GHI.<br />Δ In a patient with suspected GHI, the possibility of Laron syndrome can be assessed by molecular testing for pathogenic homozygous or compound heterozygous mutations in the GH receptor gene. Laron syndrome is the most common form of severe GHI. Alternatively, the possibility of GHI can be supported by measuring basal GH levels and GHBP, or performing an IGF-I generation test (IGF-I response to a brief trial of recombinant GH). The results of the IGF-I generation test are not always useful, because the protocols for performing this test have not been standardized and the levels of IGF-I achieved are quite variable.<br /><FONT class=lozenge>◊</FONT> In patients with clinical characteristics of severe GHI and a normal or elevated circulating GH level, a low level of GHBP strongly supports a diagnosis of Laron syndrome, but normal levels are uninformative. This is because patients with Laron syndrome have low GHBP levels only if the GH receptor mutation affects the extracellular binding domain, whereas GHBP levels are normal or high if the GH receptor mutation affects the transmembrane or cytoplasmic domain of the GH receptor.<br />§ Adequate growth response to GH confirms GHD. If the growth response is inadequate, consider the possibility of an IGF-I receptor mutation.</div><div id=\"graphicVersion\">Graphic 112625 Version 1.0</div></div></div>"},"112631":{"type":"graphic_table","displayName":"Selection of Q-switched laser for tattoo removal","title":"Selection of Quality-switched (Q-switched) laser for tattoo removal","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of Quality-switched (Q-switched) laser for tattoo removal</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tattoo color</td> <td class=\"subtitle1\">532 nm frequency doubled Nd:YAG laser</td> <td class=\"subtitle1\">694 nm ruby laser</td> <td class=\"subtitle1\">755 nm alexandrite laser</td> <td class=\"subtitle1\">1064 nm Nd:YAG laser</td> </tr> <tr> <td>Black</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Blue</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Green</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Red</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Yellow</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Orange</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Tattoo pigment particles of different colors preferentially absorb different wavelengths of light. Selection of the appropriate Q-switched laser for tattoo removal is based upon tattoo color.</div><div class=\"graphic_footnotes\">Nd: neodymium-doped; YAG: yttrium aluminum garnet.</div><div id=\"graphicVersion\">Graphic 112631 Version 2.0</div></div></div>"},"112636":{"type":"graphic_picture","displayName":"Perilunate surface anatomy","title":"Perilunate surface anatomy","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Perilunate surface anatomy</div><div class=\"cntnt\"><img style=\"width:459px; height:612px;\" src=\"images/SM/112636_Perilunate_surface_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the dorsal surface anatomy of the proximal carpal row of the wrist. The lunate (L) is in line with the third metacarpal. The black dot represents the location of Lister's tubercle on the distal radius. Just distal to the tubercle—and just radial to the lunate—is the scapholunate ligament (hashed lines), and on the ulnar side of the lunate is the lunotriquetral ligament (hashed lines).</div><div class=\"graphic_footnotes\">L: lunate; S: scaphoid; T: triquetrum.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 112636 Version 1.0</div></div></div>"},"112637":{"type":"graphic_picture","displayName":"Traumatic tattoo secondary to explosion","title":"Traumatic tattoo","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Traumatic tattoo</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/112637_Traumtc_tattoo_scndry_expls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traumatic tattoo secondary to an explosion.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112637 Version 1.0</div></div></div>"},"112642":{"type":"graphic_table","displayName":"PROMIS Depression Short Form 8a","title":"PROMIS Depression Short Form 8a","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PROMIS Depression Short Form 8a</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Please respond to each question or statement by marking one box per row.</strong></td> </tr> <tr> <td class=\"subtitle1\">In the past 7 days...</td> <td class=\"subtitle1\">Never (1)</td> <td class=\"subtitle1\">Rarely (2)</td> <td class=\"subtitle1\">Sometimes (3)</td> <td class=\"subtitle1\">Often (4)</td> <td class=\"subtitle1\">Always (5)</td> </tr> <tr> <td>I felt worthless.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt helpless.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt depressed.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt hopeless.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt like a failure.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt unhappy.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt that I had nothing to look forward to.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td>I felt that nothing could cheer me up.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"highlight_gray_text centered\" style=\"font-size:1.2em;\" colspan=\"6\"><strong>Short form conversion</strong></td> </tr> <tr> <td class=\"subtitle2\">Raw score</td> <td class=\"subtitle2\">T-score</td> <td class=\"subtitle2\">SE*</td> <td class=\"subtitle2\">Raw score</td> <td class=\"subtitle2\">T-score</td> <td class=\"subtitle2\">SE*</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">38.2</td> <td class=\"centered\">5.7</td> <td class=\"centered\">25</td> <td class=\"centered\">63.0</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">44.7</td> <td class=\"centered\">3.3</td> <td class=\"centered\">26</td> <td class=\"centered\">63.9</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">47.5</td> <td class=\"centered\">2.7</td> <td class=\"centered\">27</td> <td class=\"centered\">64.9</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">49.4</td> <td class=\"centered\">2.3</td> <td class=\"centered\">28</td> <td class=\"centered\">65.8</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">50.9</td> <td class=\"centered\">2.0</td> <td class=\"centered\">29</td> <td class=\"centered\">66.8</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">52.1</td> <td class=\"centered\">1.9</td> <td class=\"centered\">30</td> <td class=\"centered\">67.7</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">53.2</td> <td class=\"centered\">1.8</td> <td class=\"centered\">31</td> <td class=\"centered\">68.7</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">54.1</td> <td class=\"centered\">1.8</td> <td class=\"centered\">32</td> <td class=\"centered\">69.7</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">16</td> <td class=\"centered\">55.1</td> <td class=\"centered\">1.7</td> <td class=\"centered\">33</td> <td class=\"centered\">70.7</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">17</td> <td class=\"centered\">55.9</td> <td class=\"centered\">1.7</td> <td class=\"centered\">34</td> <td class=\"centered\">71.7</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">18</td> <td class=\"centered\">56.8</td> <td class=\"centered\">1.7</td> <td class=\"centered\">35</td> <td class=\"centered\">72.8</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">19</td> <td class=\"centered\">57.7</td> <td class=\"centered\">1.7</td> <td class=\"centered\">36</td> <td class=\"centered\">73.9</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">58.5</td> <td class=\"centered\">1.7</td> <td class=\"centered\">37</td> <td class=\"centered\">75.0</td> <td class=\"centered\">1.9</td> </tr> <tr> <td class=\"centered\">21</td> <td class=\"centered\">59.4</td> <td class=\"centered\">1.7</td> <td class=\"centered\">38</td> <td class=\"centered\">76.4</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">22</td> <td class=\"centered\">60.3</td> <td class=\"centered\">1.7</td> <td class=\"centered\">39</td> <td class=\"centered\">78.2</td> <td class=\"centered\">2.4</td> </tr> <tr> <td class=\"centered\">23</td> <td class=\"centered\">61.2</td> <td class=\"centered\">1.7</td> <td class=\"centered\">40</td> <td class=\"centered\">81.3</td> <td class=\"centered\">3.4</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">62.1</td> <td class=\"centered\">1.8</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All questions must be answered to produce a valid raw score. The raw score is then converted to a T-score that rescales the raw score into a standardized, 100 point score with a mean of 50 and a standard deviation (SD) of 10.</div><div class=\"graphic_footnotes\">* Standard error (SE) on T-score.</div><div class=\"graphic_reference\">Reprinted with permission from: HealthMeasures. PROMIS Short Form v1.0 - Depression 8a. Available at: <A href=\"http://www.healthmeasures.net/index.php?option=com_instruments&amp;view=measure&amp;id=156\" target=_blank>http://www.healthmeasures.net/index.php?option=com_instruments&amp;view=measure&amp;id=156</A> (Accessed on June 5, 2017). Access full scoring instructions at <A href=\"http://www.healthmeasures.net/administrator/components/com_instruments/uploads/PROMIS%20Depression%20Scoring%20Manual%2002222017.pdf\" target=_blank>http://www.healthmeasures.net/administrator/components/com_instruments/uploads/PROMIS%20Depression%20Scoring%20Manual%2002222017.pdf</A>. ©2008-2017 PROMIS Health Organization.</div><div id=\"graphicVersion\">Graphic 112642 Version 1.0</div></div></div>"},"112645":{"type":"graphic_table","displayName":"PROMIS Anxiety Short Form 8a","title":"PROMIS Anxiety Short Form 8a","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PROMIS Anxiety Short Form 8a</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Please respond to each question or statement by marking one box per row.</strong></td> </tr> <tr> <td class=\"subtitle1\">In the past 7 days...</td> <td class=\"subtitle1\">Never (1)</td> <td class=\"subtitle1\">Rarely (2)</td> <td class=\"subtitle1\">Sometimes (3)</td> <td class=\"subtitle1\">Often (4)</td> <td class=\"subtitle1\">Always (5)</td> </tr> <tr> <td>I felt fearful.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I found it hard to focus on anything other than my anxiety.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>My worries overwhelmed me.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt uneasy.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt nervous.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt like I needed help for my anxiety.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr> <td>I felt anxious.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td>I felt tense.</td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> <td class=\"centered\" style=\"padding-top:0.7em;\"><span class=\"primarybox_left\" style=\"float: none;\">&nbsp;</span></td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"highlight_gray_text centered\" style=\"font-size:1.2em;\" colspan=\"6\"><strong>Short form conversion</strong></td> </tr> <tr> <td class=\"subtitle2\">Raw score</td> <td class=\"subtitle2\">T-score</td> <td class=\"subtitle2\">SE*</td> <td class=\"subtitle2\">Raw score</td> <td class=\"subtitle2\">T-score</td> <td class=\"subtitle2\">SE*</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">37.1</td> <td class=\"centered\">5.5</td> <td class=\"centered\">25</td> <td class=\"centered\">63.5</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">43.2</td> <td class=\"centered\">3.3</td> <td class=\"centered\">26</td> <td class=\"centered\">64.5</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">45.9</td> <td class=\"centered\">2.8</td> <td class=\"centered\">27</td> <td class=\"centered\">65.6</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">47.8</td> <td class=\"centered\">2.5</td> <td class=\"centered\">28</td> <td class=\"centered\">66.6</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">49.4</td> <td class=\"centered\">2.3</td> <td class=\"centered\">29</td> <td class=\"centered\">67.7</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">50.8</td> <td class=\"centered\">2.2</td> <td class=\"centered\">30</td> <td class=\"centered\">68.7</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">52.1</td> <td class=\"centered\">2.1</td> <td class=\"centered\">31</td> <td class=\"centered\">69.8</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">53.2</td> <td class=\"centered\">2.0</td> <td class=\"centered\">32</td> <td class=\"centered\">70.8</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">16</td> <td class=\"centered\">54.3</td> <td class=\"centered\">2.0</td> <td class=\"centered\">33</td> <td class=\"centered\">71.9</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">17</td> <td class=\"centered\">55.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">34</td> <td class=\"centered\">73.0</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">18</td> <td class=\"centered\">56.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">35</td> <td class=\"centered\">74.1</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">19</td> <td class=\"centered\">57.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">36</td> <td class=\"centered\">75.4</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">58.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">37</td> <td class=\"centered\">76.7</td> <td class=\"centered\">2.1</td> </tr> <tr> <td class=\"centered\">21</td> <td class=\"centered\">59.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">38</td> <td class=\"centered\">78.2</td> <td class=\"centered\">2.3</td> </tr> <tr> <td class=\"centered\">22</td> <td class=\"centered\">60.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">39</td> <td class=\"centered\">80.0</td> <td class=\"centered\">2.6</td> </tr> <tr> <td class=\"centered\">23</td> <td class=\"centered\">61.4</td> <td class=\"centered\">2.0</td> <td class=\"centered\">40</td> <td class=\"centered\">83.1</td> <td class=\"centered\">3.4</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">62.5</td> <td class=\"centered\">2.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All questions must be answered to produce a valid raw score. The raw score is then converted to a T-score that rescales the raw score into a standardized, 100 point score with a mean of 50 and a standard deviation (SD) of 10.</div><div class=\"graphic_footnotes\">* Standard error (SE) on T-score.</div><div class=\"graphic_reference\">Reprinted with permission from: HealthMeasures. PROMIS Short Form v1.0 - Anxiety 8a. Available at: <A href=\"http://www.healthmeasures.net/index.php?option=com_instruments&amp;view=measure&amp;id=147\" target=_blank>http://www.healthmeasures.net/index.php?option=com_instruments&amp;view=measure&amp;id=147</A> (Accessed on June 5, 2017). Access full scoring instructions at <A href=\"http://www.healthmeasures.net/administrator/components/com_instruments/uploads/PROMIS%20Anxiety%20Scoring%20Manual%2009202016.pdf\" target=_blank>http://www.healthmeasures.net/administrator/components/com_instruments/uploads/PROMIS%20Anxiety%20Scoring%20Manual%2009202016.pdf</A>. ©2008-2017 PROMIS Health Organization.</div><div id=\"graphicVersion\">Graphic 112645 Version 1.0</div></div></div>"},"112646":{"type":"graphic_picture","displayName":"Bandage of open wound for athlete or laborer","title":"Bandage of open wound for athlete or laborer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bandage of open wound for athlete or laborer</div><div class=\"cntnt\"><img style=\"width:440px; height:1383px;\" src=\"images/SM/112646_Bandage_opn_wound_athlt_lbr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Christopher McGrew, MD.</div><div id=\"graphicVersion\">Graphic 112646 Version 1.0</div></div></div>"},"112647":{"type":"graphic_picture","displayName":"Labial melanotic macule","title":"Labial melanotic macule","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Labial&nbsp;melanotic macule</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/112647_Oral_melanotic_macule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A brown hyperpigmented macule is visible on the lower lip of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112647 Version 1.0</div></div></div>"},"112648":{"type":"graphic_picture","displayName":"Oral melanotic macule gingiva","title":"Oral melanotic macule​","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Oral melanotic macule​</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/112648_Oral_melanotic_macule_gingi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A darkly pigmented macule is present on the gingival mucosa.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.</div><div id=\"graphicVersion\">Graphic 112648 Version 1.0</div></div></div>"},"112649":{"type":"graphic_picture","displayName":"Oral melanotic macule palate","title":"Oral melanotic macule","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Oral melanotic macule</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/112649_Oral_melanotic_macule_palat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.</div><div id=\"graphicVersion\">Graphic 112649 Version 1.0</div></div></div>"},"112650":{"type":"graphic_figure","displayName":"Supine position","title":"Supine position","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Supine position</div><div class=\"cntnt\"><img style=\"width:756px; height:482px;\" src=\"images/ANEST/112650_Supine_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>If the arm is adducted in the supine position, it should be positioned with the palm facing the patient's body (ie, neutral), and not in contact with the bed frame. The arm should be secured by loosely wrapping the lift sheet around the arm and then under the patient. For pregnant patients, and for those with a mobile abdominal mass, the table should be tilted left or a wedge placed under the left hip, to avoid aortocaval compression by the abdomen.</li>&#xD;&#xA;    <li>Physiologic changes that occur in the supine position include the following:&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Right sided filling pressures and cardiac output increase, often resulting in decreased heart rate and decreased peripheral vascular resistance.</li>&#xD;&#xA;        <li>Abdominal contents displace the diaphragm cephalad, which results in decreased tidal volume and functional residual capacity during spontaneous ventilation. During anesthesia with mechanical ventilation, ventilation/perfusion mismatch may occur due to over-ventilation of anterior lung fields.</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;    <li>For further information, refer to UpToDate content on patient positioning for surgery and anesthesia.</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 112650 Version 2.0</div></div></div>"},"112651":{"type":"graphic_figure","displayName":"Trendelenburg position","title":"Trendelenburg position","html":"<div class=\"graphic\"><div style=\"width: 756px\" class=\"figure\"><div class=\"ttl\">Trendelenburg position</div><div class=\"cntnt\"><img style=\"width:736px; height:462px;\" src=\"images/ANEST/112651_Trendelenburg_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologic changes that can occur in Trendelenburg position include the following: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>​Increased venous return can lead to increased right and left sided cardiac filling pressures, mean pulmonary artery pressure, and mean arterial pressure. Such changes may be poorly tolerated by patients with heart failure.</LI>&#xD;&#xA;<LI>Abdominal contents shift cephalad, which may lead to atelectasis and decreased functional residual capacity and pulmonary compliance, and ventilation/perfusion mismatching. These changes can cause difficulty with ventilation and oxygenation, particularly with abdominal insufflation for laparoscopy.</LI>&#xD;&#xA;<LI>Increased intracranial pressure can occur. Trendelenburg positioning should be avoided in patients with traumatic brain injury.</LI>&#xD;&#xA;<LI>There is increased risk of passive regurgitation of gastric contents and aspiration.</LI>&#xD;&#xA;<LI>Facial edema and airway swelling can occur.</LI>&#xD;&#xA;<LI>There is conflicting evidence on effects on intraocular pressure and the risk of postoperative visual loss after prolonged procedures.</LI></UL>For further information, refer to UpToDate content on patient positioning for surgery and anesthesia.</div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 112651 Version 2.0</div></div></div>"},"112652":{"type":"graphic_figure","displayName":"Reverse Trendelenburg position","title":"Reverse Trendelenburg position","html":"<div class=\"graphic\"><div style=\"width: 765px\" class=\"figure\"><div class=\"ttl\">Reverse Trendelenburg position</div><div class=\"cntnt\"><img style=\"width:745px; height:583px;\" src=\"images/ANEST/112652_Reverse_Trendelenburg_postn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologic changes that occur with reverse Trendelenburg positioning include the following: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>​Decreased venous return can cause decreased cardiac preload, cardiac output, and mean arterial pressure. Compensatory mechanisms include increased heart rate, sympathetic tone, and peripheral vascular resistance.</LI>&#xD;&#xA;<LI>Lung volumes and functional residual capacity increase, compared with supine.</LI>&#xD;&#xA;<LI>Cerebral perfusion pressure decreases with the head above the heart. Measurement of blood pressure at the level of the Circle of Willis gives a more accurate representation of cerebral perfusion than measurement at the level of the upper arm. Arm cuff measurements should be adjusted to account for the gradient in hydrostatic pressure.</LI></UL>For further information, refer to UpToDate content on patient positioning for surgery and anesthesia.</div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 112652 Version 2.0</div></div></div>"},"112656":{"type":"graphic_table","displayName":"Common conditions associated with chronic pelvic pain in women","title":"Common non-malignant conditions associated with chronic pelvic pain in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common non-malignant&nbsp;conditions associated with chronic pelvic pain in women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Gynecologic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Endometriosis* </li> <li>Leiomyoma* </li> <li>Adenomyosis* </li> <li>Recurrent ovarian cysts </li> <li>Hydrosalpinx </li> <li>Ovarian remnant syndrome* </li> <li>Pelvic inflammatory disease* </li> <li>Pelvic adhesive disease </li> <li>&nbsp;Post-tubal ligation pain syndrome </li> </ul> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Urologic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Interstitial cystitis/painful bladder syndrome* </li> <li>Radiation cystitis* </li> <li>Bladder cancer* </li> <li>Urethral syndrome </li> <li>Recurrent cystitis </li> <li>Recurrent/chronic urolithiasis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Gastroenterologic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Irritable bowel syndrome* </li> <li>Inflammatory bowel disease* </li> <li>Chronic constipation* </li> <li>Colorectal carcinoma* </li> <li>Celiac disease </li> <li>Abdominal/pelvic hernias </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Musculoskeletal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Abdominal wall myofascial pain (including trigger points)* </li> <li>Pelvic floor tension myalgia* </li> <li>Fibromyalgia* </li> <li>Coccygodynia* </li> <li>Piriformis syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Abdominal wall cutaneous nerve entrapment (ilioinguinal and iliohypogastric)* </li> <li>Pudendal neuralgia </li> <li>Central sensitization of pain* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Vulvar varicosities </li> <li>Pelvic congestion syndrome </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Conditions with level A evidence of a causal relationship to chronic pelvic pain.</div><div class=\"graphic_reference\">Data from: Howard F. Chronic pelvic pain. Obstetrics &amp; Gynecology 2003; 101:594.</div><div id=\"graphicVersion\">Graphic 112656 Version 3.0</div></div></div>"},"112657":{"type":"graphic_table","displayName":"Physical examination for women with chronic pelvic pain","title":"Physical examination for women with chronic pelvic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination for women with chronic pelvic pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Vital signs </li> <li>General appearance, mood, affect, or emotional state </li> <li>Gait, posture </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Back &ndash; patient sitting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Spine curvature, evidence of previous injury or surgery </li> <li>Spinal (including sacrum and coccyx), paraspinal and sacroiliac joint tenderness </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Abdomen &ndash; patient supine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Appearance: Fat distribution, scars, or evidence of previous trauma or surgery </li> <li>Evidence of masses, hernia, inguinal adenopathy, pubic symphysis pain </li> <li>Light palpation or stroking: Evaluate for allodynia </li> <li>Single digit deep palpation: Differentiate focal versus diffuse pain, trigger points (focal area that worsens with abdominal wall flexion) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Extremity &ndash; patient supine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hip flexion, extension, internal and external rotation; hip abduction and adduction to evaluate for range of motion </li> <li>Muscle strength, tone, spasticity, or asymmetry </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Pelvic &ndash; patient lithotomy</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>External genitalia: Lesions, abrasions, ulcerations, erythema, or edema of clitoris, urethral meatus, vulva, and/or vestibule (cotton swab exam if patient has dyspareunia and/or vulvar pain) </li> <li>Single digit vaginal exam: Tenderness or spasticity of pelvic floor muscles (pubococcygeus, obturator internus, piriformis), urethra, bladder, cervix, lower uterine segment, and vaginal fornices </li> <li>Bimanual exam: Uterine size, mobility, adnexal masses, and tenderness </li> <li>Rectovaginal exam: Tenderness and/or nodularity of rectovaginal septum and uterosacral ligaments </li> <li>Speculum exam: Lesions, ulcerations, or erythema of vaginal mucosa, cervix, and posterior vaginal fornix; cervical and/or vaginal cultures if purulent discharge noted </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112657 Version 1.0</div></div></div>"},"112659":{"type":"graphic_picture","displayName":"Phytophotodermatitis arm","title":"Phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/112659_Phytophotodermatitis_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear, hyperpigmented lesions distributed in a bizarre pattern in a patient with phytophotodermatitis. The lesions typically mark the skin areas that had come in contact with the offending substance.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112659 Version 1.0</div></div></div>"},"112660":{"type":"graphic_picture","displayName":"Serpentine hyperpigmentation","title":"Serpentine supravenous hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serpentine supravenous hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:348px; height:582px;\" src=\"images/DERM/112660_Serpentinehyprpigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear streak of hyperpigmentation along the tributaries of long saphenous vein of left lower limb.</div><div class=\"graphic_reference\">From: Das A, Kumar D, Mohanty S, et al. Serpentine supravenous hyperpigmentation induced by docetaxel. Indian J Dermatol Venereol Leprol 2015; 81:434. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2015;volume=81;issue=4;spage=434;epage=434;aulast=Das\" target=\"_blank\">10.4103/0378-6323.156191</a>. Copyright &copy; 2015 Indian Association of Dermatologists, Venereologists &amp; Leprologists (IADVL). Reproduced with permission from Wolters Kluwer Medknow. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112660 Version 2.0</div></div></div>"},"112661":{"type":"graphic_picture","displayName":"Flagellate hyperpigmentation","title":"Flagellate hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Flagellate hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/112661_Flagellate_hyperpigmentatn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple linear, hyperpigmented streaks in a patient treated with bleomycin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112661 Version 1.0</div></div></div>"},"112674":{"type":"graphic_figure","displayName":"LDL-C concentrations in severe hypercholesteremia","title":"Range of LDL cholesterol concentrations in severe hypercholesterolemia according to monogenic defects","html":"<div class=\"graphic\"><div style=\"width: 674px\" class=\"figure\"><div class=\"ttl\">Range of LDL cholesterol concentrations in severe hypercholesterolemia according to monogenic defects</div><div class=\"cntnt\"><img style=\"width:654px; height:298px;\" src=\"images/CARD/112674_LDL-C_conc_svr_hyprchlstrma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LDL cholesterol concentrations might overlap in individuals with different genetic defects.<SUP>[1,</SUP><SUP>2]</SUP> They might also vary according to the presence or absence of small-effect gene variants.<SUP>[3,</SUP><SUP>4]</SUP> Homozygotes have the same mutation in two alleles of the same gene. Double heterozygotes have different mutations, one on each allele of the same gene. Compound heterozygotes have mutations in two different genes. LDLR null mutations defined as LDL receptor activity &lt;2% in fibroblasts. LDLR defective mutations defined as LDL receptor activity 2 to 25% in fibroblasts.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015; 132:2167.</li>&#xD;&#xA;    <li>Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management&mdash;a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146.</li>&#xD;&#xA;    <li>Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381:1293.</li>&#xD;&#xA;    <li>Futema M, Shah S, Cooper JA, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61:231.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4:850. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112674 Version 1.0</div></div></div>"},"112675":{"type":"graphic_figure","displayName":"Mechanism of action of angiotensin receptor-neprilysin inhibitor","title":"Mechanism of action of angiotensin receptor-neprilysin inhibitor​","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Mechanism of action of angiotensin receptor-neprilysin inhibitor​</div><div class=\"cntnt\"><img style=\"width:500px; height:332px;\" src=\"images/CARD/112675_Angiotnsnrcptrnprlysninh.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neprilysin, a neutral endopeptidase, degrades vasoactive neurohormones including natriuretic peptides, bradykinin, and adrenomedullin. Neprilysin also degrades angiotensin II. When a pure neprilysin inhibitor is administered, it prevents the degradation of these peptides, leading to an increase in the neurohormones that exert favorable effects (eg, natriuretic peptides) but also an increase in angiotensin II, which exerts detrimental effects. The up arrows depict the increase in levels resulting from neprilysin inhibition. In order to mitigate the latter, a strategy has emerged to combine a neprilysin inhibitor with an angiotensin receptor blocker. This class of agents is called ARNI, an abbreviation for angiotensin receptor-neprilysin inhibitor. In this manner, the deleterious effect of increased angiotensin II levels is prevented by preventing angiotensin II from interacting with its type 1 receptor, while the favorable effects of neprlysin inhibition can accrue. Because both neprilysin inhibitors and ACE inhibitors increase bradykinin, and bradykinin leads to angioedema, administration of a neprilysin inhibitor&nbsp;within 36 hours of administration of an&nbsp;ACE inhibitor is contraindicated, as this combination can result in an unacceptably high incidence of angioedema.</div><div class=\"graphic_footnotes\">BNP: brain natriuretic peptide; ANP: atrial natriuretic peptide; CNP: C-type natriuretic peptide; Ang II: angiotensin II; ARB: angiotensin receptor blocker; SNS: sympathetic nervous system; NEP: neprilysin; ACE: angiotensin-converting enzyme.</div><div id=\"graphicVersion\">Graphic 112675 Version 2.0</div></div></div>"},"112677":{"type":"graphic_algorithm","displayName":"H. pylori diagnosis","title":"Suggested initial diagnostic evaluation in patients with suspected <em>Helicobacter pylori</em> infection","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Suggested initial diagnostic evaluation in patients with suspected <em>Helicobacter pylori</em> infection</div><div class=\"cntnt\"><img style=\"width:772px; height:504px;\" src=\"images/GAST/112677_H_pylori_diagnosis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Endoscopy is not indicated solely for the purpose of establishing <em>H. pylori</em> status.<br />&para; PPI use within one to two weeks and bismuth/antibiotic use within four weeks of testing can decrease sensitivity for <em>H. pylori</em>. When feasible, PPIs should be discontinued one to two weeks prior to testing and testing should be performed at least four weeks after last bismuth/antibiotic use.<br />&Delta; The choice of test depends on local availability. Serologic testing for <em>H. pylori</em> should not be performed.<br /><span class=\"lozenge\">&loz;</span> If biopsy urease test is not available, gastric biopsies should be performed for histology.<br />&sect; In patients with actively bleeding peptic ulcer on upper endoscopy, testing for <em>H. pylori</em> with a urea breath test or stool antigen can be performed when there is no evidence of ongoing bleeding and PPIs can safely be discontinued for one to two weeks prior to testing.</div><div id=\"graphicVersion\">Graphic 112677 Version 1.0</div></div></div>"},"112678":{"type":"graphic_algorithm","displayName":"H. pylori treatment","title":"Initial approach to antibiotic treatment for <em>Helicobacter pylori</em> infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initial approach to antibiotic treatment for <em>Helicobacter pylori</em> infection</div><div class=\"cntnt\"><img style=\"width:407px; height:376px;\" src=\"images/GAST/112678_Hpyloritreatment.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Bismuth quadruple therapy consists of bismuth, metronidazole, tetracycline, and a PPI.</li>&#xD;&#xA;    <li>Clarithromycin based triple therapy with amoxicillin consists of clarithromycin, amoxicillin, and a PPI.</li>&#xD;&#xA;    <li>Clarithromycin based triple therapy with metronidazole consists of clarithromycin, metronidazole, and a PPI.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* In the United States, given the limited information on antimicrobial resistance rates, we generally assume clarithromycin resistance rates are &ge;15% unless local data indicate otherwise.<br />&para; Alternative first-line antibiotic regimens include bismuth quadruple therapy and clarithromycin based concomitant therapy. Other potential treatment regimens include clarithromycin based sequential or hybrid therapy. However, hybrid therapy has not been universally endorsed as an option for first-line therapy and some North American guidelines do not support the use of sequential therapy. Refer to UpToDate topic on treatment regimens for <em>H. pylori</em> for additional details.</div><div id=\"graphicVersion\">Graphic 112678 Version 2.0</div></div></div>"},"112679":{"type":"graphic_algorithm","displayName":"H. pylori salvage","title":"Approach to antibiotic treatment in patients with persistent <em>Helicobacter pylori</em> infection","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Approach to antibiotic treatment in patients with persistent <em>Helicobacter pylori</em> infection</div><div class=\"cntnt\"><img style=\"width:796px; height:350px;\" src=\"images/GAST/112679_H_pylori_salvage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Clarithromycin based triple therapy consists of clarithromycin, amoxicillin/metronidazole, and a PPI.</li>&#xD;&#xA;    <li>Bismuth quadruple therapy consists of bismuth subsalicylate or bismuth subcitrate, metronidazole, tetracycline, and a PPI.</li>&#xD;&#xA;    <li>Levofloxacin triple therapy consists of levofloxacin, amoxicillin/metronidazole, and a PPI.</li>&#xD;&#xA;    <li>High dose dual therapy consists of amoxicillin and a PPI.</li>&#xD;&#xA;    <li>Rifabutin triple therapy consists of rifabutin, amoxicillin, and a PPI.</li>&#xD;&#xA;    <li>Clarithromycin based concomitant therapy consists of clarithromycin, amoxicillin, nitroimidazole (eg, metronidazole), and a PPI.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Eradication of <EM>H. pylori</EM> after antibiotic treatment may be confirmed by a urea breath test, stool atigen test, or upper endoscopy-based testing. A positive result on one of these tests is indicative of a persistent <EM>H. pylori</EM> infection.<br />¶ Only in patients with no risk factors for macrolide resistance (no prior marolide exposure and local clarithromycin resistance known to be &lt;15%). This regimen should be avoided if local clarithromycin resistance is unknown.<br />Δ Eradication of <EM>H. pylori</EM> infection can be confirmed with a urea breath test, stool antigen testing, or upper endoscopy-based testing. The choice of test depends on the need for an upper endoscopy (eg, follow-up of bleeding peptic ulcer) and local availability. <EM>H. pylori</EM> serology should not be used to confirm eradication of <EM>H. pylori</EM>. Refer to UpToDate topic on diagnostic tests for <EM>H. pylori</EM>.</div><div id=\"graphicVersion\">Graphic 112679 Version 1.0</div></div></div>"},"112680":{"type":"graphic_picture","displayName":"Early corneal arcus","title":"Early corneal arcus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early corneal arcus</div><div class=\"cntnt\"><img style=\"width:339px; height:222px;\" src=\"images/CARD/112680_Early_corneal_arcus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112680 Version 1.0</div></div></div>"},"112681":{"type":"graphic_picture","displayName":"Mature corneal arcus","title":"Mature corneal arcus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Mature corneal arcus</div><div class=\"cntnt\"><img style=\"width:756px; height:495px;\" src=\"images/CARD/112681_Mature_corneal_arcus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 112681 Version 1.0</div></div></div>"},"112683":{"type":"graphic_diagnosticimage","displayName":"TEE in mid-esophageal long axis imaging plane and epiaortic scan","title":"TEE in the mid-esophageal long axis imaging plane and epiaortic scan","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">TEE in the mid-esophageal long axis imaging plane and epiaortic scan</div><div class=\"cntnt\"><img style=\"width:511px; height:765px;\" src=\"images/ANEST/112683_TEE_md-eso_lng_axs_epiaortc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A TEE still in the mid-esophageal long axis imaging plane (A) demonstrates heavy calcification of the root, sinotubular junction, and tubular ascending aorta. There is a particularly heavy calcium burden on the posterior wall (nearest to the TEE probe). An epiaortic scan (B) of the same patient demonstrates a significant circumferential atheroma which would preclude cannulation or cross-clamping at this site.</div><div id=\"graphicVersion\">Graphic 112683 Version 1.0</div></div></div>"},"112684":{"type":"graphic_diagnosticimage","displayName":"TEE proximal descending thoracic aorta","title":"TEE proximal descending thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">TEE proximal descending thoracic aorta</div><div class=\"cntnt\"><img style=\"width:756px; height:519px;\" src=\"images/ANEST/112684_TEE_prxml_dscndg_thrcc_arta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A TEE image of the proximal descending thoracic aorta. Large atheromatous plaques such as these should be communicated to the surgeon in case the use of an intra-aortic balloon pump is being considered.</div><div id=\"graphicVersion\">Graphic 112684 Version 1.0</div></div></div>"},"112686":{"type":"graphic_table","displayName":"PACC recommendations for intrathecal infusion cancer pain","title":"Recommendations from the Polyanalgesic Consensus Conference (PACC) on intrathecal drug infusion systems for cancer or other terminal condition-associated pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations from the Polyanalgesic Consensus Conference (PACC) on intrathecal drug infusion systems for cancer or other terminal condition-associated pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Localized nociceptive or neuropathic pain</td> </tr> <tr> <td class=\"subtitle2_single\">Evidence strongest for:</td> </tr> <tr> <td class=\"indent2\">Ziconotide</td> </tr> <tr> <td class=\"indent2\">Morphine</td> </tr> <tr> <td class=\"indent2\">Fentanyl</td> </tr> <tr> <td class=\"indent2\">Hydromorphone</td> </tr> <tr> <td class=\"indent2\">Morphine or fentanyl or hydromorphone plus bupivacaine</td> </tr> <tr> <td class=\"indent2\">Morphine or fentanyl or hydromorphone plus clonidine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Morphine or fentanyl or hydromorphone plus ziconotide</td> </tr> <tr> <td class=\"subtitle1_single\">Diffuse nociceptive or neuropathic pain</td> </tr> <tr> <td class=\"subtitle2_single\">Evidence strongest for:</td> </tr> <tr> <td class=\"indent2\">Ziconotide</td> </tr> <tr> <td class=\"indent2\">Morphine</td> </tr> <tr> <td class=\"indent2\">Hydromorphone</td> </tr> <tr> <td class=\"indent2\">Morphine or hydromorphone plus clonidine</td> </tr> <tr> <td class=\"indent2\">Morphine or hydromorphone plus bupivacaine</td> </tr> <tr> <td class=\"indent2\">Morphine or hydromorphone plus ziconotide</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation 2017; 20:96.</div><div id=\"graphicVersion\">Graphic 112686 Version 1.0</div></div></div>"},"112708":{"type":"graphic_figure","displayName":"MGRS-associated kidney disease","title":"MGRS-associated kidney disease","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">MGRS-associated kidney disease</div><div class=\"cntnt\"><img style=\"width:730px; height:207px;\" src=\"images/NEPH/112708_MGRS-assocd_kidney_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MGRS: monoclonal gammopathy of renal significance; Ig: immunoglobulin; MG: monoclonal gammopathy; MIDD: monoclonal immunoglobulin deposition disease; AL: immunoglobulin light chain; AH: immunoglobulin heavy chain; AHL: immunoglobulin heavy and light chain; GN: glomerulonephritis; LCPT: light chain proximal tubulopathy; PGNMID: proliferative glomerulonephritis with monoclonal immunoglobulin deposits.</div><div id=\"graphicVersion\">Graphic 112708 Version 1.0</div></div></div>"},"112717":{"type":"graphic_table","displayName":"Pretest likelihood of CAD in symptomatic patients","title":"Comparing pretest likelihood of CAD in low-risk symptomatic patients with high-risk symptomatic patients (Duke Database)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparing pretest likelihood of CAD in low-risk symptomatic patients with high-risk symptomatic patients (Duke Database)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14.2%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (year)</td> <td class=\"subtitle1\" colspan=\"2\">Nonanginal chest pain</td> <td class=\"subtitle1\" colspan=\"2\">Atypical angina</td> <td class=\"subtitle1\" colspan=\"2\">Typical angina</td> </tr> <tr> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> </tr> <tr> <td class=\"centered\">35</td> <td class=\"centered\">3-35</td> <td class=\"centered\">1-19</td> <td class=\"centered\">8-59</td> <td class=\"centered\">2-39</td> <td class=\"centered\">30-88</td> <td class=\"centered\">10-78</td> </tr> <tr> <td class=\"centered\">45</td> <td class=\"centered\">9-47</td> <td class=\"centered\">2-22</td> <td class=\"centered\">21-70</td> <td class=\"centered\">5-43</td> <td class=\"centered\">51-92</td> <td class=\"centered\">20-79</td> </tr> <tr> <td class=\"centered\">55</td> <td class=\"centered\">23-59</td> <td class=\"centered\">4-21</td> <td class=\"centered\">45-79</td> <td class=\"centered\">10-47</td> <td class=\"centered\">80-95</td> <td class=\"centered\">38-82</td> </tr> <tr> <td class=\"centered\">65</td> <td class=\"centered\">49-69</td> <td class=\"centered\">9-29</td> <td class=\"centered\">71-86</td> <td class=\"centered\">20-51</td> <td class=\"centered\">93-97</td> <td class=\"centered\">56-84</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Each value represents the percentage with significant CAD. The&nbsp;lowest (first) value of each range&nbsp;is the likelihood of CAD for a low-risk patient without diabetes mellitus, smoking, or hyperlipidemia. The highest (second) value of each range&nbsp;is the likelihood of CAD for a high-risk patient of the same age with diabetes mellitus, smoking, and hyperlipidemia. Both high- and low-risk patients have normal resting ECGs. If ST-T-wave changes or Q waves had been present, the likelihood of CAD would be higher in each entry of the table. This information was included in the 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease.<SUP>[1]</SUP></div><div class=\"graphic_footnotes\">CAD: coronary artery disease; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60:e44.</LI></OL>Source: Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993; 118:81.</div><div id=\"graphicVersion\">Graphic 112717 Version 1.0</div></div></div>"},"112718":{"type":"graphic_waveform","displayName":"Polysomnogram showing sleep-related bruxism episode","title":"Polysomnogram showing sleep-related bruxism episode","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">Polysomnogram showing sleep-related bruxism episode</div><div class=\"cntnt\"><img style=\"width:820px; height:285px;\" src=\"images/SLEEP/112718_Plysmngam_slp_rltd_buxsm_ep.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polysomnogram showing an episode of bruxism (<FONT color=#000000>red asterisk</FONT>) characterized by tonic chin contractions lasting more than two seconds, in association with rhythmic artifact in the electroencephalography (EEG) recording. The episode&nbsp;was associated with typical audible teeth grinding sounds.<br />Standard polysomnogram montage includes (from top to bottom): left and right outer canthus (LOC/ROC) electrooculography electrodes; chin electromyography (EMG); F4 (right frontal), C4 (right central), and O2 (right occipital) references to M1 (left mastoid) EEG electrodes; standard electrocardiogram (EKG) lead; left and right lower leg EMG electrodes; snore microphone; airflow; pressure transducer airflow (PTAF); chest and abdominal wall motion sensors; and pulse oximetry by finger probe (SaO2).</div><div class=\"graphic_reference\">Reproduced with permission from Alon Y Avidan, MD, MPH.</div><div id=\"graphicVersion\">Graphic 112718 Version 2.0</div></div></div>"},"112719":{"type":"graphic_table","displayName":"Risk factors for sleep-related bruxism","title":"Risk factors for sleep-related bruxism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for sleep-related bruxism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Comorbid sleep disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Obstructive sleep apnea </li> <li>Parasomnias (eg, sleep talking, sleepwalking, enuresis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Medications and substances</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Antipsychotic drugs </li> <li>Selective serotonin reuptake inhibitors </li> <li>Serotonin noradrenaline reuptake inhibitors </li> <li>Noradrenaline-dopamine reuptake inhibitors </li> <li>Amphetamines </li> <li>Cocaine </li> <li>Ecstasy </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic disorders*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Rett syndrome </li> <li>Down syndrome </li> <li>Cerebral palsy </li> <li>Autism spectrum disorders </li> <li>Dentatorubral pallidoluysian atrophy </li> <li>Cranial-cervical dystonia </li> <li>Advanced Alzheimer disease </li> <li>Huntington disease </li> <li>Multiple system atrophy </li> <li>Severe traumatic brain injury </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Psychiatric disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Anxiety </li> <li>Psychotic disorders </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Others</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Gastroesophageal reflux disease </li> <li>Temporomandibular joint disorders </li> <li>Family history </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Awake bruxism&nbsp;may predominate.</div><div id=\"graphicVersion\">Graphic 112719 Version 1.0</div></div></div>"},"112742":{"type":"graphic_figure","displayName":"HDL C synthesized by the liver, intestine, and peripheral cells","title":"Percentage of HDL cholesterol synthesized by the liver, intestine, and peripheral cells","html":"<div class=\"graphic\"><div style=\"width: 913px\" class=\"figure\"><div class=\"ttl\">Percentage of HDL&nbsp;cholesterol&nbsp;synthesized by the liver, intestine, and peripheral cells</div><div class=\"cntnt\"><img style=\"width:893px; height:516px;\" src=\"images/PC/112742_HDLCsynthszdlvrintstnpr.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ABCA1 = ATP-binding cassette transporter A1; HDL: high-density lipoprotein; CE: cholesterol efflux;&nbsp;SR-BI: scavenger receptor class B type I; ABCG1 = ATP-binding cassette transporter G1.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 2001; 108:1315.</LI>&#xD;&#xA;<LI>Vaisman BL, Lambert G, Amar M, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108:303.</LI>&#xD;&#xA;<LI>Wellington CL, Brunham LR, Zhou S, et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res 2003; 44:1470.</LI>&#xD;&#xA;<LI>Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115:1333.</LI></OL>Modified from: Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905.</div><div id=\"graphicVersion\">Graphic 112742 Version 2.0</div></div></div>"},"112743":{"type":"graphic_figure","displayName":"HDL particle subclasses and cholesterol efflux","title":"HDL particle subclasses and cholesterol efflux from cholesterol-loaded cells","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">HDL particle subclasses and cholesterol efflux from cholesterol-loaded cells</div><div class=\"cntnt\"><img style=\"width:620px; height:469px;\" src=\"images/CARD/112743_HDLprtclsbclsschlstrlef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of cholesterol efflux via ATP-binding cassette transporter G1 (ABCG1), scavenger receptor class B type I (SR-B1), and passive diffusion.</div><div class=\"graphic_footnotes\">HDL: high-density lipoprotein; M: medium; S: small; VS: very small; ABCA1: APT binding cassette transporter A1.</div><div class=\"graphic_reference\">From: Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125(15):1905-19. DOI: <A href=\"http://circ.ahajournals.org/content/125/15/1905\" target=_blank>10.1161/CIRCULATIONAHA.111.066589</A>. Copyright © 2012 American Heart Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 112743 Version 2.0</div></div></div>"},"112748":{"type":"graphic_figure","displayName":"Resting instantaneous pressure during wave-free period = iFR","title":"Resting (ie, no adenosine) instantaneous pressure during wave-free period = iFR","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Resting (ie, no adenosine) instantaneous pressure during wave-free period = iFR</div><div class=\"cntnt\"><img style=\"width:764px; height:822px;\" src=\"images/CARD/112748_Rstg_nstns_ps_dg_wvfrpd_iFR.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Sen S, Escaned J, Malik IS, et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol 2012; 59:1392. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112748 Version 1.0</div></div></div>"},"112749":{"type":"graphic_figure","displayName":"Clinical iFR and FFR cut-points","title":"Clinical iFR and FFR cut-points","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Clinical iFR and FFR cut-points</div><div class=\"cntnt\"><img style=\"width:791px; height:295px;\" src=\"images/CARD/112749_Clinical_iFR_FFR_cut_points.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Escaned J, Echavarria-Pinto M, Garcia-Garcia HM, et al. Prospective Assessment of the Diagnostic Accuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance: Results of ADVISE II International, Multicenter Study (ADenosine Vasodilator Independent Stenosis Evaluation II). JACC Cardiovasc Interv 2015; 8:824.</li>&#xD;&#xA;    <li>Jeremias A, Maehara A, Genereux P, et al. Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study. J Am Coll Cardiol 2014; 8:63.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Dr. Justin E. Davies.</div><div id=\"graphicVersion\">Graphic 112749 Version 2.0</div></div></div>"},"112751":{"type":"graphic_picture","displayName":"Right axillary artery injury with reconstruction","title":"Right axillary artery injury with reconstruction","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Right axillary artery injury with reconstruction</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SURG/112751_Rt_axllry_artery_recnstrctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture (patient's head to the left) shows the repair of the second portion of an injured right axillary artery using a 6-mm Dacron graft with infraclavicular exposure. The superior incision is a supraclavicular exposure that was used for proximal vascular control prior to exploration of the hematoma at the site of the injury. </div><div id=\"graphicVersion\">Graphic 112751 Version 1.0</div></div></div>"},"112752":{"type":"graphic_picture","displayName":"Temporary intravascular shunt placement","title":"Temporary intravascular shunt placement","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Temporary intravascular shunt placement</div><div class=\"cntnt\"><img style=\"width:756px; height:546px;\" src=\"images/SURG/112752_Temp_intrvsclr_shunt_plcmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows a temporary intravascular shunt placed into the transected&nbsp;ends of the right brachial artery, which was injured due to a stab wound.</div><div id=\"graphicVersion\">Graphic 112752 Version 1.0</div></div></div>"},"112753":{"type":"graphic_picture","displayName":"Reconstruction with a reversed saphenous vein graft","title":"Reconstruction with a reversed saphenous vein graft","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Reconstruction with a reversed saphenous vein graft</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SURG/112753_Recon_revd_saphns_vein_grft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following temporary intravascular shunt placement, the transected brachial artery was reconstructed using a reversed saphenous vein graft.</div><div id=\"graphicVersion\">Graphic 112753 Version 1.0</div></div></div>"},"112756":{"type":"graphic_table","displayName":"DOACs PK and drug interactions","title":"Pharmacokinetics and drug interactions of direct oral anticoagulants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics and drug interactions of direct oral anticoagulants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Bioavailability</td> <td class=\"subtitle1\">Metabolism and clearance*<sup>&#182;</sup></td> <td class=\"subtitle1\">Half-life</td> <td class=\"subtitle1\">Potential for pharmacokinetic drug interactions*<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Dabigatran<br /> (Pradaxa)</td> <td> <ul> <li>3 to 7% bioavailable </li> <li>Unaffected by food </li> <li>Capsule must be taken intact and requires gastric acidity for absorption </li> </ul> </td> <td> <ul> <li>Over 80% renally cleared </li> <li>P-gp substrate* </li> </ul> </td> <td> <ul> <li>12 to 17 hours </li> <li>Prolonged in renal impairment and older adults </li> </ul> </td> <td> <ul> <li>P-gp inhibitors can increase dabigatran effect </li> <li>P-gp inducers can decrease dabigatran effect </li> <li>Avoidance of some combinations or dose adjustment may be needed </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Apixaban<br /> (Eliquis)</td> <td> <ul> <li>50% bioavailable </li> <li>Unaffected by food </li> </ul> </td> <td> <ul> <li>27% renally cleared </li> <li>Metabolized, primarily by CYP3A4<sup>&#182;</sup> </li> <li>P-gp substrate* </li> </ul> </td> <td> <ul> <li>12 hours </li> <li>Prolonged in older adults </li> </ul> </td> <td> <ul> <li>Strong CYP3A4 inhibitors and/or strong P-gp inhibitors&nbsp;can increase apixaban effect </li> <li>Strong CYP3A4 inducers and/or strong P-gp inducers&nbsp;can decrease apixaban effect </li> <li>Avoidance of some combinations or dose adjustment may be needed </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Betrixaban</p> <p>(Bevyxxa)</p> </td> <td> <ul> <li>34% bioavailable </li> <li>Taken with food at the same time each day. Absorption is increased if taken without food. </li> </ul> </td> <td> <ul> <li>Minimal renal clearance (5 to 7%) </li> <li>Undergoes minimal CYP metabolism </li> <li>P-gp substrate* </li> <li>85% eliminated via hepatobiliary route </li> </ul> </td> <td> <ul> <li>19 to 27 hours (effective half-life); peak-to-trough ratio is low and terminal serum half-life is 37 hours, and betrixaban may persist in the circulation for longer than predicted by the effective half-life </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>P-gp inhibitors can increase betrixaban effect </li> <li>P-gp inducers may decrease betrixaban effect </li> <li>Avoidance of some combinations or dose adjustment may be needed </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Edoxaban<br /> (Savaysa, Lixiana)</td> <td> <ul> <li>62% bioavailable </li> <li>Unaffected by food </li> </ul> </td> <td> <ul> <li>50% renally cleared </li> <li>Reduced efficacy in patients with NVAF and CrCl &#62;95 mL/minute<sup>​&#916;</sup><sup></sup> </li> <li>Undergoes minimal CYP metabolism<sup>&#182;</sup> </li> <li>P-gp substrate* </li> </ul> </td> <td> <ul> <li>10 to 14 hours </li> <li>Prolonged in renal impairment </li> </ul> </td> <td> <ul> <li>P-gp inhibitors&nbsp;can increase edoxaban effect </li> <li>P-gp inducers can decrease edoxaban effect </li> <li>Avoidance of some combinations or dose adjustment may be needed </li> </ul> </td> </tr> <tr> <td>Rivaroxaban<br /> (Xarelto)</td> <td> <ul> <li>10 mg dose: <ul> <li>80 to 100% bioavailable </li> <li>Unaffected by food </li> </ul> </li> </ul> <br /> <ul> <li>20 mg dose: <ul> <li>66% bioavailable if taken when fasting; increased if taken with food </li> </ul> </li> </ul> </td> <td> <ul> <li>36% renally cleared </li> <li>Metabolized, primarily by CYP3A4<sup>&#182;</sup> </li> <li>P-gp substrate* </li> </ul> </td> <td> <ul> <li>7&nbsp;to&nbsp;11&nbsp;hours&nbsp; </li> <li>Prolonged in renal impairment and older adults </li> </ul> </td> <td> <ul> <li>Strong CYP3A4&nbsp;inhibitors and/or strong P-gp inhibitors&nbsp;can increase rivaroxaban effect </li> <li>Strong CYP3A4 inducers and/or strong P-gp inducers can decrease rivaroxaban effect </li> <li>Avoidance of some combinations or dose adjustment may be needed </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for dosing in specific clinical settings, including nonvalvular AF, VTE treatment, and&nbsp;VTE prophylaxis. Data on clearance may help assess the potential for accumulation in patients with renal impairment. Data on metabolism may help assess potential drug interactions through alteration of CYP3A4 metabolism and/or P-gp-mediated drug efflux. Refer to Lexi-Interact, the drug interactions tool included with UpToDate, for specific drug interactions. Tables of P-gp inhibitors and inducers and CYP3A4 inhibitors and inducers are available separately in UpToDate.</div><div class=\"graphic_footnotes\">P-gp: P-glycoprotein drug efflux pump;&nbsp;CYP3A4: cytochrome p450 3A4 isoform; CrCl: creatinine clearance estimated by the Cockcroft-Gault equation; AF: atrial fibrillation; VTE: venous thromboembolism, includes deep vein thrombosis and pulmonary embolism;&nbsp;DOAC: direct oral anticoagulant.<br />* Examples of P-gp inhibitors that reduce metabolism of DOACs, leading to increased DOAC levels, include clarithromycin, ombitasvir- or ritonavir-containing combinations, and verapamil. Examples of P-gp inducers that increase DOAC metabolism, leading to lower DOAC levels, include phenytoin, rifampin, and St. John's wort.<br />¶ Examples of strong CYP3A4 inhibitors that reduce metabolism of some DOACs, leading to increased DOAC levels, include clarithromycin and ombitasvir- or ritonavir-containing combinations. Examples of strong CYP3A4 inducers that increase metabolism of some DOACs, leading to lower DOAC levels, include carbamazepine, phenytoin, and rifampin.<br />Δ Blood levels of edoxaban were reduced and a higher rate of ischemic stroke was observed in patients with AF and CrCl &gt;95 mL/minute who were treated with edoxaban compared with those receiving warfarin. Refer to the UpToDate topic on anticoagulation in AF for additional information.</div><div class=\"graphic_reference\">Prepared with data from Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved with additional data from US prescribing information available at <A href=\"https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A>.<br /><br />Reference:<br /><OL>&#xD;&#xA;<LI>Rivaroxaban (Xarelto) Health Canada product monograph. Bayer Inc. (revised February 16, 2018) <A href=\"https://pdf.hres.ca/dpd_pm/00043960.PDF\">https://pdf.hres.ca/dpd_pm/00043960.PDF</A> </LI></OL></div><div id=\"graphicVersion\">Graphic 112756 Version 9.0</div></div></div>"},"112757":{"type":"graphic_figure","displayName":"Trousseau's sign","title":"Trousseau's sign","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Trousseau's sign</div><div class=\"cntnt\"><img style=\"width:459px; height:490px;\" src=\"images/ENDO/112757_Trousseaus_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trousseau's sign is the induction of carpopedal spasm by inflation of a sphygmomanometer above systolic blood pressure for three minutes. It may be present in patients with neuromuscular irritability due to acute hypocalcemia.&nbsp;</div><div id=\"graphicVersion\">Graphic 112757 Version 2.0</div></div></div>"},"112758":{"type":"graphic_figure","displayName":"Chvostek’s sign","title":"Chvostek's sign","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Chvostek's sign</div><div class=\"cntnt\"><img style=\"width:463px; height:501px;\" src=\"images/ENDO/112758_Chvosteks_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chvostek's sign is contraction of the ipsilateral facial muscles elicited by tapping the facial nerve just anterior to the ear.&nbsp;The response ranges from twitching of the lip to spasm of all facial muscles and depends upon the severity of the hypocalcemia.</div><div id=\"graphicVersion\">Graphic 112758 Version 2.0</div></div></div>"},"112759":{"type":"graphic_figure","displayName":"Factors that impact male reproductive aging","title":"Factors that impact male reproductive aging","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Factors that impact male reproductive aging</div><div class=\"cntnt\"><img style=\"width:615px; height:619px;\" src=\"images/OBGYN/112759_Impct_male_reprodctv_aging.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Factors that impair fertility as men age.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography ©2014-2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 112759 Version 1.0</div></div></div>"},"112760":{"type":"graphic_table","displayName":"Common causes of chromhidrosis","title":"Common causes of chromhidrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of chromhidrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Color</td> </tr> <tr> <td>Lipofuscin</td> <td>Black, brown, blue, green, or yellow</td> </tr> <tr> <td colspan=\"2\">Medications and metals</td> </tr> <tr> <td class=\"indent1\">Beta-carotene</td> <td>Orange</td> </tr> <tr> <td class=\"indent1\">Clofazimine</td> <td>Orange</td> </tr> <tr> <td class=\"indent1\">Quinine</td> <td>Orange</td> </tr> <tr> <td class=\"indent1\">Tartrazine-coated bisacodyl</td> <td>Yellow-orange</td> </tr> <tr> <td class=\"indent1\">Fluorescein</td> <td>Yellow-green</td> </tr> <tr> <td class=\"indent1\">Copper</td> <td>Blue</td> </tr> <tr> <td class=\"indent1\">Methylene blue</td> <td>Blue</td> </tr> <tr> <td class=\"indent1\">Silver</td> <td>Blue</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> <td>Red</td> </tr> <tr> <td>Hyperbilirubinemia</td> <td>Yellow-green</td> </tr> <tr> <td>Uremic frost</td> <td>White</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112760 Version 1.0</div></div></div>"},"112761":{"type":"graphic_table","displayName":"Genetic conditions in offspring and advanced paternal age","title":"Genetic conditions in offspring that may be associated with advanced paternal age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic conditions in offspring that may be associated with advanced paternal age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Specific condition</td> <td class=\"subtitle1\">Age<br /> (relative to reference age)</td> <td class=\"subtitle1\">Relative risk<br /> (CI, if available)</td> <td class=\"subtitle1\">Population risk<br /> (or reference risk)</td> <td class=\"subtitle1\">Adjusted risk</td> <td class=\"subtitle1\">References<br /> (first author's name only)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"20\">Autosomal dominant</td> <td rowspan=\"6\">Achondroplasia</td> <td>&#62;50 (25 to 29)</td> <td>7.8</td> <td rowspan=\"6\">1/15,000</td> <td>1/1923</td> <td>Risch<sup>[1]</sup></td> </tr> <tr> <td>30 to 34 (&#60;20)</td> <td>3.5</td> <td>1/4285</td> <td rowspan=\"5\">Tiemann-Boege<sup>[2]</sup></td> </tr> <tr> <td>35 to 39 (&#60;20)</td> <td>4</td> <td>1/3750</td> </tr> <tr> <td>40 to 44 (&#60;20)</td> <td>8</td> <td>1/1875</td> </tr> <tr> <td>45 to 49 (&#60;20)</td> <td>9</td> <td>1/1666</td> </tr> <tr> <td>50 to 54 (&#60;20)</td> <td>12</td> <td>1/1250</td> </tr> <tr> <td>Apert</td> <td>&#62;50 (25 to 29)</td> <td>9.5</td> <td>1/50,000</td> <td>1/5263</td> <td>Risch<sup>[1]</sup></td> </tr> <tr> <td>Pfeiffer</td> <td>&#62;50 (25 to 29)</td> <td>6</td> <td>1/100,000</td> <td>1/16,666</td> <td rowspan=\"5\">Glaser<sup>[3]</sup></td> </tr> <tr> <td>Crouzon</td> <td>&#62;50 (25 to 29)</td> <td>8</td> <td>1/50,000</td> <td rowspan=\"4\">1/6250</td> </tr> <tr> <td>Progeria</td> <td>Unknown</td> <td>Effect seen</td> <td>\"Exceedingly rare\"</td> </tr> <tr> <td>MEN2A</td> <td>Unknown</td> <td>Effect seen</td> <td>1/30,000</td> </tr> <tr> <td>MEN2B</td> <td>Unknown</td> <td>Effect seen</td> <td>1/30,000</td> </tr> <tr> <td rowspan=\"2\">Neurofibromatosis I</td> <td>&#62;50 (25 to 29)</td> <td>3.7*</td> <td rowspan=\"2\">1/3000 to 1/4000</td> <td>1/810 to 1/1080</td> <td>Risch<sup>[1]</sup></td> </tr> <tr> <td>&#62;40 (&#60;30)</td> <td>2.9</td> <td>1/1034 to 1/1380</td> <td>Bunin<sup>[4]</sup></td> </tr> <tr> <td rowspan=\"2\">Osteogenesis imperfecta</td> <td>&#62;35 (&#60;25)</td> <td>2.5</td> <td rowspan=\"2\">1/10,000</td> <td>1/4000</td> <td>Carothers<sup>[5]</sup></td> </tr> <tr> <td>&#62;35 (&#60;35)</td> <td>1.37 (0.73 to 6.89)</td> <td>1/7300</td> <td>Orioli<sup>[6]</sup></td> </tr> <tr> <td>Thanatophoric dysplasia</td> <td>&#62;35 (&#60;35)</td> <td>3.18 (1.48 to 6.89)</td> <td>1/20,000 to 1/50,000</td> <td>1/6290 to 1/15,723</td> <td>Orioli<sup>[6]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Retinoblastoma</td> <td>&#62;45</td> <td>3* (0.21 to 41.7)</td> <td class=\"divider_bottom\" rowspan=\"3\">1/15,000 to 1/20,000</td> <td>1/5000 to 1/6667</td> <td>Dockerty, Yip<sup>[7,8]</sup></td> </tr> <tr> <td>&#62;35 (&#60;35)</td> <td>1.34 (1.04 to 1.74)</td> <td>1/11,200 to 1/14,925</td> <td>Moll<sup>[9]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#62;50 (32.5)</td> <td>5</td> <td>1/3000 to 1/4000</td> <td>DerKinderen<sup>[10]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Chromosomal</td> <td rowspan=\"8\">Down syndrome</td> <td>40 to 44 (20 to 29)</td> <td>1.37 (0.48 to 3.86)</td> <td rowspan=\"3\">1/1200 (maternal age 20 to 29)</td> <td>1/876</td> <td rowspan=\"3\">Zhu<sup>[11]</sup></td> </tr> <tr> <td>45 to 49 (20 to 29)</td> <td>2.68 (0.76 to 9.51)</td> <td>1/448</td> </tr> <tr> <td>&#62;49 (20 to 29)</td> <td>4.5 (1.0 to 20.3)</td> <td rowspan=\"6\">1/267</td> </tr> <tr> <td>40 to 44 (25 to 29)</td> <td>1.45 (1.26 to 1.68)</td> <td rowspan=\"5\">Use maternal age as baseline for counseling purposes<sup>&#182;</sup></td> <td rowspan=\"3\">Yang<sup>[12]</sup></td> </tr> <tr> <td>45 to 49 (25 to 29)</td> <td>1.28 (1.04 to 1.57)</td> </tr> <tr> <td>&#62;49 (25 to 29)</td> <td>1.39 (1.04 to 1.83)</td> </tr> <tr> <td>None given</td> <td>\"May be increased\"</td> <td>Kuhnert<sup>[13]</sup></td> </tr> <tr> <td>None given</td> <td>\"Paternal age effect in association with maternal age (&#62;35) effect\"</td> <td>Fisch<sup>[14]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Klinefelter syndrome</td> <td>&#62;50 (20s)</td> <td>1.6<sup>&#916;</sup> (0.69 to 3.0)</td> <td>1/500 men</td> <td>1/312 men</td> <td>Lowe<sup>[15]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Congenital anomalies</td> <td>VSD</td> <td>&#62;40 (&#60;40)</td> <td>1.69*</td> <td>1/200</td> <td>1/118</td> <td>Olshan<sup>[16]</sup></td> </tr> <tr> <td>ASD</td> <td>&#62;35</td> <td>1.95*</td> <td>1/400</td> <td>1/205</td> <td>Lian<sup>[17]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Tracheoesophageal fistula</td> <td>&#62;50 (25 to 29)</td> <td>2.55 (1.28 to 4.6)</td> <td>1/3600</td> <td>1/1412</td> <td>Yang<sup>[12]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"21\">Other complex disorders</td> <td rowspan=\"2\">Childhood leukemia</td> <td>&#62;35</td> <td>1.5</td> <td rowspan=\"2\">1/25,000</td> <td>1/16,667</td> <td>Murray<sup>[18]</sup></td> </tr> <tr> <td>&#62;40 (&#60;25)</td> <td>1.14 (0.85 to 1.53)</td> <td>1/21,930</td> <td>Yip<sup>[8]</sup></td> </tr> <tr> <td rowspan=\"3\">Childhood CNS tumor</td> <td>30 to 34 (&#60;25)</td> <td>1.34 (1.04 to 1.72)</td> <td rowspan=\"3\">1/36,000</td> <td>1/26,866</td> <td rowspan=\"3\">Yip<sup>[8]</sup></td> </tr> <tr> <td>35 to 39 (&#60;25)</td> <td>1.4 (1.04 to 1.86)</td> <td>1/25,714</td> </tr> <tr> <td>&#62;40 (&#60;25)</td> <td>1.69 (1.21 to 2.35)</td> <td>1/21,302</td> </tr> <tr> <td>Childhood type 1 diabetes</td> <td>&#62;34 (&#60;25)</td> <td>1.52 (1.1 to 2.09)</td> <td>1/415</td> <td>1/273</td> <td>Cardwell<sup>[19]</sup></td> </tr> <tr> <td rowspan=\"2\">Epilepsy</td> <td>35 to 39</td> <td>1.18 (1.02 to 1.26)</td> <td rowspan=\"2\">1/100</td> <td>1/85</td> <td rowspan=\"2\">Vestergaard<sup>[20]</sup></td> </tr> <tr> <td>40 to 45</td> <td>1.3 (1.08 to 1.55)</td> <td>1/770</td> </tr> <tr> <td rowspan=\"6\">Schizophrenia</td> <td>&#62;50 (20 to 24)</td> <td>4.62 (2.28 to 9.36)</td> <td rowspan=\"6\">1/100</td> <td>1/22</td> <td>Rasmussen<sup>[21]</sup></td> </tr> <tr> <td>35 to 44 (15 to 24)</td> <td>1.6 (1.0 to 2.6)</td> <td>1/62.5</td> <td rowspan=\"3\">Zammit<sup>[22]</sup></td> </tr> <tr> <td>45 to 54 (15 to 24)</td> <td>1.6 (0.8 to 3.1)</td> <td>1/62.5</td> </tr> <tr> <td>&#62;54 (15 to 24)</td> <td>3.8 (1.3 to 11.8)</td> <td>1/26</td> </tr> <tr> <td>&#62;49 (&#60;25)</td> <td>3</td> <td>1/33</td> <td>Malaspina<sup>[23]</sup></td> </tr> <tr> <td>&#62;32 (&#60;28)</td> <td>3 (1.49 to 6.04)</td> <td>1/33</td> <td>Tsuchiya<sup>[24]</sup></td> </tr> <tr> <td rowspan=\"2\">Autism</td> <td>&#62;40 (&#60;30)</td> <td>5.75 (2.65 to 12.46)</td> <td rowspan=\"2\">1/1000</td> <td rowspan=\"2\">1/174</td> <td>Reichenberg<sup>[25]</sup></td> </tr> <tr> <td>Unknown</td> <td>Effect seen</td> <td>Cantor<sup>[26]</sup></td> </tr> <tr> <td rowspan=\"2\">Autism spectrum disorders</td> <td>35 to 39 (25 to 29)</td> <td>1.38 (1.04 to 1.84)</td> <td rowspan=\"2\">1/200</td> <td>1/145</td> <td rowspan=\"2\">Croen<sup>[27]</sup></td> </tr> <tr> <td>&#62;39 (25 to 29)</td> <td>1.52 (1.1 to 2.1)</td> <td>1/131</td> </tr> <tr> <td>Breast cancer</td> <td>&#62;40 (&#60;30)</td> <td>1.6 (1.04 to 2.32)</td> <td>1/8.5</td> <td>1/5.3</td> <td>Choi<sup>[28]</sup></td> </tr> <tr> <td>Prostate cancer</td> <td>&#62;38 (&#60;27)</td> <td>1.7 (1.0 to 2.8)</td> <td class=\"divider_bottom\" rowspan=\"2\">1/5.9</td> <td class=\"divider_bottom\" rowspan=\"2\">1/3.5</td> <td>Zhang<sup>[29]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Multiple sclerosis</td> <td>51 to 55 (21 to 25)</td> <td>2.0 (1.35 to 2.96)</td> <td>Montgomery<sup>[30]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Other</td> <td rowspan=\"2\">Spontaneous miscarriages</td> <td>&#62;35 (&#60;35)</td> <td>1.26 (1.0 to 1.6)</td> <td rowspan=\"2\">1/7</td> <td>1/5.3</td> <td>Slama<sup>[31]</sup></td> </tr> <tr> <td>&#62;39 (25 to 29)</td> <td>1.6 (1.2 to 2.0)</td> <td>1/4</td> <td>Kleinhaus<sup>[32]</sup></td> </tr> <tr> <td>Relative infertility</td> <td>&#62;39 (&#60;39)</td> <td>2.3 (1.67 to 3.17)</td> <td>1/14 couples</td> <td>1/6.2</td> <td>De la Rochebrochard<sup>[33]</sup></td> </tr> <tr> <td>Low birth weight</td> <td>&#62;34 (20 to 34)</td> <td>1.7 (1.3 to 2.2)</td> <td>1/40</td> <td>1/23</td> <td>Reichman<sup>[34]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Preeclampsia</td> <td>35 to 44 (25 to 34)</td> <td>1.24 (1.05 to 1.46)</td> <td>1/62</td> <td>1/50</td> <td>Harlap<sup>[35]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#62;44 (25 to 34)</td> <td>1.8 (1.04 to 1.51)</td> <td>1/62</td> <td>1/34</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Total risk</td> <td rowspan=\"2\">For 86 examined congenital anomalies</td> <td>&#62;40 (&#60;20)</td> <td>1.2</td> <td rowspan=\"2\">1/50</td> <td>1/42</td> <td rowspan=\"2\">Lian<sup>[17]</sup></td> </tr> <tr> <td>&#62;50 (&#60;20)</td> <td>1.3</td> <td>1/38</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is meant to show the findings of various studies examining the effect of paternal age on the condition in question. It is not meant to be a comprehensive guide to counseling, but to merely indicate conditions which have been studied and results obtained from those studies.</div><div class=\"graphic_footnotes\">MEN: multiple endocrine neoplasia; VSD: ventricular septal defect; ASD: autism spectrum disorder; CNS: central nervous system.<br />* Increased risk not shown by other studies.<br />&para; Suggestion for this adjustment made by the author of this document. There are no data regarding use of paternal age for counseling for serum screening results.<br />&Delta; Based on frequency of XY sperm.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Risch N, Reigh EW, Wishnick MW, McCarthy JG. Spontaneous mutation and parental age in humans. Am J Hum Genet 1987; 41:218.</li>&#xD;&#xA;    <li>Tiemann-Boege I, Navidi W, Grewal R, et al. The observed human sperm mutation frequency cannot explain the achondroplasia paternal age effect. Proc Natl Acad Sci U S A 2002; 99:14952.</li>&#xD;&#xA;    <li>Glaser RL, Jabs EW. Dear old dad. Sci Aging Knowledge Environ 2004; 21:2004:re1.</li>&#xD;&#xA;    <li>Bunin GR, Needle M, Riccardi VM. Paternal age and sporadic neurofibromatosis 1: A case-control study and consideration of the methodologic issues. Genet Epidemiol 1997; 14:507.</li>&#xD;&#xA;    <li>Carothers AD, McAllion SJ, Paterson CR. Risk of dominant mutation in older fathers: evidence from osteogenesis imperfecta. J Med Genet 1986; 23:227.</li>&#xD;&#xA;    <li>Orioli IM, Castilla EE, Scarano G, Mastroiacovo P. Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. Am J Med Genet 1995; 59:209.</li>&#xD;&#xA;    <li>Dockerty JD, Draper G, Vincent T, et al. Case-control study of parental age, parity and socioeconomic level in relation to childhood cancers. Int J Epidemiol 2001; 30:1428.</li>&#xD;&#xA;    <li>Yip BH, Pawitan Y, Czene K. Parental age and risk of childhood cancers: A population-based cohort study from Sweden. Int J Epidemiol 2006; 35:1495.</li>&#xD;&#xA;    <li>Moll AC, Imhof SM, Kuik DJ, et al. High parental age is associated with sporadic hereditary retinoblastoma: the Dutch retinoblastoma register 1862&ndash;1994. Hum Genet 1996; 98:109.</li>&#xD;&#xA;    <li>DerKinderen DJ, Koten JW, Tan KE, et al. Parental age in sporadic hereditary retinoblastoma. Am J Ophthalmol 1990; 110:605.</li>&#xD;&#xA;    <li>Zhu JL, Madsen KM, Vestergaard M, et al. Paternal age and congenital malformations. Hum Reprod 2005; 20:3173.</li>&#xD;&#xA;    <li>Yang Q, Wen SW, Leader A, et al. Paternal age and birth defects: How strong is the association? Hum Reprod 2007; 22:696.</li>&#xD;&#xA;    <li>Kuhnert B, Nieschlag E. Reproductive functions of the ageing male. Hum Reprod Update 2004; 10:327.</li>&#xD;&#xA;    <li>Fisch H, Hyun G, Golden R, et al. The influence of paternal age on Down syndrome. J Urol 2003; 169:2275.</li>&#xD;&#xA;    <li>Lowe X, Eskenazi B, Nelson DO, et al. Frequency of XY sperm increases with age in fathers of boys with Klinefelter syndrome. Am J Hum Genet 2001; 69:1046.</li>&#xD;&#xA;    <li>Olshan AF, Schnitzer PG, Baird PA. Paternal age and the risk of congenital heart defects. Teratol 1994; 50:80.</li>&#xD;&#xA;    <li>Lian ZH, Zack MM, Erickson JD. Paternal age and the occurrence of birth defects. Am J Hum Genet 1986; 39:648.</li>&#xD;&#xA;    <li>Murray L, McCarron P, Bailie K, et al. Association of early life factors and acute lymphoblastic leukaemia in childhood: Historical cohort study. Br J Cancer 2002; 86:356.</li>&#xD;&#xA;    <li>Cardwell CR, Carson DJ, Patterson CC. Parental age at delivery, birth order, birth weight and gestational age are associated with the risk of childhood Type 1 diabetes: A UK regional retrospective cohort study. Diabet Med 2005; 22:200.</li>&#xD;&#xA;    <li>Vestergaard M, Mork A, Madsen KM, Olsen J. Paternal age and epilepsy in the offspring. Eur J Epidemiol 2005; 20:1003.</li>&#xD;&#xA;    <li>Rasmussen F. Paternal age, size at birth, and size in young adulthood &mdash; Risk factors for schizophrenia. Eur J Endocrin 2006; 155:S65.</li>&#xD;&#xA;    <li>Zammit S, Allebeck P, Dalman C, et al. Paternal age and risk for schizophrenia. Br J Psychiatr 2003; 183:405.</li>&#xD;&#xA;    <li>Malaspina D, Harlap S, Fennig S, et al. Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry 2001; 58:361.</li>&#xD;&#xA;    <li>Tsuchiya KJ, Takagai S, Kawai M, et al. Advanced paternal age associated with an elevated risk for schizophrenia in offspring in a Japanese population. Schizophr Res 2005; 76:337.</li>&#xD;&#xA;    <li>Reichenberg A, Gross R, Weiser M, et al. Advancing paternal age and autism. Arch Gen Psychiatry 2006; 63:1026.</li>&#xD;&#xA;    <li>Cantor RM, Yoon JL, Furr J, Lajonchere CM. Paternal age and autism are associated in a family-based sample. Mol Psychiatr 2007; 12:419.</li>&#xD;&#xA;    <li>Croen LA, Najjar DV, Fireman B, Grether JK. Maternal and paternal age and risk of autism spectrum disorders. Arch Pediatr Adolesc Med 2007; 161:334.</li>&#xD;&#xA;    <li>Choi JY, Lee KM, Park SK, et al. Association of paternal age at birth and the risk of breast cancer in offspring: a case control study. BMC Cancer 2005; 5:143.</li>&#xD;&#xA;    <li>Zhang Y, Kreger BE, Dorgan JF, et al. Parental age at child's birth and son's risk of prostate cancer. The Framingham study. Am J Epidemiol 1999; 150:1208.</li>&#xD;&#xA;    <li>Montgomery SM, Lambe M, Olsson T, Ekbom A. Parental age, family size, and risk of multiple sclerosis. Epidemiology 2004; 15:717.</li>&#xD;&#xA;    <li>Slama R, Bouyer J, Windham G, et al. Influence of paternal age on the risk of spontaneous abortion. Am J Epidemiol 2005; 161:816.</li>&#xD;&#xA;    <li>Kleinhaus K, Perrin M, Friedlander Y, et al. Paternal age and spontaneous abortion. Obstet Gynecol 2006; 108:369.</li>&#xD;&#xA;    <li>De La Rochebrochard E, Thonneau P. Paternal age &ge;40 years: An important risk factor for infertility. Am J Obstet Gynecol 2003; 189:901.</li>&#xD;&#xA;    <li>Reichman NE, Teitler JO. Paternal age as a risk factor for low birthweight. Am J Public Health 2006; 96:862.</li>&#xD;&#xA;    <li>Harlap S, Paltiel O, Deutsch L, et al. Paternal age and preeclampsia. Epidemiology 2002; 13:660.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted by permission from Macmillan Publishers Ltd: Genetics in Medicine. Toriello HV, Meck JM. Statement on guidance for genetic counseling in advanced paternal age. Genet Med 2008; 10:457. Copyright &copy; 2008. <a href=\"http://www.nature.com/gim/index.html?foxtrotcallback=true\" target=\"_blank\">www.nature.com/gim</a>.</div><div id=\"graphicVersion\">Graphic 112761 Version 1.0</div></div></div>"},"112762":{"type":"graphic_table","displayName":"Common causes of pseudochromhidrosis","title":"Common causes of pseudochromhidrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of pseudochromhidrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Color</td> </tr> <tr> <td>Antiperspirants</td> <td>Yellow</td> </tr> <tr> <td>Sunless tanning agents</td> <td>Orange/brown</td> </tr> <tr> <td>Dyes or dusts</td> <td>Any color of clothing or dust</td> </tr> <tr> <td colspan=\"2\">Infection</td> </tr> <tr> <td class=\"indent1\"><em>Serratia marcescens</em></td> <td>Red-pink</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas</em></td> <td>Green-black</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium</em></td> <td>Black-brown</td> </tr> <tr> <td class=\"indent1\">Black piedra</td> <td>Black</td> </tr> <tr> <td class=\"indent1\"><em>Malassezia furfur</em></td> <td>Blue</td> </tr> <tr> <td class=\"indent1\"><em>Bacillus</em> species</td> <td>Blue</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112762 Version 1.0</div></div></div>"},"112777":{"type":"graphic_table","displayName":"Vermont opioid limits for adults","title":"Vermont opioid limits for adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vermont opioid limits for adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pain</td> <td class=\"subtitle1\">Average daily MME<br /> (allowing for tapering)</td> <td class=\"subtitle1\">Prescription&nbsp;TOTAL MME based on expected duration of pain</td> <td class=\"subtitle1\">Common average&nbsp;DAILY pill counts</td> <td class=\"subtitle1\">Commonly associated injuries, conditions, and surgeries</td> </tr> <tr> <td><strong>Minor</strong> pain</td> <td>No opioids</td> <td>0 total MME</td> <td>0 hydrocodone<br /> 0 oxycodone<br /> 0 hydromorphone</td> <td>Molar removal, sprains, non-specific low back pain, headaches, fibromyalgia, undiagnosed dental pain</td> </tr> <tr> <td><strong>Moderate</strong> pain</td> <td>24 MME/day</td> <td> <p><strong>0 to 3 days:</strong> 72 MME</p> <strong>1 to 5 days:</strong> 120 MME</td> <td>4 hydrocodone 5 mg, or<br /> 3 oxycodone 5 mg, or<br /> 3 hydromorphone 2 mg</td> <td>Non-compound bone fractures, most soft tissue surgeries, most outpatient laparoscopic surgeries, shoulder arthroscopy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Severe</strong> pain</td> <td>32 MME/day</td> <td> <p><strong>0 to 3 days:</strong> 96 MME</p> <strong>1 to 5 days:</strong> 160 MME</td> <td>6 hydrocodone 5 mg, or<br /> 4 oxycodone 5 mg, or<br /> 4 hydromorphone 2 mg</td> <td>Many non-laparoscopic surgeries, maxillofacial surgery, total joint replacement, compound fracture repair</td> </tr> <tr> <td class=\"subtitle2_left highlight_blue_text\" colspan=\"5\">For patients with severe pain and extreme circumstance, the provider can make a clinical judgment to prescribe up to 7 days so long as the reason is documented in the medical record</td> </tr> <tr> <td><strong>Extreme</strong> pain</td> <td>50 MME/day</td> <td><strong>7 day max:</strong> 350 MME</td> <td>10 hydrocodone 5 mg, or<br /> 6 oxycodone 5 mg, or<br /> 6 hydromorphone 2 mg</td> <td>Similar to the severe pain category, but with complications or other special circumstances</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the opioid prescription guidelines that appear in the state of Vermont administrative law that was adopted in 2016.</div><div class=\"graphic_footnotes\">MME: morphine milligram equivalent.</div><div class=\"graphic_reference\">Reproduced with permission from the Vermont Department of Health. Rule governing the prescribing of opioids for pain (Adopted rule, effective July 1, 2017). Available at: <a href=\"http://www.healthvermont.gov/sites/default/files/documents/2016/12/REG_opioids-prescribing-for-pain.pdf\" target=\"_blank\">http://www.healthvermont.gov/sites/default/files/documents/2016/12/REG_opioids-prescribing-for-pain.pdf</a> (Accessed on April 21, 2017).</div><div id=\"graphicVersion\">Graphic 112777 Version 1.0</div></div></div>"},"112782":{"type":"graphic_table","displayName":"TLR and TLR signaling defects leading to PID","title":"Toll-like receptors (TLRs) and signaling defects leading to primary immunodeficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toll-like receptors (TLRs) and signaling defects leading to primary immunodeficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Genetic defect</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Infectious complications</td> <td class=\"subtitle1\">Noninfectious clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Innate immunodeficiency</td> </tr> <tr> <td class=\"indent1\">IRAK4 or MyD88</td> <td>AR</td> <td> <p>Recurrent severe infections (cellulitis, arthritis, meningitis, osteomyelitis, organ abscesses, and sepsis), mostly affecting upper respiratory tract and skin.</p> <p>Most common organisms: <em>Staphylococcus aureus</em>, <em>Streptococcus pneumoniae</em>, <em>Pseudomonas aeruginosa.</em></p> The lack of significant fever in the setting of a serious bacterial infection can be a clue.</td> <td>Presents in childhood; may improve with age if patient survives.</td> </tr> <tr> <td class=\"indent1\">TLR3</td> <td>AR</td> <td>HSV encephalitis.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">TRIF</td> <td>AD, AR</td> <td>HSV encephalitis.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">TRAF3</td> <td>AD</td> <td>HSV encephalitis.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">TBK1</td> <td>AD</td> <td>HSV encephalitis.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">UNC93B1</td> <td>AR</td> <td>HSV encephalitis.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Combined immunodeficiency</td> </tr> <tr> <td class=\"indent1\">NEMO/IKK-gamma</td> <td>X-linked</td> <td> <p>Ba, MB, V, F, Op.</p> Severity and range of infectious complications is variable.</td> <td> <p>Incontinentia pigmenti in female infants.</p> Hypomorphic mutations in male infants often have (ED-ID).</td> </tr> <tr> <td class=\"indent1\">I-kappa-B-alpha</td> <td>AD</td> <td>Ba, MB, V, F, Op.</td> <td>ED-ID.</td> </tr> <tr> <td class=\"indent1\">NF-kappa-B1</td> <td>AD</td> <td>Recurrent Ba, V.</td> <td>Hypogammaglobulinemia.</td> </tr> <tr> <td class=\"indent1\">NF-kappa-B2</td> <td>AD</td> <td>Ba, MB, V, F, Op.</td> <td> <p>Hypogammaglobulinemia.</p> <p>Autoimmunity.</p> Adrenal insufficiency.</td> </tr> <tr> <td class=\"indent1\">HOIL-1<br /> <em>HOIP</em></td> <td>AR</td> <td>Pyogenic Ba (eg, <em>S. pneumoniae</em> or <em>Haemophilus influenzae</em>).</td> <td> <p>Autoinflammation (recurrent episodes of fever).</p> <p>Hepatosplenomegaly.</p> Muscular amylopectinosis.</td> </tr> <tr> <td class=\"indent1\">DOCK8</td> <td>AR</td> <td>Pyogenic Ba, V, F.</td> <td> <p>Autosomal recessive hyperimmunoglobulin E.</p> Hypereosinophilia.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IRAK4: interleukin-1 receptor-associated kinase 4; MyD88: myeloid differentiation primary response protein 88; AR: autosomal recessive; TLR3: toll-like receptor 3; HSV: herpes simplex virus; TRIF: toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter-inducing interferon-beta (IFN-beta); AD: autosomal dominant; TRAF3: tumor necrosis factor (TNF) receptor-associated factor 3; TBK1: tank-binding kinase 1; UNC93B1: UNC93 homolog B1; NEMO: nuclear factor (NF)-kappa-B essential modulator; IKK-gamma: inhibitor of NF-kappa-B kinase-gamma; Ba: bacteria; MB: mycobacteria; V: viral; F: fungal; Op: opportunistic infections; ED-ID: ectodermal dysplasia with immunodeficiency; NF: nuclear factor; HOIL-1: heme-oxidized iron-responsive element-binding protein 2 (IRP2) ubiquitin ligase 1, a component of the linear ubiquitination chain assembly complex (LUBAC); <EM>HOIP</EM>: the gene encoding the catalytic component of LUBAC; DOCK8: dedicator of cytokinesis 8.</div><div id=\"graphicVersion\">Graphic 112782 Version 1.0</div></div></div>"},"112783":{"type":"graphic_algorithm","displayName":"Management major pelvic trauma in ED","title":"Initial ED management of major pelvic trauma as determined by examination or plain radiograph*","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Initial ED management of major pelvic trauma as determined by examination or plain radiograph*</div><div class=\"cntnt\"><img style=\"width:828px; height:498px;\" src=\"images/EM/112783_Mgmt_major_pelvic_trauma_ED.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; DPA: diagnostic peritoneal aspirate; ED: emergency department; FAST: focused assessment with sonography in trauma; REBOA: resuscitative endovascular balloon occlusion of the aorta.<br />* This algorithm assumes the pelvis is the major site of trauma based on the initial clinical examination or plain radiographs performed in the ED.<br />¶ Interventions listed are in addition to standard initial resuscitation of any major trauma patient.<br />Δ Other interventions may include surgery, admission to intensive care unit.</div><div id=\"graphicVersion\">Graphic 112783 Version 2.0</div></div></div>"},"112788":{"type":"graphic_algorithm","displayName":"Selection of patients for augmentation with pooled human AAT","title":"Selection of patients for augmentation with pooled human alpha-1 antiprotease (alpha-1 antitrypsin)","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Selection of patients for augmentation with pooled human alpha-1 antiprotease (alpha-1 antitrypsin)</div><div class=\"cntnt\"><img style=\"width:797px; height:473px;\" src=\"images/PULM/112788_Select_ptnts_AAT_aug_AT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AAT: alpha-1 antitrypsin (also known as alpha-1 antiprotease); IgA: immunoglobulin A; FEV<SUB>1</SUB>: forced expiratory volume in one second; CT: computed tomography.<br />¶ For example, PI*ZZ or PI*Null.<br />Δ Patients with severe IgA deficiency (&lt;7 mg/dL) are at increased risk of anaphylaxis. Refer to UpToDate topic reviews.</div><div id=\"graphicVersion\">Graphic 112788 Version 1.0</div></div></div>"},"112789":{"type":"graphic_diagnosticimage","displayName":"CT emphysema","title":"Computed tomography of emphysema","html":"<div class=\"graphic\"><div style=\"width: 809px\" class=\"figure\"><div class=\"ttl\">Computed tomography of emphysema</div><div class=\"cntnt\"><img style=\"width:789px; height:517px;\" src=\"images/PULM/112789_CT_emphysema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image of upper lung zones in a patient with extensive emphysematous changes. The interlobular septa are prominent, making it difficult to differentiate from advanced cystic lung disease.</div><div id=\"graphicVersion\">Graphic 112789 Version 1.0</div></div></div>"},"112790":{"type":"graphic_diagnosticimage","displayName":"CT advanced cystic lung disease","title":"Computed tomography advanced cystic lung disease","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Computed tomography advanced cystic lung disease</div><div class=\"cntnt\"><img style=\"width:497px; height:402px;\" src=\"images/PULM/112790_CT_adv_cystic_lung_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image of advanced cystic lung disease due to lymphangioleiomyomatosis. The lung cysts have coalesced, making it difficult to differentiate this from emphysema.</div><div id=\"graphicVersion\">Graphic 112790 Version 1.0</div></div></div>"},"112791":{"type":"graphic_diagnosticimage","displayName":"CT honeycombing in IPF","title":"Computed tomography of advanced honeycombing in idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Computed tomography of advanced honeycombing in idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:507px; height:511px;\" src=\"images/PULM/112791_CT_honeycombing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image of bibasilar honeycombing in a patient with advanced idiopathic interstitial lung disease and extensive honeycombing at the lung bases.</div><div id=\"graphicVersion\">Graphic 112791 Version 1.0</div></div></div>"},"112792":{"type":"graphic_diagnosticimage","displayName":"CT cystic bronchiectasis","title":"Computed tomography cystic bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Computed tomography cystic bronchiectasis</div><div class=\"cntnt\"><img style=\"width:749px; height:431px;\" src=\"images/PULM/112792_CT_cystic_bronchiectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image from a patient with cystic fibrosis demonstrating bilateral upper lobe cystic bronchiectasis and thickened bronchial walls. Tram lines, another feature of bronchiectasis, are seen in the anteromedial portion of the right upper lobe.</div><div id=\"graphicVersion\">Graphic 112792 Version 1.0</div></div></div>"},"112793":{"type":"graphic_diagnosticimage","displayName":"Cavitary lung lesions","title":"Computed tomography of lung cavities due to large B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of lung cavities due to large B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:382px; height:275px;\" src=\"images/PULM/112793_Cavitary_lung_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography images showing bilateral upper lobe thick-walled cavities due to large B cell lymphoma.</div><div id=\"graphicVersion\">Graphic 112793 Version 1.0</div></div></div>"},"112794":{"type":"graphic_diagnosticimage","displayName":"Renal angiomyolipoma CT II","title":"Computed tomography of renal angiomyolipoma","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Computed tomography of renal angiomyolipoma</div><div class=\"cntnt\"><img style=\"width:633px; height:514px;\" src=\"images/PULM/112794_Renal_angiomyolipoma_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial abdominal computed tomography image of renal angiomyolipomas in a patient with tuberous sclerosis complex and lymphangioleiomyomatosis (TSC-LAM). Note multiple lesions of fat density in the kidneys (arrows).</div><div id=\"graphicVersion\">Graphic 112794 Version 2.0</div></div></div>"},"112795":{"type":"graphic_picture","displayName":"Birt-Hogg-Dubé fibrofolliculomas","title":"Birt-Hogg-Dubé fibrofolliculomas","html":"<div class=\"graphic\"><div style=\"width: 695px\" class=\"figure\"><div class=\"ttl\">Birt-Hogg-Dub&eacute; fibrofolliculomas</div><div class=\"cntnt\"><img style=\"width:675px; height:506px;\" src=\"images/PULM/112795_Brt_Hgg_Db_fibrofoliculomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple whitish dome-shaped papules at the base of the neck, representing fibrofolliculomas in a patient with Birt-Hogg-Dub&eacute; syndrome.</div><div class=\"graphic_reference\">Courtesy of: Dr. Andrew Haas.</div><div id=\"graphicVersion\">Graphic 112795 Version 1.0</div></div></div>"},"112796":{"type":"graphic_diagnosticimage","displayName":"Lymphangioleiomyomatosis CT III","title":"Computed tomography of lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Computed tomography of lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:749px; height:504px;\" src=\"images/PULM/112796_LymphangioleiomyomatosisCT3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image of lymphangioleiomyomatosis (LAM) showing numerous, diffusely distributed, thin-walled cysts, characteristic of LAM.</div><div id=\"graphicVersion\">Graphic 112796 Version 1.0</div></div></div>"},"112797":{"type":"graphic_diagnosticimage","displayName":"Pulmonary Langerhans cell histiocytosis CT","title":"Computed tomography of pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 711px\" class=\"figure\"><div class=\"ttl\">Computed tomography of pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:691px; height:488px;\" src=\"images/PULM/112797_Plmnry_Lngrhns_hstcytsis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image of pulmonary Langerhans cell histiocytosis (PLCH) showing multiple irregular and bizarrely shaped cysts with prominent walls, characteristic of PLCH. Also present is a left pneumothorax.</div><div id=\"graphicVersion\">Graphic 112797 Version 1.0</div></div></div>"},"112798":{"type":"graphic_diagnosticimage","displayName":"Birt-Hogg-Dubé chest CT","title":"Computed tomography of Birt-Hogg-Dubé lung cysts","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Computed tomography of Birt-Hogg-Dubé lung cysts</div><div class=\"cntnt\"><img style=\"width:511px; height:509px;\" src=\"images/PULM/112798_Birt_Hogg_Dube_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image from a patient with Birt-Hogg-Dub&eacute; (BHD), showing thin-walled lentiform (lens-shaped) cysts abutting the mediastinum and two other small round parenchymal cysts in the right lung. Lentiform, paramediastinal cysts are typical of BHD.</div><div id=\"graphicVersion\">Graphic 112798 Version 1.0</div></div></div>"},"112799":{"type":"graphic_diagnosticimage","displayName":"Lymphoid interstitial pneumonia CT","title":"Computed tomography of lung cysts in lymphoid interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Computed tomography of lung cysts in lymphoid interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:573px; height:386px;\" src=\"images/PULM/112799_Lymphid_intrsttl_pneumn_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image from a patient with lymphoid interstitial pneumonia showing thin-walled lung cysts in areas of ground glass opacities.</div><div id=\"graphicVersion\">Graphic 112799 Version 1.0</div></div></div>"},"112800":{"type":"graphic_diagnosticimage","displayName":"Pulmonary Langerhans cell histiocytosis CT with nodules","title":"Computed tomography of pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Computed tomography of pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:512px; height:356px;\" src=\"images/PULM/112800_Plmnry_Lngrhns_CT_w_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image of upper lung zones in a patient with pulmonary Langerhans cell histiocytosis. Solid nodules, cavitary nodules, and thick-walled cysts are present in the apices of both lungs.</div><div id=\"graphicVersion\">Graphic 112800 Version 1.0</div></div></div>"},"112825":{"type":"graphic_picture","displayName":"Cryoprobe back freezing","title":"Bronchoscopic view of a cryoprobe showing \"back-freezing\"","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of a cryoprobe showing \"back-freezing\"</div><div class=\"cntnt\"><img style=\"width:752px; height:604px;\" src=\"images/PULM/112825_Cryoprobe_back_freezing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image is representative of a bronchoscopic cryoprobe targeting an endobronchial lesion (seen anteriorly). The metal tip (arrow) is in clear view protruding from the end of the bronchoscope. Noteworthy, is the snow-like appearance on the outside of the probe (\"back-freezing\" effect). Damage to the bronchoscope can be avoided by keeping the probe tip in clear view beyond the tip of the bronchoscope.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2017 Erbe Elektromedizin GmbH, Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112825 Version 1.0</div></div></div>"},"112826":{"type":"graphic_figure","displayName":"Principle cryoablation","title":"Principles of cryoablation","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Principles of cryoablation</div><div class=\"cntnt\"><img style=\"width:756px; height:425px;\" src=\"images/PULM/112826_Principle_cryoablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image is representative of a how tissue freezes using a cryoprobe. Cold pressurized gas is delivered via the airway to the target tissue (dashed arrow) resulting in a freeze zone (roughly 3 mm) with the greatest effect occurring closer to the probe head.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2017 Erbe Elektromedizin GmbH, Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112826 Version 1.0</div></div></div>"},"112827":{"type":"graphic_diagnosticimage","displayName":"CT spiculated nodule","title":"Computed tomogram of a spiculated nodule in the right upper lobe representing a T1 lesion","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Computed tomogram of a spiculated nodule in the right upper lobe representing a T1 lesion</div><div class=\"cntnt\"><img style=\"width:754px; height:653px;\" src=\"images/PULM/112827_CT_spiculated_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomogram of a spiculated nodule in the right upper lobe representing a T1 lesion; the nodule has a ring of ground-glass opacity and as such may be part-solid.</div><div id=\"graphicVersion\">Graphic 112827 Version 1.0</div></div></div>"},"112828":{"type":"graphic_table","displayName":"PH severity","title":"Pulmonary hypertension severity by echocardiography and pulmonary artery catheterization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary hypertension severity by echocardiography and pulmonary artery catheterization</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Echocardiography<br /> ePASP</td> <td class=\"subtitle1\" colspan=\"2\">Pulmonary artery catheter<br /> mPAP</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Mild</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">&#8805;20 mmHg and &#60;40 mmHg</td> <td colspan=\"2\">&#8805;25* mmHg and &#60;30 mmHg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Moderate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">&#8805;40 mmHg and &#60;60 mmHg</td> <td colspan=\"2\">&#8805;30 mmHg and &#60;35 mmHg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Severe</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8805;60 mmHg</td> <td colspan=\"2\"> <p>&#8805;35 mmHg</p> <p>OR</p> &#8805;25 mmHg and elevated RA pressure and/or CI &#60;2 L/min/m<sup>2</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The values determined by echocardiography are estimations only based upon our experience and those of other pulmonary hypertension experts. Estimations by echocardiography are subject to variation and are, in general, less accurate than those achieved by pulmonary artery catheterization. Other features on echocardiography that may indicate severe PH include tricuspid regurgitant jet &gt;3 meters/second and right ventricle dilatation or dysfunction.</div><div class=\"graphic_footnotes\">ePASP: estimated pulmonary artery systolic pressure; mPAP: mean pulmonary artery pressure; RA: right atrial; CI: cardiac index.<br />* Those with mPAP between 20 and 24 mmHg are considered to have borderline elevations in PAP of uncertain significance.</div><div id=\"graphicVersion\">Graphic 112828 Version 1.0</div></div></div>"},"112832":{"type":"graphic_picture","displayName":"Acute paronychia 4","title":"Acute paronychia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acute paronychia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/112832_Acute_paronychia_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and swelling of the proximal nail fold with a collection of purulent fluid in a patient with acute paronychia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112832 Version 1.0</div></div></div>"},"112834":{"type":"graphic_diagnosticimage","displayName":"CT of medullary sponge kidney","title":"CT of medullary sponge kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of medullary sponge kidney</div><div class=\"cntnt\"><img style=\"width:384px; height:372px;\" src=\"images/RADIOL/112834_CT_medullary_sponge_kidney_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medullary sponge kidney. Coronal reconstruction image of the abdomen from a noncontrast CT shows bilateral nephrocalcinosis (arrows) at the corticomedullary junction.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Susanna I Lee MD, PhD.</div><div id=\"graphicVersion\">Graphic 112834 Version 1.0</div></div></div>"},"112835":{"type":"graphic_diagnosticimage","displayName":"Low-radiation-dose CT of renal stone","title":"Low-radiation-dose CT of renal stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low-radiation-dose CT of renal stone</div><div class=\"cntnt\"><img style=\"width:219px; height:177px;\" src=\"images/RADIOL/112835_Lw_radatn_ds_CT_renal_stone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nephrolithiasis. Coronal reconstruction image of the abdomen from a noncontrast CT performed with low-radiation-dose protocol shows a 3 mm stone (arrow) in the right renal calyx.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kasra Mojtahed MD.</div><div id=\"graphicVersion\">Graphic 112835 Version 3.0</div></div></div>"},"112836":{"type":"graphic_table","displayName":"Imaging modalities for nephrolithiasis","title":"Imaging modalities for nephrolithiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imaging modalities for nephrolithiasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Abdomen radiograph</td> <td> <ul> <li>Accurate stone size measurements and ureteral localization for treatment planning </li> </ul> </td> <td> <ul> <li>Low to moderate sensitivity and wide variability in diagnostic performance; detects 29 to 59% of stones seen with CT<sup>[1,2]</sup> </li> <li>Does not detect hydronephrosis </li> <li>Ionizing radiation; effective dose 0.8 mSv with each view </li> </ul> </td> </tr> <tr> <td>Intravenous pyelography (IVP)</td> <td> <ul> <li>Reliably detects hydronephrosis </li> <li>Accurate stone size measurements and ureteral localization for treatment planning </li> </ul> </td> <td> <ul> <li>Diagnostic performance not quantified; less accurate than CT </li> <li>Ionizing radiation; effective dose 12 mSv </li> <li>Intravenous contrast required </li> </ul> </td> </tr> <tr> <td>Ultrasound kidneys and bladder</td> <td> <ul> <li>No ionizing radiation; lower cumulative radiation dose in patients undergoing repeated imaging in settings where low-dose CT is not available </li> <li>Reliably detects hydronephrosis </li> </ul> </td> <td> <ul> <li>Low to moderate sensitivity and wide variability in diagnostic performance; detects 24 to 57% of stones seen with CT<sup>[3,4]</sup> </li> <li>Inaccurate stone size measurements and ureteral localization for treatment planning </li> <li>Likely nondiagnostic in patients with large body habitus (men &#62;285 lb, women &#62;250 lb), or those with end-stage renal disease </li> </ul> </td> </tr> <tr> <td>Noncontrast CT abdomen and pelvis</td> <td> <ul> <li>Highest diagnostic accuracy; pooled sensitivity 0.97 and specificity 0.95 for low-dose exam<sup>[5]</sup> </li> <li>Reliably detects hydronephrosis </li> <li>Accurate stone size measurements and ureteral localization for treatment planning </li> </ul> </td> <td> <ul> <li>Ionizing radiation; effective dose 2 to 3 mSv with low-dose and 10 to 12 mSv with standard-dose exam </li> <li>Rarely, a second set of images after intravenous contrast are needed for definitive diagnosis of urolithiasis* </li> </ul> </td> </tr> <tr> <td>MRI abdomen and pelvis</td> <td> <ul> <li>No ionizing radiation </li> <li>Reliably detects hydronephrosis </li> <li>Accurately localizes the site of ureteral obstruction for treatment planning </li> </ul> </td> <td> <ul> <li>Very low sensitivity as stones are nearly invisible </li> <li>Inaccurate stone size measurements for treatment planning </li> <li>Requires patient lie still in enclosed scanner for 10 to 20 minutes </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.<br />* To distinguish ureteral stones from phleboliths.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Jung SI, Kim YJ, Park HS, et al. Sensitivity of digital abdominal radiography for the detection of ureter stones by stone size and location. J Comput Assist Tomogr 2010; 34:879.</LI>&#xD;&#xA;<LI>Levine JA, Neitlich J, Verga M, et al. Ureteral calculi in patients with flank pain: correlation of plain radiography with unenhanced helical CT. Radiology 1997; 204:27.</LI>&#xD;&#xA;<LI>Fowler KA, Locken JA, Duchesne JH, Williamson MR. US for detecting renal calculi with nonenhanced CT as a reference standard. Radiology 2002; 222:109.</LI>&#xD;&#xA;<LI>Ulusan S, Koc Z, Tokmak N. Accuracy of sonography for detecting renal stone: Comparison with CT. J Clin Ultrasound 2007; 35:256.</LI>&#xD;&#xA;<LI>Niemann T, Kollmann T, Bongartz G. Diagnostic performance of low-dose CT for the detection of urolithiasis: a meta-analysis. AJR Am J Roentgenol 2008;191:396.</LI></OL></div><div id=\"graphicVersion\">Graphic 112836 Version 3.0</div></div></div>"},"112837":{"type":"graphic_table","displayName":"Salvage therapies for relapsed refractory HL","title":"Systemic salvage therapies for relapsed or refractory Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic salvage therapies for relapsed or refractory Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Salvage regimen</td> <td class=\"subtitle1\">Major toxicities</td> <td class=\"subtitle1\">Clinical utility</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td>ICE (ifosfamide, carboplatin, etoposide) </td> <td>Hematologic (universal), infections, nephrotoxicity</td> <td>Preferred initial salvage chemotherapy regimen</td> <td>Administered every 14 to 21 days, as permitted by blood counts; can be given as inpatient or outpatient therapy</td> </tr> <tr> <td>GVD (gemcitabine, vinorelbine, pegylated liposomal doxorubicin)</td> <td>Hematologic (universal), febrile neutropenia</td> <td>Preferred second-line salvage chemotherapy regimen</td> <td>Can be given as inpatient or outpatient therapy; doses should be adjusted if patient is post-HCT</td> </tr> <tr> <td>GDP (gemcitabine, dexamethasone, cisplatin) </td> <td>Hematologic (universal), febrile neutropenia, nephrotoxicity</td> <td>Alternative salvage chemotherapy</td> <td>&nbsp;</td> </tr> <tr> <td>DHAP (dexamethasone, high dose cytarabine, cisplatin)</td> <td>Hematologic (universal), infections, nephrotoxicity, neurotoxicity</td> <td>Alternative salvage chemotherapy</td> <td>&nbsp;</td> </tr> <tr> <td>BeGEV (bendamustine, gemcitabine, vinorelbine) </td> <td>Hematologic (universal)</td> <td>Alternative salvage chemotherapy</td> <td>&nbsp;</td> </tr> <tr> <td>Brentuximab vedotin (BV)</td> <td>Neurotoxicity, pancreatitis (rare), progressive multifocal leukoencephalopathy (rare)</td> <td>For relapse after autologous HCT (if BV was not previously administered), relapse after two prior multi-agent chemotherapy regimens, consolidation after partial response to systemic chemotherapy</td> <td>Targeted chemotherapy (monomethyl auristatin E linked to CD30 monoclonal antibody)</td> </tr> <tr> <td>Nivolumab or pembrolizumab</td> <td>Pneumonitis, hepatitis, nephritis, gastrointestinal and metabolic abnormalities</td> <td>For relapse after autologous HCT and post-HCT brentuximab vedotin</td> <td>Immune checkpoint inhibitors; increased risk for severe graft-versus-host disease in patients previously treated with these agents</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplantation.</div><div id=\"graphicVersion\">Graphic 112837 Version 1.0</div></div></div>"},"112838":{"type":"graphic_table","displayName":"Differential diagnosis of dysmenorrhea in an adolescent","title":"Differential diagnosis of dysmenorrhea in an adolescent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of dysmenorrhea in an adolescent</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Key clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gynecologic (secondary dysmenorrhea)</td> </tr> <tr> <td class=\"indent1\">Endometriosis</td> <td>Endometriosis often presents with menstrual pain that progressively worsens over time. The pain may be cyclic (menses-related) or noncyclic.</td> </tr> <tr> <td class=\"indent1\">Adenomyosis</td> <td>Heavy periods.</td> </tr> <tr> <td class=\"indent1\">Ovarian cysts</td> <td>Depending on the size, ovarian cysts may cause pelvic pain, constipation, and/or urgency.</td> </tr> <tr> <td class=\"indent1\">Intrauterine or pelvic adhesions</td> <td>Associated with a history of pelvic inflammatory disease (PID).</td> </tr> <tr> <td class=\"indent1\">Silent PID</td> <td>History&nbsp;consistent with&nbsp;undiagnosed and untreated PID, which can lead to scarring and adhesions, causing chronic pain.</td> </tr> <tr> <td class=\"indent1\">Congenital anatomic abnormalities <ul class=\"decimal_heading\"> <li>Imperforate/incomplete hymenal fenestration </li> <li>Cervical stenosis </li> <li>Other congenital obstructive m&#252;llerian malformations </li> </ul> </td> <td>Congenital malformations that obstruct menstrual flow tend to cause cyclic pain that commences at menarche. This pattern of pain is unlikely to be primary dysmenorrhea because most females are anovulatory for several months to several years after menarche.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Use of an intrauterine contraceptive device (IUD)</td> <td>For the first six months after IUD placement, can have cramping with bleeding. Check for strings to exclude the possibility that the IUD has been expelled.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nongynecologic</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> <td>History of bloody diarrhea or watery stools, often with attenuated growth, weight loss, or fever.</td> </tr> <tr> <td class=\"indent1\">Irritable bowel syndrome</td> <td>History of intermittent abdominal pain with constipation and diarrhea; weight loss is unusual.</td> </tr> <tr> <td class=\"indent1\">Psychogenic disorders</td> <td>Pelvic pain with a normal exam and negative&nbsp;review of systems, especially if the pain is associated with mood symptoms and psychosocial stressors.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 112838 Version 2.0</div></div></div>"},"112839":{"type":"graphic_table","displayName":"Clinical history in an adolescent with dysmenorrhea","title":"Clinical history in an adolescent with dysmenorrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical history in an adolescent with dysmenorrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Information</td> <td class=\"subtitle1\">Clinical significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Menstrual history</td> </tr> <tr> <td class=\"indent1\">Age at menarche</td> <td class=\"divider_bottom\" rowspan=\"4\">Regular menses (2 to 7 days of bleeding, at intervals of 21 to 45 days) suggest ovulatory cycles.</td> </tr> <tr> <td class=\"indent1\">Duration of menstrual cycles</td> </tr> <tr> <td class=\"indent1\">Interval between menstrual periods*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Date of last two menstrual periods</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Symptom history</td> </tr> <tr> <td class=\"indent1\">Initial onset of symptoms, and progression over time</td> <td> <ul> <li>Primary dysmenorrhea is usually associated with ovulatory menstrual cycles. Most girls have anovulatory cycles for a few months to several years after menarche. </li> <li>Acute onset of crampy pelvic pain and uterine bleeding suggests secondary cause, such as miscarriage or ectopic pregnancy (refer to UpToDate topic on evaluation of acute pelvic pain). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Relation of symptoms to periods</td> <td>Symptoms of primary dysmenorrhea typically begin several hours prior to the onset of menstruation and continue for one to three days.</td> </tr> <tr> <td class=\"indent1\">Presence or absence of nausea, vomiting, diarrhea, dizziness, fatigue, or headache during menstruation</td> <td>These systemic symptoms are consistent with severe dysmenorrhea.</td> </tr> <tr> <td class=\"indent1\">Impact of symptoms on daily activities such as school attendance, sports participation, and other activities</td> <td>Clear inhibition of activities&nbsp;suggests severe dysmenorrhea, or other pathology.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Medication use and perceived effects<sup>&#182;</sup></td> <td>Lack of relief from analgesics suggests severe dysmenorrhea, or other pathology.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sexual history</td> </tr> <tr> <td class=\"indent1\">Current sexual activity and type of contraception</td> <td>For sexually active females, hormonal contraceptives are a reasonable first-line choice for treatment of dysmenorrhea.</td> </tr> <tr> <td class=\"indent1\">History of sexually transmitted diseases, and history of pelvic inflammatory disease</td> <td>Known or suspected pelvic inflammatory disease may be associated with secondary dysmenorrhea.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The interval between menstrual periods is measured from the first day of one period to the first day of the next period.<br />¶ Medication type, dose, and timing in relation to the onset of cramps; perceived effectiveness for pain relief and ability to engage in all daily activities.</div><div id=\"graphicVersion\">Graphic 112839 Version 3.0</div></div></div>"},"112840":{"type":"graphic_algorithm","displayName":"Initial management of men with testicular seminoma","title":"Initial management of men with testicular seminoma","html":"<div class=\"graphic\"><div style=\"width: 832px\" class=\"figure\"><div class=\"ttl\">Initial management of men with testicular seminoma</div><div class=\"cntnt\"><img style=\"width:812px; height:370px;\" src=\"images/ONC/112840_Init_mgmt_testiclr_seminoma.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; beta-hCG; beta-human chorionic gonadotropin; CT: computed tomography; LN: lymph node; RT: radiation therapy; BEP: bleomycin, etoposide, and cisplatin; EP: etoposide and cisplatin; GCT: germ cell tumor.<br />* Chest CT for all patients with positive LNs; chest radiograph for those with stage I seminoma.<br />¶ Adjuvant chemotherapy is an alternative for management for men who want to minimize the risk of recurrence; for those in whom surveillance is not an option and who refuse chemotherapy, adjuvant RT may be indicated.<br />Δ Combination cisplatin-based chemotherapy is an alternative for patients in whom RT is not feasible.</div><div id=\"graphicVersion\">Graphic 112840 Version 1.0</div></div></div>"},"112844":{"type":"graphic_table","displayName":"ASRM guidance on number of embryos to transfer","title":"ASRM 2017 Committee Opinion on the limits to the number of embryos to transfer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASRM 2017 Committee Opinion on the limits to the number of embryos to transfer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prognosis</td> <td class=\"subtitle1\" colspan=\"4\">Age (years)</td> </tr> <tr> <td class=\"subtitle2\">&#60;35</td> <td class=\"subtitle2\">35 to 37</td> <td class=\"subtitle2\">38 to 40</td> <td class=\"subtitle2\">41 to 42</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cleavage-stage embryos</td> </tr> <tr> <td class=\"indent1\">Euploid</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Other favorable</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">&#8804;3</td> <td class=\"centered\">&#8804;4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">All others</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">&#8804;3</td> <td class=\"centered\">&#8804;4</td> <td class=\"centered\">&#8804;5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Blastocysts</td> </tr> <tr> <td class=\"indent1\">Euploid</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Other favorable</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">&#8804;3</td> </tr> <tr> <td class=\"indent1\">All others</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">&#8804;3</td> <td class=\"centered\">&#8804;3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Other favorable include any ONE of these criteria:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>For fresh cycle: (1) expectation of one or more high-quality embryos available for cryopreservation, or (2) previous live birth after an IVF cycle.</li>&#xD;&#xA;    <li>For frozen embryo transfer cycle: (1) availability of vitrified day 5 or day 6 blastocysts, (2) euploid embryos, (3) first frozen embryo transfer cycle, or (4) previous live birth after an in vitro fertilization cycle.</li>&#xD;&#xA;</ul>&#xD;&#xA;Justification for transferring additional embryos beyond recommended limits should be clearly documented in the patient's medical record.</div><div class=\"graphic_reference\">Reproduced from: Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Guidance on the limits to the number of embryos to transfer: committee opinion. Fertil Steril 2017; 107:901. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112844 Version 1.0</div></div></div>"},"112848":{"type":"graphic_algorithm","displayName":"Algorithm for rapid oral administration of aspirin","title":"Algorithm for rapid oral administration of aspirin to an adult patient with a history of NSAID hypersensitivity (to target dose of 81 mg or 100 mg)*","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Algorithm for rapid oral administration of aspirin to an adult patient with a history of NSAID hypersensitivity (to target dose of 81 mg or 100 mg)*</div><div class=\"cntnt\"><img style=\"width:744px; height:428px;\" src=\"images/ALLRG/112848_Algorapidorladmnaspirin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For important information on the safe use of these protocols (eg, appropriate settings, indications, and contraindications), refer to the UpToDate topic on introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug; ICS/LABA: inhaled corticosteroid/long-acting beta-agonists.<br />* These are the two common low-dose tablets of aspirin available around the world.<br />¶ The protocol is continued, even if the patient develops symptoms. The patients who most commonly develop symptoms are those with AERD. The additional dose at the end of the procedure typically does not cause further symptoms, demonstrating that the patient is desensitized.</div><div class=\"graphic_reference\">Adapted from: White AA, Stevenson DD, Woessner KM, Simon RA. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc 2013; 34:138.</div><div id=\"graphicVersion\">Graphic 112848 Version 2.0</div></div></div>"},"112849":{"type":"graphic_algorithm","displayName":"Algorithm for increasing oral aspirin dose from 81 mg to 325 mg","title":"Algorithm for increasing oral aspirin dose from 81 mg to 325 mg in an adult patient with NSAID hypersensitivity","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Algorithm for increasing oral aspirin dose from 81 mg to 325 mg in an adult patient with NSAID hypersensitivity</div><div class=\"cntnt\"><img style=\"width:573px; height:499px;\" src=\"images/ALLRG/112849_Algoincrsoralaspirindos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For important information on the safe use of these protocols (eg, appropriate settings, indications, and contraindications), refer to the UpToDate topic on introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.<br />* 81 mg is the common dose for low-dose aspirin in the United States. In many other countries, 100 mg is the common low-dose.<br />&para; If patient was not premedicated for aspirin introduction in the previous 24 hours, then give montelukast 10 mg at least one hour before beginning the procedure. If asthma is not well-controlled, give prednisone 40 mg orally at least two hours before.<br />&Delta; Symptoms should be treated if they occur:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Albuterol for wheezing, chest tightness, or cough</li>&#xD;&#xA;    <li>Oxymetazoline or other nasal decongestant spray for nasal obstruction</li>&#xD;&#xA;</ul>&#xD;&#xA;If severe symptoms occur at a certain dose, that dose should be repeated, and the protocol should be continued after 90 minutes of observation. Patients usually do not react again to the same dose when it is repeated.<br /><span class=\"lozenge\">&loz;</span> If symptoms develop, give:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Montelukast 10 mg</li>&#xD;&#xA;    <li>Cetirizine 10 mg orally or diphenhydramine 50 mg intravenously or orally, and</li>&#xD;&#xA;    <li>Prednisone 40 mg orally or methylprednisolone 40 mg intravenously</li>&#xD;&#xA;</ul>&#xD;&#xA;Then, continue the protocol without repeating steps.<br />&sect; The time interval on the right side of the algorithm could be shortened to 60 minutes, if needed. Note that the time interval on the left side of the algorithm should not be shortened.</div><div class=\"graphic_reference\">Courtesy of Ronald A Simon, MD.</div><div id=\"graphicVersion\">Graphic 112849 Version 2.0</div></div></div>"},"112850":{"type":"graphic_figure","displayName":"Wave intensity during the diastolic wave-free period","title":"Wave intensity during the diastolic wave-free period","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Wave intensity during the diastolic wave-free period</div><div class=\"cntnt\"><img style=\"width:772px; height:838px;\" src=\"images/CARD/112850_Wv_ntnsty_dr_dstlc_wv_fr_pd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative traces showing coronary artery wave intensity (upper panel) and corresponding pressure waveform (lower panel). The duration of diastole and the diastolic wave-free period are indicated with dashed vertical lines. The portion of the pressure waveform used to calculate the instantaneous wave-free ratio (iFR) in this study is highlighted in blue.</div><div class=\"graphic_reference\">Reproduced from: Sen S, Asrress KN, Nijjer S, et al. Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY (Classification Accuracy of Pressure-Only Ratios Against Indices Using Flow Study). J Am Coll Cardiol 2013; 61:1409. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112850 Version 1.0</div></div></div>"},"112854":{"type":"graphic_table","displayName":"Clinical features of Dravet syndrome","title":"Clinical features of Dravet syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of Dravet syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Presentation in young children</td> <td class=\"subtitle1\">Presentation in older, previously undiagnosed children or adults</td> </tr> <tr class=\"divider_bottom\"> <td>Age of onset</td> <td> <ul> <li>Between 1 and 18 months </li> </ul> </td> <td> <ul> <li>Early childhood or unknown</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Seizures</td> <td> <ul> <li>Recurrent generalized tonic-clonic or hemiconvulsive seizures (all patients), often prolonged </li> <li>Myoclonic seizures, commonly seen by age 2 years </li> <li>Obtundation status, focal dyscognitive seizures, and atypical absences, commonly seen after age 2 years </li> <li>Typical absences and epileptic spasms are atypical </li> </ul> </td> <td> <ul> <li>Persisting seizures*, which include: <ul> <li>Focal and/or generalized convulsive seizures </li> <li>Myoclonic, atypical, absence, and tonic seizures (less common) </li> <li>Recurrent status epilepticus becomes less frequent with age, may not be seen in adolescence or young adulthood </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Seizure triggers</td> <td> <ul> <li>Hyperthermia, which may be associated with vaccination (most patients) </li> <li>Flashing lights, visual patterns, bathing, eating, overexertion </li> <li>Sodium channel blocking antiseizure drugs </li> </ul> </td> <td> <ul> <li>Hyperthermia (may become less problematic in adolescence and adulthood) </li> <li>Sodium channel blocking antiseizure drugs </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Development and neurologic examination</td> <td> <ul> <li>Normal development and neurologic examination at baseline </li> </ul> </td> <td> <ul> <li>Intellectual disability (typically evident by 18 to 60 months of age) </li> <li>Crouched gait, hypotonia, incoordination, impaired dexterity (typically evident by 3 to 4 years of age) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>MRI</td> <td> <ul> <li>Normal at onset </li> </ul> </td> <td> <ul> <li>Typically normal, may show mild generalized atrophy and/or hippocampal sclerosis </li> </ul> </td> </tr> <tr> <td>EEG</td> <td> <ul> <li>Nonspecific findings at onset </li> </ul> </td> <td> <ul> <li>Diffuse background slowing, often with multifocal and/or generalized interictal discharges; photoparoxysmal response may be seen </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalogram; MRI: magnetic resonance imaging.<br />* Some older adults may become seizure-free. It is not clear whether antieseizure drugs can be safely stopped in this group, however.</div><div class=\"graphic_reference\">Original figure modified for this publication. Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: Recommendations from a North American consensus panel. Pediatr Neurol 2017;68:18. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112854 Version 1.0</div></div></div>"},"112884":{"type":"graphic_algorithm","displayName":"Salvage therapy for HNSCC","title":"Salvage therapy for local, regionally recurrent, or second primary HNSCC","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salvage therapy for local, regionally recurrent, or second primary HNSCC</div><div class=\"cntnt\"><img style=\"width:367px; height:349px;\" src=\"images/ONC/112884_Salvage_therapy_for_HNSCC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HNSCC: head and neck squamous cell carcinoma; RT: radiation therapy.<br />* Factors to consider in evaluating potential suitability for salvage therapy include the extent of local disease and the nature and extent of prior treatment, as well as the overall medical condition, including comorbidity.<br />&para; Refer to the discussion in the topic on treatment of metastatic and recurrent head and neck cancer.<br />&Delta; Factors to consider include the extent and location of recurrent disease, type of prior treatment, time to recurrence, and toxicity of prior treatment.<br /><span class=\"lozenge\">&loz;</span> Salvage reirradiation requires an adequate dose (&gt;60 Gy) for control of the tumor, as well as the use of contemporary, highly conformal techniques to minimize toxicity. Stereotactic body RT may also be an option for appropriately selected cases.</div><div id=\"graphicVersion\">Graphic 112884 Version 1.0</div></div></div>"},"112888":{"type":"graphic_waveform","displayName":"CW Doppler jet patterns in aortic stenosis","title":"Continuous wave (CW) Doppler patterns in mild, moderate, and severe aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Continuous wave (CW) Doppler patterns in mild, moderate, and severe aortic stenosis</div><div class=\"cntnt\"><img style=\"width:724px; height:370px;\" src=\"images/CARD/112888_Doppler_pttrns_aortic_stnss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagramatic illustration shows the shape changes in the continuous wave Doppler jet patterns associated with varying degrees of severity of aortic stenosis. Mild stenosis (A) has a rapid rising initial jet velocity, whereas the more severe degrees (B and C) have progressively slower rates of rise. The pulsus tardus on physical examination is a direct correlate of these patterns.</div><div id=\"graphicVersion\">Graphic 112888 Version 1.0</div></div></div>"},"112889":{"type":"graphic_algorithm","displayName":"Dx eval neonatal AKI","title":"Overview of the diagnostic evaluation for neonatal acute kidney injury (AKI)*","html":"<div class=\"graphic\"><div style=\"width: 968px\" class=\"figure\"><div class=\"ttl\">Overview of the diagnostic evaluation for neonatal acute kidney injury (AKI)*</div><div class=\"cntnt\"><img style=\"width:948px; height:1091px;\" src=\"images/PEDS/112889_DxevalneonatalAKI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCr: serum creatinine.<br />* This algorithm reflects the diagnostic evaluation of the author for the UpToDate topic on the evaluation, management, and prognosis of neonatal acute kidney injury.<br />&para; Details of the underlying etiologies can be found in the UpToDate topic on etiology of neonatal AKI.<br />&Delta; Refer to UpToDate topics on renal cystic disease and renal hypodysplasia.<br /><span class=\"lozenge\">&loz;</span> The fluid challenge consists of the intravenous administration of 10 to 20 mL/kg of isotonic saline given over one to two hours.</div><div id=\"graphicVersion\">Graphic 112889 Version 2.0</div></div></div>"},"112890":{"type":"graphic_table","displayName":"Diagnostic criteria for patients with possible FPIES","title":"Diagnostic criteria for patients presenting with possible FPIES","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for patients presenting with possible FPIES</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Acute FPIES</td> </tr> <tr> <td class=\"subtitle2_single\">Major criterion:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vomiting in the one- to four-hour period after ingestion of the suspect food and the absence of classic IgE-mediated allergic skin or respiratory symptoms</td> </tr> <tr> <td class=\"subtitle2_single\">Minor criteria:</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>A second (or more) episode of repetitive vomiting after eating the same suspect food </li> <li>Repetitive vomiting episode one to four hours after eating a different food </li> <li>Extreme lethargy with any suspected reaction </li> <li>Marked pallor with any suspected reaction </li> <li>Need for emergency room visit with any suspected reaction </li> <li>Need for intravenous fluid support with any suspected reaction </li> <li>Diarrhea in 24 hours (usually 5 to 10 hours) </li> <li>Hypotension </li> <li>Hypothermia </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>The diagnosis of FPIES requires that a patient meets the major criterion and at least three minor criteria.</strong><br /> If only a single episode has occurred, a diagnostic oral food challenge should be strongly considered to confirm the diagnosis, especially since viral gastroenteritis is so common in this age group. Further, while not a criteria for diagnosis, it is important to recognize that acute FPIES reactions will typically completely resolve over a matter of hours compared with the usual several-day time course of gastroenteritis. The patient should be asymptomatic and growing normally when the offending food is eliminated from the diet.</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic FPIES</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Severe presentation:</strong> When the offending food is ingested in on a regular basis (eg, infant formula), intermittent but progressive vomiting and diarrhea (occasionally with blood) develop, sometimes with dehydration and metabolic acidosis.</p> <strong>Milder presentation:</strong> Lower doses of the problem food (eg, solid foods or food allergens in breast milk) lead to intermittent vomiting and/or diarrhea, usually with poor weight gain/failure to thrive but without dehydration or metabolic acidosis.</td> </tr> <tr> <td class=\"indent1\"><strong>The most important criterion for chronic FPIES diagnosis is resolution of the symptoms within days following elimination of the offending food(s) and acute recurrence of symptoms when the food is reintroduced, onset of vomiting in one to four hours, diarrhea in 24 hours (usually 5 to 10 hours). Without confirmatory challenge, the diagnosis of chronic FPIES remains presumptive.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FPIES: food protein-induced enterocolitis syndrome; IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Reproduced from: Nowak-Wegrzyn A, Chehade M, Groetch ME, et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: Executive summary&mdash;Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2017; 139:1111. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112890 Version 2.0</div></div></div>"},"112891":{"type":"graphic_table","displayName":"Guidelines for selecting weaning foods in FPIES infants","title":"Empiric guidelines for selecting weaning foods in infants with FPIES","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric guidelines for selecting weaning foods in infants with FPIES</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ages and stages</td> <td class=\"subtitle1\">Lower risk</td> <td class=\"subtitle1\">Moderate risk</td> <td class=\"subtitle1\">Higher risk</td> </tr> <tr> <td> <p><strong>Four to six months (as per AAP, CoN): Vegetables</strong></p> <p class=\"indent1\">If developmentally appropriate and safe and nutritious foods are available</p> <ul class=\"decimal_heading\"> <li>Begin with smooth, thin, purees and progress to thicker purees </li> <li>Choose foods that are high in iron </li> <li>Add vegetables and fruits </li> </ul> </td> <td>Broccoli, cauliflower, parsnip, turnip, pumpkin</td> <td>Squash, carrot, white potato, green bean (legume)</td> <td>Sweet potato, green pea (legume)</td> </tr> <tr> <td> <p><strong>Six months (as per WHO): Fruit</strong></p> <p class=\"indent1\">Complementary feeding should begin no later than six months of age</p> <ul class=\"decimal_heading\"> <li>In the breastfed infant, high-iron foods or supplemental iron (1 mg/kg/day) is suggested by six months of age </li> <li>Continue to expand variety of fruits, vegetables, legumes, grains, meats, and other foods as tolerated </li> </ul> </td> <td>Blueberries, strawberries, plum, watermelon, peach, avocado</td> <td>Apple, pear, orange</td> <td>Banana</td> </tr> <tr> <td><strong>Eight months of age or when developmentally appropriate: High-iron foods</strong> <ul class=\"decimal_heading\"> <li>Offer soft-cooked and bite-and-dissolve textures from approximately eight months of age or as tolerated by infant </li> </ul> </td> <td>Lamb, fortified quinoa cereal, millet</td> <td>Beef, fortified grits and corn cereal, wheat (whole wheat and fortified), fortified barley cereal</td> <td>Fortified, infant rice and oat cereals</td> </tr> <tr> <td><strong>12 months of age or when developmentally appropriate: Other</strong> <ul class=\"decimal_heading\"> <li>Offer modified tolerated foods from the family table: chopped meats, soft cooked vegetables, grains, and fruits </li> </ul> </td> <td>Tree nuts and seed butters* (sesame, sunflower, etc)</td> <td>Peanut, other legumes (other than green pea and green bean)</td> <td>Milk, soy, poultry, egg, fish</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Risk assessment is based on the clinical experience and the published reports of FPIES triggers.<br />This table should be considered in the context of the following notes: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Exclusive breastfeeding until four to six months of age and continuing breastfeeding through the first year of life or longer as long as mutually desired by both mother and child.<SUP>[1]</SUP></LI>&#xD;&#xA;<LI>If an infant tolerates a variety of early foods, subsequent introduction may be more liberal. Additionally, tolerance to one food in a food group (green pea) is considered as a favorable prognostic indicator for tolerance of other foods from the same group (legumes).<SUP>[2]</SUP></LI></UL></div><div class=\"graphic_footnotes\">FPIES: food protein-induced enterocolitis syndrome; AAP: American Academy of Pediatrics; CoN: Committee on Nutrition; WHO: World Health Organization.<br />* Thinned with water or infant puree for appropriate infant texture and to prevent choking.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics 2010; 126:1040.</LI>&#xD;&#xA;<LI>Sicherer SH. Food protein-induced enterocolitis syndrome: Case presentations and management lessons. J Allergy Clin Immunol 2005; 115:149.</LI></OL>Reproduced from: Nowak-Wegrzyn A, Chehade M, Groetch ME, et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: Executive summary—Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2017; 139:1111. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112891 Version 2.0</div></div></div>"},"112935":{"type":"graphic_figure","displayName":"Simplified view of ligand-receptor pairs that regulate T cells","title":"A simplified view of co-stimulatory and co-inhibitory ligand-receptor pairs that regulate T cell activity","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">A simplified view of co-stimulatory and co-inhibitory ligand-receptor pairs that regulate T cell activity</div><div class=\"cntnt\"><img style=\"width:578px; height:462px;\" src=\"images/ONC/112935_Ligand-receptr_pairs_Tcells.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that some binding partners involving some molecules, such as VISTA, are still being explored. Many additional co-stimulatory and co-inhibitory molecules (not shown) are involved in T cell activity and in the tumor microenvironment.</div><div class=\"graphic_reference\">Original figure modified for this publication. Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013; 31:191. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112935 Version 1.0</div></div></div>"},"112936":{"type":"graphic_algorithm","displayName":"Patient with a past penicillin reaction who requires antibiotics","title":"Approach to the patient with a past penicillin reaction who requires antibiotics","html":"<div class=\"graphic\"><div style=\"width: 1260px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with a past penicillin reaction who requires antibiotics</div><div class=\"cntnt\"><img style=\"width:1240px; height:406px;\" src=\"images/ALLRG/112936_Pstpenicillinrctnantbtcs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with the UpToDate content on choice of antibiotics in penicillin-allergic hospitalized patients. It is oriented toward hospitalized patients but also applies to outpatients if test dose procedures&nbsp;can be performed in an appropriately monitored setting with the staff and equipment needed to manage allergic reactions, including anaphylaxis. </div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.<br />* Ask the following: &#xD;&#xA;<OL>&#xD;&#xA;<LI>What exactly were the symptoms? &#xD;&#xA;<UL>&#xD;&#xA;<LI>Raised, red, itchy spots with each lesion lasting less than 24 hours (hives/urticaria)?</LI>&#xD;&#xA;<LI>Swelling of the mouth, eyes, lips, or tongue (angioedema)?</LI>&#xD;&#xA;<LI>Blisters or ulcers involving the lips, mouth, eyes, urethra, vagina, or peeling skin (seen in SJS, TEN, other severe type IV reactions)?</LI>&#xD;&#xA;<LI>Respiratory or hemodynamic changes (anaphylaxis)?</LI>&#xD;&#xA;<LI>Joint pains (seen in serum sickness)?</LI>&#xD;&#xA;<LI>Did the reaction involve organs like the kidneys, lungs, or liver (seen in DRESS, other severe type IV reactions)?</LI></UL></LI>&#xD;&#xA;<LI>What was the timing of the reaction after taking penicillin: Minutes, hours, or days later? Was it after the first dose or after multiple doses?</LI>&#xD;&#xA;<LI>How long ago did the reaction happen? (After 10 years of avoidance, only 20% of patients with IgE-mediated penicillin allergy will still be allergic).</LI>&#xD;&#xA;<LI>How was the reaction treated? Was there a need for urgent care or was adrenaline/epinephrine administered?</LI>&#xD;&#xA;<LI>Has the patient tolerated similar medications, such as ampicillin, amoxicillin, or cephalexin since the penicillin reaction?</LI></OL>¶ Isolated mild hives, without other symptoms of an IgE-mediated reaction, can often occur in the setting of an infection. Patients with this history, especially if it occurred in childhood or &gt;10 years ago, may also be considered to be at minimal risk for a recurrent serious reaction.<br />Δ This algorithm is intended for use in conjunction with additional UpToDate content. For a description of how to safely perform a TEST DOSE PROCEDURE, refer to the UpToDate topic on choice of antibiotics in penicillin-allergic hospitalized patients.<br /><FONT class=lozenge>◊</FONT> Consult allergist to perform skin testing. If skin testing is not possible, patient may still be able to receive penicillins or first- or second-generation cephalosporins using a desensitization (also known as tolerance induction) procedure. Refer to the UpToDate topic on rapid drug desensitization for immediate hypersensitivity reactions.</div><div class=\"graphic_reference\">Original figure modified for this publication. Blumenthal KG, Shenoy ES, Varughese CA, et al. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol 2015; 115:294. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 112936 Version 5.0</div></div></div>"},"112946":{"type":"graphic_table","displayName":"Ethanol intoxication in the surgical patient","title":"Pathophysiologic changes due to ethanol intoxication in the surgical patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathophysiologic changes due to ethanol intoxication in the surgical patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ system</td> <td class=\"subtitle1\">Pathophysiology</td> <td class=\"subtitle1\">Intervention(s)</td> </tr> <tr> <td>Gastrointestinal</td> <td>Decreased gastric emptying and inability to protect the airway increases risk for aspiration pneumonitis.</td> <td>Rapid sequence induction and intubation.</td> </tr> <tr> <td>Cardiovascular</td> <td> <p>Cardiomyopathy (cardiomegaly, decreased cardiac function due to oxidative damage, accumulation of acetaldehyde and other metabolic products).</p> <p>Thiamine deficiency can lead to high output heart failure with systemic vasodilation.</p> </td> <td> <p>Perioperative monitoring with transthoracic or transesophageal echocardiography.</p> <p>Thiamine (vitamin B1) replacement 500 mg over 30 minutes.</p> </td> </tr> <tr> <td>Pulmonary</td> <td>\"Alcoholic lung\" (due to decreased concentration of glutathione, abnormal surfactant synthesis and secretions, changes in alveolar-capillary barrier function and permeability) predisposes to ARDS and pneumonia.</td> <td> <p>Lung protective ventilation (tidal volume of 6 to 8 mL/kg predicted body weight, titration of PEEP as required to maintain PaO<sub>2</sub>).</p> Postoperative head of bed elevation.</td> </tr> <tr> <td>Immune</td> <td>Increased risk for postoperative infections from inhibition of CD3+ T cells and decreased proliferation of CD4+ and CD8+ T cells; increased inflammatory cytokines (ie, IL-12, IFN-alpha).</td> <td> <p>Strict adherence to standard precautions.</p> <p>Timely prophylactic antibiotic administration before incision (and early re-dosing if more than one blood volume lost during surgery).</p> Replacement of all non-sterile catheters (eg, those placed emergently without a sterile field) as soon as possible (&#60;24 hours after insertion).</td> </tr> <tr> <td>Hematologic</td> <td>Megaloblastic anemia due to folate deficiency; impaired platelet activation and inhibition by ethanol; increased fibrinolysis secondary to increased tissue plasminogen activator activity.</td> <td>Utilize viscoelastic monitoring (eg, TEG or ROTEM) to identify elements of the coagulation cascade that require correction.</td> </tr> <tr> <td>Renal/metabolic</td> <td> <p>Acidosis in over 25 percent&nbsp;of patients caused by: 1) increased NADH:NAD ratio related to ethanol metabolism and volume depletion which may precipitate ketogenesis; 2) impairment of pyruvate dehydrogenase&nbsp;due to&nbsp;thiamine deficiency; and 3)&nbsp;lactic acidosis due to volume depletion.</p> <p>Electrolyte disorders including hypomagnesemia, hypokalemia (resistant to treatment until magnesium deficiency is corrected), hypophosphatemia due to increased renal excretion.</p> <p>Rhabdomyolysis.</p> </td> <td> <p>Dextrose 5% in water, administered as a background infusion at 125 mL/hr to prevent ketogenesis, stimulate insulin production, and replenish glycogen stores.</p> <p>Hydration with balanced electrolyte solutions (eg, lactated Ringer's, Plasmalyte, Normosol) according to dynamic and static indices to correct hypovolemia.</p> <p>Electrolyte repletion as indicated (especially magnesium).</p> </td> </tr> <tr> <td>Neurologic</td> <td>B1 (thiamine) deficiency leading to pathological carbohydrate metabolism, which may result in Wernicke's encephalopathy/Korsakoff's psychosis.</td> <td>Thiamine (vitamin B1) replacement 500 mg&nbsp;IV over 30 minutes.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARDS: acute respiratory distress syndrome; PEEP: positive end expiratory pressure; PaO<SUB>2</SUB>: partial pressure of oxygen in arterial blood; CD3+: cluster of differentiation - 3 glycoprotein; T cells: T lymphocyte cell; CD4+: cluster of differentiation - 4 glycoprotein; CD8+: cluster of differentiation -&nbsp;8 glycoprotein; IL-12: interleukin-12; IFN-alpha:&nbsp;interferon-alpha; TEG: thromboelastogram; ROTEM: rotational thromboelastometry; NADH-NAD: nicotinamide adenine dinucleotide (\"H\" indicates reduced form); IV: intravenous.</div><div id=\"graphicVersion\">Graphic 112946 Version 2.0</div></div></div>"},"112950":{"type":"graphic_picture","displayName":"Herpes zoster on scalp 2","title":"Herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Herpes zoster</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/112950_Herpes_zoster_scalp_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles, crusts, and erythema in a dermatomal distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112950 Version 1.0</div></div></div>"},"112952":{"type":"graphic_picture","displayName":"Allergic contact dermatitis on scalp","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/112952_Allergic_dermatitis_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112952 Version 1.0</div></div></div>"},"112956":{"type":"graphic_table","displayName":"Live vaccines","title":"Live vaccines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Live vaccines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Adenovirus vaccine </li> <li>Bacille Calmette-Gu&#233;rin (BCG) </li> <li>Live attenuated influenza vaccine (intranasal)* </li> <li>Live attenuated oral poliovirus vaccine* </li> <li>Measles, mumps, and rubella vaccine </li> <li>Measles, mumps, rubella, and&nbsp;varicella vaccine </li> <li>Measles vaccine </li> <li>Mumps vaccine </li> <li>Oral typhoid vaccine* </li> <li>Rotavirus vaccine</li> <li>Rubella vaccine </li> <li>Smallpox vaccine </li> <li>Varicella vaccine </li> <li>Yellow fever vaccine </li> <li>Zoster vaccine </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In the United States, live virus vaccines are routinely recommended for protection against rotavirus, measles, mumps, rubella, varicella, and herpes zoster. Either inactivated or live attenuated influenza vaccine may be used for people 2 through 49 years of age. Oral poliovirus vaccine is not available in the United States. Routinely recommended vaccines for other countries are available through the World Health Organization. Refer to the relevant UpToDate topic reviews for specific vaccine recommendations.</div><div class=\"graphic_footnotes\">* For some pathogens, both live attenuated and inactivated vaccines are available.</div><div id=\"graphicVersion\">Graphic 112956 Version 2.0</div></div></div>"},"112959":{"type":"graphic_algorithm","displayName":"Difficult airway management algorithm in trauma","title":"Difficult airway management algorithm in trauma","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Difficult airway management algorithm in trauma</div><div class=\"cntnt\"><img style=\"width:647px; height:1099px;\" src=\"images/ANEST/112959_Diff_airway_mgmt_alg_trauma.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMV: bag-valve mask; CP: cricoid pressure; DA: difficult airway; DL: direct laryngoscopy; FIS: flexible intubation scope; FSI: flexible scope intubation; GA: general anesthesia; LMA: laryngeal mask airway; MILS: manual in-line stabilization; RSI: rapid sequence intubation; SGA: supraglottic airway; VAL: video-assisted laryngoscopy; ASA: American Society of Anesthesiologists.<br />* Confirm ventilation, tracheal intubation or SGA placement with standard confirmatory techniques (exhaled CO<SUB>2</SUB>, misting of tube, auscultation of breath sounds, improving SpO<SUB>2</SUB>). If perfusion (and exhaled CO<SUB>2</SUB>) absent, use additional confirmation methods (eg, repeat laryngoscopy, bronchoscopy, esophageal detector device, chest radiograph).<br />¶ Other options in ASA algorithm: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Ventilation with a face mask or SGA might be difficult or impossible in a patient with maxillofacial trauma.</LI>&#xD;&#xA;<LI>Local anesthesia infiltration or regional nerve blockade are of limited value in extensive trauma surgery.</LI></UL>Δ Invasive airway access includes surgical or percutaneous cricothyrotomy or tracheostomy, transtracheal jet ventilation and retrograde intubation.<br /><FONT class=lozenge>◊</FONT> Emergency non-invasive airway ventilation consists of SGA.<br />§ Aborting the case and awakening the patient to optimize and re-attempt intubation via a different airway technique (eg, awake intubation) is impractical in most trauma cases due to the emergent condition of the patient.<br />¥ Alternative difficult intubation approaches include (but are not limited to): VAL, SGA (eg, LMA as an intubation conduit with or without flexible scope guidance), flexible scope intubation, intubating stylet or tube changer, and light wand. Blind intubation (oral or nasal) is discouraged in patients with maxillofacial trauma and laryngeal or tracheal injury.<br />‡ Surgical airway kit should be immediately available.</div><div class=\"graphic_reference\">Algorithm adapted with permission from: Hagberg CA, Kaslow O. Difficult airway management algorithm in trauma: Updated by COTEP. ASA Monitor 2014; 78:56. Copyright © 2014 American Society of Anesthesiologists. Excerpted from ASA Monitor (2014) of the American Society of Anesthesiologists. A copy of the full text can be obtained from ASA, 1061 American Lane, Schaumburg, IL, 60173-4973 or online at <A href=\"http://www.asahq.org/\" target=_blank>www.asahq.org</A>.</div><div id=\"graphicVersion\">Graphic 112959 Version 1.0</div></div></div>"},"112968":{"type":"graphic_algorithm","displayName":"Management of mild or moderate ulcerative colitis in children","title":"Management of mild or moderate ulcerative colitis extending beyond the rectum in children","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Management of mild or moderate ulcerative colitis extending beyond the rectum in children</div><div class=\"cntnt\"><img style=\"width:562px; height:956px;\" src=\"images/PEDS/112968_MgmtmildmodUCchild.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UC: ulcerative colitis; 5-ASA: 5-aminosalicylate; IV: intravenous; 6-MP: 6-mercaptopurine; AZA: azathioprine.<br />* Severity of disease is typically assessed by the pediatric ulcerative colitis activity index (PUCAI), which assigns a score based on symptoms of abdominal pain, rectal bleeding, stool consistency, stool frequency, presence of nocturnal stools, and activity level, adding to a maximum score of 85. Mild disease is defined by a PUCAI score of 10 to 34, moderate disease 35 to 64, and severe disease 65 to 85.<br />¶ Dotted line indicates that 5-ASA is a secondary option for patients with moderate ulcerative colitis. Most patients with moderate symptoms will benefit from a course of systemic glucocorticoids. However, for patients who are reluctant to use glucocorticoids, it is reasonable to offer a trial of 5-ASA, using doses at the high end of the range. Patients who do not improve on 5-ASA should move on to glucocorticoids.<br />Δ Oral glucocorticoids are typically given for two to four weeks, then gradually tapered over the next two months. Either prednisone or budesonide may be used.<br /><FONT class=lozenge>◊</FONT> Response to therapy is typically determined by changes in clinical symptoms, documented by the PUCAI score. The goal of therapy is complete resolution of symptoms, reflected by a PUCAI score of &lt;10. For patients with moderate or severe UC, a marked improvement in PUCAI (eg, PUCAI &lt;35 or a PUCAI decrease of ≥20 points) provides an initial indication of successful medical therapy. In addition, endoscopic grading of disease severity is increasingly used for assessing response to therapy in both clinical trials and clinical practice.<br />§ IV glucocorticoids are typically given for up to 14 days, transitioning to oral steroids about two days after a definite response is noted. If there is no clear response after one week of IV therapy, the patient should be reevaluated by endoscopy, and discussion initiated regarding other immunosuppressive therapy (thiopurines or infliximab). Some experts now routinely use endoscopic remission as a treatment goal, and to determine when to transition from IV to oral therapy.<br />¥ Patients who relapse during treatment with 5-ASA may be reinduced with glucocorticoids. Patients are considered to be steroid-dependent if they have been on high-dose glucocorticoids for more than two to three months, or daily glucocorticoids for four to six months, or frequently flare when the glucocorticoid dose is reduced (eg, two or three relapses per year). These patients should advance to a different immunosuppressive therapy.<br />‡ For initial medical treatment of patients with steroid-dependent/refractory disease, either a thiopurine or infliximab is a reasonable choice, and the optimal approach has not been established. If thiopurines are selected, patients may require short-term \"bridging\" with another medication (corticosteroids, tacrolimus, or cyclosporine), due to the slow onset of action of thiopurines. For those who fail initial treatment with thiopurines, it is common practice to transition to infliximab therapy. Although this type of sequential therapy is common, the risks and benefits have not been assessed compared with proceeding to colectomy. For patients who fail initial treatment with infliximab, it is common practice to move on to second-line options, rather than to a trial of thiopurines.<br />† For patients who relapse after initial success with a first- or second-line treatment for steroid-dependent or steroid-refractory colitis, colectomy should be seriously considered. The alternatives are either sequential treatment with other biologic agents, or treatment with other immunosuppressive agents in which there is only limited evidence of benefit (methotrexate, thalidomide), or experimental agents (eg, tofacitinib).</div><div id=\"graphicVersion\">Graphic 112968 Version 2.0</div></div></div>"},"112970":{"type":"graphic_figure","displayName":"Fine motor milestones using cubes","title":"Fine motor milestones demonstrated with cubes according to age","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Fine motor milestones demonstrated with cubes according to age</div><div class=\"cntnt\"><img style=\"width:578px; height:763px;\" src=\"images/PEDS/112970_Fine_motor_milestones_cubes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These milestones are presented as a guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS: Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc.</LI>&#xD;&#xA;<LI>Capute AJ, Accardo PJ. The pediatrician and the developmentally disabled child: A clinical textbook on mental retardation, University Press, Baltimore 1979.</LI></OL></div><div id=\"graphicVersion\">Graphic 112970 Version 1.0</div></div></div>"},"112971":{"type":"graphic_picture","displayName":"FDCS LN 20x","title":"Follicular dendritic cell sarcoma of lymph node","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Follicular dendritic cell sarcoma of lymph node</div><div class=\"cntnt\"><img style=\"width:753px; height:561px;\" src=\"images/HEME/112971_FDCS_LN_20x.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular dendritic cell sarcoma of lymph node composed of spindle cells arranged in a sheet-like and whorled growth pattern. Note the scattered lymphocytes (original magnification x200).</div><div class=\"graphic_reference\">Courtesy of Jason Hornick, MD, PhD, Department of Pathology, Brigham and Women's Hospital.</div><div id=\"graphicVersion\">Graphic 112971 Version 1.0</div></div></div>"},"112972":{"type":"graphic_picture","displayName":"FDCS LN 40x","title":"Follicular dendritic cell sarcoma of lymph node","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Follicular dendritic cell sarcoma of lymph node</div><div class=\"cntnt\"><img style=\"width:754px; height:563px;\" src=\"images/HEME/112972_FDCS_LN_40x.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tumor cells contain ovoid to elongated nuclei with vesicular chromatin, small nucleoli, and abundant syncytial pale eosinophilic cytoplasm (original magnification x400).</div><div class=\"graphic_reference\">Courtesy of Jason Hornick, MD, PhD, Department of Pathology, Brigham and Women's Hospital.</div><div id=\"graphicVersion\">Graphic 112972 Version 1.0</div></div></div>"},"112973":{"type":"graphic_picture","displayName":"FDCS CD21 20x","title":"Follicular dendritic cell sarcoma cells stained for CD21","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Follicular dendritic cell sarcoma cells stained for CD21</div><div class=\"cntnt\"><img style=\"width:754px; height:563px;\" src=\"images/HEME/112973_FDCS_CD21_20x.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By immunohistochemistry, the tumor cells show strong membranous staining for CD21 (original magnification x200).</div><div class=\"graphic_reference\">Courtesy of Jason Hornick, MD, PhD, Department of Pathology, Brigham and Women's Hospital.</div><div id=\"graphicVersion\">Graphic 112973 Version 1.0</div></div></div>"},"112975":{"type":"graphic_diagnosticimage","displayName":"Fibula shaft fracture ultrasound long axis","title":"Fibula shaft fracture ultrasound long axis","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Fibula shaft fracture ultrasound long axis</div><div class=\"cntnt\"><img style=\"width:754px; height:564px;\" src=\"images/SM/112975_Fbl_shft_frctr_US_lng_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The musculoskeletal&nbsp;ultrasound image above shows a&nbsp;long-axis view of a fibula fracture. The arrow&nbsp;indicates an associated&nbsp;subacute hematoma adjacent to a break in the cortex.</div><div class=\"graphic_footnotes\">m: muscle; p: periosteum.</div><div class=\"graphic_reference\">Reproduced with permission from: French AJ, English J, Stone MB, Frazee BW. Soft tissues and musculoskeletal procedures. In: Practical Guide to Emergency Ultrasound, 2nd ed, Cosby KS, Kendall JL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 112975 Version 2.0</div></div></div>"},"112978":{"type":"graphic_algorithm","displayName":"Genetic eval fetus w soft markers after a neg cfDNA screen","title":"Genetic evaluation of the fetus found to have soft markers for fetal aneuploidy on ultrasound after a negative cell-free DNA screen","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Genetic evaluation of the fetus found to have soft markers for fetal aneuploidy on ultrasound after a negative cell-free DNA screen</div><div class=\"cntnt\"><img style=\"width:483px; height:357px;\" src=\"images/OBGYN/112978_GnvlftsmrkngcfDNAscrn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft markers may include mild pyelectasis, single umbilical artery, cerebral ventriculomegaly, echogenic bowel, thick nuchal fold, hypoplastic nasal bone, or shortened humerus or femur.</div><div class=\"graphic_footnotes\">cfDNA: cell-free DNA; FISH: fluorescence in situ hybridization.<br />* Some soft markers in euploid fetuses are associated with specific disorders; this should be addressed during counseling and options for prenatal diagnosis discussed. For example, echogenic bowel has been associated with blood in the bowel lumen, cystic fibrosis, growth restriction, infection, and gastrointestinal obstruction; first-trimester nuchal thickening has been associated with congenital heart disease and Noonan syndrome; pyelectasis has been associated with kidney abnormalities. Evaluation depends on the specific marker.<br />&para; Although FISH provides a rapid result, it also adds to the cost of the fetal evaluation, so it is also reasonable to proceed directly to chromosomal microarray analysis.</div><div id=\"graphicVersion\">Graphic 112978 Version 2.0</div></div></div>"},"112980":{"type":"graphic_picture","displayName":"Dyshidrotic eczema acute fingers","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/112980_Dyshidrotic_eczema_act_fngr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pinpoint vesicles, some of which are coalescing into larger ones, are visible on the lateral and dorsal aspects of the fingers of a patients with acute palmoplantar eczema (dyshidrotic eczema).</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 112980 Version 1.0</div></div></div>"},"112986":{"type":"graphic_figure","displayName":"Accumulation of MMA in vitamin B12 deficiency","title":"Accumulation of methylmalonic acid (MMA) in vitamin B12 deficiency","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Accumulation of methylmalonic acid (MMA) in vitamin B12 deficiency</div><div class=\"cntnt\"><img style=\"width:626px; height:328px;\" src=\"images/HEME/112986_MMAmetabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adenosyl-cobalamin (dark oval), which is derived from vitamin B12 (cobalamin), is a cofactor in the conversion of methylmalonyl-CoA to succinyl-CoA. Deficiency of vitamin B12 leads to accumulation of methylmalonic acid (MMA). Refer to UpToDate topics on vitamin B12 deficiency for further details and the approach to metabolite testing.</div><div class=\"graphic_footnotes\">MMA: methylmalonic acid; MCH: D-methylmalonyl-CoA hydrolase; MCM: L-methylmalonyl-CoA mutase; MCR: D,L-methylmalonyl-CoA racemase.</div><div class=\"graphic_reference\">Reproduced with permission from: Bj&oslash;rke Monsen AL, Ueland PM. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence. Am J Clin Nutr 2003; 78:7-21, American Society for Nutrition. Copyright &copy; 2003.</div><div id=\"graphicVersion\">Graphic 112986 Version 3.0</div></div></div>"}};